




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 211/66, 309/08, A61K 31/445, 31/35, 31/16, C07C 317/44, C07D 335/02, 405/12, 409/12, 211/94, 405/14, 239/04, 417/12, 407/12</p>	A1	<p>(11) International Publication Number: WO 99/25687</p> <p>(43) International Publication Date: 27 May 1999 (27.05.99)</p>
<p>(21) International Application Number: PCT/US98/23242</p> <p>(22) International Filing Date: 12 November 1998 (12.11.98)</p> <p>(30) Priority Data: 60/066,007 14 November 1997 (14.11.97) US</p> <p>(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BARTA, Thomas, E. [US/US]; Apartment 3W, 1133 Maple Avenue, Evanston, IL 60602 (US). BECKER, Daniel, P. [US/US]; 1427 Pebble Creek Drive, Glenview, IL 60025 (US). BOEHM, Terri, L. [US/US]; 928 Clea Drive, Ballwin, MO 63021 (US). DE CRESCENZO, Gary, A. [US/US]; 7345 Spruce Hill Court, St. Charles, MO 63304 (US). VILLAMIL, Clara, I. [US/US]; 813 Long Road, Glenview, IL 60025 (US). MCDONALD, Joseph, J. [US/US]; 1036 Johanna Drive, Ballwin, MO 63105 (US). FRESKOS, John, N. [US/US]; 7572 York, Clayton, MO 63105 (US). GETMAN, Daniel,</p>		<p>P. [US/US]; 66 Sunny Hill Court, Chesterfield, MO 63017 (US).</p> <p>(74) Agents: WILLIAMS, Roger, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR</p>		



(I)

(57) Abstract

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R¹ and R² are both hydrido or R¹ and R² together with atoms to which they are bonded form a 5- to 8-membered ring containing one, two or three heteroatoms in the ring that are oxygen, sulfur or nitrogen. R³ in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

AROMATIC SULFONE HYDROXAMIC ACID
METALLOPROTEASE INHIBITOR

Description

5

Technical Field

This invention is directed to proteinase (protease) inhibitors, and more particularly to the use of aromatic sulfone hydroxamic acid compounds that, inter alia, are selective inhibitors of matrix metalloproteinases in a process for treating conditions associated with pathological matrix metalloproteinase activity, the selective inhibitors themselves, compositions of proteinase inhibitors, intermediates for the syntheses of proteinase inhibitors, and processes for the preparation of proteinase inhibitors.

Background of the Invention

20

Connective tissue, extracellular matrix constituents and basement membranes are required components of all mammals. These components are the biological materials that provide rigidity, differentiation, attachments and, in some cases, elasticity to biological systems including human beings and other mammals. Connective tissues components include, for example, collagen, elastin, proteoglycans, fibronectin and laminin. These biochemicals makeup, or are components of structures, such as skin, bone, teeth, tendon, cartilage, basement membrane, blood vessels, cornea and vitreous humor.

30

-2-

Under normal conditions, connective tissue turnover and/or repair processes are controlled and in equilibrium. The loss of this balance for whatever reason leads to a number of disease states.

5 Inhibition of the enzymes responsible loss of equilibrium provides a control mechanism for this tissue decomposition and, therefore, a treatment for these diseases.

Degradation of connective tissue or

10 connective tissue components is carried out by the action of proteinase enzymes released from resident tissue cells and/or invading inflammatory or tumor cells. A major class of enzymes involved in this function are the zinc metalloproteinases

15 (metalloproteases).

The metalloprotease enzymes are divided into classes with some members having several different names in common use. Examples are:

collagenase I (MMP-1, fibroblast collagenase; EC

20 3.4.24.3); collagenase II (MMP-8, neutrophil collagenase; EC 3.4.24.34), collagenase III (MMP-13), stromelysin 1 (MMP-3; EC 3.4.24.17), stromelysin 2 (MMP-10; EC 3.4.24.22), proteoglycanase, matrilysin (MMP-7), gelatinase A (MMP-2, 72 kDa gelatinase,

25 basement membrane collagenase; EC 3.4.24.24), gelatinase B (MMP-9, 92 kDa gelatinase; EC 3.4.24.35), stromelysin 3 (MMP-11), metalloelastase (MMP-12, HME, human macrophage elastase) and membrane MMP (MMP-14). MMP is an abbreviation or acronym

30 representing the term Matrix Metalloprotease with the attached numerals providing differentiation between specific members of the MMP group.

The uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions. Examples include rheumatoid arthritis, osteoarthritis, septic arthritis; corneal, epidermal or gastric ulceration; tumor metastasis, invasion or angiogenesis; periodontal disease; proteinuria; Alzheimers Disease; coronary thrombosis and bone disease. Defective injury repair processes also occur. This can produce improper wound healing leading to weak repairs, adhesions and scarring. These latter defects can lead to disfigurement and/or permanent disabilities as with post-surgical adhesions.

Metalloproteases are also involved in the biosynthesis of tumor necrosis factor (TNF), and inhibition of the production or action of TNF and related compounds is an important clinical disease treatment mechanism. TNF- α , for example, is a cytokine that at present is thought to be produced initially as a 28 kD cell-associated molecule. It is released as an active, 17 kD form that can mediate a large number of deleterious effects *in vitro* and *in vivo*. For example, TNF can cause and/or contribute to the effects of inflammation, rheumatoid arthritis, autoimmune disease, multiple sclerosis, graft rejection, fibrotic disease, cancer, infectious diseases, malaria, mycobacterial infection, meningitis, fever, psoriasis, cardiovascular/pulmonary effects such as post-ischemic reperfusion injury, congestive heart failure, hemorrhage, coagulation, hyperoxic alveolar injury, radiation damage and acute phase responses like those seen with infections and sepsis and during shock such as septic

shock and hemodynamic shock. Chronic release of active TNF can cause cachexia and anorexia. TNF can be lethal, and TNF can help control the growth of tumor cells.

5 TNF- α convertase is a metalloprotease involved in the formation of soluble TNF- α . Inhibition of TNF- α convertase (TACE) inhibits production of active TNF- α . Compounds that inhibit both MMPs activity and TNF- α production have been
10 disclosed in WIPO International Publication Nos. WO 94/24140, WO 94/02466 and WO 97/20824. Compounds that inhibit MMPs such as collagenase, stromelysin and gelatinase have been shown to inhibit the release of TNF (Gearing et al. *Nature* 376, 555-557 (1994),
15 McGeehan et al., *Nature* 376, 558-561 (1994)). There remains a need for effective MMP inhibitors. There also remains a need for effective TNF- α convertase inhibiting agents.

 MMPs are involved in other biochemical
20 processes in mammals as well. Included is the control of ovulation, post-partum uterine involution, possibly implantation, cleavage of APP (β -Amyloid Precursor Protein) to the amyloid plaque and inactivation of α_1 -protease inhibitor (α_1 -PI).
25 Inhibition of these metalloproteases permits the control of fertility and the treatment or prevention of Alzheimers Disease. In addition, increasing and maintaining the levels of an endogenous or administered serine protease inhibitor drug or
30 biochemical such as α_1 -PI supports the treatment and prevention of diseases such as emphysema, pulmonary

diseases, inflammatory diseases and diseases of aging such as loss of skin or organ stretch and resiliency.

Inhibition of selected MMPs can also be desirable in other instances. Treatment of cancer and/or inhibition of metastasis and/or inhibition of angiogenesis are examples of approaches to the treatment of diseases wherein the selective inhibition of stromelysin, gelatinase A or B, or collagenase III appear to be the relatively most important enzyme or enzymes to inhibit especially when compared with collagenase I (MMP-1). A drug that does not inhibit collagenase I can have a superior therapeutic profile. Osteoarthritis, another prevalent disease wherein it is believed that cartilage degradation of inflamed joints is at least partially caused by MMP-13 released from cells such as stimulated chondrocytes, may be best treated by administration of drugs one of whose modes of action is inhibition of MMP-13. See, for example, Mitchell et al., *J. Clin. Invest.*, 97:761-768 (1996) and Reboul et al., *J. Clin. Invest.*, 97:2011-2019 (1996).

Inhibitors of metalloproteases are known. Examples include natural biochemicals such as tissue inhibitors of metalloproteinases (TIMPs), α_2 -macroglobulin and their analogs or derivatives. These endogenous inhibitors are high molecular weight protein molecules that form inactive complexes with metalloproteases. A number of smaller peptide-like compounds that inhibit metalloproteases have been described. Mercaptoamide peptidyl derivatives have shown ACE inhibition *in vitro* and *in vivo*. Angiotensin converting enzyme (ACE) aids in the

-6-

production of angiotensin II, a potent pressor substance in mammals and inhibition of this enzyme leads to the lowering of blood pressure.

Thiol group-containing amide or peptidyl
5 amide-based metalloprotease (MMP) inhibitors are known as is shown in, for example, WO95/12389, WO96/11209 and U.S. 4,595,700. Hydroxamate group-containing MMP inhibitors are disclosed in a number of published patent applications such as WO 95/29892,
10 WO 97/24117, WO 97/49679 and EP 0 780 386 that disclose carbon back-boned compounds, and WO 90/05719, WO 93/20047, WO 95/09841 and WO 96/06074 that disclose hydroxamates that have a peptidyl back-bones or peptidomimetic back-bones, as does the
15 article by Schwartz et al., *Progr. Med. Chem.*, 29:271-334(1992) and those of Rasmussen et al., *Pharmacol. Ther.*, 75(1): 69-75 (1997) and Denis et al., *Invest. New Drugs*, 15(3): 175-185 (1997).

One possible problem associated with known
20 MMP inhibitors is that such compounds often exhibit the same or similar inhibitory effects against each of the MMP enzymes. For example, the peptidomimetic hydroxamate known as batimastat is reported to exhibit IC₅₀ values of about 1 to about 20 nanomolar
25 (nM) against each of MMP-1, MMP-2, MMP-3, MMP-7, and MMP-9. Marimastat, another peptidomimetic hydroxamate was reported to be another broad-spectrum MMP inhibitor with an enzyme inhibitory spectrum very similar to batimastat, except that marimastat
30 exhibited an IC₅₀ value against MMP-3 of 230 nM. Rasmussen et al., *Pharmacol. Ther.*, 75(1): 69-75 (1997).

-7-

Meta analysis of data from Phase I/II studies using marimastat in patients with advanced, rapidly progressive, treatment-refractory solid tumor cancers (colorectal, pancreatic, ovarian, prostate) indicated a dose-related reduction in the rise of cancer-specific antigens used as surrogate markers for biological activity. Although marimastat exhibited some measure of efficacy via these markers, toxic side effects were noted. The most common drug-related toxicity of marimastat in those clinical trials was musculoskeletal pain and stiffness, often commencing in the small joints in the hands, spreading to the arms and shoulder. A short dosing holiday of 1-3 weeks followed by dosage reduction permits treatment to continue. Rasmussen et al., *Pharmacol. Ther.*, 75(1): 69-75 (1997). It is thought that the lack of specificity of inhibitory effect among the MMPs may be the cause of that effect.

International application WO 98/38163, published on September 3, 1998 disclose a large group of hydroxamate inhibitors of MMPs and TACE. The compounds of WO 98/38163 contain one or two substituents adjacent to the hydroxamate functionality and a substituent that can be an aromatic sulfonyl group adjacent to those one or two substituents.

International application WO 98/37877, published on September 3, 1998 discloses compounds that contain a 5- to 7-membered heterocyclic ring adjacent to the hydroxamate functionality and can

contain an aromatic sulfonyl group adjacent to the heterocyclic ring.

Although many of the known MMP inhibitors such as batimastat, marimastat and the hydroxamates
5 of WO 98/37877 and WO 98/38163 exhibit a broad spectrum of activity against MMPs, those compounds are not particularly selective in their inhibitory activity. This lack of selectivity may be the cause of the musculoskeletal pain and stiffness observed
10 with their use. In addition, it can be therapeutically advantageous to utilize a medicament that is selective in its activity as compared to a generally active material so that treatment can be more closely tailored to the pathological condition
15 presented by the host mammal. The disclosure that follows describes a process for treating a host mammal having a condition associated with pathological matrix metalloprotease activity that utilizes a compound that selectively inhibits one or
20 more MMPs, while exhibiting less activity against at least MMP-1.


Summary of the Invention

The present invention is directed to a
25 treatment process that comprises administering a contemplated aromatic sulfone hydroxamic acid metalloprotease inhibitor in an effective amount to a host mammal having a condition associated with pathological metalloprotease activity. A
30 contemplated molecule, *inter alia*, exhibits excellent inhibitory activity of one or more matrix

metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1. By "substantially less" it is meant that a contemplated compound
5 exhibits an IC_{50} value ratio against one or more of MMP-2, MMP-9 or MMP-13 as compared to its IC_{50} value against MMP-1, e.g., IC_{50} MMP-2: IC_{50} MMP-1, that is less than about 1:10, preferably less than about 1:100, and most preferably less than about 1:1000 in
10 the *in vitro* inhibition assay utilized hereinafter. The invention also contemplates particular compounds that selectively inhibit the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1, as
15 well as a composition containing such a MMP inhibitor as active ingredient. The invention further contemplates intermediates in the preparation of a contemplated aromatic sulfone hydroxamic acid molecule and a process for preparing an aromatic
20 sulfone hydroxamic acid molecule.

Briefly, one embodiment of the present invention is directed to a treatment process that comprises administering a contemplated aromatic sulfone hydroxamic acid metalloprotease inhibitor
25 that selectively inhibits matrix metalloprotease activity as above in an effective amount to a host mammal having a condition associated with pathological metalloprotease activity. The administered enzyme inhibitor corresponds in
30 structure to formula (I), below, or a pharmaceutically acceptable salt thereof:

-10-



wherein

- 5 R^1 and R^2 are both hydrido or R^1 and R^2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two or three heteroatoms in the ring that are oxygen, sulfur or nitrogen.
- 10 R^3 in formula I is an optionally substituted aryl or optionally substituted heteroaryl radical. When R^3 is a substituted aryl or heteroaryl radical, a contemplated substituent is selected from the group consisting of an aryl, heteroaryl, aralkyl,
- 15 heteroaralkyl, aryloxy, arylthio, aralkoxy, heteroaralkoxy, aralkoxyalkyl, aryloxyalkyl, aralkanoylalkyl, arylcarbonylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, alkylthioaryl, arylthioalkyl,
- 20 alkylthioaralkyl, aralkylthioalkyl, an aralkylthioaryl radical, the sulfoxide or sulfone of any of the thio substituents, and a fused ring structure comprising two or more 5- or 6-membered rings selected from the group consisting of aryl,
- 25 heteroaryl, carbocyclic and heterocyclic.

The substituent bonded to the aryl or heteroaryl radical of which the R^3 radical is comprised itself can be substituted with one or more substituents;

-11-

i.e., the substituting substituent is optionally substituted. When that aryl or heteroaryl radical is substituted, and the substituting moiety (group, substituent, or radical) is itself substituted, the last-named substituent is independently selected from the group consisting of a cyano, perfluoroalkyl, trifluoromethoxy, trifluoromethylthio, haloalkyl, trifluoromethylalkyl, aralkoxycarbonyl, aryloxycarbonyl, hydroxy, halo, alkyl, alkoxy, nitro, thiol, hydroxycarbonyl, aryloxy, arylthio, aralkyl, aryl, arylcarbonylamino, heteroaryloxy, heteroarylthio, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, heteroaralkoxy, heteroaralkylthio, aralkoxy, aralkylthio, aralkylamino, heterocyclo, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxycarbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxycarbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxycarbonylalkoxy, alkoxycarbonylalkylthio, amino, wherein the amino nitrogen is (i) unsubstituted, or (ii) substituted with one or two substituents that are independently selected from the group consisting of an alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxycarbonyl, arylcarbonyl, aralkanoyl, heteroarylcarbonyl, heteroaralkanoyl and an alkanoyl group, or (iii) wherein the amino nitrogen and two substituents attached thereto

-12-

form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero to two additional heteroatoms that are nitrogen, oxygen or sulfur and which ring itself is (a) unsubstituted or (b) substituted with one or two groups independently selected from the group consisting of an aryl, alkyl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, alkanoyl, cycloalkyl, heterocycloalkyl, alkoxycarbonyl, hydroxyalkyl, trifluoromethyl, benzofused heterocycloalkyl, hydroxyalkoxyalkyl, aralkoxycarbonyl, hydroxycarbonyl, aryloxycarbonyl, benzofused heterocycloalkoxy, benzofused cycloalkylcarbonyl, heterocyclo-alkylcarbonyl, and a cycloalkylcarbonyl group, carbonylamino

wherein the carbonylamino nitrogen is (i) unsubstituted, or (ii) is the reacted amine of an amino acid, or (iii) substituted with one or two radicals selected from the group consisting of an alkyl, hydroxyalkyl, hydroxyheteroaralkyl, cycloalkyl, aralkyl, trifluoromethylalkyl, heterocycloalkyl, benzofused heterocycloalkyl, benzofused heterocycloalkyl, benzofused cycloalkyl, and an N,N-dialkylsubstituted alkylamino-alkyl group, or (iv) the carboxamido nitrogen and two substituents bonded thereto together form a 5- to 8-membered heterocyclo, heteroaryl or benzofused heterocycloalkyl ring that is itself unsubstituted or substituted with one or two radicals independently selected from the group consisting of an alkyl, alkoxycarbonyl, nitro, heterocycloalkyl,

-13-

hydroxy, hydroxycarbonyl, aryl, aralkyl,
heteroaralkyl and an amino group,

wherein the amino nitrogen is

(i) unsubstituted, or (ii) substituted with
5 one or two substituents that are
independently selected from the group
consisting of alkyl, aryl, and heteroaryl,
or (iii) wherein the amino nitrogen and two
substituents attached thereto form a 5- to
10 8-membered heterocyclo or heteroaryl ring,
and an aminoalkyl group

wherein the aminoalkyl nitrogen is (i) unsubstituted,
or (ii) substituted with one or two substituents
independently selected from the group consisting of
15 an alkyl, aryl, aralkyl, cycloalkyl,
aralkoxycarbonyl, alkoxycarbonyl, and an alkanoyl
group, or (iii) wherein the aminoalkyl nitrogen and
two substituents attached thereto form a 5- to 8-
membered heterocyclo or heteroaryl ring.

20 In preferred practice, R^1 and R^2 together
with the atoms to which they are bonded form a
6-membered ring.

An R^3 radical preferably has a length that
is greater than that of a pentyl group [a $-(CH_2)_4CH_3$
25 chain] and more preferably greater than about that of
a hexyl group [a $-(CH_2)_5CH_3$ chain]. An R^3 radical
preferably has a length that is less than that of an
icosyl group [a $-(CH_2)_{19}CH_3$ chain], and more
preferably a length that is less than that of a
30 stearyl group [a $-(CH_2)_{17}CH_3$ chain]. A preferred R^3
group contains two or more 5- or 6-membered rings. A


-14-

contemplated R^3 group, when rotated about an axis drawn through the SO_2 -bonded 1-position and the substituent-bonded 4-position of a 6-membered ring or the SO_2 -bonded 1-position and substituent-bonded 3-
5 or 4-position of a 5-membered ring, defines a three-dimensional volume whose widest dimension has the width in a direction transverse to that axis to rotation of about one furanyl ring to about two phenyl rings.

10 It is also preferred that a R^3 radical be a single-ringed aryl or heteroaryl group that is 5- or 6-membered, and is itself substituted at its own 4-position when a 6-membered ring or at its own 3- or 4-position when a 5-membered ring with an optionally
15 substituted substituent selected from the group consisting of one other single-ringed aryl or heteroaryl group, a C_3 - C_{14} alkyl group, a N-piperidyl group, a N-piperazyl group, a phenoxy group, a thiophenoxy group, a 4-thiopyridyl group, a phenylazo
20 group and a benzamido group. The substituent of the 5- or 6-membered aryl or heteroaryl group can itself be substituted as discussed before.

A preferred compound for use in a contemplated process has a structure that corresponds to formula
25 II, below, or a pharmaceutically acceptable salt thereof:

-15-



wherein


- R^{14} is hydrido, a pharmaceutically acceptable cation or $C(W)R^{15}$ where W is O or S and R^{15} is selected from the group consisting of an C_1 - C_6 -alkyl, aryl, C_1 - C_6 -alkoxy, heteroaryl- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, aryloxy, ar- C_1 - C_6 -alkoxy, ar- C_1 - C_6 -alkyl, heteroaryl and amino C_1 - C_6 -alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two substituents independently selected from the group consisting of an C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, ar- C_1 - C_6 -alkoxycarbonyl, C_1 - C_6 -alkoxycarbonyl, and C_1 - C_6 -alkanoyl radical, or (iii) wherein the amino C_1 - C_6 -alkyl nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring;
- m is zero, 1 or 2;
 n is zero, 1 or 2;
 p is zero, 1 or 2;
 the sum of $m + n + p = 1, 2, 3$ or 4;
 (a) one of X, Y and Z is selected from the group consisting of $C(O)$, NR^6 , O, S, $S(O)$, $S(O)_2$ and

-16-


$\text{NS(O)}_2\text{R}^7$, and the remaining two of X, Y and Z are
 CR^8R^9 , and $\text{CR}^{10}\text{R}^{11}$, or

(b) X and Z or Z and Y together constitute
 a moiety that is selected from the group consisting
 5 of $\text{NR}^6\text{C(O)}$, $\text{NR}^6\text{S(O)}$, $\text{NR}^6\text{S(O)}_2$, NR^6S , NR^6O , SS , NR^6NR^6
 and OC(O) , with the remaining one of X, Y and Z being
 CR^8R^9 , or

(c) n is zero and X, Y and Z together
 constitute a moiety selected from the group
 10 consisting of



-17-



wherein wavy lines are bonds to the atoms of the depicted ring;

- 5 R⁶ and R^{6'} are independently selected from the group consisting of hydrido, C₁-C₆-alkanoyl, C₆-aryl-C₁-C₆-alkyl, aroyl, bis(C₁-C₆-alkoxy-C₁-C₆-alkyl)-C₁-C₆-alkyl, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-perfluoroalkyl, C₁-C₆-trifluoromethylalkyl, C₁-C₆-perfluoroalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₈-heterocycloalkyl, C₃-C₈-heterocycloalkylcarbonyl, C₆-aryl, C₅-C₆-heterocyclo, C₅-C₆-heteroaryl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₆-aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, C₆-arylsulfonyl, C₁-C₆-alkylsulfonyl, C₅-C₆-heteroarylsulfonyl, carboxy-C₁-C₆-alkyl, C₁-C₄-alkoxycarbonyl-C₁-C₆-alkyl, aminocarbonyl, C₁-C₆-alkyliminocarbonyl, C₆-

aryliminocarbonyl, C₅-C₆-heterocycloiminocarbonyl, C₆-arylthio-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl, C₆-arylthio-C₃-C₆-alkenyl, C₁-C₄-alkylthio-C₃-C₆-alkenyl, C₅-C₆-heteroaryl-C₁-C₆-alkyl, halo-C₁-C₆-alkanoyl, hydroxy-C₁-C₆-alkanoyl, thiol-C₁-C₆-alkanoyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₅-alkoxycarbonyl, aryloxycarbonyl, NR⁸R⁹-C₁-C₅-alkylcarbonyl, hydroxy-C₁-C₅-alkyl, an aminocarbonyl wherein the aminocarbonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group, hydroxyaminocarbonyl, an aminosulfonyl group wherein the aminosulfonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group, an amino-C₁-C₆-alkylsulfonyl group wherein the amino-C₁-C₆-alkylsulfonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group;

R^7 is selected from the group consisting of a arylalkyl, aryl, heteroaryl, heterocyclo, C_1 - C_6 -alkyl, C_3 - C_6 -alkynyl, C_3 - C_6 -alkenyl, C_1 - C_6 -carboxyalkyl and a C_1 - C_6 -hydroxyalkyl group;

- 5 R^8 and R^9 and R^{10} and R^{11} are independently selected from the group consisting of a hydrido, hydroxy, C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl, heteroaryl, heteroar- C_1 - C_6 -alkyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyl, thiol- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -
- 10 alkyl cycloalkyl, cycloalkyl- C_1 - C_6 -alkyl, heterocycloalkyl- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, aralkoxy- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, hydroxy- C_1 - C_6 -alkyl, hydroxycarbonyl- C_1 - C_6 -alkyl, hydroxycarbonylar- C_1 - C_6 -
- 15 alkyl, aminocarbonyl- C_1 - C_6 -alkyl, aryloxy- C_1 - C_6 -alkyl, heteroaryloxy- C_1 - C_6 -alkyl, arylthio- C_1 - C_6 -alkyl, heteroarylthio- C_1 - C_6 -alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro- C_1 - C_6 -alkyl, trifluoromethyl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -
- 20 alkyl, alkoxycarbonylamino- C_1 - C_6 -alkyl and an amino- C_1 - C_6 -alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C_1 - C_6 -alkyl, ar- C_1 - C_6 -alkyl, cycloalkyl
- 25 and C_1 - C_6 -alkanoyl, or wherein R^8 and R^9 or R^{10} and R^{11} and the carbon to which they are bonded form a carbonyl group, or wherein R^8 and R^9 or R^{10} and R^{11} , or R^8 and R^{10} together with the atoms to which they

are bonded form a 5- to 8-membered carbocyclic ring, or a 5- to 8-membered heterocyclic ring containing one or two heteroatoms that are nitrogen, oxygen, or sulfur, with the proviso that only one of R⁸ and R⁹
5 or R¹⁰ and R¹¹ is hydroxy;

R¹² and R^{12'} are independently selected from the group consisting of a hydrido, C₁-C₆-alkyl, aryl, ar-C₁-C₆-alkyl, heteroaryl, heteroaralkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl,
10 cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, amino-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-alkyl,
15 aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro-C₁-C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxycarbonylamino-C₁-C₆-alkyl and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl,
20 ar-C₁-C₆-alkyl, cycloalkyl and C₁-C₆-alkanoyl;

R¹³ is selected from the group consisting of a hydrido, benzyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group; and

G-A-R-E-Y is a substituent that preferably has a length greater than that of a pentyl group, and more preferably has a length greater than that of a hexyl group. The substituent G-A-R-E-Y preferably has a length that is less than that of an icosyl group, and is more preferably less than that of a stearyl group. In this substituent:

G is an aryl or heteroaryl group;

A is selected from the group consisting of

- (1) -O-;
- (2) -S-;
- (3) -NR¹⁷-;
- (4) -CO-N(R¹⁷) or -N(R¹⁷)-CO-, wherein R¹⁷ is hydrogen, C₁-C₄-alkyl, or phenyl;
- (5) -CO-O- or -O-CO-;
- (6) -O-CO-O-;
- (7) -HC=CH-;
- (8) -NH-CO-NH-;
- (9) -C≡C-;
- (10) -NH-CO-O- or -O-CO-NH-;
- (11) -N=N-;
- (12) -NH-NH-; and
- (13) -CS-N(R¹⁸)- or -N(R¹⁸)-CS-, wherein R¹⁸ is hydrogen C₁-C₄-alkyl, or phenyl; or
- (14) A is absent and G is bonded directly to R;

R is a moiety selected from the group consisting of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aralkyl, heteroaralkyl,

-22-

heterocycloalkylalkyl, cycloalkylalkyl,
cycloalkoxyalkyl, heterocycloalkoxyalkyl,
aryloxyalkyl, heteroaryloxyalkyl, arylthioalkyl,
heteroarylthioalkyl, cycloalkylthioalkyl, and a
5 heterocycloalkylthioalkyl group wherein the aryl or
heteroaryl or cycloalkyl or heterocycloalkyl
substituent is (i) unsubstituted or (ii) substituted
with one or two radicals selected from the group
consisting of a halo, alkyl, perfluoroalkyl,
10 perfluoroalkoxy, perfluoroalkylthio,
trifluoromethylalkyl, amino, alkoxycarbonylalkyl,
alkoxy, C₁-C₂-alkylene-dioxy, hydroxycarbonylalkyl,
hydroxycarbonylalkylamino, nitro, hydroxy,
hydroxyalkyl, alkanoylamino, and a alkoxycarbonyl
15 group, and R is other than alkyl or alkoxyalkyl when
A is -O- or -S-;

E is selected from the group consisting of


- (1) -CO(R¹⁹)- or -(R¹⁹)CO-, wherein R¹⁹ is
a heterocycloalkyl, or a cycloalkyl
20 group;
- (2) -CONH- or -HNCO-; and
- (3) -CO-;
- (4) -SO₂-R¹⁹- or -R¹⁹-SO₂-;
- (5) -SO₂-;
- 25 (6) -NH-SO₂- or -SO₂-NH-; or
- (7) E is absent and R is bonded directly
to Y; and

Y is absent or is selected from the group
consisting of a hydrido, alkyl, alkoxy, haloalkyl,
30 aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy,

-23-

aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl, alkenyl, heterocycloalkyl, cycloalkyl, trifluoromethyl, alkoxycarbonyl, and a
 5 aminoalkyl group, wherein the aryl or heteroaryl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl, halo, nitro, aralkyl, aryl, alkoxy, and an amino
 10 group wherein the amino nitrogen is (i) unsubstituted or (ii) substituted with one or two groups independently selected from hydrido, alkyl, and an aralkyl group.

A particularly preferred compound for use
 15 in a contemplated process corresponds in structure to formula III, below, or a pharmaceutically acceptable salt thereof:



20

wherein


m, n, p, X, Z, Y and R¹⁴ are as defined above for formula II, and the R³ radical that is defined

below is a sub-set of the previously discussed G-A-R-E-Y substituents.

Thus, R³ is a radical that is comprised of a single-ringed aryl or heteroaryl group that is 5- or 6-membered, and is itself substituted at its own 4-position when a 6-membered ring and at its own 3- or 4-position when a 5-membered ring with a substituent selected from the group consisting of a thiophenoxy, 4-chlorophenoxy, 3-chlorophenoxy, 4-methoxyphenoxy, 3-benzodioxol-5-yloxy, 3,4-dimethylphenoxy, 4-fluorophenoxy, 4-fluorothiophenoxy, phenoxy, 4-trifluoromethoxy-phenoxy, 4-trifluoromethylphenoxy, 4-(trifluoromethylthio)-phenoxy, 4-(trifluoromethylthio)-thiophenoxy, 4-chloro-3-fluorophenoxy, 4-isopropoxyphenoxy, 4-isopropylphenoxy, (2-methyl-1,3-benzothiazol-5-yl)oxy, 4-(1H-imidazol-1-yl)phenoxy, 4-chloro-3-methylphenoxy, 3-methylphenoxy, 4-ethoxyphenoxy, 3,4-difluorophenoxy, 4-chloro-3-methylphenoxy, 4-fluoro-3-chlorophenoxy, 4-(1H-1,2,4-triazol-1-yl)phenoxy, 3,5-difluorophenoxy, 3,4-dichlorophenoxy, 4-cyclopentylphenoxy, 4-bromo-3-methylphenoxy, 4-bromophenoxy, 4-methylthiophenoxy, 4-phenylphenoxy, 4-benzylphenoxy, 6-quinolinylloxy, 4-amino-3-methylphenoxy, 3-methoxyphenoxy, 5,6,7,8-tetrahydro-2-naphthalenyloxy, 3-hydroxymethylphenoxy, N-piperidyl, N-piperazinyl and a 4-benzyloxyphenoxy group.

A more particularly preferred compound for use in a contemplated process has a structure that corresponds to formula IV, below, or a pharmaceutically acceptable salt thereof:

-25-



wherein R^3 is as defined above for formula I,
 5 more preferably as defined for formula II (wherein
 this R^3 group is the G-A-R-E-Y substituent), and more
 preferably still as defined for formula III, and

Z is selected group the group consisting of O,
 S, NR^6 , SO, SO_2 , and NSO_2R^7 ,


10 wherein R^6 is selected from the group consisting
 of hydrido, C_1 - C_5 -alkyl, C_1 - C_5 -alkanoyl, benzyl,
 benzoyl, C_3 - C_5 -alkynyl, C_3 - C_5 -alkenyl, C_1 - C_3 -alkoxy-
 C_1 - C_4 -alkyl, C_3 - C_6 -cycloalkyl, heteroaryl- C_1 - C_6 -
 alkyl, C_1 - C_5 -hydroxyalkyl, C_1 - C_5 -carboxyalkyl, C_1 - C_5 -
 15 alkoxy C_1 - C_5 -alkylcarbonyl, and NR^8R^9 - C_1 - C_5 -
 alkylcarbonyl or NR^8R^9 - C_1 - C_5 -alkyl wherein R^8 and R^9
 are independently hydrido, C_1 - C_5 -alkyl, C_1 - C_5 -
 alkoxycarbonyl or aryl- C_1 - C_5 -alkoxycarbonyl, or NR^8R^9
 together form a heterocyclic ring containing 5- to 8-
 20 atoms in the ring; and

R^7 is selected from the group consisting of an
 arylalkyl, aryl, heteroaryl, heterocyclo, C_1 - C_6 -

-26-

alkyl, C₃-C₆-alkynyl, C₃-C₆-alkenyl, C₁-C₆-carboxyalkyl and a C₁-C₆-hydroxyalkyl group.

A still more preferred group of compounds for use in a contemplated process correspond in structure to formula V, below, or a pharmaceutically acceptable salt thereof:



10

wherein

Z is as previously defined in formula IV;

W and Q are independently oxygen (O), NR⁶ or sulfur (S), and R⁶ is as defined in formula IV; and

q is zero or one such that when q is zero, the trifluoromethyl group is bonded directly to the depicted phenyl ring.

15

The use of a compound of formulas I-V, or a pharmaceutically acceptable salt of one of those compounds is contemplated in a before-described process. In addition, the compounds of formulas II, III, IV and V, and their pharmaceutically acceptable salts are contemplated compounds of this invention.


20

The present invention also contemplates a precursor or intermediate compound that is useful in preparing a compound of formulas I-V. Such an

25

-27-


intermediate compound corresponds in structure to formula VI, below:



VI


5

wherein m, n, p, X, Z and Y are as defined above for formula II, g is zero, 1 or 2 and R²⁴ is R³ as defined in formulas I, III or IV, is the
 10 substituent G-A-R-E-Y of formula II (formula VIA) or is R^{3'}, an aryl or heteroaryl group that is substituted with a coupling substituent reactive for coupling with another moiety (formula VIB), such as a nucleophilically displaceable leaving group, D.



VIA

15



VIB

Exemplary nucleophilically displaceable leaving groups, D, include a halo (fluoro, chloro, bromo, or iodo) nitro, azido, phenylsulfoxido,


-28-

aryloxy, C_1 - C_6 -alkoxy, a C_1 - C_6 -alkylsulfonate or arylsulfonate group and a trisubstituted ammonium group in which the three substituents are independently aryl, ar- C_1 - C_6 -alkyl or C_1 - C_6 -alkyl.

- 5 R^{20} is (a) $-O-R^{21}$, where R^{21} is selected from the group consisting of a hydrido, C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl group and a pharmaceutically acceptable cation, or (b) $-NH-O-R^{22}$ wherein R^{22} is a selectively removable protecting group such as a 2-
 10 tetrahydropyranyl, C_1 - C_6 -acyl, aroyl, benzyl, p-methoxybenzyloxycarbonyl (MOZ), benzyloxycarbonyl, C_1 - C_6 -alkoxycarbonyl, C_1 - C_6 -alkoxy- CH_2 -, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy- CH_2 -, trisubstituted silyl group or o-nitrophenyl group, peptide synthesis resin and
 15 the like. Trisubstituted silyl group is substituted with C_1 - C_6 -alkyl, aryl, or ar- C_1 - C_6 -alkyl.

A particularly preferred precursor intermediate to an intermediate compound of formula VI is an intermediate compound of formula VII

20



VII

wherein m , n , p , g , X , Z , Y , D and R^{20} are as defined above for formula VI.

-29-

Among the several benefits and advantages of the present invention are the provision of compounds and compositions effective as inhibitors of matrix metalloproteinase activity, the provision of
5 such compounds and compositions that are effective for the inhibition of metalloproteinases implicated in diseases and disorders involving uncontrolled breakdown of connective tissue.

More particularly, a benefit of this
10 invention is the provision of a compound and composition effective for selectively inhibiting certain metalloproteinases, such as one or more of MMP-2, MMP-9 and MMP-13, associated with pathological conditions such as, for example, rheumatoid
15 arthritis, osteoarthritis, septic arthritis, corneal, epidermal or gastric ulceration, tumor metastasis, invasion or angiogenesis, periodontal disease, proteinuria, Alzheimer's Disease, coronary thrombosis and bone disease.

20 An advantage of the invention is the provision of compounds, compositions and methods effective for treating such pathological conditions by selective inhibition of a metalloproteinase such as MMP-2, MMP-9 or MMP-13 associated with such
25 conditions with minimal side effects resulting from inhibition of other metalloproteinases, such as MMP-1, whose activity is necessary or desirable for normal body function.

Yet another advantage of the invention is
30 the provision of a process for preparing such compounds.

Another benefit is the provision of a method for treating a pathological condition

-30-

associated with abnormal matrix metalloproteinase activity.

A further advantage of the invention is the provision of a process for preparing such
5 compositions.

Still further benefits and advantages of the invention will be apparent to the skilled worker from the disclosure that follows.

10 Detailed Description of the Invention

In accordance with the present invention, it has been discovered that certain aromatic sulfone hydroxamic acids (hydroxamates) are effective for inhibition of matrix metalloproteinases ("MMPs")
15 believed to be associated with uncontrolled or otherwise pathological breakdown of connective tissue. In particular, it has been found that these certain aromatic sulfone hydroxamates are effective for inhibition of one or more enzymes such as MMP-2,
20 MMP-9 and MMP-13, which can be particularly destructive to tissue if present or generated in abnormal quantities or concentrations, and thus exhibit a pathological activity. Included in that pathological activity is the assistance of tumors and
25 tumor cells in the process of penetrating basement membrane, and developing a new or improved blood supply; i.e., angiogenesis.

Moreover, it has been discovered that these aromatic sulfone hydroxamates are selective in the
30 inhibition of one or more of MMP-2, MMP-9 and MMP-13 without excessive inhibition of other collagenases essential to normal bodily function such as tissue turnover and repair. More particularly, it has been

found that a contemplated aromatic sulfone hydroxamate of the invention, or a pharmaceutically acceptable salt thereof, is particularly active in inhibiting of one or more of MMP-2, MMP-9 and MMP-13 in an *in vitro* assay that is predictive of *in vivo* activity. In addition, while being selective for one or more of MMP-2, MMP-9 and MMP-13, a contemplated aromatic sulfone hydroxamate, or its salt, has a limited or minimal *in vitro* inhibitory effect on MMP-1.

There is thus a substantial difference in the activity of a compound used in a contemplated process toward one or more of MMP-2, MMP-9 and MMP-13 and MMP-1. This substantial difference is assayed using the *in vitro* inhibition assay discussed in the examples. A substantial difference in activity corresponds to a compound exhibiting an IC_{50} value against one or more of MMP-2, MMP-9 and MMP-13 that is about 0.1 times that of the compound against MMP-1, and more preferably 0.01 times that against MMP-1, and most preferably 0.001 times that against MMP-1, or more. Indeed, some compounds exhibit selectivity differences measured by IC_{50} values that exceed the bounds of the assay at the number 100,000-fold. These selectivities are illustrated in the Inhibition Tables hereinafter.

Put differently, a contemplated compound can inhibit the activity of MMP-2 compared to MMP-9 or MMP-13 and MMP-1. Similarly, a contemplated compound can inhibit the activity of MMP-13 and MMP-2, while exhibiting less inhibition against MMP-1 and MMP-9. In addition, a contemplated compound can inhibit the

-32-

activity of a MMP enzyme, while having less of an effect on tumor necrosis factor release.

The advantages of the selectivity of a contemplated compound can be appreciated, without
5 wishing to be bound by theory, by considering the therapeutic uses the compounds. For example, inhibition of MMP-1 is suggested to be undesirable due to its role as a housekeeping enzyme, helping to maintain normal connective tissue turnover and
10 repair. Inhibition of MMP-1 can lead to toxicities or side effects such as such as joint or connective tissue deterioration and pain. On the other hand, MMP-13 has been suggested to be intimately involved in the destruction of joint components in diseases
15 such as osteoarthritis. Thus, potent and selective inhibition of MMP-13 compared with inhibition MMP-1 is highly desirable because a MMP-13 inhibitor can have a positive effect on disease progression in a patient in addition to having an anti-inflammatory
20 effect.

Inhibition of MMP-2 and MMP-9 can be desirable for inhibition of tumor growth, metastasis, invasion and/or angiogenesis. A profile of selective inhibition of MMP-2 and MMP-9 relative to MMP-1 can
25 provide a therapeutic advantage.

Yet another advantage of a contemplated compound is the selectivity with respect to tumor necrosis factor release and/or tumor necrosis factor receptor release that provides the physician with another
30 factor to help select the best drug for a particular patient. While not wishing to be bound by theory, it is believed that there are several factors to this type of selectivity to be considered.


-33-

The first is that presence of tumor necrosis factor can be desirable for the control of cancer in the organism, so long as TNF is not present in a toxic excess. Thus, uncontrolled inhibition of
5 release of TNF can be counterproductive and actually can be considered an adverse side effect even in cancer patients. In addition, selectivity with respect to inhibition of the release of the tumor necrosis factor receptor can also be desirable. The
10 presence of that receptor can be desirable for maintaining a controlled tumor necrosis level in the mammal by binding excess TNF.

A contemplated selective MMP inhibitor compound useful in a contemplated process can be administered
15 to by various routes and provide adequate therapeutic blood levels of enzymatically active inhibitor. A compound can be administered, for example, by the oral (IG, PO) or intravenous (IV) routes. Oral administration is advantageous if the patient is
20 ambulatory, not hospitalized, physically able and sufficiently responsible to take drug at the required intervals. This is true even if the person is being treated with more than one drug for one or more diseases. On the other hand, IV drug administration
25 is an advantage in a hospital setting wherein the dose and thus the blood levels can well controlled. A contemplated inhibitor can also be formulated for IM administration if desired. This route of administration can be desirable for the
30 administration of prodrugs or regular drug delivery to patients that are either physically weak or have a poor compliance record or require constant drug blood levels.

-34-

Thus, in one embodiment, the present invention is directed to a treatment process that comprises administering a contemplated aromatic sulfone hydroxamic acid metalloprotease inhibitor, or a
5 pharmaceutically acceptable salt thereof, in an effective amount to a host mammal having a condition associated with pathological matrix metalloprotease activity. A contemplated aromatic sulfone hydroxamate inhibitor compound useful in such a
10 process inhibits the activity of one or more of MMP-2, MMP-9 and MMP-13, and exhibits substantially less inhibitory activity against at least MMP-1 in the in vitro assay noted above and discussed in detail hereinbelow. An aromatic sulfone hydroxamate
15 inhibitor compound for use in a contemplated process corresponds in structure to formula I, below:



I

wherein

20

In one embodiment, R¹ and R² are both hydrido. In another embodiment, R¹ and R² together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two or three
25 heteroatoms in the ring that are oxygen, sulfur or nitrogen.

It is preferred that R¹ and R² together with the atoms to which they are bonded form a five- to eight-

membered ring that contains one or two heteroatoms in the ring, although R^1 and R^2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two or three heteroatoms. The
5 heterocyclic ring can itself also be substituted with up to six C_1 - C_6 -alkyl groups or groups that comprise a another 5- to 8-membered carbocyclic or heterocyclic ring, an amino group, or contain one or two oxo (carbonyl) groups.

10 R^3 in formula I is an optionally substituted aryl or optionally substituted heteroaryl radical. That R^3 radical is selected from the group consisting of an aryl, heteroaryl, aralkyl, heteroaralkyl, aralkoxy, heteroaralkoxy, aralkoxyalkyl,
15 aryloxyalkyl, aralkanoylalkyl, arylcarbonylalkyl, aralkylaryl, aryloxyalkylaryl, aralkoxyaryl, arylazoaryl, arylhydrazinoaryl, alkylthioaryl, arylthioalkyl, alkylthioaralkyl, aralkylthioalkyl, an aralkylthioaryl radical, the sulfoxide or sulfone of
20 any of the thio substituents, and a fused ring structure comprising two or more 5- or 6-membered rings selected from the group consisting of aryl, heteroaryl, carbocyclic and heterocyclic.

The substituent of which R^3 is comprised itself
25 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of a cyano, perfluoroalkyl, trifluoromethylalkyl, hydroxy, halo, alkyl, alkoxy, nitro, thiol, hydroxycarbonyl, aryloxy, arylthio,
30 aralkyl, aryl, heteroaryloxy, heteroarylthio, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy,

-36-

cycloalkylthio, heteroaralkoxy, heteroaralkylthio, aralkoxy, aralkylthio, aralkylamino, heterocyclo, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxy carbonylalkoxy, alkanoyl, arylcarbonyl, 5 aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxy carbonyl, aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, 10 hydroxycarbonylalkylthio, alkoxy carbonylalkoxy, alkoxy carbonylalkylthio, amino,

wherein the amino nitrogen is (i) unsubstituted, or (ii) substituted with one or two substituents that are independently selected from the group 15 consisting of an alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxy carbonyl, arylcarbonyl, aralkanoyl, heteroarylcarbonyl, heteroaralkanoyl and an alkanoyl group, or (iii) wherein the amino 20 nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring containing zero to two additional heteroatoms that are nitrogen, oxygen or sulfur and which ring itself is (a) 25 unsubstituted or (b) substituted with one or two groups independently selected from the group consisting of an aryl, alkyl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, alkanoyl, cycloalkyl, heterocycloalkyl, 30 alkoxy carbonyl, hydroxyalkyl, trifluoromethyl, benzofused heterocycloalkyl, hydroxyalkoxyalkyl, aralkoxycarbonyl, hydroxycarbonyl, aryloxy carbonyl, benzofused heterocycloalkoxy,

benzofused cycloalkylcarbonyl, heterocycloalkylcarbonyl, and a cycloalkylcarbonyl group, carbonylamino

wherein the carboxamido nitrogen is (i)
5 unsubstituted, or (ii) is the reacted amine of an amino acid, or (iii) substituted with one or two radicals selected from the group consisting of an alkyl, hydroxyalkyl, hydroxyheteroaralkyl, cycloalkyl, aralkyl, trifluoromethylalkyl,
10 heterocycloalkyl, benzofused heterocycloalkyl, benzofused heterocycloalkyl, and an N,N-dialkylsubstituted alkylamino-alkyl group, or (iv) the carboxamido nitrogen and two substituents bonded thereto
15 together form a 5- to 8-membered heterocyclo, heteroaryl or benzofused heterocycloalkyl ring that is itself unsubstituted or substituted with one or two radicals independently selected from the group consisting of an alkyl,
20 alkoxy carbonyl, nitro, heterocycloalkyl, hydroxy, hydroxycarbonyl, aryl, aralkyl, heteroaralkyl and an amino group,

wherein the amino nitrogen is
(i) unsubstituted, or (ii) substituted with
25 one or two substituents that are independently selected from the group consisting of alkyl, aryl, and heteroaryl, or (iii) wherein the amino nitrogen and two substituents attached thereto form a 5- to
30 8-membered heterocyclo or heteroaryl ring, and an aminoalkyl group

wherein the aminoalkyl nitrogen is (i) unsubstituted, or (ii) substituted with one or two substituents independently selected from the group consisting of an alkyl, aryl, aralkyl, cycloalkyl, 5 aralkoxycarbonyl, alkoxycarbonyl, and an alkanoyl group, or (iii) wherein the aminoalkyl nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring. A compound of formula I can also be used in the form of a 10 pharmaceutically acceptable salt.

The R^3 radical has a length that is greater than that of a pentyl group [a $-(CH_2)_4CH_3$ chain], and is more preferably greater than about the length of a hexyl group [a $-(CH_2)_5CH_3$ chain]. A R^3 group has a 15 length that is less than that of an icosyl group [eicosyl; a $-(CH_2)_{19}CH_3$ chain], and more preferably, a length that is less than that of a stearyl group [a $-(CH_2)_{17}CH_3$ chain]. When rotated about an axis drawn through the SO_2 -bonded 1-position and the 20 substituent-bonded 4-position of a 6-membered ring or the SO_2 -bonded 1-position and substituent-bonded 3- or 4-position of a 5-membered ring, a contemplated R^3 radical defines a three-dimensional volume whose widest dimension has the width of about one furanyl 25 ring to about two phenyl rings in a direction transverse to that axis to rotation.

Where the SO_2 -linked R^3 radical is 4-phenoxyphenyl for purposes of illustration, a contemplated compound can be viewed as a 30 phenoxyphenylsulfone derivative of the desired 5- to

8-membered ring N-hydroxycarboxamide. Exemplary compounds can therefore be named:

N-hydroxy-1-methyl-[4-(phenoxyphenylsulfonyl)]-4-piperidinecarboxamide,

5 N-hydroxy-[4-(phenoxyphenylsulfonyl)]tetrahydro-2H-pyran-4-carboxamide,

N-hydroxy-1-methyl-[2,6-dioxo-4-(phenoxyphenylsulfonyl)]-4-piperidinecarboxamide,

10 N-hydroxy-2,2-dimethyl-[5-(phenoxyphenylsulfonyl)]-1,3-dioxane-5-carboxamide,

N-hydroxy-1,2-dimethyl-6-oxo-[4-(phenoxyphenylsulfonyl)]-4-piperidinecarboxamide,

N-hydroxy-2,2,6,6-tetramethyl-[4-(phenoxyphenylsulfonyl)]-4-piperidinecarboxamide,

15 N-hydroxy-1,3-dimethyl-[5-(phenoxyphenylsulfonyl)]-hexahydro-5-pyrimidinecarboxamide,

2-amino-N-hydroxy-[5-(phenoxyphenylsulfonyl)]-1,4,5,6-tetrahydro-5-pyrimidinecarboxamide,

20 N-hydroxy-1,1-dioxo-[4-(phenoxyphenylsulfonyl)]-1(λ 6),2,6-thiadizine-4-carboxamide,

N-hydroxy-2-oxo-[5-(phenoxyphenylsulfonyl)]-hexahydro-5-pyrimidinecarboxamide,

N-hydroxy-[2-(phenoxyphenylsulfonyl)]tetrahydro-2-furancarboxamide,

25 N-hydroxy-1-methyl-[2-(phenoxyphenylsulfonyl)]-2-pyrrolidinecarboxamide,

N-hydroxy-2-methyl-[4-(phenoxyphenylsulfonyl)]-4-piperidinecarboxamide,

30 N-hydroxy-[3-(phenoxyphenylsulfonyl)]-8-azabicyclo[3.2.1]octane-3-carboxamide,

N-hydroxy-1,1-dioxo-[4-(phenoxyphenylsulfonyl)]-hexahydro-1(λ 6)-thiopyran-4-carboxamide,

N-hydroxy- [3- (phenoxyphenylsulfonyl)] tetrahydro-
3-furancarboxamide,

N-hydroxy- [3- (phenoxyphenylsulfonyl)] -3-
pyrrolidinecarboxamide,

5 N-hydroxy-4- [[4- (phenylthio)phenyl] sulfonyl] -1-
(2-propynyl) -4-piperidinecarboxamide,
monohydrochloride,

N-hydroxy-4- [[4- (phenylthio)phenyl] sulfonyl] -1-
(2-propynyl) -4-piperidinecarboxamide,
10 monomethanesulfonate,

tetrahydro-N-hydroxy-4- [[4- [4-
[(trifluoromethyl)phenoxy]phenyl] -sulfonyl] -2H-pyran-
4-carboxamide,

N-hydroxy-1- (4-pyridinylmethyl) -4- [[4- [4-
15 (trifluoromethyl)phenoxy]phenyl] -sulfonyl] -4-
piperidinecarboxamide, hydrochloride,

N-hydroxy-1- (3-pyridinylmethyl) -4- [[4- [4-
trifluoromethyl)phenoxy]phenyl] -sulfonyl] -4-
piperidinecarboxamide, dihydrochloride,

20 N-hydroxy-1- (2-pyridinylmethyl) -4- [[4- [4-
(trifluoromethyl)phenoxy]phenyl] -sulfonyl] -4-
piperidinecarboxamide, dihydrochloride,

hydroxy-1- (3-pyridinylmethyl) -4- [[4- [4-
(trifluoromethoxy)phenoxy]phenyl] -sulfonyl] -4-
25 piperidinecarboxamide, dihydrochloride,

N-hydroxy-1- (2-methoxyethyl) -4- [[4- [4-
(trifluoromethoxy)phenoxy]phenyl] sulfonyl] -4-
piperidinecarboxamide, monohydrochloride,

N-hydroxy-1- (2-methoxyethyl) -4- [[4- [4-
30 (trifluoromethyl)phenoxy]phenyl] sulfonyl] -4-
piperidinecarboxamide, monohydrochloride,

-41-


N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-
 [(trifluoromethyl)thio]phenoxy]phenyl]sulfonyl]-4-
 piperidinecarboxamide, monohydrochloride,

1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoro-
 5 methyl)phenoxy]phenyl]sulfonyl]-4-piperidine-
 carboxamide, monohydrochloride, and the like.

Several exemplary R^1 and R^2 groups that together
 form a contemplated heterocyclic ring are shown in
 the Tables that follow hereinafter, as well as in the
 10 descriptions of those 5- to 8-membered rings and the
 specific Examples, as are several contemplated
 aromatic sulfone hydroxamic acid compounds.

In more preferred practice, R^1 and R^2 of formula
 I together with the atom to which they are bonded
 15 form a 5- to 8-membered ring that contains one, two
 or three heteroatoms. Most preferably, that ring is
 a 6-membered ring that contains one heteroatom
 located at the 4-position relative to the position at
 which the SO_2 group is bonded. Other preferred
 20 compounds for use in a contemplated process
 correspond in structure to one or more of formulas
 II, III, IV or V, which are discussed hereinafter.

In one embodiment, a preferred compound used in
 a contemplated process has a structure that
 25 corresponds to formula II, below:



wherein

R^{14} is hydrido, a pharmaceutically acceptable cation or $C(W)R^{15}$ where W is O or S and
 5 R^{15} is selected from the group consisting of an C_1 - C_6 -alkyl, aryl, C_1 - C_6 -alkoxy, heteroaryl- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, aryloxy, ar- C_1 - C_6 -alkoxy, ar- C_1 - C_6 -alkyl, heteroaryl and amino C_1 - C_6 -alkyl group wherein the aminoalkyl nitrogen is (i)
 10 unsubstituted or (ii) substituted with one or two substituents independently selected from the group consisting of an C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, ar- C_1 - C_6 -alkoxycarbonyl, C_1 - C_6 -alkoxycarbonyl, and C_1 - C_6 -
 15 alkanoyl radical, or (iii) wherein the amino C_1 - C_6 -alkyl nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or heteroaryl ring;

m is zero, 1 or 2;

20 n is zero, 1 or 2;

p is zero, 1 or 2;

the sum of $m + n + p = 1, 2, 3$ or 4;


(a) one of X, Y and Z is selected from the group consisting of $C(O)$, NR^6 , O, S, $S(O)$, $S(O)_2$ and
 25 $NS(O)_2R^7$, and the remaining two of X, Y and Z are CR^8R^9 , and $CR^{10}R^{11}$, or

(b) X and Z or Z and Y together constitute a moiety that is selected from the group consisting of $NR^6C(O)$, $NR^6S(O)$, $NR^6S(O)_2$, NR^6S , NR^6O , SS, NR^6NR^6

-43-

and OC(O), with the remaining one of X, Y and Z being CR⁸R⁹, or

(c) n is zero and X, Y and Z together constitute a moiety selected from the group
5 consisting of



wherein wavy lines are bonds to the atoms of the
10 depicted ring;

-44-

R^6 and $R^{6'}$ are independently selected from the group consisting of hydrido, C_1 - C_6 -alkanoyl, C_6 -aryl- C_1 - C_6 -alkyl, aroyl, bis(C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl)- C_1 - C_6 -alkyl, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -perfluoroalkyl, C_1 - C_6 -trifluoromethylalkyl, C_1 - C_6 -perfluoroalkoxy- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_8 -heterocycloalkyl, C_3 - C_8 -heterocycloalkylcarbonyl, C_6 -aryl, C_5 - C_6 -heterocyclo, C_5 - C_6 -heteroaryl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, C_6 -aryloxy- C_1 - C_6 -alkyl, heteroaryloxy- C_1 - C_6 -alkyl, heteroaryl- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, heteroarylthio- C_1 - C_6 -alkyl, C_6 -arylsulfonyl, C_1 - C_6 -alkylsulfonyl, C_5 - C_6 -heteroarylsulfonyl, carboxy- C_1 - C_6 -alkyl, C_1 - C_4 -alkoxycarbonyl- C_1 - C_6 -alkyl, aminocarbonyl, C_1 - C_6 -alkyliminocarbonyl, C_6 -aryliminocarbonyl, C_5 - C_6 -heterocycloiminocarbonyl, C_6 -arylthio- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl, C_6 -arylthio- C_3 - C_6 -alkenyl, C_1 - C_4 -alkylthio- C_3 - C_6 -alkenyl, C_5 - C_6 -heteroaryl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkanoyl, hydroxy- C_1 - C_6 -alkanoyl, thiol- C_1 - C_6 -alkanoyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl, C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, C_1 - C_5 -alkoxycarbonyl, aryloxycarbonyl, NR^8R^9 - C_1 - C_5 -alkylcarbonyl, hydroxy- C_1 - C_5 -alkyl, an aminocarbonyl wherein the aminocarbonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C_1 - C_6 -alkyl, ar- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl and a C_1 - C_6 -alkanoyl group,

hydroxyaminocarbonyl, an aminosulfonyl group wherein the aminosulfonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group, an amino-C₁-C₆-alkylsulfonyl group wherein the amino-C₁-C₆-alkylsulfonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group;

R⁷ is selected from the group consisting of a benzyl, phenyl, C₁-C₆-alkyl, C₃-C₆-alkynyl, C₃-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group;

R⁸ and R⁹ and R¹⁰ and R¹¹ are independently selected from the group consisting of a hydrido, hydroxy, C₁-C₆-alkyl, aryl, ar-C₁-C₆-alkyl, heteroaryl, heteroar-C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aralkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-

-46-

alkyl, aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro-C₁-C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxy-carbonylamino-C₁-C₆-alkyl and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, cycloalkyl and C₁-C₆-alkanoyl, or wherein R⁸ and R⁹ or R¹⁰ and R¹¹ and the carbon to which they are bonded form a carbonyl group, or wherein R⁸ and R⁹ or R¹⁰ and R¹¹, or R⁸ and R¹⁰ together with the atoms to which they are bonded form a 5- to 8-membered carbocyclic ring, or a 5- to 8-membered heterocyclic ring containing one or two heteroatoms that are nitrogen, oxygen, or sulfur, with the proviso that only one of R⁸ and R⁹ or R¹⁰ and R¹¹ is hydroxy;

R¹² and R^{12'} are independently selected from the group consisting of a hydrido, C₁-C₆-alkyl, aryl, ar-C₁-C₆-alkyl, heteroaryl, heteroaralkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl, cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, amino-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-alkyl,

aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl,
heteroaryloxy-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-
alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-
alkyl, the sulfoxide or sulfone of any said thio
5 substituents, perfluoro-C₁-C₆-alkyl, trifluoromethyl-
C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxycarbonylamino-
C₁-C₆-alkyl and an amino-C₁-C₆-alkyl group wherein
the aminoalkyl nitrogen is (i) unsubstituted or (ii)
substituted with one or two radicals independently
10 selected from the group consisting of C₁-C₆-alkyl,
ar-C₁-C₆-alkyl, cycloalkyl and C₁-C₆-alkanoyl;

R¹³ is selected from the group consisting of a
hydrido, benzyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkynyl,
C₂-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group; and

15 G-A-R-E-Y is a substituent that preferably has a
length greater than that of a pentyl group, and more
preferably has a length greater than that of a hexyl
group. The substituent G-A-R-E-Y preferably has a
length that is less than that of an icosyl group, and
20 is more preferably less than that of a stearyl group.
In this substituent:

G is an aryl or heteroaryl group;

A is selected from the group consisting of

- 25 (1) -O-;
- (2) -S-;
- (3) -NR¹⁷-;
- (4) -CO-N(R¹⁷) or -N(R¹⁷)-CO-, wherein R¹⁷
is hydrogen, C₁-C₄-alkyl, or phenyl;
- (5) -CO-O- or -O-CO-;

-48-

- (6) -O-CO-O-;
- (7) -HC=CH-;
- (8) -NH-CO-NH-;
- (9) -C≡C-;
- 5 (10) -NH-CO-O- or -O-CO-NH-;
- (11) -N=N-;
- (12) -NH-NH-; and
- (13) -CS-N(R¹⁸)- or -N(R¹⁸)-CS-, wherein
 R¹⁸ is hydrogen C₁-C₄-alkyl, or
 10 phenyl; or
- (14) A is absent and G is bonded directly
 to R;

R is a moiety selected from the group consisting
 of alkyl, alkoxyalkyl, aryl, heteroaryl, cycloalkyl,
 15 heterocycloalkyl, aralkyl, heteroaralkyl,
 heterocycloalkylalkyl, cycloalkylalkyl,
 cycloalkoxyalkyl, heterocycloalkoxyalkyl,
 aryloxyalkyl, heteroaryloxyalkyl, arylthioalkyl,
 heteroarylthioalkyl, cycloalkylthioalkyl, and a
 20 heterocycloalkylthioalkyl group wherein the aryl or
 heteroaryl or cycloalkyl or heterocycloalkyl
 substituent is (i) unsubstituted or (ii) substituted
 with one or two radicals selected from the group
 consisting of a halo, alkyl, perfluoroalkyl,
 25 perfluoroalkoxy, perfluoroalkylthio,
 trifluoromethylalkyl, amino, alkoxycarbonylalkyl,
 alkoxy, C₁-C₂-alkylene-dioxy, hydroxycarbonylalkyl,
 hydroxycarbonylalkylamino, nitro, hydroxy,
 hydroxyalkyl, alkanoylamino, and a alkoxycarbonyl

-49-

group, and R is other than alkyl or alkoxyalkyl when A is -O- or -S-;

E is selected from the group consisting of

- 5 (1) -CO(R¹⁹)- or -(R¹⁹)CO-, wherein R¹⁹ is a heterocycloalkyl, or a cycloalkyl group;
- (2) -CONH- or -HNCO-; and
- (3) -CO-;
- (4) -SO₂-R¹⁹- or -R¹⁹-SO₂-;
- 10 (5) -SO₂-;
- (6) -NH-SO₂- or -SO₂-NH-; or
- (7) E is absent and R is bonded directly to Y; and

Y is absent or is selected from the group

15 consisting of a hydrido, alkyl, alkoxy, haloalkyl, aryl, aralkyl, cycloalkyl, heteroaryl, hydroxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkyl, perfluoroalkoxy, perfluoroalkylthio, trifluoromethylalkyl, alkenyl, heterocycloalkyl,

20 cycloalkyl, trifluoromethyl, alkoxycarbonyl, and a aminoalkyl group, wherein the aryl or heteroaryl or heterocycloalkyl group is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of an alkanoyl,

25 halo, nitro, aralkyl, aryl, alkoxy, and an amino group wherein the amino nitrogen is (i) unsubstituted or (ii) substituted with one or two groups independently selected from hydrido, alkyl, and an aralkyl group.


-50-

The substituent -G-A-R-E-Y preferably contains two to four carbocyclic or heterocyclic rings, including the aryl or heteroaryl group, G. More preferably, each of those rings is 6-membered.

- 5 Additional separate preferences for a compound of formula II include: (a) that A is -O- or -S-, (b) R is an aryl, heteroaryl, cycloalkyl or heterocycloalkyl group, (c) E is absent, and (d) Y is selected from the group consisting of hydrido, an
 10 alkyl, alkoxy, perfluoroalkoxy and a perfluoroalkylthio group.

A more preferred compound for use in a contemplated process has a structure that corresponds to formula III, below:

15



- wherein R³ is a single-ringed aryl or heteroaryl group that is 5- or 6-membered, and is
 20 itself substituted at its own 4-position when a 6-membered ring and at its own 3- or 4-position when a 5-membered ring with a substituent selected from the group consisting of a thiophenoxy, 4-chloro-
 25 benzdioxol-5-yloxy, 3,4-dimethylphenoxy, 4-fluorophenoxy, 4-fluorothiophenoxy, phenoxy, 4-trifluoro-

methoxyphenoxy, 4-trifluoromethylphenoxy, 4-
(trifluoromethylthio)phenoxy, 4-(trifluoromethyl-
thio)thiophenoxy, 4-chloro-3-fluorophenoxy, 4-
isopropoxyphenoxy, 4-isopropylphenoxy, (2-methyl-1,3-
5 benzothiazol-5-yl)oxy, 4-(1H-imidazol-1-yl)phenoxy,
4-chloro-3-methylphenoxy, 3-methyl-phenoxy, 4-
ethoxyphenoxy, 3,4-difluorophenoxy, 4-chloro-3-
methylphenoxy, 4-fluoro-3-chlorophenoxy, 4-(1H-1,2,4-
10 triazol-1-yl)phenoxy, 3,5-difluorophenoxy, 3,4-
dichlorophenoxy, 4-cyclopentylphenoxy, 4-bromo-3-
methylphenoxy, 4-bromophenoxy, 4-methylthiophenoxy,
4-phenylphenoxy, 4-benzylphenoxy, 6-quinolinyloxy, 4-
amino-3-methylphenoxy, 3-methoxyphenoxy, 5,6,7,8-
tetrahydro-2-naphthalenyloxy, 3-hydroxymethylphenoxy,
15 and a 4-benzyloxyphenoxy group;

R^{14} is hydrido, a pharmaceutically
acceptable cation or $C(W)R^{15}$ where W is O or S and
 R^{15} is selected from the group consisting of an C_1 -
 C_6 -alkyl, aryl, C_1 - C_6 -alkoxy, heteroaryl- C_1 - C_6 -alkyl,
20 C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, aryloxy, ar- C_1 - C_6 -
alkoxy, ar- C_1 - C_6 -alkyl, heteroaryl and amino C_1 - C_6 -
alkyl group wherein the aminoalkyl nitrogen is (i)
unsubstituted or (ii) substituted with one or two
substituents independently selected from the group
25 consisting of an C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl,
 C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, ar- C_1 - C_6 -
alkoxycarbonyl, C_1 - C_6 -alkoxycarbonyl, and a C_1 - C_6 -
alkanoyl radical, or (iii) wherein the amino C_1 - C_6 -
alkyl nitrogen and two substituents attached thereto

form a 5- to 8-membered heterocyclo or heteroaryl ring;

m is zero, 1 or 2;

n is zero, 1 or 2;

5 p is zero, 1 or 2;

the sum of $m + n + p = 1, 2, 3$ or 4;


(a) one of X, Y and Z is selected from the group consisting of C(O), NR^6 , O, S, S(O), S(O)₂ and NS(O)₂R⁷, and the remaining two of X, Y and Z are

10 CR⁸R⁹, and CR¹⁰R¹¹, or


(b) X and Z or Z and Y together constitute a moiety that is selected from the group consisting of $\text{NR}^6\text{C(O)}$, $\text{NR}^6\text{S(O)}$, $\text{NR}^6\text{S(O)}_2$, NR^6S , NR^6O , SS, NR^6NR^6 and OC(O), with the remaining one of X, Y and Z being

15 CR⁸R⁹, or

(c) n is zero and X, Y and Z together constitute a moiety selected from the group consisting of



-53-



wherein wavy lines are bonds to the atoms of the depicted ring;

- 5 R⁶ and R^{6'} are independently selected from the group consisting of hydrido, C₁-C₆-alkanoyl, C₆-aryl-C₁-C₆-alkyl, aroyl, bis(C₁-C₆-alkoxy-C₁-C₆-alkyl)-C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₁-C₆-perfluoroalkyl, C₁-C₆-trifluoromethylalkyl, C₁-C₆-perfluoroalkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₃-C₈-heterocycloalkyl, C₃-C₈-heterocycloalkylcarbonyl, C₆-aryl, C₅-C₆-heterocyclo, C₅-C₆-heteroaryl, C₃-C₈-cycloalkyl-C₁-C₆-alkyl, C₆-aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, heteroaryl-C₁-C₆-alkoxy-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, C₆-arylsulfonyl, C₁-C₆-alkylsulfonyl, C₅-C₆-heteroarylsulfonyl, carboxy-C₁-C₆-alkyl, C₁-C₄-alkoxycarbonyl-C₁-C₆-alkyl, aminocarbonyl, C₁-C₆-alkyliminocarbonyl, C₆-
- 10
- 15

aryliminocarbonyl, C₅-C₆-heterocycloiminocarbonyl,
C₆-arylthio-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl,
C₆-arylthio-C₃-C₆-alkenyl, C₁-C₄-alkylthio-C₃-C₆-
alkenyl, C₅-C₆-heteroaryl-C₁-C₆-alkyl, halo-C₁-C₆-
5 alkanoyl, hydroxy-C₁-C₆-alkanoyl, thiol-C₁-C₆-
alkanoyl, C₃-C₆-alkenyl, C₃-C₆-alkynyl, C₁-C₄-alkoxy-
C₁-C₄-alkyl, C₁-C₅-alkoxycarbonyl, aryloxycarbonyl,
NR⁸R⁹-C₁-C₅-alkylcarbonyl, hydroxy-C₁-C₅-alkyl, an
aminocarbonyl wherein the aminocarbonyl nitrogen is
10 (i) unsubstituted or (ii) substituted with one or two
radicals independently selected from the group
consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-
cycloalkyl and a C₁-C₆-alkanoyl group,
hydroxyaminocarbonyl, an aminosulfonyl group wherein
15 the aminosulfonyl nitrogen is (i) unsubstituted or
(ii) substituted with one or two radicals
independently selected from the group consisting of
C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a
C₁-C₆-alkanoyl group, an amino-C₁-C₆-alkylsulfonyl
20 group wherein the amino-C₁-C₆-alkylsulfonyl nitrogen
is (i) unsubstituted or (ii) substituted with one or
two radicals independently selected from the group
consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-
cycloalkyl and a C₁-C₆-alkanoyl group and an amino-
25 C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is
(i) unsubstituted or (ii) substituted with one or two
radicals independently selected from the group
consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-
cycloalkyl and a C₁-C₆-alkanoyl group;

R^7 is selected from the group consisting of a benzyl, phenyl, C_1 - C_6 -alkyl, C_3 - C_6 -alkynyl, C_3 - C_6 -alkenyl and a C_1 - C_6 -hydroxyalkyl group;

R^8 and R^9 and R^{10} and R^{11} are independently
5 selected from the group consisting of a hydrido, hydroxy, C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl, heteroaryl, heteroar- C_1 - C_6 -alkyl, C_2 - C_6 -alkynyl, C_2 - C_6 -alkenyl, thiol- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl cycloalkyl, cycloalkyl- C_1 - C_6 -alkyl,
10 heterocycloalkyl- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, aralkoxy- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, hydroxy- C_1 - C_6 -alkyl, hydroxycarbonyl- C_1 - C_6 -alkyl, hydroxycarbonylar- C_1 - C_6 -alkyl, aminocarbonyl- C_1 - C_6 -alkyl, aryloxy- C_1 - C_6 -alkyl, heteroaryloxy- C_1 - C_6 -alkyl, arylthio- C_1 - C_6 -alkyl, heteroarylthio- C_1 - C_6 -alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro- C_1 - C_6 -alkyl, trifluoromethyl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkyl, alkoxycarbonylamino- C_1 - C_6 -alkyl and an amino-
15 C_1 - C_6 -alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C_1 - C_6 -alkyl, ar- C_1 - C_6 -alkyl, cycloalkyl and C_1 - C_6 -alkanoyl, or wherein R^8 and R^9 or R^{10} and R^{11} and the carbon to which they are bonded form a
20 carbonyl group, or wherein R^8 and R^9 or R^{10} and R^{11} , or R^8 and R^{10} together with the atoms to which they are bonded form a 5- to 8-membered carbocyclic ring,

-56-

or a 5- to 8-membered heterocyclic ring containing one or two heteroatoms that are nitrogen, oxygen, or sulfur, with the proviso that only one of R⁸ and R⁹ or R¹⁰ and R¹¹ is hydroxy;


- 5 R¹² and R^{12'} are independently selected from the group consisting of a hydrido, C₁-C₆-alkyl, aryl, ar-C₁-C₆-alkyl, heteroaryl, heteroaralkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl, cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-
- 10 C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, amino-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl,
- 15 heteroaryloxy-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro-C₁-C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxycarbonylamino-
- 20 C₁-C₆-alkyl and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, cycloalkyl and C₁-C₆-alkanoyl; and
- 25 R¹³ is selected from the group consisting of a hydrido, benzyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group. Again, the use of a compound of formula III as a

-57-

pharmaceutically acceptable salt is also contemplated.

Preferences related to a compound of formula III that also apply to a compound of formula II include the following, which are independently preferred: (a) the sum of $m + n + p = 1$ or 2 , and more preferably 2 ; (b) Z is O , S or NR^6 ; (c) R^6 is selected from the group consisting of C_3 - C_6 -cycloalkyl, C_1 - C_6 -alkyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, amino- C_1 - C_6 -alkyl, aminosulfonyl, heteroaryl- C_1 - C_6 -alkyl, aryloxycarbonyl, and C_1 - C_6 -alkoxycarbonyl; and (d) $m = n = \text{zero}$, $p = 1$, and Y is NR^6 . Another preference for a compound of both of formulas II and III is that R^{14} be hydrido, or that W of the $C(W)R^{15}$ pro-drug form be O and R^{15} be a C_1 - C_6 -alkyl, aryl, C_1 - C_6 -alkoxy, heteroaryl- C_1 - C_6 -alkyl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, or aryloxy group.

A still more preferred compound for use in a contemplated process corresponds in structure to formula IV, below:



Here, R^3 is as defined above as to formulas I, III and more preferably as defined as to formula II

-58-

(wherein the R^3 radical is the substituent G-A-R-E-Y). Most preferably, R^3 is as defined in formula III.


Z is selected group the group consisting of O,
5 S, NR^6 , SO, SO_2 , and NSO_2R^7 ,

wherein R^6 is selected from the group consisting of hydrido, C_1 - C_5 -alkyl, C_1 - C_5 -alkanoyl, benzyl, benzoyl, C_3 - C_5 -alkynyl, C_3 - C_5 -alkenyl, C_1 - C_3 -alkoxy-
10 C_1 - C_4 -alkyl, C_3 - C_6 -cycloalkyl, heteroaryl- C_1 - C_6 -alkyl, C_1 - C_5 -hydroxyalkyl, C_1 - C_5 -carboxyalkyl, C_1 - C_5 -alkoxy C_1 - C_5 -alkylcarbonyl, and NR^8R^9 - C_1 - C_5 -alkylcarbonyl or NR^8R^9 - C_1 - C_5 -alkyl wherein R^8 and R^9 are independently hydrido, C_1 - C_5 -alkyl, C_1 - C_5 -alkoxycarbonyl or aryl- C_1 - C_5 -alkoxycarbonyl, or NR^8R^9
15 together form a heterocyclic ring containing 5- to 8-atoms in the ring; and

R^7 is selected from the group consisting of an arylalkyl, aryl, heteroaryl, heterocyclo, C_1 - C_6 -alkyl, C_3 - C_6 -alkynyl, C_3 - C_6 -alkenyl, C_1 - C_6 -
20 carboxyalkyl and a C_1 - C_6 -hydroxyalkyl group. Most preferably, Z is O or NR^6 . Here too, the use of a compound of formula IV as a pharmaceutically acceptable salt is contemplated.

A still more preferred group of contemplated
25 compounds for use in a contemplated process correspond in structure to formula V, below;

-59-



wherein



Z is as previously defined for formula IV;

5 W and Q are independently oxygen (O), NR^6 or sulfur (S), and R^6 is as defined in formula IV; and

 q is zero or one such that when q is zero, Q is absent and the trifluoromethyl group is bonded directly to the depicted phenyl ring. Here again, the
 10 use of a compound of formula IV as a pharmaceutically acceptable salt is contemplated.




 Particularly preferred compounds within the group defined by formula V have the structural formulas shown below:

15




20



- 60 -





5




- 61 -





5



- 62 -



Also particularly preferred are the following
5 compounds:



10

Several particularly preferred compounds whose structures correspond to formulas I through V are illustrated in the Tables and examples provided hereinafter.

15 As was noted before, the compounds of formulas II, III, IV and V, and their pharmaceutically acceptable salts are themselves contemplated compounds of the invention.

In preferred practice, an SO₂-linked R³ radical is an aryl or heteroaryl group that is a 5- or 6-membered single-ring that is itself substituted with one other single-ringed aryl or heteroaryl group or, with an alkyl or alkoxy group having a chain length of 3 to about 16 carbon atoms (and more preferably a length of up to about 14 carbon atoms), a phenoxy group, a thiophenoxy [C₆H₅-S-] group, a phenylazo [C₆H₅-N₂-] group, a N-piperidyl [C₅H₁₀N-] group, a N-piperazyl [NC₄H₉N-] group or a benzamido [-NHC(O)C₆H₅] group. The SO₂-linked single-ringed aryl or heteroaryl R³ group here is substituted at its own 4-position when a 6-membered ring and at its own 3- or 4-position when a 5-membered ring.

The SO₂-linked aryl or heteroaryl group of a R³ radical is preferably itself substituted at the 4-position when a 6-membered ring or the 3- or 4-position when a 5-membered ring. A particularly preferred substituent is a single-ringed aryl or heteroaryl, phenoxy, thiophenoxy, phenylazo, N-piperidyl, N-piperazyl or benzamido group that is unsubstituted or can itself be substituted.

The 4- and 3-positions of rings discussed here are numbered from the sites of substituent bonding as compared to formalized ring numbering positions used in heteroaryl nomenclature, as is discussed further hereinbelow. Here, single atoms such as halogen moieties (fluoro, chloro, bromo, or iodo) or substituents that contain one to a chain length of about five atoms other than hydrogen such as phenyl, C₁-C₄ alkyl, trifluoromethyl,

trifluoromethoxy, trifluorothiomethyl or carboxyethyl groups are preferred, although longer substituents can be accommodated up to a total length of an icosyl group.

5 Exemplary particularly preferred substituted SO₂-linked R³ radicals include 4-(phenyl)phenyl [biphenyl], 4-(4'-methoxyphenyl)-phenyl, 4-(phenoxy)phenyl, 4-(thiophenyl)phenyl [4-(phenylthio)phenyl], 4-(azophenyl)phenyl, 4-[(4'-trifluoromethylthio)phenoxy]phenyl, 4-[(4'-trifluoromethylthio)thiophenyl]phenyl, 4-[(4'-trifluoromethyl)phenoxy]phenyl, 4-[(4'-trifluoromethyl)thiophenyl]phenyl, 4-[(4'-trifluoromethoxy)phenoxy]phenyl, 4-[(4'-trifluoromethoxy)thiophenyl]phenyl, 4-[(4'-phenyl)N-piperidyl]phenyl, 4-[(4'-acetyl)N-piperazyl]phenyl and 4-(benzamido)phenyl.

Inasmuch as a contemplated SO₂-linked aryl or heteroaryl radical of an R³ group is itself preferably substituted with a 6-membered ring, two nomenclature systems are used together herein for ease in understanding substituent positions. The first system uses position numbers for the ring directly bonded to the SO₂-group, whereas the second system uses ortho, meta or para for the position of one or more substituents of a 6-membered ring bonded to a SO₂-linked aryl or heteroaryl radical. Although ortho, meta and para positional nomenclature is normally not used with aliphatic ring systems, it is believed more readily understood for describing the present compounds when used in conjunction with the numerical system for the first ring bonded to the

SO₂-group. When a R³ radical is other than a 6-membered ring, substituent positions are numbered from the position of linkage to the aromatic or heteroaromatic ring. Formal chemical nomenclature is used in naming particular compounds.

Thus, the 1-position of an above-discussed SO₂-linked aryl or heteroaryl group is the position at which the SO₂-group is bonded to the ring. The 4- and 3-positions of rings discussed here are numbered from the sites of substituent bonding from the SO₂-linkage as compared to formalized ring numbering positions used in heteroaryl nomenclature.

When examined along its longest chain of atoms, an R³ radical including its own substituent has a total length that is greater than a saturated chain of five carbon atoms (a pentyl group), and preferably has a length greater than that of a saturated chain of six carbon atoms (a hexyl group); i.e., a length of about a heptyl chain or longer. An R³ radical also has a length that is less than that of a saturated chain of about 20 carbon atoms [an icosyl group (icosyl was formerly spelled eicosyl)] and more preferably about 18 carbon atoms (a stearyl group). Most preferably, the length of R³ is about that of an 8 to about 12 carbon atom chain, even though many more atoms may be present in ring structures or substituents. This length requirement is discussed further below.

Looked at more generally, and aside from specific moieties from which it is constructed, an R³ radical (group or moiety) has a length that is

greater than that of a pentyl group. Such an R^3 radical also has a length that is less than that of an icosyl (didecyl) group. That is to say that R^3 is a radical having a minimal length longer than a saturated five carbon chain, and preferably greater than a hexyl group, but is shorter than the length of a saturated twenty carbon atom chain, and preferably shorter than an eighteen carbon chain. Most preferably, R^3 has a length greater than that of an octyl group and less than that of a lauryl group.

More specifically, an R^3 group has a minimal length of a hexyl group only when that substituent is comprised of two rings that can be fused or simply covalently linked together by exocyclic bonding. When R^3 does not contain two linked or fused rings, e.g., where a R^3 radical includes an alkyl or second, third or fourth ring substituent, R^3 has a length that is greater than that of a hexyl group. Exemplary of such two ring R^3 groups are a 2-naphthyl group or a 2-quinolinyl group (each with a six carbon chain length) and 8-purinyl (with a five carbon atom chain length). Without wishing to be bound by theory, it is believed that the presence of multiple rings in R^3 enhances selectivity of the enzyme activity inhibitor profile.

The radical chain lengths are measured along the longest linear atom chain in the radical, following the skeletal atoms around a ring where necessary. Each atom in the chain, e.g. carbon, oxygen, sulfur or nitrogen, is presumed to be carbon for ease in calculation.

-67-

Such lengths can be readily determined by using published bond angles, bond lengths and atomic radii, as needed, to draw and measure a desired, usually staggered, chain, or by building models using commercially available kits whose bond angles, lengths and atomic radii are in accord with accepted, published values. Radical (substituent) lengths can also be determined somewhat less exactly by assuming that all atoms have bond lengths saturated carbon, that unsaturated bonds have the same lengths as saturated bonds and that bond angles for unsaturated bonds are the same as those for saturated bonds, although the above-mentioned modes of measurement are preferred. For example, a phenyl or pyridyl group has a length of a four carbon chain, as does a propoxy group, whereas a biphenyl group has a length of about an eight carbon chain using such a measurement mode.

In addition, a R^3 group when rotated about an axis drawn through the SO_2 -bonded 1-position and the 4-position of a 6-membered ring or the SO_2 -bonded position and substituent-bonded 3- or 4-position of a 5-membered ring defines a three-dimensional volume whose widest dimension has the width of about one furanyl ring to about two phenyl rings in a direction transverse to that axis to rotation.

Thus, a 2-naphthyl substituent or an 8-purinyll substituent is an appropriately sized R^3 group when examined using the above rotational width criterion as well as the before-discussed criterion. On the other hand, a 1-naphthyl group or a 7- or 9-

-68-

purinyl group is too wide upon rotation and is excluded from being an R^3 group.

As a consequence of these length and width requirements, R^3 radicals such as 4-(phenyl)phenyl
5 [biphenyl], 4-(4'-methoxyphenyl)-phenyl,
4-(phenoxy)phenyl, 4-(thiophenyl)phenyl [4-(phenylthio)phenyl], 4-(azophenyl)phenyl, 4-[(4'-trifluoromethylthio)phenoxy]phenyl, 4-[(4'-trifluoromethylthio)thiophenyl]phenyl, 4-[(4'-trifluoromethyl)phenoxy]phenyl, 4-[(4'-trifluoromethyl)thiophenyl]phenyl, 4-[(4'-trifluoromethoxy)phenoxy]phenyl, 4-[(4'-trifluoromethoxy)thiophenyl]phenyl, 4-[(4'-phenyl)N-piperidyl]phenyl, 4-[(4'-acetyl)N-piperazyl]phenyl
10 and 4-(benzamido)phenyl are particularly preferred R^3 radicals. Those substituents can themselves also be substituted in the second ring from the SO_2 group at the meta- or para-position or both with a single atom or a substituent containing a longest chain length
20 that is preferably of up to five atoms, excluding hydrogen.

Without wishing to be bound by theory, the length of a R^3 radical substituent bonded to the SO_2 group is believed to play a role in the overall
25 activity of a contemplated inhibitor compound against MMP enzymes generally. The length of the R^3 radical group also appears to play a role in the selective activity of an inhibitor compound against particular MMP enzymes.


30 In particularly preferred practice, R^3 is a PhR^{23} group, wherein Ph is phenyl. The phenyl ring

(Ph) of a PhR^{23} group is substituted at its para-position (4-position) by an R^{23} group that can be another single-ringed aryl or heteroaryl group, a piperidyl group, a piperazinyl group, a phenoxy group, a thiophenoxy [$\text{C}_6\text{H}_5\text{-S-}$] group, a phenylazo [$\text{C}_6\text{H}_5\text{-N}_2\text{-}$] group or a benzamido [$\text{-NHC(O)C}_6\text{H}_5$] group.

In one embodiment of a particularly preferred aromatic sulfone hydroxamate inhibitor compound, an R^{23} substituent is phenoxy and is itself substituted at its own para-position with a moiety that is selected from the group consisting of a halogen, a $\text{C}_1\text{-C}_4$ alkoxy group, a $\text{C}_1\text{-C}_4$ alkyl group, a dimethylamino group, a carboxyl $\text{C}_1\text{-C}_3$ alkylene group, a $\text{C}_1\text{-C}_4$ alkoxy carbonyl $\text{C}_1\text{-C}_3$ alkylene group, a trifluoromethylthio group, a trifluoromethoxy group, a trifluoromethyl group and a carboxamido $\text{C}_1\text{-C}_3$ alkylene group, or is substituted at the meta- and para-positions by a methylenedioxy group. It is to be understood that any R^{23} substituent can be substituted with a moiety from the above list. Such substitution at the para-position is preferred.

The present invention also contemplates an intermediate compound that is useful in preparing a compound of formulas I-V. Such an intermediate compound corresponds in structure to formula VI, below:

-70-



VI

wherein g is zero, 1 or 2;

- 5 R^{20} is (a) $-O-R^{21}$, where R^{21} is selected from the group consisting of a hydrido, C_1 - C_6 -alkyl, aryl, ar- C_1 - C_6 -alkyl group and a pharmaceutically acceptable cation, or (b) $-NH-O-R^{22}$ wherein R^{22} is a selectively removable protecting group such as a 2-tetrahydropyranyl, C_1 - C_6 -acyl, aroyl, benzyl, p-methoxybenzyl (MOZ) carbonyl- C_1 - C_6 -alkoxy, trisubstituted silyl group or o-nitrophenyl group, peptide synthesis resin and the like, wherein trisubstituted silyl group is substituted with C_1 - C_6 -
- 10 alkyl, aryl, or ar- C_1 - C_6 -alkyl;

m is zero, 1 or 2;

n is zero, 1 or 2;

p is zero, 1 or 2;

the sum of $m + n + p = 1, 2, 3$ or 4;


- 20 (a) one of X , Y and Z is selected from the group consisting of $C(O)$, NR^6 , O , S , $S(O)$, $S(O)_2$ and $NS(O)_2R^7$, and the remaining two of X , Y and Z are CR^8R^9 , and $CR^{10}R^{11}$, or

-71-

(b) X and Z or Z and Y together constitute a moiety that is selected from the group consisting of $\text{NR}^6\text{C}(\text{O})$, $\text{NR}^6\text{S}(\text{O})$, $\text{NR}^6\text{S}(\text{O})_2$, NR^6S , NR^6O , SS , NR^6NR^6 and $\text{OC}(\text{O})$, with the remaining one of X, Y and Z being

5 CR^8R^9 , or

(c) n is zero and X, Y and Z together constitute a moiety selected from the group consisting of



10

-72-

wherein wavy lines are bonds to the atoms of the depicted ring;

- R^6 and $R^{6'}$ are independently selected from the group consisting of hydrido, C_1 - C_6 -alkanoyl, C_6 -aryl-
 5 C_1 - C_6 -alkyl, aroyl, bis(C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl)- C_1 - C_6 -alkyl, C_1 - C_6 -alkyl, C_1 - C_6 -haloalkyl, C_1 - C_6 -perfluoroalkyl, C_1 - C_6 -trifluoromethylalkyl, C_1 - C_6 -perfluoroalkoxy- C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_3 - C_8 -heterocycloalkyl, C_3 -
 10 C_8 -heterocycloalkylcarbonyl, C_6 -aryl, C_5 - C_6 -heterocyclo, C_5 - C_6 -heteroaryl, C_3 - C_8 -cycloalkyl- C_1 - C_6 -alkyl, C_6 -aryloxy- C_1 - C_6 -alkyl, heteroaryloxy- C_1 - C_6 -alkyl, heteroaryl- C_1 - C_6 -alkoxy- C_1 - C_6 -alkyl, heteroarylthio- C_1 - C_6 -alkyl, C_6 -arylsulfonyl, C_1 - C_6 -alkylsulfonyl, C_5 - C_6 -heteroarylsulfonyl, carboxy- C_1 -
 15 C_6 -alkyl, C_1 - C_4 -alkoxycarbonyl- C_1 - C_6 -alkyl, aminocarbonyl, C_1 - C_6 -alkyliminocarbonyl, C_6 -aryliminocarbonyl, C_5 - C_6 -heterocycloiminocarbonyl, C_6 -arylthio- C_1 - C_6 -alkyl, C_1 - C_6 -alkylthio- C_1 - C_6 -alkyl, C_6 -arylthio- C_3 - C_6 -alkenyl, C_1 - C_4 -alkylthio- C_3 - C_6 -alkenyl, C_5 - C_6 -heteroaryl- C_1 - C_6 -alkyl, halo- C_1 - C_6 -alkanoyl, hydroxy- C_1 - C_6 -alkanoyl, thiol- C_1 - C_6 -alkanoyl, C_3 - C_6 -alkenyl, C_3 - C_6 -alkynyl, C_1 - C_4 -alkoxy- C_1 - C_4 -alkyl, C_1 - C_5 -alkoxycarbonyl, aryloxycarbonyl,
 20 NR^8R^9 - C_1 - C_5 -alkylcarbonyl, hydroxy- C_1 - C_5 -alkyl, an aminocarbonyl wherein the aminocarbonyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group

- 73 -

consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group, hydroxyaminocarbonyl, an aminosulfonyl group wherein the aminosulfonyl nitrogen is (i) unsubstituted or
5 (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group, an amino-C₁-C₆-alkylsulfonyl group wherein the amino-C₁-C₆-alkylsulfonyl nitrogen
10 is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is
15 (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, C₃-C₈-cycloalkyl and a C₁-C₆-alkanoyl group;

R⁷ is selected from the group consisting of
20 a benzyl, phenyl, C₁-C₆-alkyl, C₃-C₆-alkynyl, C₃-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group;

R⁸ and R⁹ and R¹⁰ and R¹¹ are independently selected from the group consisting of a hydrido, hydroxy, C₁-C₆-alkyl, aryl, ar-C₁-C₆-alkyl,
25 heteroaryl, heteroar-C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aralkoxy-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-


alkoxy-C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl,
hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-
alkyl, aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-
alkyl, heteroaryloxy-C₁-C₆-alkyl, arylthio-C₁-C₆-
5 alkyl, heteroarylthio-C₁-C₆-alkyl, the sulfoxide or
sulfone of any said thio substituents, perfluoro-C₁-
C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-
alkyl, alkoxycarbonylamino-C₁-C₆-alkyl and an amino-
C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is
10 (i) unsubstituted or (ii) substituted with one or two
radicals independently selected from the group
consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, cycloalkyl
and C₁-C₆-alkanoyl, or wherein R⁸ and R⁹ or R¹⁰ and
R¹¹ and the carbon to which they are bonded form a
15 carbonyl group, or wherein R⁸ and R⁹ or R¹⁰ and R¹¹,
or R⁸ and R¹⁰ together with the atoms to which they
are bonded form a 5- to 8-membered carbocyclic ring,
or a 5- to 8-membered heterocyclic ring containing
one or two heteroatoms that are nitrogen, oxygen, or
20 sulfur, with the proviso that only one of R⁸ and R⁹
or R¹⁰ and R¹¹ is hydroxy;

R¹² and R^{12'} are independently selected from the
group consisting of a hydrido, C₁-C₆-alkyl, aryl, ar-
C₁-C₆-alkyl, heteroaryl, heteroaralkyl, C₂-C₆-
25 alkynyl, C₂-C₆-alkenyl, thiol-C₁-C₆-alkyl,
cycloalkyl, cycloalkyl-C₁-C₆-alkyl, heterocycloalkyl-
C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkyl, aryloxy-C₁-C₆-
alkyl, amino-C₁-C₆-alkyl, C₁-C₆-alkoxy-C₁-C₆-alkoxy-


C₁-C₆-alkyl, hydroxy-C₁-C₆-alkyl, hydroxycarbonyl-C₁-C₆-alkyl, hydroxycarbonylar-C₁-C₆-alkyl, aminocarbonyl-C₁-C₆-alkyl, aryloxy-C₁-C₆-alkyl, heteroaryloxy-C₁-C₆-alkyl, C₁-C₆-alkylthio-C₁-C₆-alkyl, arylthio-C₁-C₆-alkyl, heteroarylthio-C₁-C₆-alkyl, the sulfoxide or sulfone of any said thio substituents, perfluoro-C₁-C₆-alkyl, trifluoromethyl-C₁-C₆-alkyl, halo-C₁-C₆-alkyl, alkoxycarbonylamino-C₁-C₆-alkyl and an amino-C₁-C₆-alkyl group wherein the aminoalkyl nitrogen is (i) unsubstituted or (ii) substituted with one or two radicals independently selected from the group consisting of C₁-C₆-alkyl, ar-C₁-C₆-alkyl, cycloalkyl and C₁-C₆-alkanoyl;

R¹³ is selected from the group consisting of a hydrido, benzyl, phenyl, C₁-C₆-alkyl, C₂-C₆-alkynyl, C₂-C₆-alkenyl and a C₁-C₆-hydroxyalkyl group; and

R²⁴ is R³ as defined in formulas I, III, IV or is the substituent G-A-R-E-Y of formula II (formula VIA). Alternatively, R²⁴ is R^{3'}, an aryl or heteroaryl group that is substituted with a coupling substituent reactive for coupling with another moiety (formula VIB), such as a nucleophilically displaceable leaving group, D.



VIA




VIB

- Exemplary nucleophilically displaceable leaving groups, D, include a halo (fluoro, chloro, bromo, or idodo) nitro, azido, phenylsulfoxido, aryloxy, C₁-C₆-alkoxy, a C₁-C₆-alkylsulfonate or arylsulfonate group and a trisubstituted ammonium group in which the three substituents are independently aryl, ar-C₁-C₆-alkyl or C₁-C₆-alkyl. Additional coupling substituents include, without limitation, a hydroxyl group and an amino group that can be coupled with carbonyl-containing moieties to form esters, urethanes, carbonates, amides and ureas. Similarly, a carboxyl coupling substituent can be used to form an ester, thioester or amide. Thus, a coupling substituent is useful in converting a coupling substituent-containing aryl or heteroaryl group into a substituent such as a G-A-R-E-Y substituent discussed hereinabove by the formation of a covalent bond.
- A compound of formula VI can be coupled with another moiety at the R^{3'} coupling substituent to form a compound whose newly formed R³ group is that of formulas I, III, IV or -G-A-R-E-Y. Exemplary of such couplings are the nucleophilic displacement to form ethers and thioethers, as well as the formation

-77-

of ester, amide, urea, carbonate, urethane and the like linkages.

A particularly preferred precursor intermediate to an intermediate compound of formula VI is an intermediate compound of formula VII, below



VII

wherein m , n , p , g , X , Z , Y , D and R^{20} are as defined above for formula VI.


R^{20} is preferably $-NH-O-R^{22}$, wherein R^{22} is a selectively removable protecting group such as a 2-tetrahydropyranyl, C_1 - C_6 -acyl, aroyl, benzyl, p -methoxybenzyl (MOZ) carbonyl- C_1 - C_6 -alkoxy, o -nitrophenyl group, a peptide synthesis resin such as a so-called Merrifield's Peptide Resin commercially available from Sigma Chemical Co., and the like, with 2-tetrahydropyranyl being particularly preferred. An $-NH-O-R^{22}$ group (R^{20}) in formulas VI and VII is therefore seen to be a reaction product of a hydroxyl amine whose oxygen is bonded to a selectively removable protecting group and a carboxyl group.

In regard to a compound of each of formulas VI and VII, the subscript letter "g" is used to show the oxidation state of the sulfur atom. Where g is zero,

-78-

the sulfur is unoxidized, and the compound depicted is typically the sulfide reaction product of a sulfur-containing synthon as is illustrated in the examples hereinafter. Where g is 1, the sulfur is
 5 oxidized to a sulfoxide, whereas when g is 2, the sulfur is oxidized to a sulfone as is also illustrated hereinafter. A compound of formulas VI or VII wherein g is zero or 1 are themselves typically intermediates in the formation of a similar
 10 compound wherein g is 2 and the intermediate is a preferred sulfone.

A preferred intermediate therefore corresponds in structure to formula VIIA, below



VIIA

15

In the written descriptions of molecules and groups, molecular descriptors can be combined to produce words or phrases that describe structural
 20 groups or are combined to describe structural groups. Such descriptors are used in this document. Common illustrative examples include such terms as aralkyl (or arylalkyl), heteroaralkyl, heterocycloalkyl, cycloalkylalkyl, aralkoxyalkoxycarbonyl and the like.
 25 A specific example of a compound encompassed with the latter descriptor aralkoxyalkoxycarbonyl is C₆H₅-CH₂-

-79-

CH₂-O-CH₂-O-(C=O)- wherein C₆H₅- is phenyl. It is also to be noted that a structural group can have more than one descriptive word or phrase in the art, for example, heteroaryloxyalkylcarbonyl can also be
5 termed heteroaryloxyalkanoyl. Such combinations are used herein in the description of the processes, compounds and compositions of this invention and further examples are described below. The following list is not intended to be exhaustive or drawn out
10 but provide illustrative examples of words or phrases (terms) that are used herein.

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing 1 to about 12
15 carbon atoms, preferably 1 to about 10 carbon atoms, and more preferably 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the
20 like.

The term "alkenyl", alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing 2 to about 12 carbon atoms preferably
25 2 to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of suitable alkenyl radicals include ethenyl (vinyl), 2-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, decenyl and the like.

30 The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing 2 to about 12 carbon atoms, preferably 2

to about 10 carbon atoms, and more preferably, 2 to about 6 carbon atoms. Examples of alkynyl radicals include ethynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, 3-butynyl, and the like.

5 The term "carbonyl" or "oxo", alone or in combination, means a $-C(=O)-$ group wherein the remaining two bonds (valences) can be independently substituted. The term carbonyl is also intended to encompass a hydrated carbonyl group $-C(OH)_2-$.

10 The term "thiol" or "sulfhydryl", alone or in combination, means a $-SH$ group. The term "thio" or "thia", alone or in combination, means a thiaether group; i.e., an ether group wherein the ether oxygen is replaced by a sulfur atom.

15 The term "amino", alone or in combination, means an amine or $-NH_2$ group whereas the term mono-substituted amino, alone or in combination, means a substituted amine $-N(H)(\text{substituent})$ group wherein one hydrogen atom is replaced with a substituent, and
20 disubstituted amine means a $-N(\text{substituent})_2$ wherein two hydrogen atoms of the amino group are replaced with independently selected substituent groups.

 Amines, amino groups and amides are compounds that can be designated as primary (I°),
25 secondary (II°) or tertiary (III°) or unsubstituted, mono-substituted or N,N -disubstituted depending on the degree of substitution of the amino nitrogen. Quaternary amine (ammonium) (IV°) means a nitrogen with four substituents $[-N^+(\text{substituent})_4]$ that is
30 positively charged and accompanied by a counter ion, whereas N -oxide means one substituent is oxygen and

-81-

the group is represented as $[-N^+(\text{substituent})_3-O^-]$;
i.e., the charges are internally compensated.

The term "cyano", alone or in combination,
means a -C-triple bond-N ($-C\equiv N$) group. The term
5 "azido", alone or in combination, means a -N-triple
bond-N ($-N\equiv N$) group. The term "hydroxyl", alone or
in combination, means a -OH group. The term "nitro",
alone or in combination, means a -NO₂ group. The
term "azo", alone or in combination, means a -N=N-
10 group wherein the bonds at the terminal positions can
be independently substituted.

The term "hydrazino", alone or in
combination, means a -NH-NH- group wherein the
depicted remaining two bonds (valences) can be
15 independently substituted. The hydrogen atoms of the
hydrazino group can be replaced, independently, with
substituents and the nitrogen atoms can form acid
addition salts or be quaternized.

The term "sulfonyl", alone or in
20 combination, means a -SO₂- group wherein the depicted
remaining two bonds (valences) can be independently
substituted. The term "sulfoxido", alone or in
combination, means a -SO- group wherein the remaining
two bonds (valences) can be independently
25 substituted.

The term "sulfone", alone or in
combination, means a -SO₂- group wherein the depicted
remaining two bonds (valences) can be independently
substituted. The term "sulfenamide", alone or in
30 combination, means a -SON= group wherein the
remaining three depicted bonds (valences) can be
independently substituted. The term "sulfide", alone

-82-

or in combination, means a -S- group wherein the remaining two bonds (valences) can be independently substituted.

5 The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy and the like.

10 The term "cycloalkyl", alone or in combination, means a cyclic alkyl radical that contains 3 to about 8 carbon atoms. The term "cycloalkylalkyl" means an alkyl radical as defined above that is substituted by a cycloalkyl radical
15 containing 3 to about 8, preferably 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

A heterocyclic (heterocyclo) or heterocyclo
20 portion of a heterocyclocarbonyl, heterocyclooxycarbonyl, heterocycloalkoxycarbonyl, or heterocycloalkyl group or the like is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic heterocycle that contains one or more
25 hetero atoms selected from nitrogen, oxygen and sulphur. Such a moiety can be optionally substituted on one or more ring carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) of the ring by alkyl,
30 aralkoxycarbonyl, alkanoyl, aryl or arylalkyl or on a tertiary nitrogen atom (i.e., =N-) by oxido and that is attached via a carbon atom. The tertiary nitrogen

-83-

atom with three substituents can also be attached to form a N-oxide [=N(O)-] group.

The term "aryl", alone or in combination, means a 5- or 6-membered carbocyclic aromatic ring-containing moiety or a fused ring system containing two or three rings that have all carbon atoms in the ring; i.e., a carbocyclic aryl radical. Exemplary carbocyclic aryl radicals include phenyl, indenyl and naphthyl radicals.

The term "heteroaryl", alone or in combination means a 5- or 6-membered aromatic ring-containing moiety or a fused ring system (radical) containing two or three rings that have carbon atoms and also one or more heteroatoms in the ring(s) such as sulfur, oxygen and nitrogen. Examples of such heterocyclic or heteroaryl groups are pyrrolidinyl, piperidyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol-4-yl, 1-benzyloxycarbonylimidazol-4-yl, and the like), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, tetrahydrofuryl, thienyl, triazolyl, oxazolyl, oxadiazoyl, thiazolyl, thiadiazoyl, indolyl (e.g., 2-indolyl, and the like), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, and the like), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, and the like), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, and the like), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, and the like), quinoxalinyl, β -carbolinyl, 2-benzofurancarbonyl, benzothiophenyl, 1-, 2-, 4- or 5-benzimidazolyl, and the like radicals.

When an aryl or heteroaryl radical is a substituting moiety (group, substituent, or radical), it can itself substituted, the last-named substituent is independently selected from the group consisting

5 of a cyano, perfluoroalkyl, trifluoromethoxy, trifluoromethylthio, haloalkyl, trifluoromethylalkyl, aralkoxycarbonyl, aryloxy carbonyl, hydroxy, halo, alkyl, alkoxy, nitro, thiol, hydroxycarbonyl, aryloxy, arylthio, aralkyl,

10 aryl, arylcarbonylamino, heteroaryloxy, heteroarylthio, heteroaralkyl, cycloalkyl, heterocyclooxy, heterocyclothio, heterocycloamino, cycloalkyloxy, cycloalkylthio, heteroaralkoxy, heteroaralkylthio, aralkoxy, aralkylthio,

15 aralkylamino, heterocyclo, heteroaryl, arylazo, hydroxycarbonylalkoxy, alkoxy carbonylalkoxy, alkanoyl, arylcarbonyl, aralkanoyl, alkanoyloxy, aralkanoyloxy, hydroxyalkyl, hydroxyalkoxy, alkylthio, alkoxyalkylthio, alkoxy carbonyl,

20 aryloxyalkoxyaryl, arylthioalkylthioaryl, aryloxyalkylthioaryl, arylthioalkoxyaryl, hydroxycarbonylalkoxy, hydroxycarbonylalkylthio, alkoxy carbonylalkoxy, alkoxy carbonylalkylthio, amino,

25 wherein the amino nitrogen is (i) unsubstituted, or (ii) substituted with one or two substituents that are independently selected from the group consisting of an alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, aralkoxycarbonyl, alkoxy carbonyl, arylcarbonyl, aralkanoyl,

30 heteroarylcarbonyl, heteroaralkanoyl and an alkanoyl group, or (iii) wherein the amino nitrogen and two substituents attached thereto form a 5- to 8-membered heterocyclo or

heteroaryl ring containing zero to two additional heteroatoms that are nitrogen, oxygen or sulfur and which ring itself is (a) unsubstituted or (b) substituted with one or two groups independently selected from the group consisting of an aryl, alkyl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, alkanoyl, cycloalkyl, heterocycloalkyl, alkoxycarbonyl, hydroxyalkyl, trifluoromethyl, benzofused heterocycloalkyl, hydroxyalkoxyalkyl, aralkoxycarbonyl, hydroxycarbonyl, aryloxycarbonyl, benzofused heterocycloalkoxy, benzofused cycloalkylcarbonyl, heterocycloalkylcarbonyl, and a cycloalkylcarbonyl group, carbonylamino

wherein the carbonylamino nitrogen is (i) unsubstituted, or (ii) is the reacted amine of an amino acid, or (iii) substituted with one or two radicals selected from the group consisting of an alkyl, hydroxyalkyl, hydroxyheteroaralkyl, cycloalkyl, aralkyl, trifluoromethylalkyl, heterocycloalkyl, benzofused heterocycloalkyl, benzofused heterocycloalkyl, benzofused cycloalkyl, and an N,N-dialkylsubstituted alkylamino-alkyl group, or (iv) the carboxamido nitrogen and two substituents bonded thereto together form a 5- to 8-membered heterocyclo, heteroaryl or benzofused heterocycloalkyl ring that is itself unsubstituted or substituted with one or two radicals independently selected from the group consisting of an alkyl, alkoxycarbonyl, nitro, heterocycloalkyl,

-86-

hydroxy, hydroxycarbonyl, aryl, aralkyl,
heteroaralkyl and an amino group,

wherein the amino nitrogen is

5 (i) unsubstituted, or (ii) substituted with
one or two substituents that are
independently selected from the group
consisting of alkyl, aryl, and heteroaryl,
or (iii) wherein the amino nitrogen and two
10 substituents attached thereto form a 5- to
8-membered heterocyclo or heteroaryl ring,
and an aminoalkyl group

wherein the aminoalkyl nitrogen is (i) unsubstituted,
or (ii) substituted with one or two substituents
independently selected from the group consisting of
15 an alkyl, aryl, aralkyl, cycloalkyl,
aralkoxycarbonyl, alkoxycarbonyl, and an alkanoyl
group, or (iii) wherein the aminoalkyl nitrogen and
two substituents attached thereto form a 5- to 8-
membered heterocyclo or heteroaryl ring.

20 The term "aralkyl", alone or in
combination, means an alkyl radical as defined above
in which one hydrogen atom is replaced by an aryl
radical as defined above, such as benzyl, 2-
phenylethyl and the like.

25 The term "aralkoxycarbonyl", alone or in
combination, means a radical of the formula aralkyl-
O-C(O)- in which the term "aralkyl" has the
significance given above. An example of an
aralkoxycarbonyl radical is benzyloxycarbonyl.

30 The term "aryloxy" means a radical of the
formula aryl-O- in which the term aryl has the

-87-

significance given above. The phenoxy radical is an exemplary aryloxy radical.

The terms "heteroaralkyl" and "heteroaryloxy" mean radicals structurally similar to aralkyl and aryloxy that are formed from heteroaryl radicals. Exemplary radicals include 4-picolinyl and 2-pyrimidinoxy, respectively.

The terms "alkanoyl" or "alkylcarbonyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include formyl, acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like.

The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid that is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl.

The terms "aralkanoyl" or "aralkylcarbonyl" mean an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl and the like.

The terms "aroyl" or "arylcarbonyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic

or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-
5 2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like.

The term "cycloalkylalkoxycarbonyl" means an acyl group of the formula cycloalkylalkyl-O-CO- wherein cycloalkylalkyl has the significance given
10 above. The term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term "heterocyclooxycarbonyl" means an acyl group having the formula heterocyclo-O-CO- wherein
15 heterocyclo is as defined above.

The term "heterocycloalkanoyl" is an acyl radical of the formula heterocyclo-substituted alkane carboxylic acid wherein heterocyclo has the significance given above. The term
20 "heterocycloalkoxycarbonyl" means an acyl radical of the formula heterocyclo-substituted alkane-O-CO- wherein heterocyclo has the significance given above. The term "heteroaryloxy carbonyl" means an acyl radical represented by the formula heteroaryl-O-CO-
25 wherein heteroaryl has the significance given above.

The term "aminocarbonyl" (carboxamide) alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amine reacted with a carboxylic acid wherein the amino
30 (amido nitrogen) group is unsubstituted (-NH₂) or a substituted primary or secondary amino group containing one or two substituents selected from the group consisting of hydrogen, alkyl, aryl, aralkyl,

cycloalkyl, cycloalkylalkyl radicals and the like, as recited. A hydroxamate is a N-hydroxycarboxamide.

The term "aminoalkanoyl" means an acyl group derived from an amino-substituted
5 alkanecarboxylic acid wherein the amino group can be a primary or secondary amino group containing substituents independently selected from hydrogen, alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like.

10 The term "halogen" means fluoride, chloride, bromide or iodide. The term "haloalkyl" means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl
15 radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like.

The term "perfluoroalkyl" means an alkyl group wherein each hydrogen has been replaced by a
20 fluorine atom. Examples of such perfluoroalkyl groups, in addition to trifluoromethyl above, are perfluorobutyl, perfluoroisopropyl, perfluorododecyl and perfluorodecyl.

The term "perfluoroalkoxy" alone or in
25 combination, means a perfluoroalkyl ether radical wherein the term perfluoroalkyl is as defined above. Examples of such perfluoroalkoxy groups, in addition to trifluoromethoxy ($\text{F}_3\text{C-O-}$), are perfluorobutoxy, perfluoroisopropoxy, perfluorododecoxy and
30 perfluorodecoxy.

The term "perfluoroalkylthio" alone or in combination, means a perfluoroalkyl thioether radical wherein the term perfluoroalkyl is as defined above.

-90-

Examples of such perfluoroalkylthio groups, in addition to trifluoromethylthio ($\text{F}_3\text{C-S-}$), are perfluorobutylthio, perfluoroisopropylthio, perfluorododecylthio and perfluorodecylthio.

5 The term "aromatic ring" in combinations such as substituted-aromatic ring sulfone or substituted-aromatic ring sulfoxide means aryl or heteroaryl as defined before.

 The term "pharmaceutically acceptable" is
10 used adjectivally herein to mean that the modified noun is appropriate for use in a pharmaceutical product. Pharmaceutically acceptable cations include metallic ions and organic ions. More preferred metallic ions include, but are not limited to
15 appropriate alkali metal (Group Ia) salts, alkaline earth metal (Group IIa) salts and other physiological acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their usual valences. Preferred
20 organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N' -dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-
25 methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid,
30 malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, glucuronic acid,

-91-

pyruvic acid oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

"M" utilized in the reaction schemes that follow represents a leaving group such as halogen, phosphate ester or sulfate ester.

10 Preparation of Useful Compounds

Schemes A through C and Schemes 1 through 19 hereinbelow illustrate chemical processes and transformations that can be useful for the preparation of compounds useful in this invention; i.e., compounds of formulas I, II, III, IV and V and similar cyclic inhibitors. In addition, the preparation of compounds of formula VI and formula VII is illustrated. Compounds of formula VI and formula VII can be used as intermediates in the preparation of the compounds of formulas I, II, III, IV and V or pro-drugs or MMP inhibitors.


In Schemes A through C, the symbol J independently represents R^{20} or other synthetically useful groups such as amides, acid chlorides, mixed anhydrides and the like. The n is 0, 1 or 2 and is preferred to be 1 or 2 in Scheme C. The n of these schemes corresponds to g in formulas VI and VII., and is zero, 1 or 2. The symbol m is 1 or 2. The symbol r is independently 1, 2 or 3. The symbol P represents a protecting group that can also be a member of the group R^6 . In Scheme A, for simplicity and clarity of illustration positional isomers are illustrated with a bond through the ring in standard

fashion. Later Schemes typically only show one positional isomer but positional isomers are represented by these structures and reactions in a manner consistent with Formula I, II, III, IV, V, VI, 5 VII above. Similarly, the symbol B represents O, S, SO, SO₂ and NR⁶. The symbols C and C' independently are electrophilic groups or groups capable of participating in a condensation reaction. Here to it should be noted that the six-membered ring is shown 10 for illustrative purposes but the procedures and/or reagents are applicable to and represent combinations the permit the preparation of 5- to 8-membered rings.

The structures in Schemes 1 through 19 are also shown with compounds that represent the other 15 compounds of this invention. The aromatic ring in Scheme C is aryl and heteroaryl. The moieties of -A-R-E-Y are as defined before. Reactions illustrated involving a spiroheterocyclic nitrogen atom may not be applicable to those compounds with sulfur or 20 oxygen.

- 93 -

Scheme A



Scheme A shows in step 1 the reduction of a heteraryl compound to a carboxyl derivative.

Generally, the first product is a hydrogen-containing amine heterocycle when the starting material is

5 aromatic or an R^6 -containing heterocycle when a partially unsaturated heterocycle is the starting material.

Compound 2 can be treated in several ways depending on the needs of the chemist. In Step 2, 10 the nitrogen can be protected by preparing, for example, a carbobenzoxy (Z) or tert-butoxycarbonyl derivative. Such acylations can be carried out by methods well known in the art, especially the art of amino acid and peptide synthesis. The process of 15 acylation with activated carboxyl group- or activated sulfonyl group-containing reagents to prepare contemplated compounds is carried out in the same manner. Examples of such acylating groups are carbonyl azides, halides, anhydrides, mixed 20 anhydrides, carbodiimide derivatives or other less traditional activated ester groups such as the hydroxybenzotriazole derivative. These acylations can be run in the presence of base including mild bases such as triethylamine or N-ethylmorpholine if 25 desired. The preparation of some activated ester reagents and their use to prepare other compounds useful in this invention is discussed below. It should be recalled that the groups constituting P and serving as a selectively removable protecting group 30 can also be included as part of the group R^6 .

Step 4 of Scheme A shows the alkylation or acylation of Compound 2 to produce compound 5. The

process of acylation and alkylation are as discussed herein. In Step 5, the group J can be changed if desired. An example of such a change is exchange of an ester for a THP-protected hydroxamate conversion of a THP-protected hydroxamate into a hydroxamate or conversion of an acid into a protected hydroxamate or the like.

Steps 3, 7 and 8 show the preparation of sulfur-containing derivatives of the contemplated compounds or intermediates to those compounds. The starting material for the above steps (e.g., compounds 2, 5 and 6) can be treated with a base to deprotonate the carbon alpha to the carbonyl function. This anion can be reacted with a sulfur electrophile to produce a sulfone, sulfoxide or sulfide. Such electrophiles can be of the form of, for example, $R^{24}S-SR^{24}$, $R^{24}SO_2Cl$, $R^{24}SCl$, $R^{24}SOCl$, $R^{24}S(O)-SR^{24}$ and the like where R^{24} is as defined before or is an aryl or heteroaryl sulfur-containing material containing a coupling substituent, $R^{3'}$, that can be used to prepare one of the R^{24} -containing groups. Preparation of the anion requires a base and a strong base may be required such as one of the metal amides, hydrides or alkyls discussed herein. The solvents are nonprotic, and dipolar aprotic solvents are preferred along with an inert atmosphere. Subsequent schemes usually utilize R^3 for the R^{24} group for ease of illustration.


It should be noted that these processes produce sulfides (thio ethers), sulfoxides or sulfones depending on starting material. In

-96-

addition, the sulfides can be oxidized to sulfoxides or sulfones, and the sulfoxides can be oxidized to their corresponding sulfone derivatives. The choice of position in the synthetic sequence to change the oxidation state of sulfur as well as the decision to change oxidation state is under the control of the chemist skilled in the art. Methods of oxidizing sulfur are discussed hereinbelow.

Scheme A, Steps 6, 9, 10 and 12 independently illustrate the interconversion of groups within J. Examples of such interconversions include exchange of an ester for hydroxamic acid or hydroxamic acid derivative, conversion of a carboxylic acid into an activated carbonyl derivative or into a hydroxamic acid or hydroxamic acid derivative (pro-drug or protected derivative), or removal of a protecting group from a hydroxamate derivative. The preparation of activated carbonyl compounds their reaction with nucleophiles such as hydroxamic acid, protected hydroxamates or hydroxamic acid pro-drugs is discussed below as is the conversion of protected hydroxamic acid derivatives into hydroxamic acids. The preparation of, for example, hydroxybenzotriazole/carbodiimide, derived products is discussed herein. The preparation or hydrolysis of esters, amides, amide derivatives, acid chlorides, acid anhydrides, mixed anhydrides and the like are synthetic methods very well known in the art, and are not discussed in detail herein. Step 6 illustrates the conversion of compound 4 into compound 9, without first being converted into compound 7.

Scheme B



5

Scheme B illustrates an alternate method of preparing contemplated compounds. The reagent shown above the arrow in Step 1 is a reagent with two

active groups in addition to the heteroatoms (B) noted before. Here again, the particular reagent illustrated was selected to permit a clear illustration of the reaction, but it is also intended to represent reagents that permit the preparation of the heteroatom position, and 5-, 7- and 8-membered ring size compounds. These reagents are readily selected by those skilled in the art.

C and C' in this Step 1 reagent are independently an electrophile or a group convertible into an electrophile. Such groups include halides, sulfonic acid esters, epoxides, thioepoxides, hydroxyl groups, and the like. This reagent is reacted with a nucleophilic anion of a sulfur containing carbonyl compound such as compound 1. The anion is formed by deprotonation of compound 1 and examples of bases suitable for such a deprotonation are discussed below. Treatment with the above electrophilic reagent is carried out under alkylating conditions well known in the art and discussed herein. The product of this reaction can be either Compound 2 or Compound 3; i.e., the reaction can be carried out as a pot or two step process as required.


Step 3 illustrates the interconversion of J groups if desired as discussed above for Scheme A. Step 4 uses reagent where C, for example, represents a nucleophile as discussed above and C' represents an electrophile or a nucleophile such as hydroxyl, thiol or R⁶-amino. It is noted that C' can be, independently, a nucleophile or an electrophile when m is 2; i.e., the C' groups are not required to be the same when m is 2. When m is 2, treatment with a second mole of base provides the skilled chemist an

-99-

alternative preparation of Compound 5. When C' is hydroxyl, thiol, or R⁶-amino and m is 2, the person skilled in the art can condense Compound 4 with, for example, an aldehyde or ketone, under reductive conditions or with subsequent reduction to form a contemplated compound. As above, the compound where m is 2 can be made in one step (one pot process) or two steps, thus permitting the chemist the choice of having the reagent(s) be the same (one pot) or different (two step).

Scheme B also illustrates the interconversions of the groups within J, the oxidation state of the sulfur and groups on nitrogen; i.e., R⁶ groups, to provide the contemplated compounds. These methods and processes are discussed above for the reactions of Scheme A.

Scheme C



-100-

Scheme C illustrates the nucleophilic displacement of a group D as defined herein. This reaction is carried out in a similar manner to the displacement reactions discussed herein. The choice of oxidation state of the sulfur is made by the person skilled in the art, but sulfoxide or sulfone groups are preferred, and the sulfone is most preferred. The displacement can be carried out either before or after the methylene next to the carbonyl group is reacted to form a spiro heterocyclic group.

Steps 1, 2 and 3 also illustrate that although the nucleophilic displacement can be carried out with one nucleophile (Nu), the product of this reaction can be modified by methods well known in the art and as shown herein to provide the group -A-R-E-Y as defined hereinbefore.

A non-limiting illustration of such a process is provided when D is fluoride. The fluoride leaving group can be directly displaced with the anion of 4-trifluoromethylphenol, 4-trifluoromethoxyphenol, 4-trifluoromethylthiophenol and the like to provide a contemplated compound. This is a one pot process from Compound 4. Other compounds included in -A-R-E-Y can be prepared by displacing the fluoride leaving group with ammonia to provide an amine, which can then be acylated by methods discussed wherein with, for example, 4-trifluoromethylbenzoyl chloride, to form another contemplated product compound.

-101-

The R⁶ function can be changed and/or further modified in compounds or at steps in the Schemes as desired or required by the person skilled in the art to prepare the contemplated compounds.

5 Interconversion of dual purpose functional groups such as short or long term protecting groups into other R⁶ groups has been mentioned. Many other routine and/or useful conversions, including the preparation of synthetic intermediates, are very well

10 known in the art. A few non-limiting examples of such conversions or reactions include: reductions; nucleophilic displacement/substitution reactions; exchange or preparation of carboxylic or sulfonic acids, amides, esters, acid halides, mixed anhydrides

15 and the like; electrophilic displacement/substitution reactions; oxidations; ring/chain conversions, ring opening reactions, condensation reactions including those involving sulfonyl or carbonyl groups and/or carbon-hydrogen bonds influenced by either or both of

20 those groups. The selection of preparative methods or conversion methods of the contemplated compounds and the order of the reaction(s) is made by the skilled person. It is expected that should a particular sequence or method prove to be undesirable

25 that an alternative will be selected and used. Included is the choice of preparing/adding the groups in a single step using a convergent inhibitor strategy or preparing the final R⁶ group following a stepwise strategy.

30 Thus, in general, the choices of starting material and reaction conditions can vary as is well known to those skilled in the art. Usually, no

-102-

single set of conditions is limiting because variations can be applied as required. Conditions are also selected as desired to suit a specific purpose such as small scale preparations or large
5 scale preparations. In either case, the use of less safe or less environmentally sound materials or reagents is usually be minimized. Examples of such materials are diazomethane, diethyl ether, heavy metal salts, dimethyl sulfide, chloroform, benzene
10 and the like.

These reactions can be carried out under a dry inert atmosphere such a nitrogen or argon if desired. Selected reactions known to those skilled in the art, can be carried out under a dry atmosphere
15 such as dry air whereas other synthetic steps, for example, aqueous acid or base ester or amide hydrolysis, can be carried out under laboratory air. In addition, some processes of these syntheses can be carried out in a pressure apparatus at pressures
20 above, equal to or below atmospheric pressure. The use of such an apparatus aids in the control of gaseous reagents such as hydrogen, ammonia, trimethylamine, methylamine, oxygen and the like, and can also help prevent the leakage of air or humidity
25 into a reaction in progress. This discussion is not intended to be exhaustive as it is readily noted that additional or alternative methods, conditions, reactions or systems can be identified and used by a chemist of ordinary skill.

30 The illustrated reactions are usually carried out at a temperature of between -25°C to solvent reflux under an inert atmosphere such as nitrogen or argon. The solvent or solvent mixture

-103-

can vary widely depending upon reagents and other conditions and can include polar or dipolar aprotic solvents as listed or mixtures of these solvents. Reactions can be carried out at lower temperatures
5 such as dry ice/acetone or liquid nitrogen temperature if desired to carry out such reactions as metalations or anion formations using strong bases.

In some cases, amines such as triethylamine, pyridine or other non-reactive bases
10 can serve as reagents and/or solvents and/or co-solvents. In some instances, in these reactions and other reactions in these Schemes, protecting groups can be used to maintain or retain groups in other parts of a molecule(s) at locations that is(are) not
15 desired reactive centers. Examples of such groups that the skilled person can maintain or retain include, amines, other hydroxyls, thiols, acids and the like. Such protecting groups can include acyl groups, arylalkyl groups, carbamoyl groups, ethers,
20 alkoxyalkyl ethers, cycloalkoxy ethers, arylalkyl groups, silyl groups including trisubstituted silyl groups, ester groups and the like. Examples of such protecting groups include acetyl, trifluoroacetyl, tetrahydropyran (THP), benzyl, tert-butoxy carbonyl
25 (BOC or TBOC), benzyloxycarbonyl (Z or CBZ), tert-butyltrimethylsilyl (TBDMS) or methoxyethoxymethylene (MEM) groups. The preparation of such protected compounds as well as their removal is well known in the art. The protecting groups can also be used as
30 substituents in the contemplated compounds whose utility is as a drug rather than as a synthetic intermediate.

-104-

Many reactions or processes involve bases that can act as reactants, reagents, deprotonating agents, acid scavengers, salt forming reagents, solvents, co-solvents and the like. Bases that can be used include, for example, metal hydroxides such as sodium, potassium, lithium, cesium or magnesium hydroxide, oxides such as those of sodium, potassium, lithium, calcium or magnesium, metal carbonates such as those of sodium, potassium, lithium, cesium, calcium or magnesium, metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, primary (I°), secondary (II°) or tertiary (III°) organic amines such as alkyl amines, arylalkyl amines, alkylarylalkyl amines, heterocyclic amines or heteroaryl amines, ammonium hydroxides or quaternary ammonium hydroxides. As non-limiting examples, such amines can include triethylamine, trimethylamine, diisopropylamine, methyldiisopropylamine, diazabicyclononane, tribenzylamine, dimethylbenzylamine, morpholine, N-methylmorpholine, N,N'-dimethylpiperazine, N-ethylpiperidine, 1,1,5,5-tetramethylpiperidine, dimethylaminopyridine, pyridine, quinoline, tetramethylethylenediamine, and the like. Non-limiting examples of ammonium hydroxides, usually made from amines and water, can include ammonium hydroxide, triethylammonium hydroxide, trimethylammonium hydroxide, methyldiisopropylammonium hydroxide, tribenzylammonium hydroxide, dimethylbenzylammonium hydroxide, morpholinium hydroxide, N-methylmorpholinium hydroxide, N,N'-dimethylpiperazinium hydroxide, N-ethylpiperidinium hydroxide, and the like. As non-limiting examples,

-105-

quaternary ammonium hydroxides can include tetraethylammonium hydroxide, tetramethylammonium hydroxide, dimethyldiisopropyl-ammonium hydroxide, benzylmethyldiisopropylammonium hydroxide, 5 methyldiazabicyclononylammonium hydroxide, methyltribenzylammonium hydroxide, N,N-dimethyl-morpholiniumhydroxide, N,N,N',N'-tetramethylpiperazinium hydroxide, and N-ethyl-N'-hexylpiperidinium hydroxide and the like.

10 Metal hydrides, amides or alcoholates such as calcium hydride, sodium hydride, potassium hydride, lithium hydride, aluminum hydride, diisobutylaluminum hydride (DIBAL) sodium methoxide, potassium tert-butoxide, calcium ethoxide, magnesium 15 ethoxide, sodium amide, potassium diisopropyl amide and the like can also be suitable reagents. Organometallic deprotonating agents such as alkyl or aryl lithium reagents such as methyl lithium, phenyl lithium, tert-butyl lithium, lithium acetylide or 20 butyl lithium, Grignard reagents such as methylmagnesium bromide or methymagnesium chloride, organocadmium reagents such as dimethylcadmium and the like can also serve as bases for causing salt formation or catalyzing the reaction. Quaternary 25 ammonium hydroxides or mixed salts are also useful for aiding phase transfer couplings or serving as phase transfer reagents. Pharmaceutically acceptable bases can be reacted with acids to form contemplated pharmaceutically acceptable salts. It should also be 30 noted that optically active bases can be used to make optically active salts which can be used for optical resolutions.

-106-

Generally, reaction media can comprise a single solvent, mixed solvents of the same or different classes or serve as a reagent in a single or mixed solvent system. The solvents can be protic, 5 non-protic or dipolar aprotic. Non-limiting examples of protic solvents include water, methanol (MeOH), denatured or pure 95% or absolute ethanol, isopropanol and the like. Typical non-protic solvents include acetone, tetrahydrofuran (THF), 10 dioxane, diethyl ether, tert-butylmethyl ether (TBME), aromatics such as xylene, toluene, or benzene, ethyl acetate, methyl acetate, butyl acetate, trichloroethane, methylene chloride, ethylenedichloride (EDC), hexane, heptane, isooctane, 15 cyclohexane and the like. Dipolar aprotic solvents include compounds such as dimethylformamide (DMF), dimethylacetamide (DMAc), acetonitrile, DMSO, hexamethylphosphorus triamide (HMPA), nitromethane, tetramethylurea, N-methylpyrrolidone and the like. 20 Non-limiting examples of reagents that can be used as solvents or as part of a mixed solvent system include organic or inorganic mono- or multi-protic acids or bases such as hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, 25 succinic acid, triethylamine, morpholine, N-methylmorpholine, piperidine, pyrazine, piperazine, pyridine, potassium hydroxide, sodium hydroxide, alcohols or amines for making esters or amides or thiols for making contemplated products and the like. 30

The preparation of compounds contemplated herein can require the oxidation of nitrogen or sulfur to N-oxide derivatives or sulfoxides or sulfones. Reagents for this process can include, in

-107-

a non-limiting example, peroxymonosulfate (OXONE®), hydrogen peroxide, meta-chloroperbenzoic acid, perbenzoic acid, peracetic acid, perlactic acid, tert-butyl peroxide, tert-butyl hypochlorite, sodium
5 hypochlorite, hypochlorous acid, sodium meta-periodate, periodic acid and the like with the weaker agents being most useful for the preparation of sulfones and sulfoxides. Protic, non-protic, dipolar aprotic solvents, either pure or mixed, can be
10 chosen, for example, methanol/water.

The oxidation can be carried out at temperature of about -78° to about 50° degrees Centigrade, and normally selected from a range -10°C to about 40°C. Sulfoxides are best prepared using
15 one equivalent of oxidizing agent. It can be desirable in the case of more active oxidizing agents, but not required, that the reactions be carried out under an inert gas atmosphere with or without degassed solvents. It should be noted that
20 the oxidation of sulfides to sulfones can be carried out in one step or two steps via the sulfoxide as desired by the chemist.

Reduction is a well known process in the art with a useful method being hydrogenation. In
25 such cases (catalytic reduction), there can be a metal catalyst such as Rh, Pd, Pt, Ni or the like with or without an additional support such as carbon, barium carbonate and the like. Solvents can be protic or non-protic pure solvents or mixed solvents
30 as required. The reductions can be carried out at atmospheric pressure to a pressure of multiple atmospheres with atmospheric pressure to about 40 pounds per square inch (psi) preferred or very high

-108-

pressures in special hydrogenation equipment well known in the art.

Reductive alkylation of amines or active methylene compounds is also a useful method of preparing compounds. Such alkylations can be carried out under reductive hydrogenation conditions as presented above using, for example, aldehydes or ketones. Hydride transfer reagents such as sodium cyanoborohydride, aluminum hydride, lithium aluminumhydride, borane, sodium borohydride, di-isobutylaluminum hydride and the like are also useful as reagents for reductive alkylation. Acyl groups can be reduced in a similar manner to produce substituted amines.

Alternative methods of alkylating carbon or nitrogen are direct alkylation. Such an alkylation, as is well known in the art, can be carried by treatment of an activated carbon containing at least one hydrogen with base to form the corresponding anion, adding an electrophilic reagent and permitting the SN2 reaction to proceed. An amine to be alkylated is treated similarly except that deprotonation may not be required. Electrophiles include halogen derivatives, sulfonate esters, epoxides and the like.

Bases and solvents for alkylation reactions are those discussed above. Preferred are bases that are hindered such that competition with the electrophile is minimized. Additional preferred bases are metal hydrides, amide anions or organometallic bases such as n-butyl lithium. The solvents, solvent mixtures or solvent/reagent mixtures discussed are satisfactory but non-protic or

-109-

dipolar aprotic solvents such as acetone, acetonitrile, DMF and the like are examples of preferred classes.

Acids are used in many reactions during various syntheses. For example, removal of the THP protecting group to produce the hydroxamic acid. The acid can be a mono-, di- or tri-protic organic or inorganic acid. Examples of acids include hydrochloric acid, phosphoric acid, sulfuric acid, acetic acid, formic acid, citric acid, succinic acid, hydrobromic acid, hydrofluoric acid, carbonic acid, phosphorus acid, p-toluene sulfonic acid, trifluoromethane sulfonic acid, trifluoroacetic acid, difluoroacetic acid, benzoic acid, methane sulfonic acid, benzene sulfonic acid, 2,6-dimethylbenzene sulfonic acid, trichloroacetic acid, nitrobenzoic acid, dinitrobenzoic acid, trinitrobenzoic acid, and the like. They can also be Lewis acids such as aluminum chloride, borontrifluoride, antimony pentafluoride and the like. Acids in a protic can also be used to hydrolyze esters, amides and the like as well as catalyze exchange reactions.

Conversion of a carboxylic acid protected as an ester or amide into a hydroxamic acid or hydroxamic acid derivative such as an O-arylalkylether or O-cycloalkoxyalkylether group is useful. In the case where hydroxylamine is used, treatment of an ester or amide with one or more equivalents of hydroxylamine hydrochloride at room temperature or above in a solvent or solvents, usually protic or partially protic, such as those listed above can provide a hydroxamic acid directly. This exchange process can be further catalyzed by the

-110-

addition of additional acid. Alternatively, a base such as a salt of an alcohol used as a solvent, for example, sodium methoxide in methanol, can be used to form hydroxylamine from hydroxylamine hydrochloride in situ which can exchange with an ester or amide. As mentioned above, exchange can be carried out with a protected hydroxyl amine such as tetrahydropyranylhydroxyamine (THPONH₂), benzylhydroxylamine (BnONH₂), and the like in which case compounds such as shown in Schemes A, B and C that are tetrahydropyranyl (THP) or benzyl (Bn) hydroxamic acid derivatives are the products. Removal of the protecting groups when desired, for example, following further transformations in another part of the molecule or following storage, is accomplished by standard methods well known in the art such as acid hydrolysis of the THP group as discussed above or reductive removal of the benzyl group with hydrogen and a metal catalyst such as palladium, platinum, palladium on carbon or nickel.

In the case where R²⁰ is hydroxyl; i.e., where the intermediate is a carboxylic acid, standard coupling reactions can be used. For example, the acid can be converted into an acid chloride, mixed anhydride or activated ester such as hydroxybenzotriazole and treated with hydroxylamine or a protected hydroxylamine in the presence of a non-competitive base to the nitrogen acylated compound. This is the same product as discussed above. Couplings of this nature are well known in the art and especially the art related to peptide and amino acid chemistry.


-111-

Compounds contemplated herein can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers, enantiomers, diastereoisomers, as well as in the form of racemic or nonracemic mixtures. A compound can also exist in other isomeric forms such as ortho, meta and para isomers, cis and trans isomers, syn and anti isomers, E and Z isomers, tautomeric isomers, alpha and beta isomers, axial and equatorial isomers and isomers due to hindered rotation. An isomer can exist in equilibrium with another isomer in a mammal or a test system. Such a compound can also exist as an isomeric equilibrium system with a solvent or water, for example, as a hydrated ketone or aldehyde, as is well known in the art. All isomers are included as compounds of this invention.

The chemical reactions described above are generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, are applicable to the preparation of the corresponding compounds that are contemplated.


- 112 -

Scheme 1




5

Scheme 2




- 113 -

Scheme 3




Scheme 4



- 114 -


Scheme 5



5


- 115 -

Scheme 6




- 116 -

Scheme 7




Scheme 8




- 118 -

Scheme 9




-119-

Scheme 10




- 120 -

Scheme 11




-121-

Scheme 12




Scheme 13


In a similar manner, the following analogs can be made.



Scheme 14




Scheme 15




-125-

Scheme 16




- 126 -

Scheme 17




- 127 -

Scheme 18



-128-

Scheme 19



5

Table 1 through Table 150, below, show several contemplated aromatic sulfone hydroxamic acid inhibitor compounds or structural formulas that illustrate substituent groups. Each group of

-129-

compounds is illustrated by a generic formula, or formulae, followed by a series of preferred moieties or groups that constitute various substituents that can be attached at the position clearly shown in the generic structure. The substituent symbols, e.g., R1 and R2 and R3, are as shown in each Table, and are typically not those used before. One or two bonds (wavy lines) are shown with those substituents to indicate the respective positions of attachment in the illustrated compound. This system is well known in the chemical communication arts and is widely used in scientific papers and presentations. For example in Table 2, R1 and R2 together with the atoms to which they are bonded is the variable group with the structural entities that can substitute for R1 and R2 together shown in the balance of that table.

20

-130-

Table 1








































Table 2





- 132 -

Table 3

 R^3 


-133-

Table 4



- 134 -



Table 5



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		



- 135 -

Table 6















-136-

Table 7




-137-

Table 8



- 138 -

Table 9



1	8	15
2	9	16
3	10	17
4	11	18
5	12	19
6	13	20
7	14	21

- 139 -

Table 10






R³

Table 11





-141-

Table 12





1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

Table 13















- 143 -

Table 14




- 144 -

Table 15



-145-




















Table 16



1	8	15
2	9	16
3	10	17
4	11	18
5	12	19
6	13	20
7	14	21



- 146 -

Table 17



-147-

Table 18



- 148 -

Table 19









Table 20





-150-

Table 21





-151-

Table 22



- 152 -

Table 23



-153-

Table 24




















 R^3 

Table 25








Table 26



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

-156-

Table 27



-157-

Table 28





Table 29








Table 30

 R^3 

-161-



Table 32



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

-162-

Table 33



-163-

Table 34





Table 35








Table 36



1 	8 	15
2 	9 	16
3 	10 	17
4 	11 	18
5 	12 	19
6 	13 	20
7 	14 	21

Table 37



-167-

Table 38







Table 39



-169-

Table 40





Table 41








Table 42



-172-

Table 43



1	8	15
2	9	16
3	10	17
4	11	18
5	12	19
6	13	20
7	14	21

Table 44





Table 45








Table 46



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		



-176-

Table 47





-177-

Table 48




-178-

Table 49



-179-

Table 50



1 	8 	15
2 	9 	16
3 	10 	17
4 	11 	18
5 	12 	19
6 	13 	20
7 	14 	21

-180-

Table 51





Table 52






Table 53



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

- 183 -

Table 54









Table 55




-185-

Table 56



-186-

Table 57



1 	8 	15
2 	9 	16
3 	10 	17
4 	11 	18
5 	12 	19
6 	13 	20
7 	14 	21

- 187 -

Table 58








Table 59



-189-



Table 60

 R^3

1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		



-190-

Table 61



-191-

Table 62



-192-

Table 63




 R^3 

Table 64



1	8	15
2	9	16
3	10	17
4	11	18
5	12	19
6	13	20
7	14	21

Table 65





Table 66







 R^3 

Table 67





- 197 -

Table 68





- 198 -

Table 69





-199-

Table 70





-200-

Table 71



-201-

Table 72



- 202 -

Table 73







Table 74



- 204 -

Table 75









Table 76




-206-

Table 77



-207-

Table 78



1 	8 	15
2 	9 	16
3 	10 	17
4 	11 	18
5 	12 	19
6 	13 	20
7 	14 	21

-208-

Table 79






 R^3 

Table 80



-210-

Table 81



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

-211-

Table 82







Table 83



- 213 -

Table 84







Table 85



-215-

Table 86






















Table 87








Table 88



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

- 218 -

Table 89



-219-

Table 90









Table 91



- 221 -

Table 92



- 222 -

Table 93








Table 94



- 224 -



Table 95



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		



- 225 -

Table 96





- 226 -

Table 97





-227-

Table 98



- 228 -

Table 99



-229-

Table 100

























Table 101



- 231 -



Table 102



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		

- 232 -

Table 103



- 233 -

Table 104








Table 105

 R^3 

- 235 -




















Table 106



1	8	15
2	9	16
3	10	17
4	11	18
5	12	19
6	13	20
7	14	21

-236-

Table 107



- 237 -

Table 108









Table 109

 R^3 



- 239 -

Table 110



- 240 -

Table 111



- 241 -

Table 112


























Table 113





- 243 -

Table 114



- 244 -

Table 115



-245-

Table 116









Table 117





- 247 -

Table 118



- 248 -

Table 119



- 249 -

Table 120













































Table 121



- 251 -

Table 122



1 	9 	16
2 	10 	17
3 	11 	18
4 	12 	19
5 	13 	20
6 	14 	21
7 	15 	22
8 		



Table 123

Table 124

















Table 125



-255-

Table 126





Table 127






Table 128



1 	8 	15
2 	9 	16
3 	10 	17
4 	11 	18
5 	12 	19
6 	13 	20
7 	14 	21

Table 129




Table 130






Table 131



-261-

Table 132



- 262 -

Table 133







Table 134





- 264 -

Table 135





- 265 -

Table 136





- 266 -

Table 137



-267-

Table 138



- 268 -

Table 139





Table 140









Table 141





- 271 -

Table 142





- 272 -

Table 143





- 273 -

Table 144





- 274 -

Table 145





- 275 -

Table 146





- 276 -

Table 147





-277-

Table 148





- 278 -

Table 149



-279-

Table 150



5

A contemplated inhibitor compound is used for treating a host mammal such as a mouse, rat, rabbit, dog, horse, primate such as a monkey, chimpanzee or human that has a condition associated with pathological matrix metalloprotease activity.

Also contemplated is use of a contemplated metalloprotease inhibitor compound in the treatment of a disease state that can be affected by the activity of metalloproteases TNF- α convertase.

-280-

Exemplary of such disease states are the acute phase responses of shock and sepsis, coagulation responses, hemorrhage and cardiovascular effects, fever and inflammation, anorexia and cachexia.

5 In treating a disease condition associated with pathological matrix metalloproteinase activity, a contemplated MMP inhibitor compound can be used in the form of an amine salt derived from an inorganic or organic acid. Exemplary salts include but are not
10 limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate,
15 hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate,
20 picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate.

Also, a basic nitrogen-containing group can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl
25 chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and
30 others to provide enhanced water-solubility. Water or oil-soluble or dispersible products are thereby obtained as desired. The salts are formed by combining the basic compounds with the desired acid.

-281-

Other compounds useful in this invention that are acids can also form salts. Examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or
5 with organic bases or basic quaternary ammonium salts.

In some cases, the salts can also be used as an aid in the isolation, purification or resolution of the compounds of this invention.

10 Total daily dose administered to a host mammal in single or divided doses can be in amounts, for example, for 0.001 to 30 mg/kg body weight daily and more usually 0.01 to 10 mg. Dosage unit compositions can contain such amounts or submultiples
15 thereof to make up the daily dose. A suitable dose can be administered, in multiple sub-doses per day. Multiple doses per day can also increase the total daily dose, should this be desired by the person prescribing the drug.

20 The dosage regimen for treating a disease condition with a compound and/or composition of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of
25 the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound
30 is administered as part of a drug combination. Thus, the dosage regimen actually employed can vary widely and therefore can deviate from the preferred dosage regimen set forth above.

-282-

A compound of the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as

-283-

oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of
5 solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa
10 butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are sold at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

15 Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of
20 administration. If administered per os, a contemplated aromatic sulfone hydroximate inhibitor compound can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate,
25 magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or
30 tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can

-284-

also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

5 For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or
10 granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. A contemplated aromatic sulfone hydroximate inhibitor compound can be dissolved in water, polyethylene glycol, propylene glycol,
15 ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration
20 can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and
25 suspending agents, and sweetening, flavoring, and perfuming agents.


The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the
30 mammalian host treated and the particular mode of administration.

Best Mode For Carrying Out The Invention

-285-

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific
5 embodiments are, therefore, to be construed as merely illustrative, and not limiting of the remainder of the disclosure in any way whatsoever.

Example 1: Preparation of N-hydroxy-2-[(4-
10 phenoxyphenyl)sulfonyl]acetamide



Part A: To a solution of 3-bromopyruvic
15 acid hydrate (1.95 g, 11.7 mmol) cooled to zero degrees Celsius in methanol (50 mL) was added 4-(phenoxy)benzenethiol (2.35 g, 11.7 mmol). The solution was stirred for 15 minutes followed by concentration in vacuo. The residue was partitioned
20 between ethyl acetate and H₂O and the organic layer was dried over magnesium sulfate. Concentration in vacuo provided the crude sulfide as a yellow solid that was used without any additional purification.


Part B: To a solution of the crude sulfide
25 of part A (1.2 g, <2.6 mmol) in methanol/H₂O cooled to zero degrees Celsius was added Oxone® (3.5 g, 5.72 mmol). The solution was stirred for 1 hour followed by removal of excess Oxone® by filtration. The

-286-

filtrate was concentrated and the residue was dissolved into ethyl acetate and washed with saturated NaHCO_3 and saturated NaCl and dried over magnesium sulfate. After concentration in vacuo the
5 resulting residue was dissolved into methanol and thionyl chloride (1.9 mL, 26 mmol) was added. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a solid (350 mg, 44%). MS(CI) MH^+ calculated for $\text{C}_{15}\text{H}_{14}\text{O}_5\text{S}$: 307, found 307.

10 Part C: To a solution of the sulfone (350 mg, 1.1 mmol) in methanol (2 mL) and THF (THF; 2 mL) was added 50 percent aqueous hydroxylamine (1 mL). The solution was stirred overnight. Trituration with ethyl acetate provided the title compound as a white
15 solid (270 mg, 77%). HPLC purity: >97%. MS(CI) MH^+ calculated for $\text{C}_{14}\text{H}_{13}\text{NO}_5\text{S}$: 308, found 308.

Example 2: Preparation of N-hydroxy-2-methyl-2-[(4-
20 phenoxyphenyl)sulfonyl]propanamide



Part A: To a solution of 4-
(phenoxy)benzenethiol (3.8 g, 18.8 mmol) in methanol
25 (60 mL) cooled to zero degrees Celsius was added t-butyl bromoacetate (2.8 mL, 18.8 mmol) and triethylamine (2.6 mL, 19.0 mmol). The solution was

-287-

stirred for 30 minutes and was then concentrated in vacuo. The residue was partitioned between ethyl acetate and H₂O and the organic layer was washed with saturated NaCl and dried over magnesium sulfate.

5 Concentration in vacuo provided the sulfide as an oil. To a solution of the sulfide in dichloromethane (85 mL) was added m-chloroperbenzoic acid (13.8 g, 43.2 mmol) over 15 minutes. The solution was stirred at ambient temperature for 2 hours. The reaction was
10 quenched by the addition of aqueous Na₂SO₃. After 30 minutes the solution was filtered through Celite®. The filtrate was washed with 25 percent aqueous hydroxylamine, 1N HCl, and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica,
15 ethyl acetate/hexane) provided the sulfone as a white solid (4.0 g, 68%).

Part B: To a solution of the sulfone of part A (3.2 g, 9.2 mmol) in THF (65 mL) cooled to zero degrees Celsius was added sodium hydride (730 mg
20 of a 60 percent dispersion in mineral oil, 18.4 mmol). After 10 minutes, methyl iodide (2.28 mL, 36.8 mmol) was added dropwise and the mixture was stirred for 18 hours at ambient temperature. The reaction was quenched with H₂O and concentrated in
25 vacuo. The aqueous residue was diluted with ethyl acetate and the organic phase was washed with H₂O and dried over Na₂SO₄. Concentration in vacuo provided the dimethyl compound as an off-white solid (3.2 g, 92%). HPLC purity: 95%.

30 Part C: To a solution of the dimethyl compound of part B (3.2 g, 8.5 mmol) in anisole (10

-288-


mL) was added trifluoroacetic acid (30 mL) and the solution was stirred for 30 minutes. Concentration in vacuo followed by trituration (ethyl ether) provided the acid as a white solid (750 mg, 28%).

5 HPLC purity: 99%. MS(CI) MH^+ calculated for $C_{16}H_{16}O_5S$: 321, found 321.

Part D: To a solution of the acid of part C (723 mg, 2.26 mmol) in DMF (DMF; 4.5 mL) was added N-hydroxybenzotriazole• H_2O (HOBT; 366 mg, 2.71 mmol)
10 and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC; 476 mg, 2.49 mmol). After the solution was stirred for 1 hour at ambient temperature 50 percent aqueous hydroxylamine (0.40 mL, 6.8 mmol) was added. After 15 minutes the
15 solution was partitioned between ethyl acetate and H_2O . The organic layer was washed with H_2O and saturated NaCl and dried over Na_2SO_4 . Reverse phase chromatography (on silica, acetonitrile/ H_2O) provided the title compound as a white foam (434 mg, 57%).
20 HPLC purity: 99%. MS(CI) $M+Li^+$ calculated for $C_{16}H_{17}NO_5O$: 342, found 342.

Example 3: Preparation of 1,1-dimethylethyl ester
4-[(hydroxyamino)carbonyl]-4-
25 [(phenoxyphenyl)-sulfonyl]-1-
piperidinecarboxylic acid

-289-



Part A: A solution of 4-(phenoxy)benzenethiol (2.03 g, 10.0 mmol) in DMSO (DMSO; 20 mL) was heated
5 to sixty-five degrees Celsius for 5 hours. The solution remained at ambient temperature for 18 hours. The solution was extracted with ethyl acetate and the combined organic layers were washed with H₂O and saturated NaCl and dried over magnesium sulfate.
10 Concentration in vacuo provided the disulfide as a yellow oil (2.3 g, quantitative yield).

Part B: To a solution of ethyl isonipecotate (15.7 g, 0.1 mol) in THF (100 mL) was added a solution of di-tert-butyl dicarbonate (21.8
15 g, 0.1 mol) in THF (5 mL) dropwise over 20 minutes. The solution was stirred overnight at ambient temperature and concentrated in vacuo to yield a light oil. The oil was filtered through silica gel (7:3 ethyl acetate/hexanes) and concentrated in vacuo
20 to give the BOC-piperidine compound (26.2 g, quantitative yield) as a clear, colorless oil.

Part C: To a solution of diisopropylamine (2.8 mL, 20 mmol) in THF (30 mL), cooled to minus
seventy-eight degrees Celsius, was added n-butyl
25 lithium (12.5 mL, 20 mmol) dropwise. After 15

-290-

minutes, the BOC-piperidine compound of part B (2.6 g, 10 mmol) in THF (10 mL) was added dropwise. After 1.5 hours the solution was cooled to minus sixty degrees Celsius and the disulfide of part A (2.0 g, 10 mmol) in THF (7 mL). The solution was stirred at ambient temperature for 2 hours. The solution was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and saturated NaCl and dried over magnesium sulfate.

10 Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as an oil (1.8 g, 40%).

Part D: To a solution of the sulfide of part C (1.8 g, 3.95 mmol) in dichloromethane (75 mL) cooled to zero degrees Celsius, was added m-chloroperbenzoic acid (1.7 g, 7.9 mmol). The solution was stirred for 1.5 hours followed by dilution with H₂O and extraction with dichloromethane. The organic layer was washed with 10 percent Na₂SO₄, H₂O, and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a solid (1.15 g, 59%).

20

Part E: To a solution of the sulfone of part D (800 mg, 1.63 mmol) in THF (9 mL) and ethanol (9 mL) was added NaOH (654 mg, 16.3 mmol) in H₂O (3 mL). The solution was heated at sixty-five degrees Celsius for 18 hours. The solution was concentrated in vacuo and the residue was dissolved in H₂O. Following acidification with 2N HCl to pH 4, the solution was extracted with ethyl acetate and the organic layer was washed with saturated NaCl and

25

30

-291-

dried over magnesium sulfate. Concentration in vacuo provided the acid as a white foam (790 mg, quantitative yield). Analytical calculated for $C_{23}H_{27}NO_7S$: C, 59.86; H, 5.90; N, 3.04; S, 6.95. Found:


5 C, 59.49; H, 6.37; N, 2.81; S, 6.59.

Part F: To a solution of the acid of part G (730 mg, 1.58 mmol) in DMF (9 mL) was added HOBT (256 mg, 1.90 mmol) followed by EDC (424 mg, 2.21 mmol), 4-methylmorpholine (0.521 mL, 4.7 mmol) and 50 percent aqueous hydroxylamine (1.04 mL, 15.8 mmol). The solution was stirred for 20 hours and additional N-hydroxybenzotriazole•H₂O (256 mg), EDC (424 mg) and 50 percent aqueous hydroxylamine (1.04 mL) were added. After an additional 24 hours of stirring the solution was diluted with H₂O and extracted with ethyl acetate and the organic layer was washed with saturated NaCl and dried over magnesium sulfate. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (460 mg, 61%).

15 HPLC purity: >99%. Analytical calculated for $C_{23}H_{28}N_2O_7S$: C, 57.97; H, 5.92; N, 5.88; S, 6.73. Found: C, 57.95; H, 6.02; N, 5.81; S, 6.85.

Example 4: Preparation of N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-4-piperidinecarboxamide,
25 monohydrochloride

-292-



Part A: A solution of 4-(phenoxy)benzenethiol (2.03 g, 10.0 mmol) in DMSO (20 mL) was heated to sixty-five degrees Celsius for 5 hours. The solution remained at ambient temperature for 18 hours. The solution was extracted with ethyl acetate and the combined organic layers were washed with H₂O and saturated NaCl and dried over magnesium sulfate. Concentration in vacuo provided the disulfide as a yellow oil (2.3 g, quantitative yield).

Part B: To a solution of ethyl isonipecotate (15.7 g, 0.1 mol) in THF (100 mL) was added a solution of di-tert-butyl dicarbonate (21.8 g, 0.1 mol) in THF (5 mL) dropwise over 20 minutes. The solution was stirred overnight at ambient temperature and concentrated in vacuo to yield a light oil. The oil was filtered through silica gel (on silica, ethyl acetate/hexane) and concentrated in vacuo to give the BOC-piperidine compound as a clear, colorless oil (26.2 g, quantitative yield).

Part C: To a solution of diisopropylamine (2.8 mL, 20 mmol) in THF (30 mL), cooled to minus seventy-eight degrees Celsius, was added n-butyl lithium (12.5 mL, 20 mmol) dropwise. After 15

-293-

minutes, the BOC-piperidine compound of part B (2.6 g, 10 mmol) in THF (10 mL) was added dropwise. After 1.5 hours the solution was cooled to minus 60 degrees Celsius and the disulfide of part A (2.0 g, 10 mmol) in THF (7 mL) was added. The solution was stirred at ambient temperature for 2 hours. The solution was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and saturated NaCl and dried over magnesium sulfate.

10 Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as an oil (1.8 g, 40%).

Part D: To a solution of the sulfide of part C (1.8 g, 3.95 mmol) in dichloromethane (75 mL) cooled to zero degrees C, was added m-chloroperbenzoic acid (1.7 g, 7.9 mmol). The solution was stirred for 1.5 hours followed by dilution with H₂O and extraction with dichloromethane. The organic layer was washed with 10 percent Na₂SO₃, H₂O, and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a solid (1.15 g, 59%).

15 20

Part E: To a solution of the sulfone of part D (800 mg, 1.63 mmol) in THF (9 mL) and ethanol (9 mL) was added NaOH (654 mg, 16.3 mmol) in H₂O (3 mL). The solution was heated at sixty-five degrees Celsius for 18 hours. The solution was concentrated in vacuo and the residue was dissolved in H₂O. Following acidification with 2N HCl to pH 4, the solution was extracted with ethyl acetate and the organic layer was washed with saturated NaCl and

25 30

-294-

dried over magnesium sulfate. Concentration in vacuo provided the acid as a white foam (790 mg, quantitative yield). analytical calculated for $C_{23}H_{27}NO_7S$: C, 59.86; H, 5.90; N, 3.04; S, 6.95. Found:

5 C, 59.49; H, 6.37; N, 2.81; S, 6.59.

Part F: To a solution of the acid of part G (730 mg, 1.58 mmol) in DMF (9 mL) was added HOBT (256 mg, 1.90 mmol) followed by EDC (424 mg, 2.21 mmol), 4-methylmorpholine (0.521 mL, 4.7 mmol) and 50

10 percent aqueous hydroxylamine (1.04 mL, 15.8 mmol). The solution was stirred for 20 hours and additional HOBT (256 mg), EDC (424 mg) and 50 percent aqueous hydroxylamine (1.04 mL) were added. After an additional 24 hours of stirring the solution was

15 diluted with H_2O , and extracted with ethyl acetate. The organic layer was washed with saturated NaCl and dried over magnesium sulfate. Reverse phase HPLC (acetonitrile/ H_2O) provided the hydroxamate as a white solid (460 mg, 61%). HPLC purity: >99%. analytical

20 calculated for $C_{23}H_{29}N_2O_7S$: C, 57.97; H, 5.92; N, 5.88; S, 6.73. Found: C, 57.95; H, 6.02; N, 5.81; S, 6.85.

Part G: Into a solution of the hydroxamate of part F (385 mg, 0.808 mmol) in ethyl acetate (25 mL), cooled to zero degrees Celsius, was bubbled HCl


25 gas for 5 minutes. After standing for 30 minutes, the solution was concentrated in vacuo. Trituration with ethyl ether provided the title compound as a white solid (330 mg, quantitative yield). MS(CI) MH^+ calculated for $C_{18}H_{20}N_2O_5S$: 377, found 377. HRMS

30 calculated for $C_{18}H_{20}N_2O_5S$: 377.1171, found 377.1170. analytical calculated for $C_{18}H_{20}N_2O_5S \cdot 1.1HCl \cdot 0.25H_2O$: C,

-295-

51.35; H, 5.17; N, 6.65; S, 7.62; Cl, 9.26. Found: C, 51.58; H, 5.09; N, 6.55; S, 8.02; Cl, 9.09.

Example 5: Preparation of (E) N-hydroxy-2-
5 [(4-phenoxyphenyl)sulfonyl]-3-
phenyl-2-propenamide



10 Part A: To a solution of 4-(phenoxy)benzenethiol (5.00 g, 24.7 mmol) in methanol (100 mL) cooled to zero degrees Celsius was added t-butylbromoacetate (3.99 mL, 24.7 mmol). Following the addition of triethylamine (3.60 mL, 25.8 mmol)
15 the solution was stirred for 40 minutes. The solution was concentrated in vacuo and the resulting residue was dissolved in ethyl acetate and washed with H₂O and saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the sulfide as an oil
20 (7.9 g, quantitative yield).

Part B: To a solution of the sulfide of part A (7.9 g, 24.7 mmol) in methanol (180 mL) and H₂O (20 mL) was added Oxone® (38.4 g, 62.5 mmol) and the mixture was stirred for 22 hours. The mixture was
25 acidified to pH 4 with 2.5N NaOH and decanted to remove insoluble salts. The decantate was

-296-

concentrated to one-half volume and partitioned between ethyl acetate and H₂O. The organic layer was washed with H₂O and saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a yellow solid (5.79 g, 67%).

Part C: To a solution of the sulfone of part B (2.5064 g, 7.20 mmol) and benzaldehyde (0.748 mL, 7.36 mmol) in benzene (20 mL) were added acetic acid (0.15 mL) and piperidine (0.05 mL). The solution was heated to reflux for 2 hours and the condensate was collected via a Dean-Stark trap. After an additional 1.5 hours of reflux, the solution was returned to ambient temperature and stirred for 18 hours. The solution was diluted with ethyl acetate and washed with H₂O and saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) followed by trituration (ethyl ether/hexane) provided the unsaturated sulfone as a white solid (1.97 g, 73%). HPLC purity: >98%.

Part D: Into a solution of the unsaturated sulfone of part C (0.5053 g, 1.16 mmol) was bubbled HCl gas for 1 hour. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate and washed with H₂O and dried over Na₂SO₄. Concentration in vacuo provided the acid as an oil (0.41 g, 93%).


Part E: To a solution of the acid of part D (461 mg, 1.21 mmol) was added thionyl chloride (3.0 mL) and the solution was heated to one hundred degrees Celsius for 1 hour. Concentration in vacuo

-297-

provided the acid chloride as an amber oil (380 mg, 79%).

Part F: To a solution of the acid chloride of part E (380 mg, 0.95 mmol) in THF (20 mL) was
5 added 50 percent aqueous hydroxylamine (1.7 mL, 9.5 mmol). The solution was stirred at zero degrees Celsius for 1 hour. The solution was diluted with ethyl acetate, washed with H₂O and saturated NaCl, and dried over Na₂SO₄. Reverse phase chromatography (on
10 silica, acetonitrile/H₂O) followed by trituration (ethyl ether/hexane) provided the title compound as a white solid (131 mg, 35%). HPLC purity: >97%.

Example 6: Preparation of N-hydroxy-4-[(4-
15 phenoxyphenyl)sulfonyl]-1-(2-propynyl)-4-
piperidinecarboxamide, monohydrochloride



20 Part A: A solution of 4-(phenoxy)benzenethiol (2.03 g, 10.0 mmol) in DMSO (20 mL) was heated to 65 degrees Celsius for 5 hours. The solution remained at ambient temperature for 18 hours. The solution was extracted with ethyl acetate and the combined
25 organic layers were washed with H₂O and saturated NaCl, and dried over magnesium sulfate.

-298-

Concentration in vacuo provided the disulfide as a yellow oil (2.3 g, quantitative yield).

Part B: To a solution of ethyl isonipecotate (15.7 g, 0.1 mol) in THF (100 mL) was
5 added a solution of di-tert-butyl dicarbonate (21.8 g, 0.1 mol) in THF (5 mL) dropwise over 20 minutes. The solution was stirred overnight at ambient temperature and concentrated in vacuo to yield a light oil. The oil was filtered through silica gel
10 (ethyl acetate/hexane) and concentrated in vacuo to give the BOC-piperidine compound as a clear, colorless oil (26.2 g, quantitative yield).

Part C: To a solution of diisopropylamine (2.8 mL, 20 mmol) in THF (30 mL), cooled to minus
15 seventy-eight degrees Celsius, was added n-butyl lithium (12.5 mL, 20 mmol) dropwise. After 15 minutes, the BOC-piperidine compound of part B (2.6 g, 10 mmol) in THF (10 mL) was added dropwise. After 1.5 hours the solution was cooled to minus sixty
20 degrees Celsius and the disulfide of part A (2.0 g, 10 mmol) in THF (7 mL) was added. The solution was stirred at ambient temperature for 2 hours. The solution was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and
25 saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as an oil (1.8 g, 40%).

Part D: To a solution of the sulfide of part C (1.8 g, 3.95 mmol) in dichloromethane (75 mL)
30 cooled to zero degrees Celsius, was added m-chloroperbenzoic acid (1.7 g, 7.9 mmol). The

-299-

solution was stirred for 1.5 hours followed by dilution with H₂O and extraction with dichloromethane. The organic layer was washed with 10 percent Na₂SO₄, H₂O, and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a solid (1.15 g, 59%).

Part E: Into a solution of the sulfone of part D (3.56 g, 7.0 mmol) in ethyl acetate (100 mL) cooled to zero degrees Celsius was bubbled HCl gas for 5 minutes. Concentration in vacuo followed by trituration with ethyl ether provided the amine hydrochloride salt as a white solid (3.5 g, quantitative yield). MS(CI) MH⁺ calculated for C₂₀H₂₃NO₃S: 390, found 390.

Part F: To a solution of the amine hydrochloride salt of part E (2.6 g, 6 mmol) and K₂CO₃ (1.66 g, 12 mmol) in DMF (50 mL) was added propargyl bromide (892 mg, 6 mmol) and the solution was stirred at ambient temperature for 4 hours. The solution was diluted with H₂O and extracted with ethyl acetate. The combined organic layers were washed with saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the propargyl amine as a white solid (2.15 g, 82%).

Part G: To a solution of the propargyl amine of part F (2.15 g, 5 mmol) in THF (30 mL) and ethanol (30 mL) was added NaOH (2.0 g, 50 mmol) and the solution was heated at 65 degrees Celsius for 48 hours. The solution was concentrated in vacuo and

-300-

the aqueous residue was acidified to a pH value of 5. Vacuum filtration of the resulting precipitate provided the acid as a white solid (2.04 g, quantitative yield).


5 Part H: To a solution of the acid of part G (559 mg, 1.4 mmol) in dichloromethane (5 mL) was added triethylamine (0.585 mL, 4.2 mmol) and 50 percent aqueous hydroxylamine (0.925 mL, 14.0 mmol) followed by bromotris(pyrrolidino)phosphonium
10 hexafluorophosphate (PyBroP®; 718 mg, 1.54 mmol). The solution was stirred at ambient temperature for 4 hours. The solution was diluted with H₂O and extracted with dichloromethane. The organic layer was washed with saturated NaCl and dried over
15 magnesium sulfate. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the hydroxamate as a white solid (140 mg, 25%). Analytical calculation for C₂₁H₂₂N₂O₅S: C, 60.85; H, 5.37; N, 6.76; S, 7.74. Found: C, 60.47; H, 5.35; N, 6.61; S, 7.46.

20 Part I: To a solution of the hydroxamate of part H (121 mg, 0.292 mmol) in methanol (2 mL) cooled to zero degrees Celsius was added acetyl chloride (0.228 mL, 0.321 mmol) in methanol (1 mL). After stirring at ambient temperature for 30 minutes
25 the solution was concentrated under a stream of N₂. Trituration with ethyl ether provided the title compound as a white solid (107 mg, 81%). Analytical calculation for C₂₁H₂₂N₂O₅S•HCl•0.3H₂O: C, 55.27; H, 5.21; N, 6.14. Found: C, 54.90; H, 5.37; N, 6.07.

30

-301-

Example 7: Preparation of N-[4-[[2-(hydroxyamino)-2-oxoethyl]sulfonyl]phenyl]benzamide



5

Part A: To a suspension of 2-(4-aminophenylthio)acetic acid (20.00 g, 0.109 mmol) in methanol (100 mL) cooled to zero degrees Celsius was added thionyl chloride (24.0 mL, 0.327 mmol) dropwise. Additional methanol was added (100 mL) and the suspension was heated to reflux for 2 hours. The solution was concentrated in vacuo and the residue was dissolved into H₂O and neutralized with saturated NaHCO₃. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the methyl ester as a dark purple oil (22.75 g, quantitative yield). HPLC purity: 99%.

Part B: To a solution of the methyl ester of part A (5.00 g, 25.35 mmol) and triethylamine (7.07 mL, 50.70 mmol) in dichloromethane (50 mL) was added benzoyl chloride (3.24 mL, 27.89 mmol) and the solution was stirred at ambient temperature for 2 hours. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate, THF and H₂O. The organic layer was washed with H₂O

-302-

and saturated NaCl and dried over Na₂SO₄.

Concentration in vacuo provided the benzamide as a purple solid (7.06 g, 92%). HPLC purity: 98%. MS(CI) M+Li⁺ calculated for C₁₆H₁₅NO₃S: 308, found 308.


5 Part C: To a solution of the benzamide of part B (4.00 g, 13.27 mmol) in THF (100 mL) and H₂O (10 mL) cooled to zero degrees Celsius was added Oxone® (potassium monopersulfate; 24.47 g, 39.81 mmol). The slurry was stirred overnight (about
10 eighteen hours) at ambient temperature. The mixture was filtered to remove excess Oxone® and the filtrate was concentrated in vacuo. The residue was dissolved into ethyl acetate and washed with H₂O and saturated NaCl, and then dried over Na₂SO₄. Concentration in
15 vacuo provided the sulfone as a pink solid (4.11 g, 93%). HPLC purity: 98%. MS(CI) M+Li⁺ calculated for C₁₆H₁₅NO₅S: 340, found 340.

 Part D: To a solution of the sulfone of part C (400 mg, 1.2 mmol) in THF (9 mL) was added 50
20 percent aqueous hydroxylamine (5.0 mL). The solution was stirred for 8 hours and was concentrated in vacuo. Trituration with hot ethyl ether provided the title compound as an off-white solid (348 mg, 78%). HPLC purity: 97%. MS(CI) MH⁺ calculated for C₁₇H₁₄N₂O₅S:
25 335, found 335.

Example 8: Preparation of N-[4-[[2-(hydroxyamino)-2-oxo-1-(piperidin-4-yl)ethyl]sulfonyl]-phenyl]-benzamide, monohydrochloride

30

-303-



Part A: To a solution of diethanolamine (22.16 g, 0.211 mol) in THF (100 mL) cooled to zero
5 degrees Celsius was added di-t-butyl dicarbonate (46.0 g, 0.211 mol) and the solution was stirred at ambient temperature for 20 hours. The solution was concentrated in vacuo and the resulting residue was filtered through a silica pad (5 percent methanol/95
10 percent dichloromethane) to provide the diol as a clear oil (45.06 g, quantitative yield). MS(CI) MH⁺ calculated for C₉H₁₁O₄S: 206, found 206.

Part B: To a suspension of 2-(4-aminophenylthio)acetic acid (20.00 g, 0.109 mmol) in
15 methanol (100 mL) cooled to zero degrees Celsius thionyl chloride (24.0 mL, 0.327 mmol) was added dropwise. After additional methanol was added (100 mL), the suspension was heated to reflux for 2 hours. The composition was concentrated in vacuo, the
20 residue was dissolved in H₂O and neutralized with saturated NaHCO₃. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the methyl ester as a
25 dark purple oil (22.75 g, quantitative yield). HPLC purity: 99%.

-304-

Part C: To a solution of the methyl ester of part B (5.00 g, 25.35 mmol) and triethylamine (7.07 mL, 50.70 mmol) in dichloromethane (50 mL) was added benzoyl chloride (3.24 mL, 27.89 mmol) and the solution was stirred at ambient temperature for 2 hours. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate, THF and H₂O. The organic layer was washed with H₂O and saturated NaCl and dried over Na₂SO₄.

Concentration in vacuo provided the benzamide as a purple solid (7.06 g, 92%). HPLC purity: 98%.

Part D: To a solution of the benzamide of part C (4.00 g, 13.27 mmol) in THF (100 mL) and H₂O (10 mL) cooled to zero degrees Celsius was added Oxone® (24.47 g, 39.81 mmol). The slurry was stirred overnight (about eighteen hours) at ambient temperature. The mixture was filtered to remove excess Oxone® and the filtrate was concentrated in vacuo. The residue was dissolved into ethyl acetate and washed with H₂O and saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the sulfone as a pink solid (4.11 g, 93%). HPLC purity: 98%.

Part E: To a solution of the diol of part A (1.03 g, 5.00 mmol) and the methyl ester of part D (2.00 g, 6.00 mmol) in THF (100 mL) was added the 1,1'-(azodicarbonyl)dipiperidine (5.05 g, 20.00 mmol). To this slurry was added trimethyl phosphine (20.00 mL of a 1.0M solution in THF, 20.00 mmol). The mixture stirred for 1 hour at ambient temperature and then was heated at 40 degrees Celsius for 18 hours. After the slurry returned to ambient

-305-

temperature, ethyl ether was added and the insoluble solids were removed by filtration. The filtrate was concentrated in vacuo and the resulting residue was dissolved into ethyl acetate, washed with H₂O and saturated NaCl, and then dried over Na₂SO₄.

Chromatography (on silica, ethyl acetate/hexane) provided the piperidine compound as a yellow solid (600 mg, 24%). MS(CI) MH⁺ calculated for C₂₅H₃₀N₂O₇S: 503, found 503.

10 Part F: To a solution of the piperidine compound of part E (950 mg, 1.89 mmol) in THF (10 mL) was added potassium silanolate (970 mg, 7.56 mmol) and the solution was stirred at ambient temperature for 72 hours. The solution was diluted with H₂O, acidified to pH 2 with 1M HCl, and extracted with ethyl acetate. The combined organic layers were washed with saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the acid as a yellow solid (772 mg, 84%).

20 Part G: To a solution of the acid of part F (772 mg, 1.48 mmol) in DMF (9 mL) was added HOBT (240 mg, 1.77 mmol), 4-methylmorpholine (0.488 mL, 4.44 mmol), O-tetrahydropyranyl hydroxylamine (538 mg, 4.54 mmol) and EDC (397 mg, 2.07 mmol). The solution stirred at ambient temperature for 2 hours. Following concentration in vacuo the residue was partitioned between ethyl acetate and H₂O. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxylamine as a white solid (608 mg, 70%). HPLC purity: >99%.


-306-

Part H: To a solution of the protected hydroxylamine of part G (596 g, 1.01 mmol) in dioxane (3 mL) and methanol (1 mL) was added 4M HCl in dioxane (2.50 mL, 10.14 mmol) and the solution
5 stirred for 50 minutes at ambient temperature. Trituration with ethyl ether provided the title compound as a white solid (433 mg, 98%). HPLC purity: 98%. MS(CI) MH^+ calculated for $C_{19}H_{21}N_3O_5S$: 404, found 404.

10

Example 9: Preparation of N-hydroxy-4-
[[4-(phenylthio)phenyl]sulfonyl]-1-
(2-propynyl)-4-piperidinecarboxamide,
monohydrochloride

15



Part A: To a solution of ethyl isonipecotate (15.7 g, 0.1 mol) in THF (100 mL) was added a
20 solution of di-tert-butyl dicarbonate (21.8 g, 0.1 mol) in THF (5 mL) dropwise over 20 minutes. The solution was stirred overnight (about eighteen hours) at ambient temperature and concentrated in vacuo to yield a light oil. The oil was filtered through
25 silica gel (ethyl acetate/hexanes) and concentrated

-307-

in vacuo to give the BOC-piperidine compound as a clear, colorless oil (26.2 g, quantitative yield).

Part B: A solution of 4-fluorothiophenol (50.29 g, 390 mmol) in DMSO (500 mL) was heated to 65
5 degrees Celsius for 6 hours. The reaction was quenched into wet ice and the resulting solid was collected by vacuum filtration to provide the disulfide as a white solid (34.4 g, 68.9%).

Part C: To a solution of the BOC-piperidine
10 compound of part A (16 g, 62 mmol) in THF (300 mL) cooled to minus 50 degrees Celsius was added lithium diisopropylamide (41.33 mL, 74 mmol) and the solution was stirred for 1.5 hours at zero degrees Celsius. To this solution was added the disulfide of part B
15 (15.77 g, 62 mmol), and the resulting solution was stirred at ambient temperature for 20 hours. The reaction was quenched with the addition of H₂O and the solution was concentrated in vacuo. The aqueous residue was extracted with ethyl acetate and the
20 organic layer was washed with 0.5N KOH, H₂O, and saturated NaCl. Chromatography (on silica, hexane/ethyl acetate) provided the sulfide as an oil (18.0 g, 75%).

Part D: To a solution of the sulfide of
25 part C (16.5 g, 43 mmol) in dichloromethane (500 mL) cooled to zero degrees Celsius was added 3-chloroperbenzoic acid (18.0 g, 86 mmol) and the solution was stirred for 20 hours. The solution was diluted with H₂O and extracted with dichloromethane.
30 The organic layer was washed with 10 percent Na₂SO₃, H₂O, and saturated NaCl and dried over magnesium

-308-

sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone as a solid (10.7 g, 60%).

Part E: Into a solution of the sulfone of
5 part D (10 g, 24.0 mmol) in ethyl acetate (250 mL)
was bubbled HCl gas for 10 minutes followed by
stirring at ambient temperature for 4 hours.
Concentration in vacuo provided the amine
hydrochloride salt as a white solid (7.27 g, 86%).

10 Part F: To a solution of the amine
hydrochloride salt of part E (5.98 g, 17.0 mmol) in
DMF (120 mL) was added potassium carbonate (4.7 g,
34.0 mmol) followed by propargyl bromide (2.02 g,
17.0 mmol) and the solution was stirred for 4 hours
15 at ambient temperature. The solution was partitioned
between ethyl acetate and H₂O, and the organic layer
was washed with H₂O and saturated NaCl and dried over
magnesium sulfate. Chromatography (on silica, ethyl
acetate/hexane) provided the propargyl amine as a
20 yellow oil (5.2 g, 86%).

Part G: To a solution of the propargyl
amine of part F in DMF (15 mL) was added thiophenol
(0.80 mL, 7.78 mmol) and CsCO₃ (2.79 g, 8.56 mmol) and
the solution was heated to 70 degrees Celsius for 6
25 hours. The solution was partitioned between ethyl
ether and H₂O. The organic layer was washed with H₂O
and saturated NaCl, and dried over magnesium sulfate.
Chromatography (on silica, ethyl acetate/hexane)
provided the S-phenoxyphenyl compound as an oil (1.95
30 g, 56%).

-309-

Part H: To a solution of the S-phenoxyphenyl of part G (1.81 g, 4.06 mmol) in ethanol (21 mL) and H₂O (3.5 mL) was added KOH (1.37 g, 24.5 mmol) and the solution was heated to 105
5 degrees Celsius for 4.5 hours. The solution was acidified to a pH value of 1 with concentrated HCl solution and then concentrated to provide the acid as a yellow residue that was used without additional purification (1.82 g).


10 Part I: To a solution of the acid of part H (1.82 g, 4.06 mmol) in acetonitrile (20 mL) was added O-tetrahydro-2H-pyran-2-yl-hydroxylamine (723 mg, 6.17 mmol) and triethylamine (0.67 mL, 4.86 mmol). To this stirring solution was added EDC (1.18
15 g, 6.17 mmol) and the solution was stirred for 18 hours. The solution was partitioned between H₂O and ethyl acetate. The organic layer was washed with H₂O, saturated NaHCO₃ and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl
20 acetate/hexane) provided the protected hydroxamate as a white solid (1.32 g, 63%).

Part J: To a solution of the protected hydroxamate of part I (9.65 g, 18.7 mmol) in methanol (148 mL) cooled to zero degrees Celsius was added
25 acetyl chloride (4.0 mL, 56.2 mmol), and the solution was stirred for 45 minutes at ambient temperature. Concentration in vacuo followed by trituration with ethyl ether provided the title compound as a white solid (8.10 g, 94%). MS(CI) MH⁺ calculated for
30 C₂₁H₂₂N₂O₄S₂: 431, found 431.

-310-

Example 10: Preparation of 4-[[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monohydrochloride

5



Part A: To a solution of the propargyl amine of Example 9, part F (7.0 g, 19.8 mmol) in DMF
10 (30 mL) were added sesamol (5.52 g, 40 mmol) and potassium carbonate (5.52 g, 40 mmol), and the solution was heated to 85 degrees Celsius for 48 hours. The solution was partitioned between ethyl acetate and H₂O. The organic layer was dried over
15 magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as an oil (9.38 g, quantitative yield).

Part B: To a solution of the sulfide of part A (2.72 g, 5.92 mmol) in ethanol (30 mL) and H₂O
20 (5 mL) was added potassium hydroxide (2.0 g, 36 mmol) and the solution was heated to reflux for 4 hours. The solution was acidified to pH=3 with concentrated HCl. The solution was concentrated in vacuo and the residue was dissolved in acetonitrile (30 mL). To
25 this solution was added O-tetrahydro-2H-pyran-2-yl-hydroxylamine (1.05 g, 9.0 mmol), triethylamine (1 mL) and EDC (1.72 g, 9.0 mmol) and the solution was


-311-

stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo and diluted with saturated NaHCO_3 and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate.

5 Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an oil (2.86 g, 93%).

Part C: To a solution of the protected hydroxamate of part B (2.86 g, 5.27 mmol) in methanol
10 (40 mL) was added acetyl chloride (1.13 mL, 15.8 mmol) and the solution was stirred for 3 hours. The solution was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile/ H_2O (HCl)) provided the title compound as a white solid (2.2 g,
15 84%). MS(CI) MH^+ calculated for $\text{C}_{22}\text{H}_{22}\text{N}_2\text{O}_7\text{S}$: 459, found 459.

Example 11: Preparation of Tetrahydro-N-hydroxy-4-
[[4-(4-phenyl-1-piperidinyl)phenyl]
20 sulfonyl]-2H-pyran-4-carboxamide,
monohydrochloride



-312-

Part A: To a solution of Na (8.97 g, 390 mmol) in methanol (1L) at zero degrees Celsius were added 4-fluorothiophenol (50 g, 390 mmol) and methyl chloroacetate (34.2 mL, 390 mmol), and the solution
5 was stirred for 4 hours at ambient temperature. The solution was filtered to remove salts and the filtrate was concentrated in vacuo to provide the sulfide as a colorless oil (75.85 g, 97%).

Part B: To a solution of the sulfide of
10 part A (75.85 g, 380 mmol) in methanol (1L) and H₂O (100 mL) was added Oxone® (720 g, 1.17 mol) and the solution was stirred for 2 hours. The reaction mixture was filtered to remove the excess salts and the filtrate was concentrated in vacuo. The residue
15 was dissolved into ethyl acetate and washed with H₂O, saturated NaHCO₃, and saturated NaCl, and then dried over magnesium sulfate. Concentration in vacuo provide the sulfone as white solid (82.74 g, 94%)

Part C: To a solution of the sulfone of
20 part B (28.5 g, 123 mmol) in N,N-dimethylacetamide (200 mL) were added potassium carbonate (37.3 g, 270 mmol), bis-(2-bromoethyl)ether (19.3 mL, 147 mmol), 4-dimethylaminopyridine (750 mg, 6 mmol) and tetrabutylammonium bromide (1.98 g, 6 mmol), and the
25 solution was stirred at ambient temperature for 72 hours. The solution was poured into 1N HCl (300 mL) and the resulting precipitate was collected by vacuum filtration. Recrystallization (ethyl acetate/hexane) provided the tetrahydropyran compound as a beige
30 solid (28.74 g, 77%).

-313-

Part D: To a solution of the tetrahydropyran compound of part C (1.21 g, 4.0 mmol) in DMSO (10 mL) were added Cs_2CO_3 (3.26 g, 10.0 mmol) and 4-phenylpiperidine (640 mg, 4.0 mmol), and the
5 solution was heated to 90 degrees Celsius for 2 hours. The solution was diluted with H_2O and extracted with ethyl acetate. The organic layer was washed with 5 percent aqueous KHSO_4 , saturated NaHCO_3 , and saturated NaCl and dried over magnesium sulfate.
10 Concentration in vacuo provided the amine as a white solid (1.2 g, 67%).

Part E: To a solution of the amine of part D (815 mg, 1.84 mmol) in methanol (5 mL) and THF (5 mL) was added 50 percent aqueous NaOH (2 mL) and the
15 solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo and the residue was diluted with H_2O and acidified to a pH value of 7. The resulting precipitate was collected by vacuum filtration to provide the acid as
20 a white solid (680 mg, 86%).


Part F: To a solution of the acid of part E (620 mg, 1.44 mmol) in dichloromethane (10 mL) and DMF (3 mL) were added PyBroP (810 mg, 1.73 mmol), N-methylmorpholine (0.5 mL, 4.3 mmol) and O-tetrahydro-
25 2H-pyran-2-yl-hydroxylamine (190 mg, 1.59 mmol) and the solution was stirred for 4 hours at ambient temperature. The solution was concentrated in vacuo, the residue dissolved into ethyl acetate and washed with H_2O and saturated NaCl , and then dried over
30 Na_2SO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as

-314-

a white solid (630 mg, 83%). MS(CI) MH^+ calculated for $C_{28}H_{36}N_2O_6S$: 529, found 529.

Part G: To a solution of the protected hydroxamate of part F (600 mg, 1.14 mmol) in dioxane (1.5 mL) and methanol (1.5 mL) was added 4N HCl in dioxane (1.5 mL), and the solution was stirred for 2 hours. The solution was poured into ethyl ether and the resulting precipitate was collected by vacuum filtration to provide the title compound as a beige solid (500 mg, 91%). MS(CI) $M+Li^+$ calculated for $C_{23}H_{28}N_2O_5S$: 445, found 445.

Example 12: Preparation of 1-acetyl-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-4-piperidinecarboxamide



Part A: To a solution of the sulfone of Example 6, part D (2.75 g, 5.6 mmol) in THF (10 mL) and ethanol (10 mL) was added NaOH (2.25 g, 56 mmol), and the solution was heated to 70 degrees Celsius for 18 hours. The solution was concentrated in vacuo, the residue was dissolved into H_2O and extracted with ethyl ether. The aqueous solution was acidified to a pH value of 2 and extracted with ethyl acetate. The

-315-

organic layer was dried over magnesium sulfate. Concentration in vacuo provided the crude acid as a solid. A solution of the acid in dichloromethane (6 mL) and trifluoroacetic acid (6 mL) was stirred for 1
5 hour at ambient temperature. Concentration in vacuo provided the amine hydrochloride salt as a solid (2.3 g, quantitative yield).


Part B: To a solution of the amine hydrochloride salt of part A (2.3 g, < 5.6 mmol) in
10 acetone (10 mL) and H₂O (10 mL) cooled to zero degrees Celsius were added triethylamine (1.17 mL, 8.4 mmol) and acetyl chloride (0.60 mL, 8.4 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo to
15 remove the acetone and the aqueous solution was extracted with ethyl ether. The aqueous layer was acidified to a pH value of 2 and extracted with ethyl acetate. The organic layer was dried over magnesium sulfate and concentration in vacuo provided the N-
20 acetyl compound as a white solid (1.5 g, 65.2%).

Part C: To a solution of the N-acetyl compound of part B (0.6 g, 1.49 mmol) in DMF (10 mL) were added EDC (401 mg, 2.1 mmol) followed by 50 percent aqueous hydroxylamine (0.9 mL) and 4-
25 methylmorpholine (0.7 mL, 6.4 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate. The organic layer was washed with H₂O and dried over magnesium sulfate.
30 Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a

-316-

white solid (101 mg, 16%). MS(CI) MH^+ calculated for $C_{20}H_{22}N_2O_6S$: 419, found 419.

Example 13: Preparation of 4-[[4-(cyclohexylthio)-
phenyl]sulfonyl]-N-hydroxy-1-(2-
propynyl)-4-piperidinecarboxamide,
monohydrochloride



Part A: To a solution of the propargyl amine of Example 9, part F (6.5 g, 18.4 mmol) in DMF (10 mL) were added potassium carbonate (3.81 g, 27.6 mmol) and cyclohexyl mercaptan (3.37 mL, 27.6 mmol). The solution was heated to 100 degrees Celsius for 6.5 hours. The solution was diluted with H_2O and extracted with ethyl acetate. The organic layers were dried over magnesium sulfate. Chromatography (on silica, hexane/ethyl acetate) provided the sulfide as a yellow oil (6.05 g, 73%).

Part B: To a solution of the sulfide of part B (612 mg, 1.4 mmol) in ethanol (8.4 mL) and H_2O (1.4 mL) was added potassium hydroxide (470 mg, 8.4 mmol), and the solution was refluxed for 3 hours.


-317-

The solution acidified to a pH value of 3 and was concentrated in vacuo. The residue was dissolved into acetonitrile (10 mL) and to this solution were added O-tetrahydro-2H-pyran-2-yl-hydroxylamine (230
5 mg, 2.0 mmol) and triethylamine (0.5 mL) followed by EDC (380 mg, 2.0 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo and the residue was diluted with saturated NaHCO₃ and extracted with ethyl
10 acetate. The organic layer was dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an oil (246 mg, 34%).

Part C: To a solution of the protected
15 hydroxamate of part B (246 mg, 0.47 mmol) in methanol (4 mL) was added acetyl chloride (0.11 mL, 1.5 mmol), and the solution was stirred at ambient temperature for 3 hours. After concentration in vacuo, reverse phase chromatography (on silica,
20 acetonitrile/H₂O(HCl)) provided the title compound as a white solid (223 mg, quantitative yield).

Example 14: Preparation of N-hydroxy-1-methyl-4-
[(phenoxyphenyl)sulfonyl]-4-
25 piperidinecarboxamide, monohydrochloride

-318-



Part A: To a solution of the sulfone of Example 6, part D (2.67 g, 5.5 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (5 mL), and the solution was stirred at ambient temperature for 2 hours. The solution was concentrated in vacuo and the residue was triturated with ethyl ether to provide the crude amine trifluoroacetic acid salt. To a solution of the crude amine salt in methanol (10 mL) were added formaldehyde (37 percent aqueous solution, 2.0 mL, 27.5 mmol) and borane pyridine (2.2 mL, 22 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo. The residue was dissolved into ethyl acetate, washed with H₂O and dried over magnesium sulfate. Concentration in vacuo provided the N-methyl compound as a yellow oil (2.17 g, 98%).

Part B: To a solution of the N-methyl compound of part A (2.17 g, 5.4 mmol) in ethanol (10 mL) and THF (10 mL) was added NaOH (2.0 g, 50 mmol), and the reaction mixture was stirred at minus 65 degrees Celsius for 18 hours. The solution was concentrated in vacuo. The residue was dissolved into H₂O and extracted with ethyl ether. The aqueous


-319-

solution was acidified to a pH value of 2 and the resulting solid was collected by vacuum filtration to provide the acid as a white solid (1.8 g, 90%).

Part C: To a solution of the acid of part
5 B (0.5 g, 1.3 mmol) in DMF (10 mL) were added EDC
(1.06 g, 5.5 mmol) followed by O-tetrahydro-2H-pyran-
2-yl-hydroxylamine (490 mg, 4.2 mmol) and 4-
methymorpholine (0.76 mL) and the solution was
stirred at ambient temperature for 18 hours. The
10 solution was concentrated in vacuo and the residue
was dissolved into ethyl acetate, washed with H₂O and
dried over magnesium sulfate. Concentration in vacuo
provided the crude protected hydroxamate. To a
solution of the crude hydroxamate in methanol (10 mL)
15 was added acetyl chloride (0.28 mL, 3.9 mmol), and
the solution was stirred for 3 hours at ambient
temperature. The solution was concentrated in vacuo.
Reverse phase chromatography (on silica,
acetonitrile/H₂O(0.0125% HCl) provided the title
20 compound as a white solid (261 mg, 46%). MS(CI) MH⁺
calculated for C₁₉H₂₂N₂O₅S: 391, found 391.

Example 15: Preparation of N-hydroxy-4-[[4-(4-
methoxyphenoxy)phenyl]sulfonyl]-1-(2-
25 propynyl)-4-piperidinecarboxamide,
monohydrochloride

-320-



Part A: To a solution of the propargyl
amine of Example 9, part F (2.00 g, 5.66 mmol) in DMF
5 (10 mL) were added cesium carbonate (4.7 g, 14.5
mmol) and 4-methoxythiophenol (1.80 g, 14.5 mmol),
and the solution was heated to 95 degrees Celsius for
24 hours. The solution was diluted with ethyl
acetate and washed with 1N NaOH and saturated NaCl,
10 and then dried over magnesium sulfate.
Chromatography (on silica, ethyl acetate/hexane)
provided the phenoxy compound as a solid (2.67 g,
quantitative yield).

Part B: To a solution of the phenoxy
15 compound of part A (2.40 g, 5.25 mmol) in ethanol (30
mL) and H₂O (6 mL) was added potassium hydroxide (2.0
g, 31.37 mmol), and the solution was heated to reflux
for 4 hours. The solution was acidified with
concentrated HCl to a pH value of 3 and the residue
20 was collected by vacuum filtration to provide the
crude acid that was carried on without additional
purification.

Part C: To a solution of the acid of part
B (2.25 g, 5.25 mmol) in acetonitrile (30 mL) were
25 added triethylamine (1 mL) and O-tetrahydro-2H-pyran-

-321-

2-yl-hydroxylamine (1.34 g, 9.0 mmol). After the solution was stirred for 15 minutes, EDC (1.72 g, 9.0 mmol) was added the solution was stirred at ambient temperature for 18 hours. The solution was
5 concentrated in vacuo and the residue was dissolved into ethyl acetate. The ethyl acetate solution was washed with saturated NaHCO₃, H₂O and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the protected
10 hydroxamate as a white solid (0.93 g, 33%).


Part D: To a solution of the protected hydroxamate of part C (0.93 g, 1.7 mmol) in methanol (15 mL) was added acetyl chloride (0.36 mL, 5.1 mmol) and the solution was stirred for 3 hours. The
15 solution was concentrated in vacuo to provide the title compound as a white solid (650 mg, 82%).
Analytical calculation for C₂₂H₂₄N₂O₆S HCl: C, 54.84; H, 5.24; N, 5.82; S, 6.67; Cl, 6.67. Found: C, 53.10; H, 5.07; N, 5.59; S, 7.04; Cl, 6.32.

20

Example 16: Preparation of 4-[[4-(4-butoxy-1-piperidinyl)phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide,
monohydrochloride

25

-322-



Part A: To a solution of the tetrahydropyran compound of Example 11, part C (1.95 g, 6.46 mmol) in DMSO (25 mL) were added Cs_2CO_3 (7.4 g, 22.6 mmol) and 4-butoxypiperidine (1.25 g, 6.46 mmol) and the solution was heated to 90 degrees Celsius for 1 hour. The solution was quenched with H_2O and extracted with ethyl acetate. The organic layer was washed with 5 percent aqueous KHSO_4 , saturated NaHCO_3 , and saturated NaCl , and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/dichloromethane) provided the amine as a yellow oil (1.85 g, 65%).

Part B: To a solution of the amine of part A (1.65 g, 3.76 mmol) in THF (10 mL) was added potassium trimethylsilanolate (530 mg, 4.13 mmol), and the solution was stirred for 22 hours at ambient temperature. The solution was concentrated in vacuo and the crude residue was used as is in the next reaction.

Part C: To a solution of the crude acid of part B (1.74 g, 3.76 mmol) in dichloromethane (10 mL) were added PyBroP (2.10 g, 4.51 mmol), N-methylmorpholine (1.24 mL, 11.3 mmol) and O-


-323-

tetrahydro-2H-pyran-2-yl-hydroxylamine (484 mg, 4.14 mmol), and the solution was stirred for 30 minutes at ambient temperature. The solution was concentrated in vacuo. The residue was dissolved into ethyl acetate and washed with H₂O and saturated NaCl, and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane/methanol) provided the protected hydroxamate as a colorless oil (1.5 g, 76% over two steps).

10 Part D: To a solution of the protected hydroxamate of part C (1.25 g, 2.4 mmol) in dioxane (3 mL) was added 4N HCl in dioxane (3 mL), and the solution was stirred for 15 minutes. After methanol (3 mL) was added the solution was stirred for 5 hours at ambient temperature. The solution was poured into ethyl ether and the resulting precipitate was collected by vacuum filtration to provide the title compound as a white solid (1.0 g, 88%). MS(CI) MH⁺ calculated for C₂₁H₃₂N₂O₆S: 441, found 441.

20

Example 17: Preparation of 1-cyclopropyl-N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-4-piperidinecarboxamide, monohydrochloride



25

-324-

Part A: To a solution of the amine hydrochloride salt of Example 6, part E (2.13 g, 5.0 mmol) in methanol (25 mL) was added 3A molecular sieves, acetic acid (2.86 mL, 50 mmol) and the solution was stirred for 5 minutes. To this solution was added ((1-ethoxycyclopropyl)oxy)-trimethylsilane (6.08 mL, 30 mmol) followed by sodium cyanoborohydride (1.41 g, 22.0 mmol), and the solution was heated to reflux for 18 hours. The excess salts and sieves were collected by filtration and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate and washed with 1N NaOH, H₂O and saturated NaCl, and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the cyclopropyl amine as a white solid (1.90 g, 86%).

Part B: To a solution of the cyclopropyl amine of part A (1.9 g, 4.2 mmol) in THF (12 mL) and ethanol (12 mL) was added NaOH (1.71 g, 4.3 mmol) in H₂O (10 mL), and the solution was heated to 62 degrees Celsius for 20 hours. The solution was concentrated in vacuo and the residue was diluted with H₂O and acidified to a pH value of 5 with 1N HCl. The resulting solid was collected by vacuum filtration to provide the acid as a white solid (1.49 g, 82%). MS(CI) MH⁺ calculated for C₂₁H₂₃NO₅S: 402, found 402. HRMS calculated for C₂₁H₂₃NO₅S: 402.1375, found 402.1350.

Part C: To a solution of the acid of part C (1.49 g, 3.4 mmol) in dichloromethane (50 mL) was added triethylamine (1.42 mL, 10.21 mmol) followed by


-325-

50 percent aqueous hydroxylamine (2.25 mL, 34.0 mmol) and PyBroP (3.17 g, 6.8 mmol), and the solution was stirred for 72 hours. The mixture was diluted with H₂O and the organic layer was separated, washed with saturated NaCl and dried over magnesium sulfate. Concentration in vacuo followed by reverse phase chromatography (on silica, acetonitrile/H₂O) provided the hydroxamate.

The hydrochloride salt was prepared by dissolving the free base (830 mg, 2.0 mmol) in methanol (20 mL) followed by the addition of acetyl chloride (0.17 mL, 2.0 mmol). The solution was stirred for 10 minutes at zero degrees Celsius. The resulting white solid was collected by vacuum filtration and washed with cold ethyl ether to provide the title compound (595 mg, 66%). HRMS calculated for C₂₁H₂₄N₂O₅S: 416.1407, found 416.1398. Analytical calculation for C₂₁H₂₄N₂O₅S: C, 55.68; H, 5.56; N, 6.18; S, 7.08; Cl, 7.83. Found: C, 55.39; H, 5.72; N, 6.15; S, 7.29; Cl, 8.17.

Example 18: Preparation of N-hydroxy-1-(methylsulfonyl)-4-(phenoxyphenyl)-sulfonyl-4-piperidinecarboxamide

25



-326-

Part A: To a solution of the amine hydrochloride salt of Example 6, part E (1.06 g, 2.5 mmol) in dichloromethane (10 mL) were added
5 triethylamine (0.76 mL, 5.5 mmol) and methanesulfonyl chloride (0.23 mL, 3.0 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate and H₂O. The
10 organic layer was washed with H₂O and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the methanesulfonamide as a solid (2.1 g, 58%).


Part B: To a solution of the
15 methanesulfonamide of part A (2.0 g, 4.15 mmol) in ethanol (12 mL) and H₂O (12 mL) was added NaOH (1.66 g, 41.5 mmol), and the solution was heated to 65 degrees Celsius for 18 hours. The solution was concentrated in vacuo and the remaining aqueous
20 solution was acidified to a pH of 4. The solution was extracted with ethyl acetate and the organic layer was washed with saturated NaCl and dried over magnesium sulfate. Concentration in vacuo provided the acid as a yellow foam (1.46 g, 80%).

25 Part C: To a solution of the acid of part B (1.46 g, 3.38 mmol) in dichloromethane (50 mL) were added triethylamine (1.41 mL, 10.1 mmol), 50 percent aqueous hydroxylamine (2.2 mL, 33.8 mmol) and PyBrop (3.16 g, 6.76 mmol), and the solution was stirred at
30 ambient temperature for 72 hours. The solution was diluted with H₂O and the organic layer was separated

-327-

and washed with saturated NaCl, and then dried over magnesium sulfate. Reverse phase chromatography (on silica, acetonitrile/H₂O) followed by trituration with ethyl ether provide the title compound as a white solid (160 mg, 11%). Analytical calculation for C₁₉H₂₂N₂O₇S₂: C, 50.21; H, 4.88; N, 6.16; S, 14.11. Found: C, 48.72; H, 5.36; N, 5.61; S, 12.81.

- 10 Example 19: Preparation of 4-[[4-(cyclohexylthio)-phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide, monohydrochloride



15

- Part A: To a solution of the sulfone of Example 9, part D (10.1 g, 24.0 mmol) in DMF (20 mL) were added K₂CO₃ (5.0 g, 36.0 mmol) and cyclohexylmercaptan (4.4 mL, 36.0 mmol), and the solution was heated at 85 degrees Celsius for 6.5 hours. The solution was partitioned between ethyl acetate and H₂O. The organic layer was washed with saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as a oil (8.2 g, 67%).


-328-

Part B: To a solution of the sulfide (2.32 g, 4.5 mmol) in ethanol (10 mL) and THF (10 mL) was added NaOH (1.81 g, 45 mmol) in H₂O (10 mL), and the solution was heated to 65 degrees Celsius for 18
5 hours. The solution was concentrated in vacuo and the aqueous residue was acidified to a pH value of 2. The solution was extracted with dichloromethane and dried over magnesium sulfate. Concentration in vacuo provided the acid as a white solid (830 mg, 38%).

10 Part C: To a solution of the acid of part B (2.0 g, 4.0 mmol) in dichloromethane (25 mL) were added N-methylmorpholine (1.32 mL, 12.0 mmol), PyBrop (2.12 g, 2.12 mmol) and 50 percent aqueous hydroxylamine (2.6 mL, 40 mmol), and the solution was
15 stirred for 18 hours at ambient temperature. The solution was diluted with H₂O and the layers were separated. The organic layer was washed with saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/methanol)
20 provided the hydroxamate as a white solid (1.4 g, 70%).

Part D: Into a solution of the hydroxamate of part C (1.31 g, 2.63 mmol) in ethyl acetate (70 mL) cooled to zero degrees Celsius was bubbled HCl
25 gas for 30 minutes. The solution was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile/H₂O(HCl)) provided the title compound as a white solid (378 mg, 33%). Analytical calculation for C₁₈H₂₆N₂O₄S₂: C, 49.70; H, 6.26; N, 6.44; S, 14.74;
30 Cl, 8.15. Found: C, 48.99; H, 6.34; N, 6.24; S, 14.66; Cl, 8.56.

Example 20: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-phenyl-1-piperazinyl)phenyl]
sulfonyl]-2H-pyran-4-carboxamide,
5 dihydrochloride



Part A: To a solution of the
10 tetrahydropyran compound of Example 11, part C (1.96
g, 6.5 mmol) in DMSO (20 mL) were added Cs₂CO₃ (4.9 g,
15 mmol) and 4-phenylpiperazine (1.1 mL, 7.15 mmol),
and the solution was heated to 90 degrees Celsius for
45 minutes. The solution was quenched by the
15 addition of H₂O and was extracted with ethyl acetate.
The organic layer was washed with 5 percent aqueous
KHSO₄, saturated NaHCO₃, and saturated NaCl and dried
over magnesium sulfate. Concentration in vacuo
provided the amine as a beige solid (1.7 g, 59%).

20 Part B: To a solution of the amine of part
A (1.5 g, 3.38 mmol) in THF (20 mL) was added
potassium trimethylsilanolate (480 mg, 3.72 mmol),
and the solution was stirred at ambient temperature
for 22 hours. Concentration in vacuo provided the

-330-


crude acid salt to be used without purification in the next step.

Part C: To a solution of the acid salt of part B (1.58 g, 3.38 mmol) in dichloromethane (10 mL) and DMF (3 mL) were added PyBroP (1.89 g, 4.06 mmol), N-methylmorpholine (1.1 mL, 10.1 mmol) and O-tetrahydro-2H-pyran-2-yl-hydroxylamine (435 mg, 3.72 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate and H₂O and the organic layer was washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, dichloromethane/methanol) provided the protected hydroxamate as a white foam (1.7 g, 95% over two steps).

Part D: To a solution of the protected hydroxamate of part C (1.28 g, 2.4 mmol) in dioxane (5 mL) and methanol (5 mL) was added 4N HCl in dioxane (5 mL), and the solution was stirred for 2 hours at ambient temperature. The solution was poured into ethyl ether and the resulting precipitate was collected by vacuum filtration to provide the title compound as a white solid (900 mg, 73%). MS(CI) MH⁺ calculated for C₂₂H₂₇N₃O₅S: 446, found 446.

Example 21: Preparation of 4-[[4-(cyclohexylthio)-phenyl]sulfonyl]-1-cyclopropyl)-N-hydroxy-4-piperidine carboxamide, monohydrochloride

-331-



Part A: To a solution of the sulfone of Example 9, part D (10.1 g, 24.0 mmol) in DMF (20 mL) were added K_2CO_3 (5.0 g, 36.0 mmol) and cyclohexylmercaptan (4.4 mL, 36.0 mmol), and the solution was heated at 85 degrees Celsius for 6.5 hours. The solution was partitioned between ethyl acetate and H_2O . The organic layer was washed with saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as a oil (8.2 g, 67%).

Part B: HCl gas was bubbled for 30 minutes into a solution of the sulfide of part B (8.2 g, 17.0 mmol) in ethyl acetate (100 mL) cooled to zero degrees Celsius. The solution was concentrated in vacuo to provide the amine as a white solid (5.99 g, 79%). MS(CI) MH^+ calculated for $C_{20}H_{29}NO_4S$: 412, found 412.

Part C: To a solution of the amine of part B (2.24 g, 5.0 mmol) in methanol (20 mL) was added acetic acid (2.86 mL, 50 mmol) followed by (1-ethoxycyclopropyl) oxytrimethylsilane (6.03 mL, 30 mmol) and sodium borohydride (1.41 g, 22.5 mmol), and the solution was refluxed for 18 hours. The solution

-332-

was concentrated in vacuo and the residue was dissolved into ethyl acetate and washed with 1N NaOH, H₂O and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the cyclopropyl amine as a white solid (1.97 g, 87%).

Part D: To a solution of the cyclopropyl amine of part C (1.9 g, 4.2 mmol) in ethanol (10 mL) and THF (10 mL) was added NaOH (1.68 g, 42.0 mmol) in H₂O (10 mL) and the solution was heated at sixty-eight degrees Celsius for 18 hours. The solution was concentrated in vacuo and the aqueous residue was acidified to a pH value of 2. The resulting solid was collected and washed with ethyl ether to provide the acid as a white solid (1.61 g, 81%). HRMS calculated for C₂₁H₂₉NO₄S₂: 424.1616, found 424.1615.

Part E: To a solution of the acid of part D (1.61 g, 3.0 mmol) in dichloromethane (30 mL) were added N-methylmorpholine (1.0 g, 9.0 mmol), PyBroP (1.54 g, 3.3 mmol) and 50 percent aqueous hydroxylamine (2.0 mL, 30 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo. The residue was partitioned between ethyl acetate and H₂O, the organic layer washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Filtration through a silica pad (ethyl acetate/methanol) gave the hydroxamate as a white solid (1.07 g, 80%).

Part F: To a solution of the hydroxamate of part F (1.07 g, 2.4 mmol) in cold methanol (2 mL) was added acetyl chloride (0.27 mL, 3.6 mmol), and


-333-

the solution was stirred for 30 minutes. The solution was concentrated in vacuo. Reverse phase chromatography (acetonitrile/H₂O(HCl)) provided the title compound as a white solid (245 mg, 21%).

5

Example 22: Preparation of 4-[[4-[(4-fluorophenyl)thio]phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide, monohydrochloride

10



Part A: To a solution of the sulfone of Example 9, part D (6.0 g, 14.4 mmol) in DMF (30 mL) were added potassium carbonate (2.39 mg, 17.3 mmol) and 4-fluorothiophenol (3.0 mL, 28.1 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was diluted with ethyl acetate and washed with 1N NaOH and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as a solid (6.6 g, 87%).

Part B: To a solution of the sulfide of part A (6.6 g, 12.6 mmol) in ethanol (90 mL) and H₂O (20 mL) was added sodium hydroxide (5.04 g, 126 mmol), and the solution was heated at 70 degrees Celsius for 18 hours. The mixture was acidified to a

-334-


pH value of 4 and the solution was extracted with ethyl acetate. The organic layer was washed with saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/ethanol) provided the solid acid (4.8 g, 79%).

Part C: To a solution of the acid of part B (4.8 g, 10.0 mmol) in DMF (30 mL) was added 4-methylmorpholine (3.03 g, 30.0 mmol) followed by O-tetrahydro-2H-pyran-2-yl-hydroxylamine (7.45 g, 50.0 mmol) and PyBroP (5.59 g, 12.0 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated in vacuo. The residue was dissolved into ethyl acetate and washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as a white solid (4.0 g, 67%).

Part D: HCl gas was bubbled for 5 minutes into a solution of the protected hydroxamate of part D (4.0 g, 6.7 mmol) in ethyl acetate (120 mL) followed by stirring at ambient temperature for 1.5 hours. The resulting solid was collected by vacuum filtration to provide the title compound as a white solid (1.90 g, 64%). MS(CI) MH⁺ calculated for C₁₈H₁₉N₂O₄S₂F: 411, found 411.

Example 23: Preparation of N-hydroxy-4-[[4-[4-(1H-imidazol-1-yl)phenoxy] phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide, dihydrochloride

-335-



Part A: To a solution of the amine hydrochloride salt of Example 9, part F (3.00 g, 8.49 mmol) in DMF (13 mL) were added K₂CO₃ (2.35 g, 17.0 mmol) and 4-(imidazol-1-yl)phenol (2.72 g, 17.0 mmol), and the solution was heated to 85 degrees Celsius for 64 hours. The solution was concentrated and the residue was partitioned between ethyl acetate and H₂O. The organic layer was washed with H₂O and saturated NaCl and dried over magnesium sulfate. Chromatography (on silica, chloroform/methanol) provided the ethyl ester as a white foam (2.36 g, 56%).

Part B: To a solution of the ethyl ester of part A (2.36 g, 5.33 mmol) in ethanol (2.8 mL) and H₂O (4.6 mL) was added KOH (1.80 g, 32.1 mmol), and the solution was heated to 100 degrees Celsius for 4.5 hours. The solution was acidified to a pH value of 1 with concentrated HCl solution and then concentrated to provide the acid as a tan solid that was used without additional purification (2.87 g).

Part C: To a solution of the acid of part B (2.87 g, 5.33 mmol) in acetonitrile (24 mL) were added O-tetrahydro-2H-pyran-2-yl-hydroxylamine (870


-336-

mg, 7.45 mmol), EDC (1.43 g, 7.45 mmol) and N-methylmorpholine (1.21 mL, 11.0 mmol) and the solution was stirred for 18 hours at ambient temperature. The solution was concentrated and the residue was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and saturated NaCl and dried over magnesium sulfate. Chromatography (chloroform, methanol) provided the protected hydroxylamine as a white solid (1.62 g, 53%).

Part D: To a solution of the protected hydroxylamine of part C (1.60 g, 2.83 mmol) in methanol (23 mL) was added acetyl chloride (0.61 mL, 8.52 mmol), and the solution was stirred for 1 hour. The solution was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (975 mg, 62%). MS(CI) MH⁺ calculated for C₂₄H₂₅N₄O₅S: 481, found 481. Analytical calculation for C₂₄H₂₅N₄O₅S 2HCl: C, 52.08; H, 4.73; N, 10.12; S, 5.79; Cl, 12.81. Found: C, 51.59; H, 4.84; N, 10.93; S, 5.51; Cl, 11.98.

Example 24: Preparation of 4-[[4-[(4-fluorophenyl)thiophenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monohydrochloride

-337-



Part A: To a solution of the propargyl amine of Example 9, part F (4.06 g, 11.49 mmol) in
5 DMF (20 mL) were added potassium carbonate (3.18 g, 22.98 mmol) and 4-fluorothiophenol (2.95 g, 22.98 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was diluted with ethyl acetate, washed with 1N NaOH and saturated
10 NaCl, and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as a solid (4.46 g, 84%).

Part B: To a solution of the sulfide of part A (4.46 g, 9.7 mmol) in tetrahydropyran (90 mL),
15 H₂O (30 mL) and ethanol (30 mL) was added NaOH (3.86 g, 97.0 mmol), and the solution was heated to 65 degrees Celsius for 2 hours. The solution was concentrated in vacuo and the residue was dissolved into H₂O and acidified to a pH value of 4 with 2N HCl.
20 The resulting residue was collected by vacuum filtration to provide the acid as a white solid (4.0 g, 95%).


Part C: To a solution of the acid of part B (4.0 g, 9.2 mmol) in DMF (50 mL) and 4-
25 methylmorpholine (2.8 g, 27.7 mmol) was added O-

-338-

tetrahydro-2H-pyran-2-yl-hydroxylamine (6.88 g, 46.1 mmol) and PyBroP (5.16 g, 11.1 mmol), and the solution was stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo and the residue was dissolved into ethyl acetate. The solution was washed with H₂O and saturated NaCl, and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as a white solid (2.8 g, 56%).

Part D: HCl gas was bubbled for 10 minutes into a solution of the protected amine of part C (2.8 g, 5.1 mmol) in ethyl acetate (100 mL), and the solution was then stirred for 1 hour. The solution was concentrated in vacuo and the solid recrystallized (ethanol) to provide the title compound as a white solid (1.12 g, 45%). MS(CI) MH⁺ calculated for C₂₁H₂₁N₂O₄S₂F: 449, found 449.

Example 25: Preparation of 4-[[4-[(4-chlorophenyl)-thio]phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



Part A: To a solution of the tetrahydropyran compound of Example 11, part C (8.0 g, 26.5 mmol) in THF (250 mL) was added potassium

-339-

trimethylsilonate (10.2 g, 79.5 mmol), and the solution was stirred for 1.5 hours. The reaction was quenched by the addition of H₂O, acidified to a pH value of 2.5, and the solution was extracted with
5 ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provide the acid salt as a white solid (5.78 g, 76%).

Part B: To a solution of the acid salt of
10 part A (5.4 g, 18.7 mmol) in DMF (35 mL) were added HOBT (3.04 g, 22.5 mmol), N-methylmorpholine (6.2 mL, 56.2 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (6.8 g, 58.1 mmol) and EDC (5.0 g, 26.2 mmol), and the solution was stirred for 3 hours at ambient
15 temperature. The solution was concentrated in vacuo, the residue partitioned between ethyl acetate and H₂O, and the organic layer was washed with 5 percent aqueous KHSO₄, H₂O, saturated NaHCO₃, and saturated NaCl, and then dried over Na₂SO₄. Concentration in
20 vacuo provided the protected hydroxamate as a white solid (6.34 g, 87%).


Part C: To a solution of p-chlorothiophenol (2.71 g, 18.7 mmol) in DMF (10 mL) was added K₂CO₃ (2.6 g, 18.7 mmol) followed by the
25 protected hydroxamate of part B (2.9 g, 7.5 mmol) and the solution was heated at 75 degrees Celsius for 5 hours. The solution was concentrated in vacuo, the residue partitioned between ethyl acetate and H₂O, the organic layer was washed with saturated NaCl, and
30 dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane/methanol) provided the sulfide as a

-340-

white foam (3.56 g, 93%). MS(CI) MH^+ calculated for $C_{23}H_{26}ClNO_6S_2$: 512, found 512.

Part D: To a solution of the sulfide of part C (3.5 g, 6.8 mmol) in dioxane (10 mL) was added 4N HCl in dioxane (10 mL). After 10 minutes of stirring, methanol (10 mL) was added with continued stirring for one hour. The solution was concentrated in vacuo. Recrystallization (acetone/hexane) provided the title compound as a white solid (2.4 g, 83%). MS(CI) MH^+ calculated for $C_{18}H_{18}ClNO_5S$: 428, found 428.

Example 26: Preparation of Tetrahydro-N-hydroxy-4-[[4-[4-(1H-1,2,4-triazol-1-yl)phenoxy]-phenyl]-sulfonyl]-2H-pyran-4-, carboxamide, monohydrochloride




Part A: To a solution of the protected hydroxamate of Example 25, part B (2.9 g, 7.5 mmol) in DMF (10 mL) was added 4-(1,2,4-triazol-1-yl)phenol (2.47 g, 15 mmol) in DMF (5 mL) followed by Cs_2CO_3 (7.33 g, 22.5 mmol), and the solution was heated at 95 degrees Celsius for 5 hours. The solution was concentrated in vacuo and the residue was partitioned between ethyl acetate and H_2O . The organic layer was

-341-

washed with saturated NaCl and dried over Na_2SO_4 .
Chromatography (on silica, ethyl
acetate/hexane/methanol) provided the phenol as a
white solid (3.16 g, 80%).

5 Part B: To a solution of the phenol of
part A (2.8 g, 5.3 mmol) in dioxane (10 mL) was added
4N HCl in dioxane (10 mL). After 5 minutes of
stirring, methanol (10 mL) was added and stirring was
continued for 1 hour. The solution was then poured
10 into ethyl ether, and the resulting precipitate was
collected by vacuum filtration to provide the title
compound as a white solid (2.44 g, 96%). MS(CI) MH^+
calculated for $\text{C}_{20}\text{H}_{20}\text{N}_4\text{O}_6\text{S}$: 445, found 445.

15 Example 27: Preparation of 1-cyclopropyl-4-[[4-[(4-
fluorophenyl)thio] phenyl]sulfonyl]-N-
hydroxy-4-piperidinecarboxamide,
monohydrochloride



20

Part A: HCl gas was bubbled for 7 minutes
into a solution of the sulfide of Example 9, part D
(7.06 g, 13.5 mmol) in ethyl acetate (150 mL), and
25 the solution was stirred for 15 minutes at zero
degrees Celsius. The solution was concentrated in

-342-

vacuo to provide the amine as a white solid (6.43 g, quantitative yield).

Part B: To a solution of the amine of part A (6.4 g, 13.9 mmol) in methanol (65 mL) was added
5 acetic acid (7.96 mL, 139 mmol) and a scoop of 3A molecular sieves. To this mixture was added (1-ethoxycyclopropyl)-oxytrimethylsilane (16.8 mL, 84 mmol) followed by sodium cyanoborohydride (3.9 g, 62 mmol). The solution was heated to reflux for 6
10 hours. The solution was filtered and the filtrate was concentrated in vacuo. The residue was dissolved into ethyl acetate, washed with H₂O, 2N NaOH and saturated NaCl, and dried over magnesium sulfate. Filtration through a pad of silica (hexane/ethyl
15 acetate) provided the cyclopropyl amine as a white solid (6.49 g, quantitative yield).

Part C: To a solution of the cyclopropyl amine of part B (6.4 g, 13.8 mmol) in ethanol (30 mL) and THF (30 mL) was added NaOH (5.5 g, 138 mmol) in
20 H₂O (23 mL), and the solution was heated to 65 degrees Celsius for 12 hours. The solution was concentrated in vacuo and the aqueous layer was acidified to a pH value of 2 with 2N HCl. The resulting white precipitate was collected by filtration to provide
25 the acid as a white solid (5.2 g, 87%). MS(CI) MH⁺ calculated for C₂₁H₂₂NO₄S₂F: 436, found 436.

Part D: To a solution of the acid of part C (2.27 g, 5.2 mmol) in DMF (60 mL) was added HOBT (845 mg, 6.2 mmol) followed by N-methylmorpholine
30 (1.71 mL, 15.6 mmol), EDC (1.40 g, 7.28 mmol) and O-tetrahydro-2H-pyran-2-yl-hydroxylamine (913 mg, 7.8


-343-

mmol), and the solution was stirred at ambient temperature for 72 hours. The solution was concentrated in vacuo, the residue was dissolved into dichloromethane and washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, hexane/ethyl acetate) provided the protected hydroxamate as a white solid (1.95 g, 70%).

Part E: To a solution of the protected hydroxamate of part D (3.2 g, 6.0 mmol) in cold methanol (100 mL) was added acetyl chloride (1.3 mL, 18.0 mmol) in methanol (30 mL), and the solution was stirred at ambient temperature for 4 hours. The solution was concentrated in vacuo and the residue was triturated with ethyl ether to provide the title compound as a white solid (2.86 g, 98%). MS(CI) MH⁺ calculated for C₂₁H₂₃N₂O₄S₂F: 451, found 451. Analytical calculation for C₂₁H₂₃N₂O₄S₂F 0.25H₂O HCl: C, 51.32; H, 5.02; N, 5.70; S, 13.05; Cl, 7.21. Found: C, 50.99; H, 4.91; N, 5.65; S, 13.16; Cl, 7.83.

Example 28: Preparation of N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propenyl)-4-piperidine carboxamide, monohydrochloride

-344-



Part A: To a solution of the amine hydrochloride salt of Example 9, part E (4.78 g, 10.8 mmol) in DMF (25 mL) were added K_2CO_3 (2.98 g, 21.6 mmol) and allyl bromide (0.935 mL, 10.8 mmol), and the solution was stirred for 5 hours at ambient temperature. The solution was partitioned between ethyl acetate and H_2O , and the organic layer was washed with H_2O and saturated NaCl, and dried over magnesium sulfate. Filtration through a pad of silica (hexane/ethyl acetate) provided the allyl amine as an oil (4.80 g, quantitative yield).

Part B: To a solution of the allyl amine of part A (4.8 g, 10.8 mmol) in ethanol (25 mL) and THF (25 mL) was added NaOH (4.3 g, 108 mmol) in H_2O (20 mL), and the solution was heated to 65 degrees Celsius for 18 hours. The solution was concentrated in vacuo and diluted with H_2O . The aqueous solution was acidified to a pH value of 3. The resulting precipitate was collected by vacuum filtration to provide the acid as a beige solid (4.1 g, 84%). MS(CI) MH^+ calculated for $C_{21}H_{23}NO_4S_2$: 418, found 418.

Part C: To a solution of the acid of part B (4.1 g, 9.0 mmol) in DMF (90 mL) was added


-345-

HOBT(1.46 g, 11.0 mmol) followed by N-methylmorpholine (2.97 mL, 2.7 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (1.58 g, 13.5 mmol) and EDC (2.42 g, 13.0 mmol), and the solution was stirred
5 for 72 hours. The solution was concentrated in vacuo. The residue was dissolved in dichloromethane and washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/methanol) provided the
10 protected hydroxylamine as a white solid (4.11 g, 88%).

Part D: To a solution of the protected hydroxylamine of part C (4.11 g, 8.0 mmol) in ethyl acetate (100 mL) cooled to zero degrees Celsius was
15 added acetyl chloride (1.71 mL, 24.0 mmol), and the solution was stirred for 4 hours at ambient temperature. The solution was concentrated in vacuo and trituration with ethyl ether provided the title compound as a white solid (3.53 g, 95%). Analytical
20 calculation for C₂₁H₂₄N₂O₄S₂ HCl 0.5H₂O: C, 52.76; H, 5.48; N, 5.86; S, 13.42; Cl, 7.42. Found: C, 52.57; H, 5.69; N, 6.29; S, 12.59; Cl, 7.80.

Example 29: Preparation of 1-(cyclopropylmethyl)-N-
25 hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-4-
piperidine carboxamide monohydrochloride

-346-



Part A: To a solution of the amine hydrochloride salt of Example 6, part E (2.13 g, 5.0 mmol) in DMF (10 mL) were added K₂CO₃ (1.4 g, 10.0 mmol) and bromomethylcyclopropane (0.48 mL, 5.0 mmol), and the solution was stirred for 18 hours at ambient temperature. The solution was partitioned between ethyl acetate and H₂O, the organic layer was washed with H₂O and saturated NaCl, and then dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided the solid cyclopropylmethylamine (2.09 g, 91%).

Part B: To a solution of the cyclopropylmethylamine of part A (2.0 g, 4.4 mmol) in ethanol (12 mL) and THF (12 mL) was added NaOH (1.75 g, 44 mmol) in H₂O (10 mL), and the solution was heated to 65 degrees Celsius for 18 hours. The solution was concentrated in vacuo and the aqueous residue was acidified to a pH value of 5. The resulting precipitate was collected by vacuum filtration to provide the acid as a white solid (1.58 g, 79%). HRMS calculated for C₂₂H₂₅NO₅S: 414.1375, found 414.1334.


-347-

Part C: To a solution of the acid of part B (1.58 g, 3.5 mmol) in dichloromethane (50 mL) was added triethylamine (1.46 mL, 10.5 mmol) followed by 50 percent aqueous hydroxylamine (2.3 mL, 35 mmol) and PyBroP (3.26 g, 6.99 mmol), and the solution was stirred at ambient temperature for 72 hours. The solution was washed with H₂O and saturated NaCl, and dried over magnesium sulfate. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the hydroxamate as a white solid (3.2 g, quantitative yield).

Part D: To a solution of the hydroxamate of part C (1.5 g, 3.5 mmol) in cold methanol (20 mL) was added acetyl chloride (0.25 mL, 3.5 mmol) in methanol (5 mL) and the solution was stirred at zero degrees Celsius for 15 minutes. After the solution had stirred for an additional 30 minutes at ambient temperature, it was concentrated in vacuo. Trituration with ethyl ether provided the title compound as a white solid (229 mg, 7 %).

Example 30: Preparation of N-hydroxy-1-(2-methoxyethyl)-4-[(4-phenoxyphenyl)-sulfonyl]-4-piperidine carboxamide, monohydrchloride

-348-



Part A: To a solution of the amine HCl salt of part E, Example 6 (2.5 g, 5.87 mmol) and K_2CO_3 (1.6 g, 11.57 mmol) in N,N-dimethylformamide (25 mL) was
5 added 2-bromoethyl methyl ether (0.66 mL, 7.0 mmol) and then stirred at ambient temperature for 18 hours. Then N,N-dimethylformamide was evaporated under high vacuum and residue was diluted with ethyl acetate. The organic layer was washed with water and dried
10 over Mg_2SO_4 . Concentration in vacuo provided the methoxyl ethyl amine as light yellow gel (2.63 g, quantitative yield).

Part B: To a solution of the methoxyl ethyl amine of part A (2.63 g, 5.87 mmol) in
15 tetrahydrofuran (18 mL) and ethanol (18 mL) was added NaOH (2.1 g, 5.25 mmol) in water (6 mL). The solution was heated to reflux for 12 hours. The solution was concentrated in vacuo and diluted with water. The aqueous layer was extracted with ether
20 (2X100 mL) and was acidified to pH=2. Vacuum filtration of the resulting precipitation provided the acid as a white solid (2.4 g, quantitative yield).

Part C: To a solution of the acid of part
25 B (2.0 g, 4.33 mmol), also containing N-methyl

-349-

morpholine (1.8 mL, 16.4 mmol), and O-tetrahydro-2H-pyran-yl-hydroxylamine (0.767 g, 6.44 mmol) in N,N-dimethylformamide (20 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (3.1 g, 16.2 mmol), and solution was stirred at ambient temperature for 20 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with H₂O and dried over Mg₂SO₄. Concentration in vacuo provided the amide as off white foam (1.60 g, 71.1%).


Part D: To a solution of the amide of part C (1.58 g, 3.05 mmol) in methanol (20 mL) cooled to zero degrees Celsius was added acetyl chloride (0.65 mL, 9.15 mmol) and the resulting solution was stirred at the same temperature for 3 hours. The solution was concentrated and reverse phase chromatography (on C-18 silica, acetonitrile/H₂O with 0.01% HCl) provided hydroxamate HCl salt as a white solid (0.65 g, 45.5%). Analytical calculation for C₂₁H₂₆N₂O₆S.HCl.0.75H₂O: C, 52.06; H, 5.93; N, 5.78; S, 6.62. Found: C, 51.94; H, 5.67; N, 5.91; S, 6.66. HSMS calculated for C₂₁H₂₆N₂O₆S: 435.1590, found 435.1571.

25

Example 31: Preparation of N-hydroxy-4-[(4-phenoxyphenyl)sulfonyl]-1-(1-pyrrolidinylacetyl)-4-piperidine carboxamide, monohydrochloride

30

-350-



Part A: To a solution of the sulfone of part D, Example 6 (2.75g, 5.6mmol) in tetrahydrofuran (10mL) and ethanol (10mL) was added NaOH (2.25g, 56mmol) in H₂O (20 mL), and the solution was heated to 70 degrees Celsius for 20 hours. The solution was concentrated in vacuo and the dry residue was dissolved in H₂O. The aqueous layer was extracted with ether and was acidified to pH=2 followed by the extraction with ethyl acetate. The combined organic layers were washed again with H₂O and dried over Mg₂SO₄. Concentration in vacuo provided the BOC-acid as white foam (2.3g, 88.8%)

Part B: To a solution of BOC-acid of part A (2.3g, 4.98mmol) in dichloromethane (6 mL) was added trifluoroacetic acid (6 mL, 77.8 mmol), and the resulting solution was stirred at ambient temperature for 1 hour. Concentration in vacuo provided the amine as white foam (2.44g, quantitative yield).

Part C: To the solution of the amine of part B (2.4 g, 4.9 mmol) and triethylamine (3.5 mL, 24.4 mmol) in acetone (15 mL) and H₂O (15 mL) was added chloroacetyl chloride (1.2 mL, 14.7 mmol), and solution was stirred at ambient temperature for 20

-351-

hours. Then acetone was evaporated and aqueous layer was acidified to pH=2. The aqueous layer was extracted with ethyl acetate and the organic layer was washed with water and dried over Mg_2SO_4 .

- 5 Concentration in vacuo provided the chloroacetyl amide as light yellow gel (2.78 g, quantitative yield).

Part D: To the solution of the chloroacetyl amide of part C (2.78 g, 4.93mmol) and
10 K_2CO_3 (5 g, 36 mmol) in N,N-dimethylformamide (20 mL) was added pyrrolidine (3 mL, 36 mmol). The solution was then stirred at ambient temperature for 18 hours. Then N,N-dimethylformamide was evaporated under high vacuum and reverse phase chromatography (on C-18
15 silica, acetonitrile/ H_2O with 0.01% HCl) provided pyrrolidine acetyl amide (0.25g, 10.7%).

Part E: To a solution of the pyrrolidine acetyl amide of part D (0.25 g, 0.53 mmol), also containing N-methyl morpholine (0.14 mL, 1.27 mmol),
20 1-hydroxybenzotriazole (0.17 g, 1.2 mmol) and O-tetrahydro-2H-pyran-yl-hydroxylamine (0.15 g, 1.26 mmol) in N,N-dimethylformamide (4 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.23 g, 1.2 mmol). The solution was
25 then stirred at ambient temperature for 18 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated $NaHCO_3$, H_2O and dried over Mg_2SO_4 . Concentration in vacuo
30 provided the THP amide as white foam (0.25 g, 83.3%).

-352-


Part F: To a solution of the amide of part E (0.25 g, 0.437 mmol) in methanol (4 mL) cooled to zero degrees Celsius was added acetyl chloride (0.075 mL, 1.05 mmol), and the resulting solution was

5 stirred at ambient temperature for 2.5 hours. The solution was concentrated and reverse phase chromatography (on C-18 silica, acetonitrile/H₂O with 0.01% HCl) provided hydroxamate HCl salt as a white solid (80 mg, 29%). Analytical calculation for

10 C₂₄H₂₉N₃O₆S.HCl.0.9H₂O: C, 53.36; H, 5.98; N, 7.78. Found: C, 53.61; H, 5.71; N, 7.94. HSMS calculated for C₂₄H₂₉N₃O₆S: 488.1855, found 488.1835.

Example 32: Preparation of 1-cyclopropyl-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidine carboxamide,

15 monohydrochloride



20

Part A: A solution of 4-fluorothiophenol (50.29 g, 0.39 mmol) in dimethylsulfoxide (500 mL) was heated to 65 degrees Celsius for 5 hours. The solution was cooled to ambient temperature and poured

25 into vigorously stirred ice water. The precipitate was filtered and washed twice with water. Drying

-353-

under high vacuum provided the disulfide as a yellow oil (34.39 g, 68.9%) at ambient temperature.

Part B: A solution of di-tert-butyl dicarbonate (21.8 g, 0.1 mol) in tetrahydrofuran (5 mL) was added dropwise over 20 minutes to a solution of ethyl isonipecotate (15.7 g, 0.1 mol) in tetrahydrofuran (100 mL). The resulting solution was stirred overnight (about eighteen hours) at ambient temperature and concentrated in vacuo to yield a light oil. The oil was filtered through silica gel (ethyl acetate/hexane) and concentrated in vacuo to give the BOC-piperidine compound as a clear, colorless oil (26.2g, quantitative yield).

Part C: To a solution of BOC-piperidine compound of part B (15.96 g, 62 mmol) in tetrahydrofuran (300 mL), cooled to minus forty degrees Celsius, was added lithium diisopropylamide (41.33 mL, 74 mmol). The solution was then stirred at minus forty degrees C for one hour and zero degrees C for one-half hour. Then the solution was cooled to minus forty degrees Celsius again and the disulfide of part A (15.77 g, 62 mmol) in tetrahydrofuran (20 mL) was added. The resulting solution as stirred at ambient temperature for 18 hours. The solution was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with H₂O and saturated NaCl and dried over MgSO₄. Chromatography (on silica, ethyl acetate/hexane) provided the sulfide as an oil (18 g, 75%).

-354-

Part D: To a solution of the sulfide of part C (16.5 g, 43 mmol) in dichloromethane (500 mL) cooled to zero degrees Celsius, was added m-chloroperbenzoic acid (18.5 g, 107 mmol). After 2 hours, the solution was diluted with dichloromethane and washed with 1N KOH, H₂O and dried over MgSO₄. Concentration in vacuo provided the sulfone as a solid (21 g, quantitative yield).

Part E: To a solution of sulfone (40 g, 96 mmol) of part D and powdered K₂CO₃ (26 g, 188 mmol) in N,N-dimethylformamide (200 mL) cooled to zero degrees Celsius was added thiolphenol (19.8 mL, 192 mmol), and the resulting composition was then stirred at ambient temperature for 36 hours. That solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with H₂O and dried over magnesium sulfate. Chromatography (on silica, ethyl acetate/hexane) provided phenyl thiophenyl Boc-sulfone as white solid (44.34 g, 91%).

Part F: To a solution of phenyl thiophenyl Boc-sulfone of part E (8.6 g, 17 mmol) in dichloromethane (30 mL) cooled to zero degrees Celsius was added trifluoroacetic acid (TFA; 30 mL), and the resulting solution was stirred at ambient temperature for 2 hours. Concentration in vacuo provided the amine TFA salt as a light yellow gel (8.7 g, quantitative yield).

Part G: To a solution of amine TFA salt of part F (6g, 11.9mmol) was added acetic acid (6.8 mL, 119mmol). After 5 minutes stirring at ambient

-355-

temperature, (1-ethoxycyclopropyl)oxytriethylsilane (14.3 mL, 71.4 mmol) was added followed 5 minutes later by the addition of sodium cyanoborane hydrate (3.35 g, 53.55mmol). Then the solution was heated to reflux for 18 hours. Methanol was evaporated and residue was dissolved in ethyl acetate. The organic layer was washed with 1N NaOH, H₂O and dried over Mg₂SO₄. Concentration in vacuo gave the cyclopropylamine as an off-white powder (4.9 g, 92.6%).


Part H: To a solution of the cyclopropylamine of part G (4.88 g, 10.95 mmol) in tetrahydrofuran (12.5 mL) and ethanol (12.5 mL) was added NaOH (4.3 g, 100 mmol) in water (25 mL). The solution was then heated to 50-55 degrees Celsius for 12 hours and was stirred at ambient temperature for 18 hours. Solution was acidified to pH=2 and concentration in vacuo provided the acid as white solid together with NaCl in the mixture. To a solution of this mixture in acetonitrile (50 mL) were added O-tetrahydropyronylamine (1.95 g, 16.3 mmol), N-methylmorpholine (2.4 mL, 21.9 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (3.14 g, 16.3mmol) in sequence. The solution was then stirred at ambient temperature for 18 hours. The solution was concentrated in vacuo and the residue was dissolved in ethyl acetate. The organic layer was washed with H₂O and dried over Mg₂SO₄. Concentration in vacuo provided the tetrehyrdopyranyl (THP) amide as white solid (3.0 g, 53.1%).

-356-

Part I: To a solution of the THP amide of part H (3 g, 5.8 mmol) in methanol (45 mL) cooled to zero degrees Celsius was added acetyl chloride (1.5 mL, 21.1 mmol), and the solution was stirred at ambient temperature for 2.5 hours. Vacuum filtration of the precipitate provided hydroxamate HCl salt as a white solid (1.844 g, 68.3%). Analytical calculation for $C_{21}H_{24}N_2O_4S_2 \cdot HCl$: C, 53.78; H, 5.37; N, 5.97; S, 13.67. Found: C, 53.40; H, 5.26; N, 5.95; S, 13.68.

10

Example 33: Preparation of N-hydroxy-1-methyl-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide, monohydrochloride



15

Part A: To a solution of amine TFA salt of part F, Example 32 (2.67 g, 5.14 mmol) and 37% formaldehyde in aqueous solution (2.0 mL, 25.7 mmol) in methanol (20 mL) was added borane pyridine (2.6 mL, 25.7 mmol) at ambient temperature. The solution was then stirred at ambient temperature for 18 hours. The solution was acidified to destroy excess reagent. Methanol was evaporated and the residue was partitioned between $NaHCO_3$ aqueous solution and ethyl acetate. The $NaHCO_3$ aqueous layer was extracted with ethyl acetate. The combined organic layers were

25

-357-

washed with H₂O and dried over Mg₂SO₄. Concentration in vacuo gave the methyl amine as off white foam (1.6 g, 76%).

Part B: To a solution of the methyl amine
5 of part A (1.63 g, 3.88 mmol) in ethanol (20 mL) was added KOH (1.31 g, 23.2 mmol) in water (4 mL), and the resulting solution was heated to 50 degrees Celsius for 8 hours, 70 degree Celsius for 4 hours and stirred at ambient temperature for 18 hours. The
10 solution was acidified and concentrated in vacuo providing the acid as white solid together with NaCl in the mixture. To a solution of this mixture in N,N-dimethylformamide (50 mL) were added O-tetrahydropyrylamine (0.92 g, 7.76 mmol), N-
15 methylmorpholine (1.05 mL, 7.76 mmol), and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (1.5 g, 7.76mmol) in sequence. The solution was stirred at ambient temperature for 72 hours. The solution was concentrated in high vacuum
20 and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated NaHCO₃, H₂O and dried over Mg₂SO₄. Concentration in vacuo and chromatography (silica, dichloromethane/methanol) provided the THP amide as white solid (0.46 g,
25 24.2%).

Part C: To a solution of the THP amide of part B (0.22 g, 0.45 mmol) in methanol (5 mL) cooled to zero degrees Celsius was added acetyl chloride (0.096 mL, 13.5 mmol), and the resulting solution was
30 stirred at ambient temperature for 3 hours. The solution was concentrated in vacuo and reverse phase


-358-

chromatography (on C-18 silica, acetonitrile/H₂O with 0.01% HCl) provided hydroxamate HCl salt as a white solid (0.12 g, 60.6%). HSMS calculated for C₁₉H₂₂N₂O₄S₂: 407.1099, found 407.1105.

5

Example 34: Preparation of N-hydroxy-1-(1-methylethyl)-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide, monohydrochloride

10



Part A: Into a solution of BOC-sulfone of part E, Example 32 (11.19 g, 22.12 mmol) in ethyl acetate (150 mL) cooled to zero degrees Celsius was bubbled HCl gas for 20 minutes. The solution was stirred at the same temperature for another 40 minutes. Concentration in vacuo and titration with ether provided the amine HCl salt (9.88 g, quantitative yield).

Part B: To a solution of amine HCl salt of part A (4.7 g, 10.6 mmol), triethylamine (2.0 mL, 14.4 mmol) and acetone (2.0 mL, 27.2 mmol) in dichloromethane (100 mL) were added sodium triacetoxylborohydride (5.7 g, 26.9 mmol) followed by acetic acid (1.5 mL, 26.9 mmol) at ambient

-359-

temperature. The solution was stirred for 18 hours and then partitioned in 1N NaOH and ether. The aqueous layer was extracted with ether and combined organic layers were washed with 1N NaOH, H₂O and dried
5 over Mg₂SO₄. Concentration in vacuo gave the isopropyl amine as white foam (4.58 g, 96.2%).

Part C: To a solution of the isopropyl amine of part B (4.58 g, 10.2 mmol) in tetrahydrofuran (10 mL) and ethanol (10 mL) was added
10 NaOH (2.1 g, 5.25 mmol) in water (20 mL). The solution was heated to 60 degrees Celsius for 13.5 hours, then stirred at ambient temperature for 18 hours. The solution was acidified and concentrated in vacuo providing the acid as white solid together
15 with NaCl in the mixture. To a solution of this mixture in N,N-dimethylformamide (75 mL) were added 1-hydroxybenzotriazole (1.94 g, 14.4 mmol), O-tetrahydropyronylamine (1.8 g, 15.1 mmol), N-methylmorpholine (3.37 mL, 30.7 mmol), and 1-[3-
20 (dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (2.74 g, 14.3mmol) in sequence. The solution was stirred at ambient temperature for 48 hours. The solution was concentrated in high vacuum and the residue was dissolved in ethyl acetate. The
25 organic layer was washed with saturated NaHCO₃, H₂O and dried over Mg₂SO₄. Concentration in vacuo and chromatography (silica, dichloromethane/methanol) provided the THP amide as white solid (3.78 g, 71.3%).

30 Part D: To a solution of the THP amide of part C (1.15 g, 2.2 mmol) in methanol (20 mL) was


-360-

added acetyl chloride (0.096 mL, 13.5 mmol), and the resulting solution was stirred at ambient temperature for 2.5 hours. The solution was concentrated in vacuo and reverse phase chromatography (on C-18 silica, acetonitrile/H₂O with 0.01% HCl) provided hydroxamate HCl salt as a white solid (0.69 g, 66.3%). Analytical calculation for C₂₁H₂₆N₂O₄S₂.HCl.H₂O: C, 51.58; H, 5.98; N, 5.73; S, 13.11. Found: C, 51.76; H, 5.47; N, 5.72; S, 12.68.

10

Example 35: Preparation of N-hydroxy-1-(2-methoxyethyl)-4-[[4-(phenylthio)phenyl]-sulfonyl]-4-piperidinecarboxamide, monohydrochloride

15



Part A: To the solution of the amine HCl salt of part A, Example 34 (4.3 g, 9.43 mmol) and K₂CO₃ (2.62 g, 19.0 mmol) in N,N-dimethylformamide (40 mL) was added 2-bromoethyl methyl ether (1.9 mL, 20.2 mmol). The solution was stirred at ambient temperature for 48 hours. Then N,N-dimethylformamide was evaporated under high vacuum and the residue was

25

-361-

diluted with ethyl acetate. The organic layer was washed with water and dried over Mg_2SO_4 .

Concentration in vacuo provided the methoxyl ethyl amine as white foam (4.26 g, 95.3%).

5 Part B: To a solution of the methoxyl ethyl amine of part A (4.26 g, 9.2 mmol) in tetrahydrofuran (5 mL) and ethanol (5 mL) was added NaOH (3.7 g, 92.5 mmol) in water (9 mL). The solution resulting was heated to 60 degrees Celsius for 12 hours and stirred
10 at ambient temperature for 18 hours. The solution was concentrated in vacuo and diluted with water. The aqueous layer was extracted with ether (2X100 mL) and was acidified to pH=2. Vacuum filtration of the resulting precipitate provided the acid as a white
15 solid (3.5 g, 87.5%).

 Part C: To a solution of the acid of part B (3.4 g, 7.8 mmol), also containing N-methyl morpholine (2.6 mL, 23.4 mmol), 1-hydroxybenzotriazole (3.16 g, 23.4 mmol), and O-
20 tetrahydro-2H-pyran-2-yl-hydroxylamine (1.85 g, 15.5 mmol) in N,N-dimethylformamide (20 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (4.47 g, 23.4 mmol). The solution was stirred at ambient temperature for 36 hours. The
25 solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated $NaHCO_3$, H_2O and dried over Mg_2SO_4 . Concentration in vacuo provided the amide as off white solid (2.98 g, 71.5%).

30 Part D: To a solution of the amide of part C (2.98 g, 5.6 mmol) in methanol (40 mL) cooled to


-362-

zero degrees Celsius was added acetyl chloride (1.19 mL, 16.8 mmol), and the resulting solution was stirred at the ambient temperature for 3 hours. The solution was concentrated and reverse phase

5 chromatography (on C-18 silica, acetonitrile/H₂O with 0.01% HCl) provided hydroxamate HCl salt as a white solid (2.29 g, 84.6%). Analytical calculation for C₂₁H₂₆N₂O₆S.HCl.0.9H₂O: C, 50.12; H, 5.77; N, 5.57; S, 12.74. Found: C, 50.41; H, 5.85; N, 5.73; S, 12.83.

10

Example 36: Preparation of 1-acetyl-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide, monohydrochloride



15

Part A: To a solution of the phenyl thiophenyl BOC-sulfone of part E, Example 32 (7 g, 1.29 mmol) in tetrahydrofuran (25 mL) and ethanol (25 mL) was added NaOH (5.1 g, 12.9 mmol) in H₂O (50 mL). The solution was heated to reflux for 20 hours. On cooling, the solution was concentrated in vacuo and the dry residue was dissolved in H₂O. The aqueous layer was extracted with ether and was acidified to

20 pH=2 followed by the extraction with ethyl acetate. The combined organic layers were washed again with H₂O

25

-363-

and dried over Mg_2SO_4 . Concentration in vacuo provided the BOC-acid as white foam (3.9 g, 60%)

Part B: To a solution of BOC-acid of part A (2.3g, 4.98mmol) in dichloromethane (6 mL) was
5 added trifluoroacetic acid (6 mL, 77.8 mmol), and the solution was stirred at ambient temperature for 1 hour. Concentration in vacuo provided the amine as white foam (2.44g, quantitative yield).

Part C: To a solution of the amine of part
10 B (5.0 g, 12.08 mmol) and triethylamine (8.7 mL, 60.4 mmol) in acetone (20 mL) and H_2O (20 mL) cooled to zero degrees Celsius was added acetyl chloride (4.6 mL, 36 mmol), and the solution was stirred at ambient temperature for 40 hours. The acetone was evaporated
15 and the aqueous layer was acidified to pH=2. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with water and dried over Mg_2SO_4 . Concentration in vacuo provided the acetyl amide as light yellow foam (5 g,
20 quantitative yield).


Part D: To a solution of acetyl amide of part C (5 g, 11.9 mmol), also containing N-methyl morpholine (5.3 mL, 47.6 mmol), 1-hydroxybenzotriazole (4.8 g, 35.7 mmol) and O-
25 tetrahydro-2H-pyran-yl-hydroxylamine (2.8 g, 23.5 mmol) in N,N-dimethylformamide (50 mL) was added 1-[3(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (6.8 g, 35.7 mmol), and the solution was stirred at ambient temperature for 20 hours. The
30 solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic

-364-

layer was washed with saturated NaHCO_3 , KHSO_4 , H_2O and dried over Mg_2SO_4 . Concentration in vacuo provided the THP amide as white foam (6.07 g, 98.2%).

Part E: To a solution of the THP amide of
5 part D (6.07 g, 11.7 mmol) in methanol (100 mL) cooled to zero degrees Celsius was added acetyl chloride (2.5 mL, 35.1 mmol), and the solution was stirred at ambient temperature for 3 hours. The solution was concentrated and chromatography (on
10 silica, methanol/ dichloromethane) provided hydroxamate HCl salt as a white solid (3.3 g, 65%). Analytical calculation for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_6\text{S} \cdot \text{HCl} \cdot 0.9\text{H}_2\text{O}$: C, 53.36; H, 5.98; N, 7.78. Found: C, 53.61; H, 5.71; N, 7.94. HSMS calculated for $\text{C}_{24}\text{H}_{29}\text{N}_3\text{O}_6\text{S}$: 488.1855,
15 found 488.1835.

Example 37: Preparation of 1-acetyl-4-[[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide,
20 monohydrochloride



25

-365-

Part A: To a solution of sulfone from Part D, Example 32 (25g, 67.3 mmol) and powdered K_2CO_3 (23.3 g, 16.9 mmol) in N,N-dimethylformamide was added sesamol (23.24 g, 16.8 mmol) at ambient
5 temperature, and solution was heated to ninety degrees Celsius for 24 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with 1N NaOH, H_2O and dried over $MgSO_4$.
10 Chromatography (on silica, ethyl acetate/hexane) provided sesamol BOC-sulfone as a white foam (33.6 g, 93.6%).

Part B: To a solution of sesamol BOC-sulfone of part E (29.31 g, 54.93 mmol) in ethanol
15 (60 mL) and tetrahydrofuran (60 mL) was added NaOH (21.97 g, 544 mmol) from addition funnel over 20 minutes at ambient temperature. The solution was then heated to sixty degrees Celsius for 9 hours, then ambient temperature for 12 hours. The solution
20 was concentrated in vacuo and diluted with water. The aqueous layer was extracted with ether and acidified to pH=2. It was then extracted with ethyl acetate and the combined organic layers were washed with H_2O and dried over $MgSO_4$. Concentration in vacuo
25 provided the acid as white solid (25.3, 91%).

Part C: HCl gas was bubbled into a solution of the acid of part F (20.3 g, 40.15 mmol) in ethyl acetate cooled to zero degrees Celsius. After 1.5 hours, vacuum filtration of white precipitate
30 provided the amine HCl salt as a white solid (16 g, 93.6%).

-366-

Part D: To the solution of the amine HCl salt of part G (8.1 g, 19.01 mmol) and triethylamine (13.2 mL, 95.05 mmol) in acetone (150 mL) and H₂O (150 mL) cooled to zero degrees Celsius was added acetyl chloride (5.4 mL, 76 mmol). The solution was stirred at ambient temperature for 18 hours. The acetone was evaporated and aqueous layer was acidified to pH=2. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with water and dried over Mg₂SO₄. Concentration in vacuo provided the acetyl amide as light yellow foam (9.24 g, quantitative yield).

Part E: To the solution of the acetyl amide of part D (9.1 g, 20.33 mmol), N-methyl morpholine (6.7 mL, 61 mmol), 1-hydroxybenzotriazole (8.2 g, 60 mmol) and O-tetrahydro-2H-pyran-yl-hydroxylamine (4.85 g, 40 mmol) in N,N-dimethylformamide (40 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (11.65 g, 60 mmol). The resulting solution was stirred at ambient temperature for 20 hours. The solution was then concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated NaHCO₃, KHSO₄, H₂O and dried over Mg₂SO₄. Concentration in vacuo and chromatography (on silica, ethyl acetate/hexane) provided the THP amide as white a foam (10 g, 89.7%).


Part F: To a solution of 4N HCl in dioxane (20 mL) was added a solution of the amide of part E (5.0 g, 9.1 mmol) in methanol (5 mL) and dioxane (15

-367-

mL). That solution was stirred at ambient temperature for 30 minutes. Vacuum filtration of the white precipitate provided the hydroxamate HCl salt as a white solid (3.3 g, 65%). Analytical

5 calculation for $C_{21}H_{22}N_2O_8S \cdot HCl$: C, 54.34; H, 5.15; N, 5.49; S, 6.43. Found: C, 54.54; H, 4.79; N, 6.06; S, 6.93. HSMS calculated for $C_{21}H_{22}N_2O_8S$: 463.1175, found 463.118.

10 Example 38: Preparation of 4-[[4-(3,4-dimethoxyphenoxy)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monohydrochloride



15

Part A: HCl gas was bubbled into a solution of the sulfone of part D, Example 32 (10 g, 24 mmol) in ethyl acetate cooled to zero degrees Celsius.

20 After 4 hours, vacuum filtration of the white precipitate provided the amine HCl salt as a white solid (7.27 g, 86%).

Part B: To a solution of the amine HCl salt of part A (5.98 g, 17 mmol) and powered K_2CO_3 (4.7 g, 34 mmol) in N,N-dimethylformamide (120 mL) was added propargyl bromide (2.022 g, 17 mmol) at

25

-368-

ambient temperature, followed by stirring for 4 hours. The solution was diluted with ethyl acetate and washed with H₂O, saturated NaCl and dried over Mg₂SO₄. Concentration in vacuo and chromatography (on
5 silica, ethyl acetate/hexane) provided the propargyl amine as a white solid (5.2 g, 86%).

Part C: To a solution of the propargyl amine of part B (8 g, 22.63 mmol) and powdered K₂CO₃ (8.8 g, 56.6 mmol) in N,N-dimethylformamide (150 mL)
10 was added 3,4-dimethoxyphenol (6.98 g, 45 mmol) at ambient temperature. The composition was heated to 90 degrees Celsius for 36 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was
15 washed with 1N NaOH, H₂O and dried over MgSO₄. Chromatography (on silica, ethyl acetate/hexane) provided phenoxy propargyl amine as light yellow gel (10 g, 90.9%).

Part D: A solution of NaOH (8.2 g, 200
20 mmol) in H₂O (30 mL) from addition funnel was added to a solution of the phenoxy propargyl amine of part C (10 g, 20.5 mmol) in ethanol (15 mL) and tetrahydrofuran (15 mL) at ambient temperature. The resulting solution was then heated to 60 degrees
25 Celsius for 48 hours and at ambient temperature for 48 hours. The solution was concentrated in vacuo and diluted with water. The aqueous layer was extracted with ether and acidified to pH=2. Vacuum filtration of the white precipitate provided the acid as a white
30 solid (9.4 g, quantitative yield).

-369-

Part E: To a solution of the acid of part D (9.4g, 20.5 mmol), N-methyl morpholine (6.8 mL, 62 mmol), 1-hydroxybenzotriazole (8.3 g, 60 mmol) and O-tetrahydro-2H-pyran-yl-hydroxylamine (4.8 g, 40 mmol) in N,N-dimethylformamide (50 mL) was added 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (11.7 g, 60 mmol). The resulting solution was then stirred at ambient temperature for 20 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated NaHCO₃, H₂O and dried over Mg₂SO₄. Concentration in vacuo and chromatography (on silica, ethyl acetate/hexane) provided the THP amide as white foam (10 g, 89.7%).


Part F: To a solution of 4N HCl in dioxane (38 mL, 152 mmol)) was added a solution of the amide of part E (8.5 g, 15.2 mmol) in methanol (8 mL) and dioxane (24 mL). The resulting composition was stirred at ambient temperature for 80 minutes. Concentration in vacuo and titration with ether provided hydroxamate HCl salt as a white solid (7.7 g, quantitative yield). HSMS calculated for C₂₃H₂₆N₂O₇S: 475.1461, found 475.1539.

25

Example 39: Preparation of 4-[[4-(3,5-dimethoxyphenoxy)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monohydrochloride

30

-370-



Part A: To a solution of the propargyl
amine of Part B, Example 38 (2 g, 5.6 mmol) and
5 powdered K_2CO_3 (1.9 g, 13.7 mmol) in N,N-
dimethylformamide (20 mL) was added 3,5-
dimethoxyphenol (2.18 g, 13.7 mmol) at ambient
temperature. The resulting composition was heated to
90 degrees Celsius for 36 hours. The solution was
10 concentrated under high vacuum and the residue was
dissolved in ethyl acetate. The organic layer was
washed with 1N NaOH, H_2O and dried over $MgSO_4$.
Chromatography (on silica, ethyl acetate/hexane)
provided phenoxy propargyl amine as light yellow gel
15 (2.76 g, quantitative yield).

Part B: To a solution of the phenoxy
propargyl amine of part A (2.75 g, 5.6 mmol) in
ethanol (5 mL) and tetrahydrofuran (5 mL) was added
NaOH (2.3 g, 56 mmol) in H_2O (10 mL) at ambient
20 temperature. The solution was then heated to 60
degrees Celsius for 18 hours. The solution was
concentrated in vacuo and diluted with water. The
aqueous layer was extracted with ether and acidified
to pH=2. Vacuum filtration of white precipitate
25 provided the acid as white solid (2 g, 77.2%).

Part C: To a solution of the acid of part
B (2 g, 4.3 mmol), also containing N-methyl

-371-


morpholine (1.9 mL, 17.2 mmol), 1-hydroxybenzotriazole (1.74 g, 13.2 mmol) and O-tetrahydro-2H-pyran-yl-hydroxylamine (1.02 g, 8.6 mmol) in N,N-dimethylformamide (20 mL) was added 1-
5 [3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (2.47 g, 12.9 mmol). The resulting composition was stirred at ambient temperature for 20 hours. The solution was concentrated under high vacuum and the residue was dissolved in ethyl
10 acetate. The organic layer was washed with saturated NaHCO₃, H₂O and dried over Mg₂SO₄. Concentration in vacuo and chromatography (on silica, ethyl acetate/hexane) provided the THP amide as white foam (2.4 g, quantitative yield).

15 Part D: To a solution of 4N HCl in dioxane (13 mL, 52 mmol)) was added a solution of the THP amide of part C (2.43 g, 4.35 mmol) in methanol (2 mL) and dioxane (6 mL), and the composition was stirred at ambient temperature for 80 minutes.
20 Vacuum filtration of the precipitate and washing with ether provided the hydroxamate HCl salt as a white solid (1.25 g, 56.3%). Analytical calculation for C₂₃H₂₆N₂O₇S.1.5HCl: C, 52.20; H, 5.24; N, 5.29. Found: C, 52.00; H, 5.05; N, 5.17.

25

Example 40: Preparation of 4-[[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl]-N-hydroxy-4-
piperidinecarboxamide, monohydrochloride

-372-



Part A: To a solution of the N-BOC
carboxylic acid compound of part B, Example 37 (1.25
5 g, 2.47 mmol), N-methylmorpholine (1.00 g, 9.89 mmol)
and 1-hydroxybenzotriazole hydrate (0.40 g, 2.96
mmol) in N,N-dimethylformamide (8 mL) at ambient
temperature was added 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (0.616 g, 3.21 mmol).
10 After 5 minutes a solution of O-tetrahydro-2H-pyran-
2-yl-hydroxylamine (0.39 g, 3.33 mmol) in N,N-
dimethylformamide (2 mL) was added. After 2 days the
pale yellow solution was concentrated *in vacuo* to
afford a residue which was dissolved in ethyl acetate
15 and washed successively with water (3X) and brine and
dried over sodium sulfate. Concentration afforded a
residue that was chromatographed on silica gel
eluting with ethyl acetate/hexane (20/80) to afford
the THP-protected hydroxamate as an oil (1.54 g,
20 100%).

Part B: To a solution of THP-protected
hydroxamate of part A (1.49 g, 2.46 mmol) in dioxane
(9 mL) and methanol (3 mL) was added 4 N HCl in
dioxane (10 mL, 40 mmol). After 1.5 hours at ambient
25 temperature the suspension was treated with diethyl
ether (15 mL) and filtered to afford the title
hydroxamate (1.00 g, 89%) as a colorless powder. MS


-373-

(CI) MH⁺ calculated for C₁₉H₂₀N₂SO₇: 421, found 421.
Analytical calculation for C₁₉H₂₀N₂SO₇.HCl: C, 49.95;
H, 4.63; N, 6.13; Cl, 7.76; S, 7.02. Found: C,
49.82; H, 4.60; N, 5.98; Cl, 17.38; S, 7.10.

5

Example 41: Preparation of N-hydroxy-4-[[4-(3-methylphenoxy)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide,
monohydrochloride

10



Part A: To a solution of propargylamine of
15 part F, Example 9 (8.0 gm, 22.6 mmol) and K₂CO₃ in
N,N-dimethylformamide (30 mL) was added m-cresol (3.5
g, 33.9 mmol) and the solution was stirred at 90
degrees Celsius for 18 hours. The solution was
diluted with H₂O and extracted with ethyl acetate. The
20 combined organic layers were washed with saturated
NaCl and dried over MgSO₄. Chromatography (on silica,
eluting with 10% ethyl acetate/hexane) provided the
3-methyl phenoxyphenyl compound as a solid (10.3 g,
98%). Cal'd MS for C₂₄H₂₈NSO₅, 441.1688, found 442.1697

25

Part B: To a solution of 3-methyl
phenoxyphenyl compound of part A (10.3 g, 22.0 mmol)
in tetrahydrofuran (50 mL) and ethanol (50 mL) was

-374-

added NaOH (8.9 g, 22.3 mol) and the solution was heated at 65 degrees Celsius for 24 hours. The solution was concentrated in vacuo and the aqueous residue was acidified to pH=3. Vacuum filtration of the resulting precipitate provided the acid as a white solid (9.0 g, 91%). MS cal'd for $C_{22}H_{24}NSO_5$ = 414.1375. Found = 414.1389.


Part C: To a solution of the acid of part B (9.0 g, 19.5 mmol) was added 1-hydroxybenzotriazole (3.24 g, 23.9 mmol), N-methylmorpholine (6.58 mL, 59.9 mmol), O-tetrahydro-2H-pyran-yl-hydroxylamine (3.5 g, 29.9 mmol) followed by 1-3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (5.35 g, 27.9 mmol). The solution was stirred at ambient temperature for 18 hours. The solution was diluted with H_2O (400 mL) and extracted with ethyl acetate. The organic layer was washed with saturated NaCl and dried over $MgSO_4$. Chromatography (on silica, eluting with 40% ethyl acetate/hexane) provided the desired THP-protected hydroxamate as a solid (6.9 g, 67%). Analytical calculation for $C_{27}H_{33}N_2SO_6 \cdot 0.1 H_2O$: C, 62.92, H, 6.49, N, 5.43, S, 6.23. Found: C, 62.69, H, 6.47, N, 5.57, S, 6.33. Cal'd MS for $C_{27}H_{33}N_2SO_6$: 513.2059. Found 513.2071.

Part D: To a solution of THP-protected hydroxamate of part C (6.4 gm, 12.5 mmol) in dioxane (56 mL) and methanol (19 mL) was added 4 N HCl/dioxane (40 mL). After stirring at ambient temperature for 1 hours, the solution was concentrated in vacuo. Trituration with ethyl ether

-375-

provided the title compound as a white solid (5.66 g, 97.4%). Cal'd MS for $C_{22}H_{24}N_2SO_5+1$: 429.1484.. Found M+1: 429.1493

- 5 Example 42: Preparation of 4-[[4-(1,3-benzodioxol-5-yloxy)phenyl]sulfonyl]-N-hydroxy-1-
(methylsulfonyl)-4-piperidinecarboxamide



10

- Part A: To a solution of sulfone of part D, Example 32 (25.g, 67.3 mmol) in N,N-dimethylformamide was added potassium carbonate (23.3 g, 0.169 mol) and sesamol (23.2 g, 0.164 mol). The solution was submerged in an oil bath at 90°C and stirred for 25 hours. Ethyl acetate was added to the solution, and the organic phase was washed with water, 1N NaOH and water, dried over magnesium sulfate, filtered and concentrated *in vacuo*.
- 15 Chromatography on silica, eluting with ethyl acetate/hexane (15/85) provided the ethyl ester compound as an oil (29.3 g, 82%).

- Part B: To a solution of ethyl ester from part A (29.3 gm, 54.93 mmol) in ethanol (60 mL) and tetrahydrofuran (60 mL) was added a solution of NaOH (21.9 g, 0.549 mol) in water 120 mL) and the solution was heated at 65 degrees Celsius for 10 hours. The
- 25

-376-

solution was concentrated in vacuo and the aqueous residue was acidified to pH=3. The solution was extracted with ethyl acetate. The solution was dried over magnesium sulfate, filtered and concentrated in vacuo to give the acid as a yellow foam (25.6 g 92.1%).

Part C: To a solution of the acid of Part B (20.3 g, 40.15 mmol) in ethyl acetate at zero degrees C was bubbled gas HCl for 20 minutes. The solution stirred at Zero degrees Celsius for 1.5 hours. The precipitate formed was filtered and washed with ether to give the amine hydrochloride as a white solid (16.0 g, 93.5%)

Part D: To a solution of amine hydrochloride of part C (7.5g, 17.0 mmol) in methylene chloride (200 mL) was added methanesulfonyl chloride (2.0 g, 25.0 mol) and the solution was stirred at ambient temperature for 18 hours. The solution was washed with water and saturated NaCl, dried over magnesium sulfate, concentrated in vacuo to provide the acid as a white solid (6.97g, 85%).

Part E: To a solution of the acid of part D (7.37 g, 15.0 mmol) was added 1-hydroxybenzotriazole (2.43 g, 18.0 mmol), N-methylmorpholine (4.94 mL, 45.0 mmol), O-tetrahydro-2H-pyran-yl-hydroxylamine (2.65 g, 22.5 mmol) followed by 1-3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (4.02 g, 21.0 mmol). The solution was stirred at ambient temperature for 18 hours. The solution was diluted with H₂O (400 mL) and extracted with ethyl acetate. The organic layer


-377-

was washed with saturated NaCl and dried over MgSO_4 . Chromatography (on silica, eluting with 50% ethyl acetate/hexane) provided the desired THP-protected hydroxamate as a solid (7.54 g, 85%).

5 Part F: To a solution of THP-protected hydroxamate of part E (6.32 gm, 10.8 mmol) in dioxane (75 mL) and methanol (25 mL) was added 4 N HCl/dioxane (30 mL). After stirring at ambient temperature for 1 hour, the solution was concentrated
10 in vacuo. Trituration with ethyl ether provided the title compound. Chromatography (on silica, 5% methanol/ethyl acetate) provided the hydroxamate as a white solid (4.32 g, 80%) Cal'd MS for $\text{C}_{22}\text{H}_{22}\text{N}_2\text{S}_2\text{O}_9+1$: 499.0845. Found 499.0848.

15

Example 43: Preparation of 4-[[4-(3,4-Dimethylphenoxy)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monhydrochloride



Part A: A mixture of the fluoro compound from part F, Example 9 (2.0 g, 5.66 mmol), 3,4-dimethylphenol (2.0 g, 16.5 mmol), and potassium carbonate (2.3 g, 16.5 mmol) in N,N-dimethylformamide
25 (15 mL) was heated at 90 degrees Celsius overnight

-378-

(about 18 hours) under an atmosphere of nitrogen. The brown mixture was concentrated in vacuo and purified by chromatography (on silica, ethyl acetate/hexane) to afford the 3,4-dimethylphenoxy phenyl compound as a clear, yellow oil (2.0 g, 79% yield). Analytical calculation for $C_{25}H_{29}NO_5S$: C, 65.91; H, 6.42; N, 3.04; S, 7.04. Found: C, 65.76; H, 6.37; N, 3.03; S, 7.00.

Part B: A solution of the 3,4-dimethylphenoxy phenyl compound of part A (2.0, 4.93 mmol) and potassium hydroxide (1.7 g, 29.7 mmol) in a mixture of ethanol (25 mL) and water (4 mL) was stirred at reflux for four hours under a nitrogen atmosphere. The solution was cooled with an ice bath, subsequently acidified with concentrated hydrochloric acid, and concentrated to a crude residue. The crude residue, O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.88 g, 7.50 mmol), triethylamine (0.81 mL, 5.81 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in acetonitrile (24 mL) was stirred at ambient temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with water, a saturated sodium bicarbonate solution, water, and a saturated salt solution. After drying over magnesium sulfate, the filtrate, as the THP-protected hydroxamate, was concentrated to a yellow foam.

Part C: The THP-protected hydroxamate (920 mg, 1.75 mmol) of part B was dissolved in methanol (16 mL). Acetyl chloride (0.37 mL, 5.3 mmol) was

-379-



added. After three hours, concentration followed by reverse phase HPLC afforded the title compound as a white solid (611 mg, 79%). MS (EI) MH^+ calculated for $C_{23}H_{26}N_2O_5S$: 443, found 443.

5

Example 44: Preparation of 4-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-1-(propynyl)-4-piperidinecarboxylic acid, monohydrochloride and 4-[[4-(4-chlorophenyl)thiophenyl]sulfonyl]-N-hydroxy-1-(propynyl)-4-piperidinecarboxamide, monohydrochloride

10

15



20

25

Part A: A mixture of the fluoro compound from part F, Example 9 (2.0 g, 5.66 mmol), 4-chlorothiophenol (1.0 g, 6.94 mmol), and potassium carbonate (1.1 g, 8.00 mmol) in N,N-dimethylformamide (12 mL) was stirred overnight (about 18 hours) under an atmosphere of nitrogen at ambient temperature. The mixture was concentrated in vacuo. The residue was diluted with water and extracted with ethyl acetate. The organic layer was washed with water and a saturated salt solution, dried over magnesium sulfate, and concentrated in vacuo to a yellow oil.

-380-

The oil was purified by chromatography (on silica, ethyl acetate/hexane) to afford the 4-chlorophenylthiolphenyl compound as a white solid (2.0 g, 75% yield). Analytical calculation for

5 $C_{23}H_{24}NO_4S_2Cl$: C, 57.791; H, 5.06; N, 2.93; S, 13.42; Cl, 7.42. Found: C, 57.57; H, 5.11; N, 2.94; S, 13.19; Cl, 7.73.

Part B: The chlorophenylthiophenyl compound from part A (2.04 g, 4.27 mmol) was diluted with

10 ethanol (30 mL) and water (5mL). Potassium hydroxide (1.55 g, 27.7 mmol) was added, and the mixture was heated at reflux for 3 hours. After complete reaction, the solution was cooled and was acidified to pH=1-3 with concentrated HCl. The solvent was

15 removed by rotary evaporation and the residue was azeotroped to dryness by repeated addition of acetonitrile. The acid hydrochloride was further dried on a vacuum line, then carried as is through the coupling reaction. The saponification was

20 presumed to be quantitative.

Part C: The carboxylic acid hydrochloride from the previous step (4.27 mmol) was suspended in acetonitrile (20 mL). N-Methylmorpholine (about 1.0 mL) was added, followed by O-tetrahydro-2H-pyran-2-

25 yl-hydroxylamine (585 mg, 5 mmol). After 5 minutes, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC; 955 mg, 5 mmol) was added. The mixture was stirred overnight (about 18 hours), then solvent was removed by rotary evaporation, the

30 residue was diluted with half-saturated $NaHCO_3$ solution (50 mL), and the product was extracted into


-381-

ethyl acetate (2 X100 mL). In this example, an intractable emulsion complicated compound recovery. The combined organic layers were dried over MgSO_4 , filtered through silica, concentrated, and subjected to chromatography (flash silica, ethyl acetate/hexane) affording, on concentration, the title O-THP-protected hydroxamate (162 mg, 7%, from ester) as a foam. MS (EI) MH^+ calculated for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_4\text{S}_2\text{Cl}$: 450, found 450. Because mass recovery was poor, the silica filter cake was extracted with 1:1 methanol:ethyl acetate affording 4-[[4-(4-chlorophenyl)thiolphenyl]sulfonyl]-1-(propynyl)-4-piperidinecarboxylic acid, monohydrochloride (540 mg, 26%)

Part D: The O-THP-protected hydroxamate of part C (441 mg, 0.80 mmol) was dissolved in methanol (2 mL). Acetyl chloride (0.2 mL, 3 mmol) was added. After three hours, concentration followed by reverse phase HPLC afforded the title hydroxamate compound as a pink solid (162 mg, 44%). MS (EI) MH^+ calculated for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_4\text{S}_2$: 465, found 465.

Example 45: Preparation of 4-[[4-(Cyclopentylthio)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide, monohydrochloride

-382-



Part A: The propargyl amine of part F, Example 9 (3.05 g, 8.5 mmol) was combined with K₂CO₃ (1.38 g, 10 mmol), N,N-dimethylformamide (6 mL) and cyclopentyl mercaptan (1.02 mL, 10 mmol). The mixture was heated to 80 degrees Celsius for 4 hours and 95 degrees Celsius for 2.5 hours, monitoring by TLC. Aqueous workup was accomplished using water (10 mL) and ethyl acetate (2 X 100 mL). The combined organic layers were dried over magnesium sulfate, concentrated, and chromatographed (flash silica; ethyl acetate/hexane eluant) affording the cyclopentylmercaptyl compound as an oil (3.2 g, 86%)

Part B: The cyclopentylmercaptyl compound from part A (3.12 g 7.13 mmol) was diluted with ethanol (50 mL) and water (8 mL). Potassium hydroxide (2.59 g, 46.3 mmol) was added, and the mixture was heated at reflux for 3.5 hours. After complete reaction, the solution was cooled and was acidified to pH=1-3 with concentrated HCl. The solvent was removed by rotary evaporation and the residue was azeotroped to dryness by repeated addition of acetonitrile. The carboxylic acid hydrochloride was further dried on a vacuum line, then carried as is through the coupling reaction. The saponification was presumed to be quantitative.


-383-

Part C: The carboxylic acid hydrochloride from Part B (7.13 mmol) was suspended in acetonitrile (50 mL). N-Methylmorpholine (ca. 2.0 mL) was added, followed by O-tetrahydro-2H-pyran-2-yl-hydroxylamine (1.05 g, 9 mmol). After 5 minutes, EDC (1.72 g, 9 mmol) was added. The mixture was stirred overnight (about 18 hours), then solvent was removed by rotary evaporation. The residue was diluted with half-saturated NaHCO_3 solution (50 mL), and the product was extracted into ethyl acetate (2 X100 mL). The combined organic layers were dried over MgSO_4 , filtered through silica, concentrated, and subjected to chromatography (flash silica, ethyl acetate/hexane) affording, on concentration, the O-THP-protected hydroxamate (2.0 g, 51%, from ester) as a foam.

Part D: The O-THP-protected hydroxamate from Part D (2.00 g, 3.95 mmol) was dissolved in methanol (16 mL). Acetyl chloride (0.86 mL, 12 mmol) was added over 2 minutes. The reaction was stirred at ambient temperature for 4 hours, then concentrated, with repeated addition of chloroform and acetonitrile to effect drying. The title compound precipitated as a white solid (1.77 g, 98%). MS (EI) MH^+ calculated for $\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_4\text{S}_2$: 422, found 422.

-384-

Example 47: Preparation of N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide, 1-oxide and N-hydroxy-4-[[4-(phenylsulfinyl)-phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide




m-Chloroperbenzoic acid (57-86%, 120 mg) was added to a solution of N-hydroxy-4-[[4-(phenylthio)phenyl]-sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide (title compound, Example 9) (215 mg, 0.5 mmol) in methanol (5 mL) at zero degrees Celsius. The reaction was permitted to warm slowly to ambient temperature and after 16 hours, the mixture was passed through a micron filter and concentrated. Reverse phase HPLC (Delta Pak 50 X 300 mm; 15 micron C₁₈ 100 Angstrom; 30 minute gradient method starting with dilute HCl (0.5 mL/4 L): acetonitrile 80:20, ending with 50:50) separated 5 major components. The first and second peaks off the column afforded, upon concentration, 14 (6%) and 16 mg (7%) of two compounds, which were assigned as diastereomers of N-Hydroxy-4-[[4-(phenylsulfinyl)-phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide on the basis of their NMR

-385-

spectra. The third peak was unidentified. The 4th peak was assigned by NMR as N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide, 1-oxide (147 mg, 66%) MS (EI)

5 MH^+ calculated for $C_{21}H_{22}N_2O_5S_2$: 447, found 447. The last peak contained 73 mg of recovered 3-chlorobenzoic acid.

Example 48: Preparation of N-hydroxy-2,2-dimethyl-
10 5-[(4-phenoxyphenyl)sulfonyl]-
1,3-dioxane-4-carboxamide



15 Part A: A fresh sodium methoxide solution was prepared by slowly adding hexane-washed sodium spheres (9.4 g, 410 mmol) to methanol (1.0 L) at zero degrees Celcius. To this cooled solution was added the 4-fluorothiophenol (50.0 g, 390 mmol) followed by
20 methyl 2-chloro acetate (42.3 g, 390 mmol). After warming to ambient temperature the reaction was stirred overnight (about 18 hours). The methanol was removed in vacuo and the residue was taken up in ethyl acetate (300 mL). The organic layer was washed
25 with water (2x-200 mL) and dried over $MgSO_4$.

-386-

Concentrating afforded the methyl ester sulfide product as a clear oil (71.8 g, 92%).

Part B: To a solution of the methyl ester sulfide product of part A (71.8 g, 358 mmol) in 70% methanol/H₂O (1.0 L) was slowly added Oxone™ (660 g, 1.08 mol). The mixture stirred overnight (about 18 hours) at ambient temperature. The excess Oxone™ was filtered off and the methanol was removed from the filtrate in vacuo. The remaining aqueous solution was extracted with ethyl acetate (3x 300 mL). The organic layers were washed with water (2x-300 mL) and dried over MgSO₄. Concentrating afforded the sulfone product as a tan oil (82 g, 98%).

Part C: To a prepared slurry of potassium bicarbonate (1.0 g, 9.8 mmol) in 37% formaldehyde solution was added the sulfone product of part B (28.6 g, 123 mmol). The reaction was stirred for one hour and then a saturated solution of sodium sulfate (20 mL) was added. After stirring for thirty minutes, the mixture was extracted with diethyl ether (4x-100 mL). The organic layers were dried over MgSO₄. Chromatography (on silica, ethyl acetate/hexane) provided the sulfone diol product as a clear oil (15.3 g, 42%).

Part D: The sulfone diol product of Part C (1.3 g, 4.5 mmol) was dissolved in acetone (40 mL) along with 2,2-dimethoxypropane (1.1 mL, 9.0 mmol) and p-toluenesulfonic acid monohydrate (0.03 mg, 0.14 mmol) and the resulting composition was refluxed for 6 hours. After cooling, the mixture was neutralized with solid Na₂CO₃ (pH-7), filtered, and concentrated.

-387-

The residue was dissolved in chloroform (50 mL) and washed with water (2x-30 mL). Drying over MgSO_4 and concentrating gave the dimethyl ketal product as an opaque oil (1.4 g, 94%).

5 Part E: Phenol (0.6 g, 6.3 mmol) and cesium carbonate (2.0g, 6.3 mmol) were added to a solution of the dimethyl ketal product (1.4 g, 4.2 mmol) of part D in N,N-dimethylformamide (20 mL). The mixture was heated at 90 degrees Celsius for five
10 hours, diluted with water (20mL), and extracted with ethyl acetate (4x-100 mL). The organic layers were washed with brine (1x-100 mL) and water (1x-100 mL). Concentrating afforded the phenol-O-phenol dimethyl
15 ketal as a dark brown oil (1.51 g, 88%).

Part F: To a solution of the phenol-O-phenol dimethyl ketal product (1.5 g, 3.4 mmol) of
15 part E in tetrahydrofuran (10 mL) was added an aqueous lithium hydroxide solution (0.34 g, 14.8 mmol, in 5 mL of H_2O). The reaction was stirred for
20 two hours and then was diluted with water (15 mL) and acidified via 30% HCl_{aq} to pH=3. The acidic solution was extracted with diethyl ether (3x-100 mL). Drying
over MgSO_4 and concentrating afforded the carboxylic acid product as a brown oil (1.5 g, quantitative
25 yield).


Part G: To a solution of the carboxylic acid product of Part F (1.3 g, 3.3 mmol) and N-hydroxybenzotriazole hydrate (0.54g, 4.0 mmol) in DMF
(15 mL) was added 4-methylmorpholine (1.67 g, 16.5
30 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (1.2 g, 10.2 mmol), and EDC (0.88 g, 4.6 mmol),

-388-

respectively. After stirring overnight, the DMF was removed in vacuo and the residue was taken up in ethyl acetate/water (1:1, 50 mL). The organic layer was washed with brine (1x-20 mL) and water (1x-20 mL) and dried over MgSO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the THP-protected hydroxylamine product as a white solid (0.36 g, 22%) as well as the decarboxylated by-product (0.27 g, 24%).

Part H: To a solution of the THP-protected hydroxylamine product of Part G (0.36 g, 0.73 mmol) in dioxane (3 mL) and methanol (1 mL) was added 4 N HCl in dioxane (2 mL). The reaction was stirred for five minutes and then the solvents were removed in vacuo. Chromatography (reverse phase C-18, acetonitrile/water) gave the title compound as a white solid (0.13 g, 44%). MS (FAB) M^+H calculated for $\text{C}_{19}\text{H}_{21}\text{NO}_5\text{S}$: 408, found 408.

Example 49: Preparation of tetrahydro-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-2H-thiopyran-4-carboxamide



25

Part A: To a solution of methyl 2-chloroacetate (322 g, 2.96 mol) in N,N-

-389-

dimethylacetamide(1.0 L) were added thiophenol (400 g, 3.12 mol) and potassium carbonate (408 g, 2.96 mol). The reaction was stirred at ambient temperature overnight (about 18 hours). After
5 diluting with a minimal amount of water (800 mL), the mixture was extracted with ethyl acetate (4x-1L). The organic layers were washed with water (1x-800 mL), dried over MgSO_4 , and concentrated to afford the sulfide product as a clear oil (614 g, quantitative
10 yield).

Part B: To a solution of the sulfide from part A (75.85 g, 0.38 mol) in methanol (1000 mL) was added water (100 mL) and Oxone[®] (720 g, 1.17 mol) at twenty degrees Celsius. An exotherm to 67 degrees
15 Celsius was noted. After two hours, the reaction was filtered and the cake washed well with methanol. The filtrate was concentrated *in vacuo*. The residue was taken up in ethyl acetate and washed with brine, dried over MgSO_4 , filtered, and concentrated *in vacuo*
20 to give the sulfone as a crystalline solid (82.74 g, 94%).

Part C: To a solution of the sulfone of part B (60.0 g, 258 mmol) in DMA (350 mL) was added the dibromoethylthioether (76.9 g, 310 mmol),
25 followed by potassium carbonate (78.3 g, 568 mmol). The mixture was stirred five minutes before adding catalytic amounts of 4-dimethylaminopyridine and tetrabutylammonium bromide. The reaction was stirred overnight (about 18 hours), after which it was poured
30 into a stirring solution of 10% HCl_{aq} (2.5 L). The resulting precipitate was filtered and washed with

-390-

hexane to remove the excess thioether. Drying in vacuo overnight (about 18 hours) yielded the methylester thiopyran -Ph-p-F as a yellow powder (76.1 g, 93%).


5 Step D: To a solution of the methylester thiopyran -Ph-p-F of part C (4.0 g, 12.6 mmol) in N,N-dimethylacetamide (25 mL) were added cesium carbonate (6.1 g, 18.9 mmol) and thiophenol (2.1 g, 18.9 mmol). The mixture was stirred 2 hours at 90
10 degrees Celsius. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (3x-100 mL). The organic layers were washed with brine (1x-75 mL) and water (1x-75 mL) and was then dried over MgSO₄. Chromatography (on silica, ethyl acetate / hexane)
15 provided the phenyl-S-phenyl methyl ester as a yellowish solid (3.6 g, 71%).

 Step E: Potassium trimethylsilonate (1.24 g, 9.7 mmol) was added to a solution of the phenyl-S-phenyl methyl ester of part D (3.6 g, 8.8 mmol) in
20 tetrahydrofuran (15 mL). The mixture was stirred 2-3 hours at ambient temperature or until a solid precipitate developed. After the hydrolysis was complete, N-methylmorpholine (2.9 mL, 26.4 mmol) was added followed by PyBrop (4.9 g, 10.6 mmol). The
25 solution was stirred for 10 minutes. Aqueous hydroxylamine (0.32 g, 9.7 mmol) was added and the mixture stirred for an additional 2 hours. After completion, the solvent was removed in vacuo. Chromatography (reverse phase C-18, acetonitrile /
30 water) of the residue provided the title compound as

-391-

an off white solid (0.82 g, 23%). MS (FAB) M⁺H
calculated for C₁₈H₁₉NO₄S₃: 410, found 410.

5 Example 50: Preparation of 4-[(4-fluorophenyl)-
sulfonyl]tetrahydro-N-[(tetrahydro-2H-
pyran-2-yl)oxy]-2H-thiopyran-4-
carboxamide



10

Part A: Thiophenol (400 g, 3.12 mol) and
potassium carbonate (408 g, 2.96 mol) were added to a
solution of methyl 2-chloroacetate (322 g, 2.96 mol)
in N,N-dimethylacetamide (1.0 L). The reaction was
15 stirred at ambient temperature overnight (about 18
hours). After diluting with a minimal amount of
water (800 mL), the mixture was extracted with ethyl
acetate (4x-1L). The organic layers were washed with
water (1x-800 mL), dried over MgSO₄, and concentrated
20 to afford the sulfide product as a clear oil (614 g,
quantitative yield).

Part B: To a solution of the sulfide from
part A (75.85 g, 0.38 mol) in methanol (1000 mL) was
added water (100 mL) and Oxone[®] (720 g, 1.17 mol) at
25 20 degrees Celsius. An exotherm to 67 degrees
Celsius was noted. After two hours, the reaction was
filtered and the cake was washed well with methanol.

-392-

The filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate and washed with brine, dried over MgSO_4 , filtered, and concentrated in vacuo to give the methyl ester sulfone as a crystalline solid (82.74 g, 94%).

Part C: To a solution of the methyl ester sulfone product of part B (60.0 g, 258 mmol) in N,N-dimethylacetamide (350 mL) was added 2,2-dibromoethylthioether (76.9 g, 310 mmol) followed by potassium carbonate (78.3 g, 568 mmol). The mixture was stirred five minutes before adding catalytic amounts of 4-dimethylaminopyridine and tetrabutylammonium bromide. The reaction was stirred overnight (about 18 hours), after which it was poured into a stirring solution of 10% HCl_{aq} (2.5 L). The resulting precipitate was filtered and washed with hexane to remove the excess thioether. Drying in vacuo overnight (about 18 hours) yielded the thiopyran methyl ester as a yellow powder (76.1 g, 93%).

Step D: To a solution of the thiopyran methyl ester of part C (30.0 g, 94 mmol) in tetrahydrofuran (250 mL) was added potassium trimethylsilonate (28.9 g, 226 mmol). The mixture was stirred 2-3 hours at ambient temperature or until a solid precipitate developed. After the hydrolysis was complete, the solvent was removed in vacuo. Water (200 mL) was added and the mixture was washed with diethyl ether (1x-200 mL). The aqueous layer was cooled to zero degrees Celsius and 10% HCl_{aq} was slowly added until a precipitate formed. The solid


-393-

was collected and dried in vacuo with phosphorous pentoxide to afford the thiopyran carboxylic acid as a yellow solid (17.8 g, 62%).

Part E: To a solution of the thiopyran
5 carboxylic acid of part D (17.8 g, 58.5 mmol) in N,N-dimethylformamide (100 mL) was added N-methylmorpholine (19.3 mL, 176 mmol) followed by N-hydroxybenzotriazole hydrate (9.5 g, 70.2 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (10.3 g, 87.8
10 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (16.8 g, 87.8 mmol). The mixture was stirred three hours and was then diluted with water (100 mL). The mixture was extracted with ethyl acetate (4x-200 mL). Organic
15 layers were washed with an aqueous saturated potassium carbonate solution (1x-200 mL), 1% HCl_{aq}, and brine (1x- 200 mL). Drying over MgSO₄ and concentrating in vacuo afforded the title compound as an off white solid (30.8 g, quantitative yield). MS
20 (FAB) M⁺H calculated for C₁₇H₂₂FNO₅S₂: 404, found 404.

Example 51: Preparation of Tetrahydro-N-hydroxy-4-
[[4-[(4-methoxyphenyl)thio]phenyl]
sulfonyl]-2H-thiopyran-4-carboxamide

25




-394-

Part A: To a solution of the title compound of Example 50 (6.0 g, 14.9 mmol) in N,N-dimethylacetamide (25mL) was added 4-methoxy thiophenol (2.5 g, 17.8 mL), followed by potassium carbonate (6.2 g, 44.7 mmol). The reaction was heated at 60 degrees Celsius for three hours. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (4x-100 mL). The organic layers were washed with water (2x-50 mL) and dried over MgSO_4 . Concentrating *in vacuo* provided the THP-protected - Phenyl -S- pPhenyl-OMe product as a yellowish solid (9.2 g, quantitative yield).

Part B: To a solution of the THP-protected - Phenyl -S- pPhenyl-OMe product from part A (9.2 g, 14.9 mmol) in dioxane was slowly added 4N HCl in dioxane (10 mL). After stirring overnight (about 18 hours), the solvent was removed. Chromatography on the resultant residue (reverse phase C-18, acetonitrile/water) gave the title compound as a white solid (1.84 g, 28.3%). MS (FAB) M^+H calculated for $\text{C}_{19}\text{H}_{21}\text{NO}_5\text{S}_3$: 440, found 440.

Example 52: Preparation of Tetrahydro-N-hydroxy-4-
[(4-phenylthio)phenyl]sulfonyl]-2H-
thiopyran-4-carboxamide 1,1-dioxide



-395-

Part A: To a solution of the title compound of Example 50 (13.0 g, 24.5 mmol) in methylene chloride (100 mL) cooled to zero degrees Celsius was slowly added 50-60% m-chloroperbenzoic acid (17.1 g, 49.5 mmol). The mixture was stirred one hour at zero degrees Celsius followed by an additional 3 hours as the temperature rose to ambient conditions. Water (200 mL) was added and the mixture was neutralized with 10% ammonium hydroxide (100 mL). The organic layer was washed with water (1x-200 mL) and dried over MgSO_4 . Concentrating in vacuo provided an orangish oil (3.5 g, 33%). The water/10% ammonium hydroxide solution was saturated with sodium chloride and extracted with ethyl acetate (2x-400 mL). Organic layer was dried over MgSO_4 and concentrated to afford the THP-protected sulfone-thiopyran-p-F compound as an orange foam (6.1 g, 57%).


Part B: To a solution of the THP-protected sulfone-thiopyran-p-F from Part A (9.6 g, 22 mmol) in N,N-dimethylacetamide (120 mL) was added thiophenol (2.9 g, 26.4 mmol), followed by potassium carbonate (9.1 g, 66 mmol). The reaction was heated at 60 degrees Celsius for four hours. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (4x-100 mL). The organic layers were washed with water (2x-50 mL) and dried over MgSO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the THP-protected -phenyl-S-phenyl product as an orange oil (5.1 g, 43%).

-396-

Part C: To a solution of the THP-protected
-phenyl-S-phenyl product from part B (5.1 g, 9.4
mmol) in dioxane was slowly added 4N HCl in dioxane
(10 mL). After stirring overnight (about 18 hours),
5 the solvent was removed. Chromatography of the
resultant residue (reverse phase C-18,
acetonitrile/water) gave the title compound as a pink
solid (1.2 g, 29%). MS (FAB) M⁺H calculated for
C₁₈H₁₉NO₆S₃: 442, found 442.

10

Example 53: Preparation of Tetrahydro-N-hydroxy-4-
[[4-[4-(1H-1,2,4-triazol-1-yl)
phenoxy]-phenyl]-sulfonyl]-2H-thiopyran-
4-carboxamide 1,1-dioxide,
15 monohydrochloride



Part A: To a solution of the title compound
20 of Example 50 (13.0 g, 24.5 mmol) in methylene
chloride (100 mL) cooled to zero degrees Celsius was
slowly added 50-60% m-chloroperbenzoic acid (17.1 g,
49.5 mmol). The mixture was stirred one hour at zero
degrees Celsius followed by an additional 3 hours as
25 the temperature rose to ambient conditions. Water
(200 mL) was added and the mixture was neutralized
with 10% ammonium hydroxide (100 mL). The organic

-397-

layer was washed with water (1x-200 mL) and dried over MgSO_4 . Concentrating in vacuo provided an orangish oil (3.5 g, 33%). The water/10% ammonium hydroxide solution was saturated with sodium chloride and extracted with ethyl acetate (2x-400 mL). Organic layer was dried over MgSO_4 and concentrated to afford the THP-protected sulfone-thiopyran-p-F as an orange foam (6.1 g, 57%).


Part B: To a solution of the THP-protected sulfone-thiopyran-p-F from A (6.0 g, 13.8 mmol) in N,N-dimethylformamide (25 mL) was added 4-(1H-1,2,4-triazol-1-yl)phenol (4.4 g, 27.5 mmol), followed by cesium carbonate (13.4 g, 41.4 mmol). The reaction was heated at 95 degrees Celsius for five hours. The reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (4x-100 mL). The organic layers were washed with water (2x-50 mL) and dried over MgSO_4 . Concentrating afforded the THP-protected phenyl-O-phenyl triazole product as a tan solid (9.7 g, quantitative yield).

Part C: To a solution of the crude THP-protected phenyl-O-phenyl triazole product from B (8.0 g, 13.8 mmol) in acetonitrile (40 mL) was slowly added 10% HCl_{aq} (100 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a tan solid (1.3 g, 18%). MS (FAB) M^+H calculated for $\text{C}_{20}\text{H}_{21}\text{ClN}_4\text{O}_2\text{S}_2$: 493, found 493.

30

-398-

Example 54: Preparation of 4-[[4-[4-(2-aminoethyl))-
phenoxy]phenyl]sulfonyl]tetrahydro-N-
hydroxy-2H-thiopyran-4-carboxamide 1,1-
dioxide monohydrochloride



5

Part A: To a solution of the title compound
of Example 50 (13.0 g, 24.5 mmol) in methylene
chloride (100 mL) cooled to zero degrees Celsius was
slowly added 50-60% m-chloroperbenzoic acid (17.1 g,
49.5 mmol). The mixture was stirred one hour at zero
degrees Celsius followed by an additional 3 hours as
the temperature rose to ambient conditions. Water
(200 mL) was added and the mixture was neutralized
with 10% ammonium hydroxide (100 mL). The organic
layer was washed with water (1x-200 mL) and dried
over MgSO_4 . Concentrating *in vacuo* provided an
orangish oil (3.5 g, 33%). The water/10% ammonium
hydroxide solution was saturated with sodium chloride
and extracted with ethyl acetate (2x-400 mL). The
organic layer was dried over MgSO_4 and concentrated to
afford the THP-protected sulfone-thiopyran-p-F as an
orange foam (6.1 g, 57%).

Part B: To a solution of the THP-protected
sulfone-thiopyran-p-F from A (6.0 g, 13.8 mmol) in
N,N-dimethylacetamide (25 mL) was added tyramine (3.8
g, 28 mmol) followed by cesium carbonate (13.6 g, 42

-399-

mmol). The reaction was heated at 95 degrees Celsius for five hours. Removing the N,N-dimethylacetamide in vacuo afforded a brown solid (20 g).


Chromatography (reverse phase, C-18,

5 acetonitrile/water) gave the THP-protected tyramine product as a tan oil (1.0 g, 13%).

Part C: To a solution of the crude THP-protected tyramine product from part B (1.0 g, 1.8 mmol) in acetonitrile (40 mL) was slowly added 10%
10 HCl_{aq} (100 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a tan solid (0.9 g, 99%). MS (FAB) M⁺H calculated for C₂₀H₂₅ClN₂O₇S₂: 469, found 469.

15

Example 55: Preparation of 4-[(4-fluorophenyl)-sulfonyl]tetrahydro-N-[(tetrahydro-2H-pyran-2-yl)oxyl]-2H-pyran-4-carboxamide



20

Part A: In dry equipment under nitrogen, sodium metal (8.97 g, 0.39 mol) was added to methanol (1000 mL) at two degrees Celsius. The reaction was
25 stirred at ambient temperature for forty five minutes at which time the sodium had dissolved. The solution was chilled to five degrees Celsius and p-fluorothiophenol (41.55 mL, 0.39 mmol) was added,

-400-

followed by methyl 2-chloroacetate (34.2 mL, 0.39 mol). The reaction was stirred at ambient temperature for four hours, filtered, and concentrated in vacuo to give the sulfide as a clear
5 colorless oil (75.85 g, 97%).

Part B: To a solution of the sulfide from part A (75.85 g, 0.38 mol) in methanol (1000 mL) were added water (100 mL) and Oxone® (720 g, 1.17 mol) at 20 degrees Celsius. An exotherm to 67 degrees
10 Celsius was noted. After two hours, the reaction was filtered and the cake was washed well with methanol. The filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate and washed with brine, dried over MgSO_4 , filtered, and concentrated in vacuo
15 to give the sulfone as a crystalline solid (82.74 g, 94%).

Part C: To a solution of the sulfone from part B (28.5 g, 0.123 mol) in N,N-dimethylacetamide (200 mL) were added potassium carbonate (37.3 g, 0.27
20 mol), bis-(2-bromoethyl)ether (19.3 mL, 0.147 mol), 4-dimethylaminopyridine (0.75 g, 6 mmol), and tetrabutylammonium bromide (1.98 g, 6 mmol). The reaction was stirred overnight (about 18 hours) at ambient temperature. The reaction was slowly poured
25 into 1N HCl (300 mL), the resultant solid filtered and the cake washed well with hexanes. The solid was recrystallized from ethyl acetate/hexanes to give the pyran compound as a beige solid (28.74 g, 77%). MS (ES+) MH^+ calculated for $\text{C}_{13}\text{H}_{15}\text{O}_5\text{S}_1\text{F}_1$: 303, found 303.

30 Part D: In dry equipment under nitrogen, the pyran compound from part C (8.0 g, 26.5 mmol) was

-401-


dissolved in dry tetrahydrofuran (250 mL) and a solution of potassium trimethylsilonate (10.2 g, 79.5 mmol) in dry tetrahydrofuran (15 mL) was added at ambient temperature. After ninety minutes, water (100 mL) was added and the solution concentrated in vacuo. The residue was taken up in water and extracted with ethyl acetate to remove unreacted starting material. The aqueous solution was treated with 6N HCl until pH=1. The slurry was extracted with ethyl acetate and the combined extracts washed with water, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The residue was heated in diethyl ether, the solid filtered and dried to give the carboxylic acid as a crystalline solid (5.78 g, 76%). HRMS (ES-) M-H calculated for $\text{C}_{12}\text{H}_{13}\text{O}_5$, S_1F_1 : 287.04, found 287.04.

Part E: In dry equipment under nitrogen, the carboxylic acid from part D (9.1g, 31.6 mmol) was dissolved in dry N,N-dimethylformamide (70 mL) and the remaining reagents were added to the solution in the following order: N-hydroxybenzotriazole hydrate (5.1 g, 37.9 mmol), N-methylmorpholine (10.4 mL, 94.8 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (11.5 g, 98 mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (8.48 g, 44.2 mmol). After three hours at ambient temperature, the reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with water, 5% KHSO_4 , saturated NaHCO_3 , brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the title compound as a crystalline solid (9.7 g, 80%). HRMS

-402-

(ES+) MH⁺ calculated for C₁₇H₂₂NO₆ S₁F₁: 388.12, found 388.12.

5 Example 56: Preparation of 4-[[4-(3,4-difluorophenoxy)-phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



10


Part A: To a solution of the title compound of Example 55 (2.0 g, 5.2 mmol) in N,N-dimethylacetamide (6 mL) was added 3,4-difluorophenol (1.0 g, 7.7 mmol), followed by cesium carbonate (6.6 g, 20.2 mmol). The reaction was heated at 95 degrees Celsius for five hours. Removing the N,N-dimethylacetamide in vacuo afforded a brown solid (8.3 g, quantitative). Chromatography (reverse phase, C-18, acetonitrile/water) gave the THP-protected difluoro product in solution.

Part B: To the collected THP-protected difluoro product from A in acetonitrile/ water (50 mL) was slowly added 10% HCl_{aq} (100 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a white

-403-

solid (1.02 g, 48.6%). MS (FAB) M⁺H calculated for
C₁₈H₁₇INO₆S: 414, found 414.

Example 57: Preparation of Tetrahydro-N-hydroxy-
4-[[4-(4-iodophenoxy) phenyl]sulfonyl]-
2H-pyran-4-carboxamide




Part A: To a solution of the title compound
of Example 55 (2.0 g, 5.2 mmol) in N,N-
dimethylacetamide (6 mL) was added 4-iodophenol (1.7
g, 7.8 mmol), followed by cesium carbonate (6.6 g,
20.2 mmol). The reaction was heated at 95 degrees
Celsius for five hours. Removing the N,N-
dimethylacetamide in vacuo afforded a brown solid
(5.7 g, quantitative) Chromatography (reverse phase,
C-18, acetonitrile/water) gave the THP-protected iodo
product in solution.

Part B: To the solution of the crude THP-
protected iodo product from A in acetonitrile/water
(40 mL) was slowly added 10% HCl_{aq} (100 mL). After
stirring overnight (about 18 hours), the acetonitrile
was removed. The resultant precipitate was
collected, giving the title compound as a white solid
(2.6 g, 99%). MS (FAB) M⁺H calculated for C₁₈H₁₆INO₆S:
504, found 504.

-404-

Example 58: Preparation of Tetrahydro-N-hydroxy-4-
[[4-(2,4,5-trifluorophenoxy)phenyl]-
sulfonyl]-2H-pyran-4-carboxamide

5




Part A: To a solution of the title compound of Example 55 (2.0 g, 5.2 mmol) in N,N-dimethylacetamide (6 mL) was added 2,4,5-trifluorophenol (1.2 g, 7.8 mmol), followed by cesium carbonate (10.1 g, 31.0 mmol). The reaction was heated at 95 degrees Celsius for thirty-two hours. Removing the N,N-dimethylacetamide *in vacuo* afforded a brown solid (5.7 g, quantitative). Chromatography (reverse phase, C-18, acetonitrile/water) gave the THP-protected phenol product (1.2 g, 44%).

Part B: To the solution of the crude THP-protected phenol product from Part A (1.2 g, 2.3 mmol) in acetonitrile/water (40 mL) was slowly added 10% HCl_{aq} (100 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a white solid (0.79 g, 79%). MS (FAB) M⁺H calculated for C₁₈H₁₆F₃NO₆S: 430, found 430.

-405-

Example 59: Preparation of 4-[[4-(3,5-dichlorophenoxy)-phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide

5




Part A: To a solution of the title compound of Example 55 (2.0 g, 5.2 mmol) in N,N-dimethylacetamide (6 mL) was added 3,5-dichlorophenol (1.3 g, 7.8 mmol), followed by cesium carbonate (6.6 g, 20.2 mmol). The reaction was heated at 95 degrees Celsius for twelve hours. Removing the N,N-dimethylacetamide in vacuo afforded a brown solid (5.7 g, quantitative). The residue was taken up in acetonitrile/water (20 mL) and acidified to pH=6. A white precipitate formed and was collected affording the THP-protected product as a white cake (1.8 g, 64%).

Part B: To the THP-protected product from Part A (1.8 g, 3.4 mmol) in acetonitrile/water (20 mL) was slowly added 10% HCl_{aq} (40 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a white solid (0.71 g, 47%). MS (FAB) M⁺H calculated for C₁₈H₁₇Cl₂NO₆S: 447, found 447.

-406-

Example 59: Preparation of Tetrahydro-N-hydroxy- 4-
[[4-[[5-(trifluoromethyl)-2-pyridinyl]-
thio]phenyl]sulfonyl]-2H-pyran-4-
5 carboxamide monohydrochloride




Part A: To a solution of the title compound
10 of Example 55 (2.0 g, 5.2 mmol) in N,N-
dimethylacetamide (6 mL) was added 5-
(trifluoromethyl)-2-pyridinyl thiophenol (1.4 g, 7.8
mmol), followed by potassium carbonate (2.2 g, 15.6
mmol). The reaction was heated at 65 degrees Celsius
15 for twelve hours. Removing the N,N-dimethylacetamide
in vacuo afforded a brown solid (5.4 g,
quantitative). Chromatography (reverse phase, C-18,
acetonitrile/water) gave the THP-protected product in
solution.

20 Part B: To the solution of the crude THP-
protected product from Part A in acetonitrile/water
(40 mL) was slowly added 10% HCl_{aq} (40 mL). After
stirring overnight (about 18 hours), the acetonitrile
was removed. The resultant precipitate was
25 collected, giving the title compound as a white solid
(0.20 g, 8%). MS (FAB) M⁺H calculated for
C₁₈H₁₇F₃N₂O₅S₂: 463, found 463.

-407-

Example 60: Preparation of 4-[[4-(3,4-
dichlorophenyl]-thio]phenyl]sulfonyl]-
tetrahydro-N-hydroxy-2H-pyran-4-
5 carboxamide




Part A: To a solution of the title compound
10 of Example 55 (2.0 g, 5.2 mmol) in N,N-
dimethylacetamide (6 mL) was added 3,4-
dichlorothiophenol (1.4 g, 7.8 mmol) followed by
potassium carbonate (2.2 g, 15.6 mmol). The reaction
was heated at 70 degrees Celsius for six hours.
15 Removing the N,N-dimethylacetamide in vacuo afforded
a brown solid (5.6 g, quantitative). Chromatography
(reverse phase, C-18, acetonitrile/water) gave the
THP protected product in solution.

Part B: To the solution of the THP-
20 protected product from Part A in acetonitrile/water
(40 mL) was slowly added 10% HCl_{aq} (40 mL). After
stirring overnight (about 18 hours), the acetonitrile
was removed. The resultant precipitate was
collected, giving the title compound as a white solid
25 (1.5 g, 62%). MS (FAB) M⁺H calculated for C₁₈H₁₇Cl₂NO₅S:
463, found 463.

-408-

Example 61: Preparation of 4-[[4-[[2-amino-4-(trifluoromethyl)phenyl]thio]phenyl]-sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide, monohydrochloride

5



Part A: To a solution of the title compound of Example 55 (2.0 g, 5.2 mmol) in N,N-dimethylacetamide (6 mL) was added 2-amino-4-(trifluoromethyl)thiophenol hydrochloride (1.8 g, 7.8 mmol), followed by potassium carbonate (3.6 g, 26 mmol). The reaction was heated at 70 degrees Celsius for eight hours. Removing the dimethylacetamide in vacuo afforded a brown solid (14 g, quantitative).

10 (trifluoromethyl)thiophenol hydrochloride (1.8 g, 7.8 mmol), followed by potassium carbonate (3.6 g, 26 mmol). The reaction was heated at 70 degrees Celsius for eight hours. Removing the dimethylacetamide in vacuo afforded a brown solid (14 g, quantitative).

15 Chromatography (reverse phase, C-18, acetonitrile/water) gave the THP protected product in solution.


Part B: To the solution of the THP-protected product in acetonitrile / water (40 mL) was slowly added 10% HCl_{aq} (40 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a white solid (1.3 g, 52%). MS (FAB) M⁺H calculated for C₁₈H₁₇Cl₂NO₆S: 477, found 477.

20 slowly added 10% HCl_{aq} (40 mL). After stirring overnight (about 18 hours), the acetonitrile was removed. The resultant precipitate was collected, giving the title compound as a white solid (1.3 g, 52%). MS (FAB) M⁺H calculated for C₁₈H₁₇Cl₂NO₆S: 477, found 477.

25 found 477.

-409-

Example 62: Preparation of Tetrahydro-4[[4-(4-phenyl-1-piperidinyl)phenyl]sulfonyl]-2H-pyran-4-carboxamide, monohydrochloride



5

Part A: In dry equipment under nitrogen, sodium metal (8.97 g, 0.39 mol) was added to methanol (1000 mL) at two degrees Celsius. The reaction was stirred at ambient temperature for forty-five minutes at which time the sodium had dissolved. The solution was chilled to five degrees Celsius and p-fluorothiophenol (41.55 mL, 0.39 mmol) was added, followed by methyl 2-chloroacetate (34.2 mL, 0.39 mol). The reaction was stirred at ambient temperature for four hours, filtered, and concentrated in vacuo to give the sulfide as a clear colorless oil (75.85 g, 97%).

Part B: To a solution of the sulfide from part A (75.85 g, 0.38 mol) in methanol (1000 mL) was added water (100 mL) and Oxone® (720 g, 1.17 mol) at 20 degrees Celsius. An exotherm to 67 degrees Celsius was noted. After two hours, the reaction was filtered and the cake was washed well with methanol. The filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate and washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo

-410-

to give the sulfone as a crystalline solid (82.74 g, 94%).

Part C: To a solution of the sulfone from part B (28.5 g, 0.123 mol) in N,N-dimethylacetamide (200 mL) were added potassium carbonate (37.3 g, 0.27 mol), bis-(2-bromoethyl)ether (19.3 mL, 0.147 mol), 4-dimethylaminopyridine (0.75 g, 6 mmol), and tetrabutylammonium bromide (1.98 g, 6 mmol). The reaction was stirred overnight (about 18 hours) at ambient temperature. The reaction was slowly poured into 1N HCl (300 mL), the resultant solid filtered and the cake washed well with hexanes. The solid was recrystallized from ethyl acetate/hexanes to give the pyran compound as a beige solid (28.74 g, 77%). MS (ES+) MH+ calculated for $C_{11}H_{15}O_5S_1F_1$. 303, found 303.

Part D: To a solution of the pyran compound from part C (1.21 g, 4.0 mmol) in dimethyl sulfoxide (10 mL) were added cesium carbonate (3.26 g, 10 mmol) and 4-phenylpiperidine (0.64 g, 4.0 mmol) in methyl sulfoxide (10 mL). The slurry was stirred at 90 degrees Celsius for two hours. The reaction was cooled, diluted with water and extracted with ethyl acetate. The combined organic layers were washed with 5% $KHSO_4$, saturated $NaHCO_3$, brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The resultant solid was slurried in diethyl ether, filtered and dried to give the N-substituted piperidine as a white solid (1.2 g, 67%). MS (FAB+) MH+ calculated for $C_{24}H_{29}N_1O_5S_1$. 444, found 444.

Part E: To a slurry of the N-substituted piperidine from part D (815 mg, 1.84 mmol) in

-411-

methanol (5 mL) and tetrahydrofuran (5 mL) was added
50% sodium hydroxide (3 mL). After twenty-four hours
at ambient temperature, the reaction was concentrated
in vacuo. The slurry was diluted with water (10 mL)
5 and 6N HCl was added until the pH=7. Vacuum
filtration of the resulting precipitate provided the
acid as a white solid (705 mg, 89%). MS (FAB+) MH+
calculated for $C_{23}H_{27}N_1O_5S_1$: 430, found 430.


Part F: In dry equipment under nitrogen,
10 the carboxylic acid from part E (620 mg, 1.44 mmol)
was slurried in methylene chloride (10 mL) and N,N-
dimethylformamide (3 mL) and the remaining reagents
were added to the slurry in the following order:
bromo-tris-pyrrolidino-phosphonium
15 hexafluorophosphate (810 mg, 1.73 mmol), N-
methyldimorpholine (0.5 mL, 4.34 mmol), and O-
tetrahydro-2H-pyran-2-yl-hydroxylamine (190 mg, 1.59
mmol). After four hours at ambient temperature, the
reaction was concentrated in vacuo. The residue was
20 taken up in ethyl acetate, washed with water, brine,
dried over Na_2SO_4 , filtered, and concentrated in
vacuo. Chromatography (on silica, ethyl
acetate/hexanes) provided the THP-protected
hydroxamate as a white solid (630 mg, 83%). MS (FAB+)
25 MH+ calculated for $C_{28}H_{22}N_2O_6$, S_1 : 529, found 529.

Part G: To a slurry of the THP-protected
hydroxamate from part F (600 mg, 1.14 mmol) in
dioxane (1.5 mL) was added a 4N HCl dioxane solution
(1.5 mL) and methanol (1.5 mL). After two hours at
30 ambient temperature the reaction was poured into
diethyl ether (100 mL). Vacuum filtration of the

-412-

resulting precipitate provided the title compound as a light beige solid (500 mg, 91%). MS (FAB+) M+Li calculated for $C_{23}H_{28}N_2O_5S_1$: 445, found 445.

- 5 Example 63: Preparation of 4-[[4-[4-(1,3-Benzodioxol-5-yloxy)-1-piperidinyl]phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-
carboxamide, monohydrochloride



Part A: In dry equipment under nitrogen, 4-hydroxypiperidine (20.2 g, 0.2 mol) was dissolved in tetrahydrofuran (200 mL) and triethylamine (29 mL,
15 0.21 mol). A solution of di-t-butyl dicarbonate (43.65 g, 0.2 mol) was added at such a rate that the temperature remained below 30 degrees Celsius. After stirring at ambient temperature for four hours, the reaction was concentrated in vacuo. The residue was
20 taken up in ethyl acetate, washed with water, 5% $KHSO_4$, saturated $NaHCO_3$, brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo to give the BOC piperidine as a white solid (37.7 g, 94%).

Part B: In dry equipment under nitrogen,
25 the BOC piperidine from part A (5.0 g, 24.8 mmol) in dry tetrahydrofuran (100 mL) was cooled to zero

-413-

degrees Celsius and triphenylphosphine (9.77 g, 37.3 mmol) was added. After fifteen minutes of stirring at zero degrees Celsius, sesamol (5.15 g, 37.3 mmol) was added to the reaction followed by the dropwise
5 addition of diethylazodicarboxylate (5.87 mL, 37.7 mmol). The reaction was stirred for thirty minutes at zero degrees Celsius and then at ambient temperature for twenty hours. The reaction was concentrated in vacuo. The residue was slurried in
10 diethyl ether, the triphenyl phosphine oxide filtered off and the filtrate concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted BOC piperidine as a white solid (3.14 g, 39%).

15 Part C: To a slurry of the substituted BOC piperidine from part B (3.14 g, 9.8 mmol) in dioxane (15 mL) was added a 4N HCl dioxane solution (15 mL). After three hours at ambient temperature, the reaction was concentrated in vacuo. The residue was
20 slurried in diethyl ether and vacuum filtration of the resulting precipitate provided the hydrochloride salt as a white solid (2.3 g, 100%).


Part D: To a slurry of the hydrochloride salt from part C (0.93 g, 3.6 mmol) in N,N-
25 dimethylformamide (10 mL) were added cesium carbonate (2.93 g, 9 mmol) and the title compound of Example 55 (1.16 g, 3.0 mmol). The slurry was stirred at 90 degrees Celsius for twenty four hours. The reaction was concentrated in vacuo. The residue was taken up
30 in ethyl acetate, washed with water, 5% KHSO₄, saturated NaHCO₃, brine, dried over Na₂SO₄, filtered,

-414-

and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white solid (640 mg, 36%). MS (FAB+) MH+ calculated for $C_{29}H_{36}N_2O_9$, S_1 : 589, found 589.

Part E: To a slurry of the THP-protected hydroxamate from part D (600 mg, 1.02 mmol) in dioxane (3 mL) were added a 4N HCl dioxane solution (3 mL) and methanol (3 mL). After one hour at ambient temperature, the reaction was poured into diethyl ether (100 mL). Vacuum filtration of the resulting precipitate provided the title compound as a light beige solid (440 mg, 80%). HRMS (ES+) MH+ calculated for $C_{24}H_{28}N_2O_8S_1$: 505.16, found 505.16.

Example 64: Preparation of Tetrahydro-N-hydroxy-4-
[[4-(4-methoxyphenoxy)phenyl]sulfonyl]-
2H-pyran-4-carboxamide



20

Part A: To a solution of the title compound of Example 55 (3.48 g, 9 mmol) in N,N-dimethylformamide (20 mL) were added cesium carbonate (8.8 g, 27 mmol) and p-methoxyphenol (2.23 g, 18 mmol). The slurry was stirred at 95 degrees Celsius for twenty four hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate,

-415-

washed with brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a beige foam (3.82 g, 86%).

5 MS (FAB+) MH^+ calculated for $\text{C}_{24}\text{H}_{29}\text{N}_1\text{O}_8$, S_1 : 492, found 492.


Part B: To a slurry of the THP-protected hydroxamate from part A (3.6 g, 7.33 mmol) in dioxane (18 mL) were added a 4N HCl dioxane solution (18 mL)

10 and methanol (18 mL). After fifteen minutes at ambient temperature, the reaction was diluted with ethyl acetate and washed with water, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give

15 the title compound as a white solid (2.1 g, 70%).

HRMS (ES+) MH^+ calculated for $\text{C}_{19}\text{H}_{21}\text{N}_1\text{O}_7\text{S}_1$: 408.11, found 408.11.

Example 65: Preparation of Tetrahydro-N-hydroxy-4-
20 [[4-(4-methoxyphenylthio)phenyl]-sulfonyl]-2H-pyran-4-carboxamide



25 Part A: To a solution of the title compound of Example 55 (3.1 g, 8 mmol) in N,N-dimethylformamide (20 mL) were added potassium carbonate (1.33 g, 9.6 mmol) and p-


-416-

methoxybenzenethiol (1.48 mL, 12 mmol). The slurry was stirred at 65 degrees Celsius for twenty-four hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with
5 brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white foam (4.1 g, 100%). HRMS (ES+) $\text{M}+\text{NH}_4^+$ calculated for $\text{C}_{24}\text{H}_{29}\text{N}_1\text{O}_7\text{S}_2$: 525.17, found
10 525.17.

Part B: To a slurry of the THP-protected hydroxamate from part A (4.0 g, 7.9 mmol) in dioxane (20 mL) was added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at
15 ambient temperature, the reaction was diluted with ethyl acetate, washed with water, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give the title compound as a white solid (2.21 g, 67%). HRMS (ES+) MH^+ calculated for $\text{C}_{19}\text{H}_{21}\text{N}_1\text{O}_6\text{S}_2$: 424.09, found 424.09.
20

Example 66: Preparation of 4-[(4-fluorophenyl)-sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide

25




-417-

Part A: To a slurry of the title compound of Example 55 (530 mg, 1.38 mmol) in dioxane (5 mL) was added a 4N HCl dioxane solution (5 mL) and methanol (5 mL). After fifteen minutes at ambient temperature the reaction was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile/water) provided the title compound as a beige solid (140 mg, 34%). HRMS (ES+) $M + NH_4^+$ calculated for $C_{12}H_{14}N_1O_5S_1F_1$: 321.09, found 321.09.

10

Example 67: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-piperidinyloxy)phenyl]sulfonyl]-
2H-pyran-4-carboxamide, monohydrochloride



15

Part A: In dry equipment under nitrogen, 4-hydroxy-N-t-(butoxycarbonyl)piperidine (844 mg, 4.2 mmol) was added to 60% sodium hydride (210 mg, 5.25 mmol) in dry N,N-dimethylformamide (10 mL) at zero degrees Celsius. The slurry was stirred for two hours at ambient temperature. At five degrees Celsius, the title compound of Example 55 (1.35 g, 3.5 mmol) was added and the reaction heated to 50 degrees Celsius for three hours. The reaction was cooled, quenched with water, and concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na_2SO_4 , filtered, and concentrated


25

-418-

in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white foam (283 mg, 14%). MS (FAB+) MH⁺ calculated for C₂₇H₄₀N₂O₉S₁: 569, found 5 569.

Part B: To a slurry of the THP-protected hydroxamate from part A (530 mg, 0.93 mmol) in dioxane (5 mL) were added a 4N HCl dioxane solution (5 mL) and methanol (5 mL). After fifteen minutes at 10 ambient temperature the reaction was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile /water buffered with 0.01% HCl) provided the title compound as a beige solid (240 mg, 62%). HRMS (ES+) MH⁺ calculated for C₁₇H₂₄N₂O₆S₁: 385.14, 15 found 385.14.

Example 68: Preparation of tetrahydro-N-hydroxy-4-
[[4-[(4-phenylmethyl)amino]phenyl]-
sulfonyl]-2H-pyran-4-carboxamide,
20 monohydrochloride




Part A: In a solid phase reaction vessel, 25 benzylamine (11.0 mL, 100 mmol) was added to Resin II (in a procedure described hereinafter; 5.0 g, 4.55 mmol) swollen in dry 1-methyl-2-pyrrolidinone (40 mL). The reaction was heated to 100 degrees Celsius

-419-

for forty-eight hours with good shaking. The resin was transferred to a frit and washed four times with N,N-dimethylformamide (30 mL), four times with methanol (30 mL), four times with methylene chloride (30 mL), and dried. The dried resin was transferred to a flask and a solution of 95% trifluoroacetic acid/5%water (50 mL) was added. The slurry was stirred for one hour, filtered and the cake was washed with methylene chloride. The combined filtrates were concentrated in vacuo. The residue was dissolved in ethyl acetate and saturated sodium bicarbonate solution was added until pH=7. The organic layer was dried over Na₂SO₄, filtered, and concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile/water buffered with 0.01% HCl) provided the title compound as a reddish solid (1.01 g, 52%). HRMS (ES+) M+ NH₄⁺ calculated for C₁₉H₂₂N₂O₅S₁ : 408.16, found 408.16.

Example 69: Preparation of Tetrahydro-N-hydroxy-4-[[4-[4-trifluoromethoxy)phenoxy)phenyl]-sulfonyl]-2H-pyran-4-carboxamide



25


Part A: To a solution of the title compound of Example 55 (3.1 g, 8 mmol) in N,N-dimethylacetamide (20 mL) were added cesium carbonate

-420-

(8.8 g, 27 mmol) and p-(trifluoromethoxy)phenol (2.1 mL, 16 mmol). The slurry was stirred at 95 degrees Celsius for nineteen hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white foam (4.2 g, 96%). HRMS (ES+) MH⁺ calculated for C₂₄H₂₆N₁O₈ S₁F₃: 546.14, found 546.14.

Part B: To a slurry of the THP-protected hydroxamate from part A (4.0 g, 7.3 mmol) in dioxane (20 mL) were added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at ambient temperature, the reaction was diluted with ethyl acetate and washed with water, dried over Na₂SO₄, filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give the title compound as a white solid (2.2 g, 65%). HRMS (ES+) M⁺ NH₄⁺ calculated for C₁₉H₁₈N₁O₇S₁F₃: 479.11, found 479.11.

Example 70: Preparation of 4-[[4-(3,5-difluorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



-421-


Part A: To a solution of the title compound of Example 55 (3.1 g, 8 mmol) in N,N-dimethylacetamide (20 mL) were added cesium carbonate (8.8 g, 27 mmol) and 3,5-difluorophenol (2.1 g, 16 mmol). The slurry was stirred at 95 degrees Celsius for forty-eight hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a beige foam (3.23 g, 81%). HRMS (ES+) MH⁺ calculated for C₂₃H₂₅N₁O₇ S₁F₂ : 498.14, found 498.14.

Part B: To a slurry of the THP-protected hydroxamate from part A (3.2 g, 6.3 mmol) in dioxane (20 mL) were added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at ambient temperature the reaction was diluted with ethyl acetate and washed with water, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was slurried in diethyl ether and vacuum filtration of the resulting precipitate provided the title compound as a white solid (1.5 g, 57%). HRMS (ES+) M⁺ NH₄⁺ calculated for C₁₈H₁₇N₁O₆ S₁F₂: 431.11, found 431.11.

-422-

Example 71: Preparation of 4-[[4-(3,4-dichlorophenoxy)-phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide

5



Part A: To a solution of the title compound of Example 55 (3.1 g, 8 mmol) in N,N-dimethylacetamide (20 mL) were added cesium carbonate (8.8 g, 27 mmol) and 3,4-dichlorophenol (2.61 g, 16 mmol). The slurry was stirred at 95 degrees Celsius for forty-one hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white foam (4.17 g, 98%). HRMS (ES+) M+ NH₄⁺ calculated for C₂₃H₂₅N₁O₅ S₁Cl₂: 547.11, found 547.10.


Part B: To a slurry of the THP-protected hydroxamate from part A (3.5 g, 6.6 mmol) in dioxane (20 mL) were added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at ambient temperature the reaction was diluted with ethyl acetate and washed with water, dried over Na₂SO₄, filtered, and concentrated in vacuo. The residue was slurried in diethyl ether and vacuum

-423-

filtration of the resulting precipitate provided the title compound as a white solid (2.98 g, 100%). HRMS (ES+) $M + NH_4^+$ calculated for $C_{18}H_{17}N_1O_6 S_1Cl_2$: 463.05, found 463.05.

5

Example 72: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-[(phenylmethyl)oxy]phenoxy]-
phenyl]-sulfonyl]-2H-pyran-4-carboxamide



10

Part A: To a solution of the title compound of Example 55 (2.7 g, 7 mmol) in N,N-dimethylacetamide (20 mL) were added cesium carbonate (6.84 g, 21 mmol) and 4-(benzyloxy)phenol (2.8 g, 14 mmol). The slurry was stirred at 95 degrees Celsius for six hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexanes) provided the substituted THP-protected hydroxamate as a white foam (3.94 g, 99%). HRMS (ES+) $M + NH_4^+$ calculated for $C_{30}H_{33}N_1O_8 S_1$: 585.23, found 585.23.


25

Part B: To a slurry of the THP-protected hydroxamate from part A (1.42 g, 2.5 mmol) in dioxane (6.3 mL) were added a 4N HCl dioxane solution (6.3 mL) and methanol (6.3 mL). After fifteen minutes at

-424-

ambient temperature the reaction was diluted with ethyl acetate and washed with water, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give
5 the title compound as a white solid (0.56 g, 46%).
HRMS (ES+) MH^+ calculated for $\text{C}_{25}\text{H}_{25}\text{N}_1\text{O}_7$, S_1 : 484.14, found 484.14.

Example 73: Preparation of tetrahydro-N-hydroxy-4-
10 [[4-[4-(trifluoromethoxy)phenylthio]-
phenyl]-sulfonyl]-2H-pyran-4-carboxamide




15 Part A: To a solution of the title compound of Example 55 (3.1 g, 8 mmol) in N,N-dimethylformamide (20 mL) were added potassium carbonate (2.21 g, 16mmol) and p-(trifluoromethoxy)benzenethiol (2.33 g, 12 mmol).
20 The slurry was stirred at 70 degrees Celsius for two hours. The reaction was concentrated in vacuo. The residue was taken up in ethyl acetate, washed with brine, dried over Na_2SO_4 , filtered, and concentrated in vacuo. Chromatography (on silica, ethyl
25 acetate/hexanes) provided the substituted THP-protected hydroxamate as a white solid (4.4 g, 98%).
HRMS (ES+) $\text{M}+\text{NH}_4^+$ calculated for $\text{C}_{24}\text{H}_{26}\text{N}_1\text{O}_7\text{S}_2\text{F}_3$: 579.14, found 579.14.

-425-

Part B: To a slurry of the THP-protected hydroxamate from part A (4.15 g, 7.4 mmol) in dioxane (20 mL) were added a 4N HCl dioxane solution (20 mL) and methanol (20 mL). After fifteen minutes at ambient temperature the reaction was diluted with ethyl acetate and washed with water, dried over Na_2SO_4 , filtered, and concentrated in vacuo. The product was recrystallized (acetone/hexanes) to give the title compound as a white solid (3.0 g, 85%).

HRMS (ES+) $\text{M}+\text{NH}_4^+$ calculated for $\text{C}_{19}\text{H}_{18}\text{N}_1\text{O}_6$ S_2F_3 : 495.09, found 495.09.

Example 74: Preparation of phenylmethyl-[4-[[2-(hydroxyamino)-2-oxoethyl]-sulfonylphenyl]carbamate



Part A: To a suspension of 2-(4-aminophenylthio) acetic acid (20.0 g, 0.11 mol) in methanol (100 mL), cooled to zero degrees Celsius, was slowly added thionyl chloride (24.0 mL, 0.33 mol). Additional methanol (100 mL) was added and the cooling bath was removed. The resulting mixture was heated at reflux for 2 hours. The reaction mixture was then cooled to ambient temperature and concentrated in vacuo. The residue was dissolved in H_2O and neutralized with saturated NaHCO_3 . The aqueous reaction mixture was extracted with ethyl

-426-

acetate. The organic layer was washed with saturated NaCl and dried over Na_2SO_4 . Concentration in vacuo provided the methyl ester sulfide as a dark purple oil (22.75 g, quantitative yield).

5 Part B: To a solution of the methyl ester sulfide of part A (10.0 g, 50.7 mmol) in dichloromethane (100 mL) was added *N*-methyldmorpholine (11.2 mL, 101.4 mmol), followed by *N*-(benzyloxycarbonyloxy)succinimide (12.6 g, 50.7
10 mmol). The resulting mixture was stirred at ambient temperature overnight (about 18 hours) and then concentrated in vacuo. The residue was dissolved in ethyl acetate and then washed with H_2O , 5% KHSO_4 , saturated NaCl and dried over Na_2SO_4 . Concentration
15 in vacuo provided the benzyloxy carbamate sulfide as a dark oil (16.2 g, 96%).


 Part C: To a solution of the benzyloxy carbamate sulfide of part B (16.2 g, 48.7 mmol) in tetrahydrofuran (100 mL) and H_2O (10 mL) was added
20 Oxone® (90.0 g, 146.4 mmol), and the resulting mixture was stirred at ambient temperature for 16 hours. The reaction mixture was then filtered and the filtrate was concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with H_2O ,
25 saturated NaCl and dried over Na_2SO_4 . Concentration in vacuo provided the benzyloxy carbamate sulfone as a tan solid (15.6 g, 88%).

 Part D: To a solution of the benzyloxy carbamate sulfone of part C (0.25 g, 0.69 mmol) in
30 tetrahydrofuran (3 mL) was added 50% aqueous hydroxylamine (1.5 mL). The resulting mixture was

-427-

stirred at ambient temperature for 24 hours. The mixture was then diluted with ethyl acetate (30 mL), washed with H₂O, saturated NaCl and dried over Na₂SO₄. Concentration in vacuo followed by washing with hot
5 diethyl ether provided the title compound as a pale pink solid (0.20 g, 80%). MS MH⁺ calculated for C₁₆H₁₇O₆N₂S: 365, found 365.

Example 75: Preparation of N-hydroxy-2-[[4-
10 [[(phenylamino)carbonyl]amino]-
phenyl]sulfonyl]acetamide



15 Part A: Hydrogen gas was bubbled into a suspension of the benzyloxy carbamate sulfone of part C, Example 74 (13.4 g, 36.8 mmol) and 4% Pd/C in tetrahydrofuran (100 mL). After the uptake of H₂ ceased the mixture was purged with N₂ and then
20 filtered through a pad of Celite® washing with tetrahydrofuran. The filtrate was concentrated in vacuo to give the aniline as a brown solid (8.1 g, 96%).

Part B: To a suspension of the aniline of
25 part A (0.50 g, 2.2 mmol) in dichloromethane (4 mL) was added phenyl isocyanate (0.36 mL, 3.3 mmol). The mixture was stirred at ambient temperature overnight (about 18 hours) and then diluted with


-428-

dichloromethane (50 mL). The mixture was then washed with H₂O, saturated NaCl and dried over Na₂SO₄.

Chromatography (on silica, ethyl acetate/hexane) provided the urea as a white solid (0.59 g, 78%).

5 Part C: To a solution of the urea of part B (0.32 g, 0.92 mmol) in tetrahydrofuran (3 mL) was added 50% aqueous hydroxylamine (1.5 mL). The resulting mixture was stirred at ambient temperature for 24 hours. The mixture was then diluted with
10 ethyl acetate (30 mL), washed with H₂O, saturated NaCl and dried over Na₂SO₄. Concentration in vacuo, followed by washing with hot diethyl ether provided the title compound as a pale pink solid (0.24 g, 76%). MS MH⁺ calculated for C₁₅H₁₆O₅N₃S: 350, found
15 350.

Example 78: Preparation of 5-[4-(3,4-dimethylphenoxy)phenyl]sulfonyl-N⁵-hydroxy-1,3-dimethylhexahydro-5-
20 pyrimidinecarboxamide, dihydrochloride



Part A: To a solution of part B, Example
25 55 (2.00 g, 8.61 mmol) and 1,3,5-trimethylhexahydro-1,3,5-triazine (1.21 mL, 8.61 mmol) in benzene (20 mL) was slowly added trifluoroacetic acid (0.66 mL,

-429-

8.61 mmol). The resulting mixture was heated at reflux for 1 hour and then cooled to ambient temperature. The mixture was then extracted with 2N HCl. The aqueous layer was neutralized with
5 saturated NaHCO₃ and then extracted with diethyl ether. The organic layers were washed with saturated NaCl and dried over Na₂SO₄. Concentration in vacuo provided the tetrahydropyrimidine as a clear oil (2.31 g, 81%).

10 Part B: To a solution of the tetrahydropyrimidine of part A (1.26 g, 3.81 mmol) in *N,N*-dimethylformamide (5.0 mL) were added 3,4-dimethylphenol (0.559 g, 4.58 mmol) and Cs₂CO₃ (3.72 g, 11.43 mmol). The resulting mixture was heated at
15 90 degrees Celsius for 16 hours. After cooling to ambient temperature, the reaction was diluted with H₂O and extracted with ethyl acetate. The organic layers were washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate) gave the
20 biaryl ether as a pale amber oil (1.40 g, 85%).


Part C: To a solution of the biaryl ether of part B (0.936 g, 2.16 mmol) in tetrahydrofuran (5.0 mL) was added potassium trimethylsilanolate (0.360 g, 2.81 mmol). The resulting mixture was
25 stirred at ambient temperature for 48 hours and then the solvent was removed. The resulting residue was dissolved in dichloromethane (5.0 mL) then, *N*-methylmorpholine (0.712 mL, 6.48 mmol) and *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.278 g, 2.38
30 mmol) were added. After stirring at ambient temperature for 10 minutes, PyBroP® (1.21 g, 2.59

-430-

mmol) was added. The resulting mixture was stirred at ambient temperature overnight (about 18 hours), then diluted with dichloromethane (50 mL) and washed with H₂O. The organic layer was removed and washed
5 with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate) provided the hydroxamate as a white solid (0.970 g, 87%).

Part F: To a suspension of the hydroxamate of part E (0.667 g, 1.29 mmol) in dioxane (3.0 mL)
10 and methanol (1.0 mL) was added a solution of 4N HCl in dioxane (3.22 mL, 12.9 mmol). After stirring at ambient temperature for 30 minutes, the reaction mixture was concentrated *in vacuo*. Reverse phase chromatography (on silica, acetonitrile/H₂O/
15 trifluoroacetic acid) provided the title compound as a white solid (0.379 g, 58%). MS MH⁺ calculated for C₂₁H₂₈O₅N₃S: 434, found 434.

Example 79: Preparation of 4-[[4-(4-chloro-3-
20 methylphenoxy)phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide,
monohydrochloride



25

Part A: To a suspension of isonipectic acid (50.0 g, 0.39 mol) in methanol (300 mL) cooled to zero degrees Celsius was slowly added dropwise

-431-

thionyl chloride (85.0 mL, 1.16 mol). Once the addition was complete the cooling bath was removed and the mixture was heated at reflux for 2 hours. After cooling to ambient temperature the reaction
5 mixture was concentrated in vacuo. The resulting solids were suspended in ethyl acetate and then washed with saturated NaHCO_3 . The aqueous layer was concentrated in vacuo and the resulting solids were dissolved in hot ethyl acetate and decanted from the
10 salts. The organic layers were then concentrated in vacuo to give the methyl ester as a white solid (55.4 g, quantitative yield).

Part B: To a solution of di-tert-butyl dicarbonate (15.3 g, 70.0 mmol) in tetrahydrofuran
15 (100 mL) was added the methyl ester of part A (10.0 g, 70.0 mmol). The resulting mixture was stirred at ambient temperature overnight (about 18 hours) and then concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexane) provided the Boc-
20 piperidine methyl ester as a pale yellow oil (10.1 g, 59%).

Part C: To a solution of the Boc-piperidine methyl ester of part B (23.31 g, 0.096 mol) in tetrahydrofuran (500 mL), cooled to minus 40
25 degrees Celsius, was slowly added lithium diisopropylamide (57.5 mL, 2.0 M in THF, 0.115 mol). The resulting mixture was stirred at minus 40 degrees Celsius for 1 hour and then at zero degrees Celsius for 30 minutes. The mixture was then recooled to
30 minus 40 degrees Celsius and a solution of the disulfide from Part A, Example 6 (24.37 g, 0.096 mol)

-432-

in tetrahydrofuran (60 mL) was slowly added. The resulting mixture was slowly warmed to ambient temperature overnight (about 18 hours) and then H₂O (200 mL) was added. The mixture was then

5 concentrated in vacuo and the aqueous layer was extracted with ethyl acetate. The organic layers were washed with 0.5 M NaOH, H₂O, saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) gave the sulfide as an amber oil

10 (28.1 g, 79%).

Part D: To a solution of the sulfide of part C (28.2 g, 0.076 mol) in dichloromethane (250 mL), cooled to zero degrees Celsius, was added m-chloroperoxy-benzoic acid (48 g, 0.152 mol). The

15 resulting mixture was stirred at zero degrees Celsius for 1 hour, and then at ambient temperature for 2.5 hours. The mixture was then diluted with H₂O and 10% NH₄OH. The organic layer was washed with 10% NH₄OH, H₂O and dried over Na₂SO₄. Chromatography (on silica,

20 ethyl acetate/hexane) provided the sulfone as a white solid (24.7 g, 81%).

Part E: To a solution of the sulfone of part D (3.00 g, 7.47 mmol) in *N,N*-dimethylformamide (15 mL) were added 4-chloro-3-methylphenol (1.28 g,

25 8.96 mmol) and Cs₂CO₃ (7.30 g, 22.42 mmol). The resulting mixture was heated at 80 degrees Celsius for 8 hours. The mixture was then concentrated in vacuo, and the residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with

30 saturated NaCl and dried over Na₂SO₄. Chromatography

-433-

(on silica, ethyl acetate/hexane) gave the biaryl ether as a clear oil (3.26 g, 83%).

Part F: To a solution of the biaryl ether of part E (3.17 g, 6.05 mmol) in tetrahydrofuran (30 mL) was added potassium trimethylsilanolate (1.01 g, 7.87 mmol). The resulting mixture was stirred at ambient temperature for 20 hours. Additional tetrahydrofuran (40 mL) was added and the mixture was stirred at ambient temperature for 36 hours.

10 Additional potassium trimethylsilanolate (0.233 g, 1.82 mmol) was added and the mixture was stirred at ambient temperature for 23 hours. The tetrahydrofuran was removed and the resulting residue was suspended in dichloromethane (30 mL). To the

15 suspension was added N-methylmorpholine (2.00 mL, 18.15 mmol) and O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.780 g, 6.66 mmol) followed by PyBroP® (3.38 g, 7.26 mmol). The mixture was stirred at ambient temperature for 24 hours and then

20 concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with H₂O, saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the hydroxamate as an off-white foam (2.98

25 g, 81%).


Part G: To a solution of the hydroxamate of part F (2.98 g, 4.89 mmol) in dioxane (14 mL) and methanol (6 mL) was added a solution of 4N HCl in dioxane (10 mL). The resulting mixture was stirred

30 at ambient temperature for 3.5 hours, then diethyl ether (40 mL) was added and the precipitate was

-434-

collected by filtration to provide the title compound as a light pink solid (2.00 g, 88%). MS MH⁺ calculated for C₁₉H₂₂O₅N₂ClS: 425, found 425.

- 5 Example 80: Preparation of 4-[[4-(4-chloro-3-methylphenoxy)phenyl]sulfonyl]-4-(hydroxyamino)carbonyl]-1-
piperidineacetic acid, monohydrochloride



- Part A: To a suspension of the title compound of Example 80 (0.250 g, 0.542 mmol) in acetonitrile (4.0 mL) were added tert-butylbromoacetate (0.088 mL, 0.542 mmol) and K₂CO₃,
15 (0.150 g, 1.08 mmol). The resulting mixture was stirred at ambient temperature for 18 hours, then filtered through a pad of Celite®, washing with ethyl acetate. The filtrate was then concentrated in vacuo. Reverse phase chromatography (on silica,
20 acetonitrile/H₂O/trifluoroacetic acid) provided the tert-butyl ester as a white solid (0.156 g, 53%).

- Part B: The tert-butyl ester of part A (0.156 g, 0.289 mmol) was treated with a solution of 4N HCl in dioxane (1.5 mL) and the resulting mixture
25 was stirred at ambient temperature for 3.5 hours at which time additional dioxane (2 mL) was added.


-435-

After stirring at ambient temperature for 8 hours the reaction mixture was concentrated in vacuo. The residue was treated again with a solution of 4N HCl in dioxane (1.5 mL) at ambient temperature for 4
5 hours. Diethyl ether was added to the reaction mixture and the precipitate was collected by filtration to give the title compound as an off-white solid (0.111 g, 74%). MS MH^+ calculated for $C_{21}H_{24}O_7N_2SCl$: 483, found 483.

10

Example 81: Preparation of 4-[[4-(4-chloro-3-methylphenoxy)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-
piperidinecarboxamide, monohydrochloride

15




Part A: To a suspension of the title compound of Example 79 (0.500 g, 1.08 mmol) in
20 acetonitrile (8.0 mL) were added propargyl bromide (0.126 mL, 80% solution in toluene, 1.13 mmol) and K_2CO_3 (0.300 g, 2.17 mmol). The resulting mixture was stirred at ambient temperature for 24 hours, then filtered through a pad of Celite®, washing with
25 methanol and the filtrate was then concentrated in vacuo. Chromatography (on silica, ethyl acetate)

-436-

provided the *N*-propargyl hydroxamate as a tan solid (0.200 g, 40%).

Part B: To a solution of the *N*-propargyl hydroxamate of part A (0.200 g, 0.432 mmol) in
5 acetonitrile (3.0 mL) and H₂O (0.5 mL) was added concentrated HCl (0.05 mL). The resulting mixture was stirred at ambient temperature for 5 minutes and the concentrated in vacuo to provide the title compound as a pink solid (0.200 g, 93%). MS MH⁺
10 calculated for C₂₂H₂₄O₅N₂SCl: 463, found 463.

Example 82: Preparation of 4-[[4-(4-chloro-3-methylphenoxy)phenyl]sulfonyl]-*N*-hydroxy-1-(2-propenyl)-4-
15 piperidinecarboxamide, monohydrochloride




Part A: To a suspension of the title
20 compound of Example 79 (0.500 g, 1.08 mmol) in acetonitrile (8.0 mL) were added allyl bromide (0.093 mL, 1.08 mmol) and K₂CO₃ (0.300 g, 2.17 mmol). The resulting mixture was stirred at ambient temperature for 22 hours. Additional allyl bromide (0.054 mL, 1M
25 in acetonitrile, 0.054 mmol) was added and stirring was continued at ambient temperature for 6 hours. The resulting mixture was filtered through a pad of

-437-

Celite®, washing with ethyl acetate and the filtrate was concentrated in vacuo. Chromatography (on silica, methanol/ethyl acetate) provided the *N*-allyl hydroxamate as an off-white solid (0.080 g, 15%).

- 5 Part B: To a solution of the *N*-allyl hydroxamate of part A (0.080 g, 0.172 mmol) in acetonitrile (3.0 mL) and H₂O (1.0 mL) was added concentrated HCl (0.05 mL). The resulting mixture was stirred at ambient temperature for ten minutes
10 and then concentrated in vacuo to provide the title compound as a white solid (0.100 g, quantitative yield). MS MH⁺ calculated for C₂₂H₂₆O₅N₂SCl: 465, found 465.

- 15 Example 83: Preparation of 4-[[4-(4-fluoro-3-methylphenoxy)phenyl]sulfonyl]-*N*-hydroxy-4-piperidine carboxamide,
monohydrochloride



- Part A: To a solution of the sulfone of part D, Example 79 (5.00 g, 12.45 mmol) in tetrahydrofuran (100 mL) was added potassium
25 trimethylsilanolate (4.79 g, 37.36 mmol). The resulting mixture was stirred at ambient temperature for 1.5 hours, diluted with H₂O and diethyl ether (100

-438-

mL). The aqueous layer was extracted with diethyl ether and the combined organic layers were washed with H₂O. The aqueous layers were combined and acidified with 2N HCl (pH=2) and then extracted with
5 ethyl acetate. The combined organic layers were washed with saturated NaCl and dried over Na₂SO₄ to provide the acid as an off-white solid (4.61 g, 96%).

Part B: To a suspension of the acid of
10 part A (0.830 g, 2.14 mmol) in dichloromethane (10 mL) was added *N*-methylmorpholine (0.706 mL, 6.42 mmol) and *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.276 g, 2.35 mmol). After stirring at ambient temperature for 5 minutes, PyBroP® (1.20 g, 2.57
15 mmol) was added and the resulting mixture was stirred at ambient temperature for 19 hours. The mixture was concentrated in vacuo and the residue was partitioned between H₂O and ethyl acetate. The aqueous layer was further extracted with ethyl acetate and the combined
20 organic layers were washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the *p*-fluorosulfone as a white crystalline solid (0.993 g, 95%).

Part C: To a solution of the *p*-
25 fluorosulfone of part B (0.485 g, 0.996 mmol) in *N,N*-dimethylformamide (5 mL) were added 4-fluoro-3-methylphenol (0.133 mL, 1.20 mmol) and Cs₂CO₃ (0.973 g, 2.99 mmol). The resulting mixture was heated at 60 degrees Celsius for 17 hours. Additional 4-
30 fluoro-3-methylphenol (0.055 mL, 0.498 mmol) was added and the temperature of the reaction mixture was


-439-

increased to 80 degrees Celsius for 4 hours and then to 100 degrees Celsius for 3 hours. Additional 4-fluoro-3-methylphenol (0.133 mL, 1.20 mmol) was added and the reaction mixture was heated at 100 degrees Celsius for 7.5 hours. Additional Cs_2CO_3 was added and heating continued at 100 degrees Celsius for 17 hours. The reaction was cooled to ambient temperature and then concentrated in *vacuo*. The residue was partitioned between H_2O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na_2SO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an off-white solid (0.490 g, 83%).

Part D: To a solution of the protected hydroxamate of part C (0.479 g, 0.808 mmol) in dioxane (3 mL) and methanol (1 mL) was added a solution of 4N HCl in dioxane (2.02 mL, 8.08 mmol). The resulting mixture was stirred at ambient temperature for 1.5 hours. Diethyl ether (5 mL) was added and the precipitate was collected by filtration to give the title compound as an off-white solid (0.323 g, 90%). MS MH^+ calculated for $\text{C}_{19}\text{H}_{22}\text{O}_5\text{N}_2\text{SF}$: 409, found 409.

Example 84: Preparation of 4-[[4-(3-chloro-4-fluorophenoxy)phenyl]sulfonyl]-N-hydroxy-4-piperidine carboxamide,
monohydrochloride

-440-




Part A: To a solution of the p-fluorosulfone of Part B, Example 83 (0.485 g, 0.996 mmol) in *N,N*-dimethylformamide (5.0 mL) were added 4-fluoro-3-chlorophenol (0.176 g, 1.20 mmol) and Cs₂CO₃ (0.973 g, 2.99 mmol). The resulting mixture was heated at 60 degrees Celsius for 17 hours, then additional 4-fluoro-3-chlorophenol (0.073 g, 0.498 mmol) was added and the reaction mixture was heated at 80 degrees Celsius for 24 hours then increased to 90degrees Celsius. After heating 90 degrees Celsius for 7 hours additional 4-fluoro-3-chlorophenol (0.176 g, 1.20 mmol) was added and heating was contiuned at 90 degrees Celsius for 7.5 hours. Additional Cs₂CO₃ (0.973 g, 2.99 mmol) was added and the mixture was heated at 90 degrees Celsius for 24 hours. After cooling to ambient temperature, the reaction mixture was concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an off-white solid (0.550 g, 90%).

Part B: To a solution of the protected hydroxamate of part A (0.530 g, 0.864 mmol) in dioxane (3 mL) and methanol (1 mL) was added a solution of 4*N* HCl in dioxane (2.00 mL, 8.00 mmol).

-441-

The resulting mixture was stirred at ambient temperature for 1.5 hours. Diethyl ether (5 mL) was added and the precipitate was collected by filtration to give the title compound as an off-white solid
5 (0.377 g, 94%). MS MH^+ calculated for $C_{19}H_{19}O_5N_2SFCl$: 429, found 429.

Example 85: Preparation of 4-[[4-(4-chlorophenoxy)-
phenyl]sulfonyl]-N-hydroxy-1-(2-
10 propynyl)-4-piperidinecarboxamide,
monohydrochloride



15 Part A: To a solution of sulfone of part D, Example 79 (4.53 g, 11.28 mmol) in *N,N*-dimethylformamide (20 mL) were added 4-chlorophenol (4.41 g, 13.54 mmol) and Cs_2CO_3 (11.03 g, 33.85 mmol). The resulting mixture was heated at 90 degrees
20 Celsius for 5 hours. After cooling to ambient temperature, the reaction mixture was concentrated in vacuo. The residue was partitioned between H_2O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na_2SO_4 . Chromatography
25 (on silica, ethyl acetate/hexane) provided the biaryl ether as a white solid (4.60 g, 78%).

-442-

Part B: To a solution of the biaryl ether of part A (4.57 g, 8.96 mmol) in dioxane (10 mL) was added a solution of 4N HCl in dioxane (10 mL). The resulting mixture was stirred at ambient temperature for 2.5 hours and then additional dioxane (10 mL) was added. After stirring at ambient temperature for 1.5 hours the mixture was concentrated in vacuo. The resulting solid was suspended in dioxane (20 mL) and retreated with a solution of 4N HCl in dioxane (10 mL). The mixture was stirred at ambient temperature for 1 hour, methanol (1 mL) was added and stirring was continued at ambient temperature. After 1 hour, the mixture was concentrated in vacuo to give the amine as a white solid (4.09 g, quantitative yield).

Part C: To a suspension of the amine of part B (4.00 g, 8.96 mmol) in acetonitrile (20 mL) were added propargyl bromide (1.05 mL, 80% solution in toluene, 9.41 mmol) and K_2CO_3 (2.60 g, 18.82 mmol). The resulting mixture was stirred at ambient temperature for 18 hours, filtered through a pad of Celite®, washing with ethyl acetate, and then the filtrate was concentrated in vacuo to provide the N-propargyl amine as a sticky foam (4.14 g, quantitative yield).

Part D: To a suspension of the N-propargyl amine of part C (4.14 g, 8.96 mmol) in tetrahydrofuran (20 mL) was added potassium trimethylsilanolate (1.26 g, 9.86 mmol). The resulting mixture was stirred at ambient temperature for 17 hours and additional tetrahydrofuran (5 mL) and potassium trimethylsilanolate (0.350 g, 2.73

-443-

mmol) were added. After stirring at ambient temperature for 4 hours, additional tetrahydrofuran (5 mL) was added and stirring was continued at ambient temperature for 24 hours. Additional
5 potassium trimethylsilanolate (0.115 g, 0.896 mmol) was added and the mixture was stirred at ambient temperature for 24 hours, at which time, additional potassium trimethylsilanolate was added and the resulting mixture was stirred at ambient temperature
10 for another 24 hours. The tetrahydrofuran was removed and the residue was suspended in dichloromethane (20 mL).


To the dichloromethane suspension were added *N*-methylmorpholine (2.96 mL, 26.9 mmol) and *O*-
15 tetrahydro-2H-pyran-2-yl-hydroxylamine (1.15 g, 9.86 mmol), followed by PyBroP® (5.01 g, 10.75 mmol). The resulting mixture was stirred at ambient temperature overnight and then concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate.
20 The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an off-white foam (3.29 g, 69%).

Part E: To a solution of the protected
25 hydroxamate of part D (3.27 g, 6.13 mmol) in dioxane (21 mL) and methanol (7 mL) was added a solution of 4*N* HCl in dioxane (10 mL). The resulting mixture was stirred at ambient temperature for 4 hours and then diethyl ether (75 mL) was added. The solids were
30 collected by filtration, washing with diethyl ether, to give the title compound as an off-white solid

-444-

(2.95 g, 99%). MS MH^+ calculated for $C_{22}H_{22}O_5N_2SCl$:
449, found 449.

Example 86: Preparation of 4-[[4-(phenylthio)-
phenyl]-sulfonyl]-N-hydroxy-4-
piperidine-carboxamide,
monohydrochloride



10

Part A: To a solution of the sulfone of
part D, Example 79 (0.500 g, 1.25 mmol) in *N,N*-
dimethylformamide (3.0 mL) were added thiophenol
(0.154 mL, 1.50 mmol) and K_2CO_3 (0.518 g, 3.75 mmol).
The resulting mixture was stirred at ambient
temperature for 24 hours and then concentrated in
vacuo. The residue was partitioned between H_2O and
ethyl acetate. The organic layers were washed with
saturated NaCl and dried over Na_2SO_4 . Chromatography
(on silica, ethyl acetate/hexane) provided the biaryl
thioether as a clear sticky oil (0.480 g, 78%).

Part B: To a solution of the biaryl
thioether of part A (2.01 g, 4.09 mmol) in
tetrahydrofuran (40 mL) was added potassium
trimethylsilanolate (0.682 g, 5.31 mmol). The
resulting mixture was stirred at ambient temperature
for 23 hours and then concentrated in *vacuo*. The


-445-

residue was then suspended in dichloromethane (20 mL) then *N*-methylmorpholine (1.35 mL, 12.27 mmol) and 50% aqueous hydroxylamine (0.265 mL, 4.50 mmol) were added, followed by PyBroP® (2.29 g, 4.91 mmol). The resulting mixture was stirred at ambient temperature for 16 hours and then concentrated in vacuo. The residue was partitioned between ethyl acetate and H₂O. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. A portion of the sample was subjected to reverse phase chromatography (on silica, acetonitrile/H₂O/trifluoroacetic acid) to give the hydroxamate as an off-white solid (0.190 g).

Part C: To a solution of the hydroxamate of part B (0.181 g, 0.367 mmol) in dioxane (5 mL) and methanol (1 mL) was added a solution of 4*N* HCl in dioxane (3 mL). The resulting mixture was stirred at ambient temperature for 3 hours and then concentrated in vacuo to give the title compound as an off-white solid (0.170 g, quantitative yield). MS MH⁺ calculated for C₁₈H₂₁O₄N₂S₂: 393, found 393.

Example 87: Preparation of 4-[(hydroxyamino)-carbonyl]-4-[[4-(phenylthio)phenyl]-sulfonyl]-1-piperidineacetic acid, monohydrochloride

-446-




Part A: To a solution of the compound of Example 86 (0.322 g, 0.751 mmol) in acetonitrile (4.0 mL) were added tert-butylbromoacetate (0.121 mL, 0.751 mmol) and K_2CO_3 (0.207 g, 1.50 mmol). The resulting mixture was stirred at ambient temperature for 18 hours, filtered through a pad of Celite®, washing with ethyl acetate, and the filtrate was concentrated in vacuo. Reverse phase chromatography (on silica, acetonitrile /H₂O/trifluoroacetic acid) provided the tert-butyl ester as an off-white solid (0.150 g, 40%).

Part B: The tert-butyl ester of part A (0.145 g, 0.286 mmol) was treated with a solution of 4N HCl in dioxane (3.0 mL). The resulting mixture was stirred at ambient temperature for 7 hours, diethyl ether was added and the precipitate was collected by filtration. Reverse phase chromatography (on silica, acetonitrile /H₂O/HCl) provided the title compound as an off-white solid (0.060 g, 43%). MS MH^+ calculated for $C_{20}H_{23}O_6N_2S_2$: 451, found 451.

-447-

Example 88: Preparation of 4-[[4-(4-chlorophenoxy)-phenyl]sulfonyl]-4-[(hydroxyamino)-carbonyl]-1-piperidineacetic acid, monohydrochloride

5



Part A: To a suspension of 4-bromopiperidine hydrobromide (40.0 g, 0.16 mol) in tetrahydrofuran (200 mL) was slowly added triethylamine (45.4 mL, 0.33 mol), followed by di-tert-butyl dicarbonate (37.4 g, 0.17 mol), which was added in several portions. The resulting mixture was stirred at ambient temperature for 17 hours then filtered and concentrated in vacuo. The solids were washed with hexanes and then collected by filtration to give the Boc-piperidine compound as an amber oil (45.8 g, >100%).

Part B: To a solution of 4-fluorophenol (25.0 g, 0.20 mol) in acetone (150 mL), degassed with N₂, was added Cs₂CO₃ (79.7 g, 0.25 mol). After degassing the resulting mixture with N₂ for 5 minutes, the Boc-piperidine compound of part A (43.1 g, 0.16 mol) was added. The resulting mixture was stirred at ambient temperature for 22 hours and then filtered through a pad of Celite®, washing with acetone. The

-448-

residue was washed with diethyl ether and the solids were collected by filtration to provide the sulfide as a yellow oil (47.6 g, 93%).

Part C: To a solution of the sulfide of
5 part B (47.3 g, 0.15 mol) in dichloromethane (350 mL), cooled to zero degrees Celsius, was added m-chloroperoxy-benzoic acid (80 g, 57-86%). Additional dichloromethane (50 mL) was added and the mixture was stirred at zero degrees Celsius for 1 hour and then
10 for 1.5 hours at ambient temperature. The reaction mixture was diluted with H₂O and aqueous sodium metabisulfite (4.0 g in 50 mL) was added. The mixture was concentrated *in vacuo* and then extracted with diethyl ether and ethyl acetate. The combined
15 organic layers were washed with 10% NH₄OH, saturated NaCl and dried over Na₂SO₄. Recrystallization from ethyl acetate provided the sulfone as a white solid (18.9 g, 36%).

Part D: To a solution of the sulfone of
20 part C (8.00 g, 23.3 mmol) in *N,N*-dimethylformamide (40 mL) were added 4-chlorophenol (3.59 g, 27.96 mmol) and K₂CO₃ (22.77 g, 69.90 mmol). The resulting mixture was heated at 60 degrees Celsius for 4 hours and then increased to 80 degrees Celsius for 7 hours.
25 The reaction was cooled to ambient temperature and then concentrated *in vacuo*. To the residue was added H₂O (100 mL) and the solids were collected by filtration to give the biaryl ether as an off-white solid (10.5 g, 99%).

30 Part E: To a solution of the biaryl ether of part D (5.00 g, 11.1 mmol) in tetrahydrofuran (50

-449-

mL), cooled to zero degrees Celsius, was added lithium bis(trimethylsilyl)amide (13.3 mL, 1M in tetrahydrofuran, 13.3 mmol), at such a rate that the temperature of the reaction mixture never exceeded 2
5 degrees Celsius. The resulting mixture was stirred at zero degrees Celsius for 30 minutes, then dimethyl carbonate (1.40 mL, 16.6 mmol) was slowly added at such a rate that the temperature of the reaction mixture never exceeded 2 degrees Celsius. The
10 resulting mixture was then slowly permitted to warm to ambient temperature.

After 17 hours, the reaction was recooled to zero degrees Celsius and additional lithium bis(trimethylsilyl)amide (5.50 mL, 1M in
15 tetrahydrofuran, 5.50 mmol) was slowly added at a rate such that the temperature of the reaction never exceeded 2 degrees Celsius. After stirring for 30 minutes, dimethyl carbonate (0.048 mL, 0.570 mmol) was added and stirring was continued at zero degrees
20 Celsius for 45 minutes. Additional lithium bis(trimethylsilyl)amide (0.500 mL, 1M in tetrahydrofuran, 0.500 mmol) was slowly added and after 1 hour additional dimethyl carbonate (0.010 mL, 0.119 mmol) was added. After stirring at zero
25 degrees Celsius for 20 minutes, saturated NH_4Cl was added and the reaction mixture was then concentrated in vacuo. The residue was diluted with H_2O and extracted with ethyl acetate. The combined organic layers were washed with saturated NaCl and dried over
30 Na_2SO_4 . Recrystallization from methanol provided the

-450-

methyl ester as a white crystalline solid (3.56 g, 63%).

Part F: To a solution of the methyl ester of part E (3.54 g, 6.94 mmol) in dioxane (18 mL) and
5 methanol (6 mL) was added a solution of 4N HCl in dioxane (10 mL). The resulting mixture was stirred at ambient temperature for 5 hours and then concentrated in vacuo to provide the amine as an off-white solid (3.10 g, quantitative yield).

10 Part G: To a solution of the amine of part F (1.50 g, 3.36 mmol) in acetonitrile (15 mL) were added tert-butylbromoacetate (0.570 mL, 3.53 mmol) and K_2CO_3 (1.16 g, 8.40 mmol). The resulting mixture was stirred at ambient temperature for 3 hours, then
15 filtered through a pad of Celite®, washing with ethyl acetate. The filtrate was concentrated in vacuo to provide the tert-butyl ester as a pale yellow oil (1.83 g, >100%).

Part H: To a solution of the tert-butyl
20 ester of part G (1.76 g, 3.36 mmol) in tetrahydrofuran (15 mL) was added potassium trimethylsilanolate (0.475 g, 3.70 mmol). The resulting mixture was stirred at ambient temperature overnight (about 18 hours) and additional
25 tetrahydrofuran (10 mL) was added. After stirring at ambient temperature overnight (about 18 hours), additional potassium trimethylsilanolate (0.475 g, 3.70 mmol) was added. The resulting mixture was stirred at ambient temperature for 4 hours then
30 diluted with H_2O . The reaction mixture was acidified (pH=7) with 1N HCl and then concentrated in vacuo.

-451-

The solids were washed with diethyl ether and then with H₂O to provide the acid as an off-white solid (0.597 g, 32%).

Part I: To a suspension of the acid of
5 part H (0.597 g, 1.17 mmol) in dichloromethane (5 mL) was added N-methylmorpholine (0.386 mL, 3.51 mmol) and O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.151 g, 1.29 mmol), followed by PyBroP® (0.655 g, 1.40 mmol). The resulting mixture was stirred at ambient
10 temperature overnight (about 18 hours) and then concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane)
15 provided the protected hydroxamate as a white foam (0.510 g, 72%).


Part J: The protected hydroxamate of part I (0.510 g, 0.837 mmol) was treated with a solution of 4N HCl in dioxane (10 mL). The resulting mixture
20 was stirred at ambient temperature for 24 hours, then diethyl ether (20 mL) was added and the solids were collected by filtration to provide the title compound as a white solid (0.370 g, 87%). MS MH⁺ calculated for C₂₀H₂₂O₇N₂SCl: 469, found 469.

25

Example 89: Preparation of 4-[[4-(4-chlorophenoxy)-phenyl]sulfonyl]-N-hydroxy-1-[2-(4-morpholinyl)ethyl]-4-piperidine-
carboxamide, dihydrochloride

30

-452-



Part A: To a solution of the amine of part F, Example 88 (1.00 g, 2.24 mmol) in acetonitrile (10 mL) were added 4-(2-chloroethyl)morpholine (0.438 g, 2.35 mmol) and K_2CO_3 (1.24 g, 8.96 mmol). The resulting mixture was stirred at ambient temperature for 1.5 hours then a catalytic amount of NaI was added and stirring was continued at ambient temperature for 21 hours. The temperature of the reaction mixture was then increased to 60 degrees Celsius for 29 hours. After cooling to ambient temperature, the reaction mixture was filtered through a pad of Celite®, washing with ethyl acetate. The filtrate was concentrated in vacuo to provide the ester as an oily solid (1.15 g, 98%).

Part B: To a solution of the ester of part A (1.15 g, 2.20 mmol) in tetrahydrofuran (10 mL) was added potassium trimethylsilanolate (0.579 g, 4.51 mmol). The reaction mixture was stirred at ambient temperature for 4 hours then additional tetrahydrofuran (10 mL) was added and stirring was continued at ambient temperature overnight (about 18 hours). The reaction mixture was diluted with H_2O (10 mL) and acidified (pH-7) with 1N HCl. The resulting

-453-

precipitate was collected by filtration to provide the acid as a gray solid (0.753 g, 72%).


Part C: To a suspension of the acid of part B (0.750 g, 1.47 mmol) in dichloromethane (7 mL) were added *N*-methylmorpholine (0.500 mL, 4.55 mmol), and *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.198 g, 1.62 mmol), followed by PyBroP® (0.822 g, 1.76 mmol). The resulting mixture was stirred at ambient temperature for 24 hours then additional *N*-methylmorpholine (0.242 mL, 2.21 mmol), *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.052 g, 0.441 mmol) and PyBroP® (0.343 g, 0.735 mmol) were added. The resulting mixture was stirred at ambient temperature for 23 hours and then additional *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.017 g, 0.145 mmol) and PyBroP® (0.073 g, 0.157 mmol) were added. The resulting mixture was stirred at ambient temperature overnight (about 18 hours) and then concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, methanol/chloroform) provided the protected hydroxamate as an off-white solid (0.750 g, 84%).

Part D: The protected hydroxamate of part C (0.730 g, 1.20 mmol) was treated with a solution of 4N HCl in dioxane (10 mL) and methanol (1 mL). The resulting mixture was stirred at ambient temperature for 1 hour, then diethyl ether (20 mL) was added and the solids were collected by filtration to provide the title compound as a pale yellow solid (0.625 g,

-454-

87%). MS MH^+ calculated for $C_{24}H_{31}O_6N_3SCl$: 525, found 525.

5 Example 90: Preparation of 4-[[4-(4-chlorophenoxy)-phenyl]sulfonyl]-N⁴-hydroxy-N¹-(1-methylethyl)-1,4-piperidine dicarboxamide



10

Part A: To a suspension of the amine of part F, Example 88 (0.600 g, 1.34 mmol) in dichloromethane (5 mL) were added triethylamine (0.411 mL, 2.95 mmol) and isopropyl isocyanate (0.198 mL, 2.01 mmol). The resulting mixture was stirred at ambient temperature for 2 hours then diluted with dichloromethane (50 mL). The mixture was washed with H₂O, saturated NaCl and dried over Na₂SO₄ to give the urea as an off-white solid (0.670 g, >100%).

20 Part B: To a solution of the urea of part A (0.640 g, 1.29 mmol) in tetrahydrofuran (10 mL) was added potassium trimethylsilanolate (0.199 g, 1.55 mmol). The resulting mixture was stirred at ambient temperature for 17 hours at which time additional
25 potassium trimethylsilanolate (0.015 g, 0.117 mmol) was added. The resulting mixture was stirred for an additional 24 hours then the tetrahydrofuran was


-455-

removed by blowing N₂ over the mixture. To a suspension of the residue in dichloromethane (5 mL) were added *N*-methylmorpholine (0.426 mL, 3.87 mmol) and *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.181 g, 1.55 mmol), followed by PyBroP® (0.902 g, 1.94 mmol). The resulting mixture was stirred at ambient temperature for 7 hours and then concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as an off-white solid (0.330 g, 44%).

Part C: To a solution of the protected hydroxamate of part B (0.330 g, 0.569 mmol) in dioxane (3 mL) and methanol (1 mL) was added a solution of 4N HCl in dioxane (10 mL). The resulting mixture was stirred at ambient temperature for 3.5 hours then diethyl ether was added. The solids were collected by filtration to give the title compound as a white solid (0.259 g, 92%). MS MH⁺ calculated for C₂₂H₂₇O₆N₃SCl: 496, found 496.

Example 91: Preparation of 4-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-*N*-hydroxy-4-piperidinecarboxamide, monohydrochloride

-456-



Part A: To a solution of 4-bromothiophenol (16.98 g, 89.80 mmol) in acetone (200 mL), degassed
5 with N_2 , was added K_2CO_3 (12.41 g, 89.80 mmol). After degassing the resulting mixture with N_2 for 5 minutes, the Boc-piperidine compound of part A, Example 88 (21.57 g, 81.64 mmol) was added. The resulting mixture was stirred at ambient temperature for 19
10 hours and then filtered through a pad of Celite®, washing with acetone. The residue was washed with diethyl ether and the solids were collected by filtration to provide the sulfide as a green oil (31.7 g, >100%).

15 Part B: To a solution of the sulfide of part A (31.68 g, 81.64 mmol) in dichloromethane (200 mL), cooled to zero degrees Celsius, was added m-chloroperoxybenzoic acid (56.35 g, 50-60%, 163.28 mmol). The resulting mixture became very thick, and
20 additional dichloromethane (100 mL) was added. The mixture was stirred at zero degrees Celsius for 1.5 hours and then at ambient temperature for 1.5 hours. The reaction mixture was diluted with H_2O (300 mL) and aqueous sodium meta-bisulfite (8.00 g, 42.08 mmol in
25 50 mL of H_2O) was added. The dichloromethane was removed in vacuo and the aqueous reaction mixture was extracted with ethyl acetate. The combined organic

-457-

layers were washed with 10% NH_4OH , saturated NaCl and dried over Na_2SO_4 . Concentration in vacuo provided the sulfone as a yellow oil (33.42 g, >100%).

Part C: To a solution of the sulfone of
5 part B (7.80 g, 19.34 mmol) in tetrahydrofuran (100 mL), cooled to zero degrees Celsius, was added lithium bis(trimethylsilyl)amide (23.8 mL, 1M in tetrahydrofuran, 23.8 mmol) at such a rate that the temperature of the reaction never exceeded 2 degrees
10 Celsius. After stirring at zero degrees Celsius for 30 minutes a solution of methyl chloroformate (2.30 mL, 29.8 mmol) in tetrahydrofuran (5 mL) was added at such a rate that the temperature of the reaction never exceeded 2 degrees Celsius. The resulting
15 mixture was then slowly allowed to warm to ambient temperature. The mixture was diluted with saturated NH_4Cl and the tetrahydrofuran was removed in vacuo. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with
20 saturated NaCl and dried over Na_2SO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the ester as a yellow solid (6.33 g, 69%).

Part D: To a solution of the ester of part C (4.74 g, 10.28 mmol) in dimethoxyethane (50 mL)
25 were added 4-chlorophenylboronic acid (1.77 g, 11.30 mmol), aqueous Cs_2CO_3 (25 mL, 2.0 M, 50.0 mmol) and tetrakis(triphenylphosphine)palladium (0) (1 g). The resulting mixture was stirred at ambient temperature for 3 days. The reaction mixture was filtered
30 through a pad of Celite®, washing with ethyl acetate, and the filtrate was concentrated in vacuo.

-458-

Chromatography (on silica, ethyl acetate/hexane) provided the biphenyl compound as an off-white solid (4.16 g, 82%).

Part E: To a solution of the biphenyl
5 compound of part D (1.50 g, 3.04 mmol) in tetrahydrofuran (10 mL) was added potassium trimethylsilanolate (0.468 g, 3.65 mmol). The resulting mixture was stirred at ambient temperature for 1 hour, additional tetrahydrofuran (5 mL) was
10 added and the reaction mixture was stirred at ambient temperature overnight (about 18 hours). Additional tetrahydrofuran (15 mL) was added and the mixture was stirred for another 26 hours at ambient temperature. Additional potassium trimethylsilanolate (0.040 g,
15 0.304 mmol) was added and the mixture was stirred at ambient temperature overnight (about 18 hours) and then the solvent was removed by blowing N₂ over the reaction mixture.


To a suspension of the residue in
20 dichloromethane (20 mL) were added N-methylmorpholine (1.00 mL, 9.12 mmol), O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.427 g, 3.65 mmol), followed by PyBrop® (2.13 g, 4.56 mmol). The resulting mixture was stirred at ambient temperature
25 for 24 hours and then concentrated *in vacuo*. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as
30 a white solid (1.25 g, 71%).

-459-

Part F: To a solution of the protected hydroxamate of part E (1.25 g, 2.16 mmol) in dioxane (3 mL) and methanol (1 mL) was added a solution of 4N HCl in dioxane (10 mL). The resulting mixture was stirred at ambient temperature for 3.5 hours, then diethyl ether (20 mL) was added. The solids were collected by filtration to give the title compound as a white solid (0.900 g, 97%). MS MH^+ calculated for $C_{18}H_{20}O_4N_2S \cdot Cl$: 395, found 395.

10

Example 92: Preparation of N-hydroxy-4-[[4-(methylphenylamino)phenyl]sulfonyl]-4-piperidinecarboxamide, monohydrochloride



15

Part A: To a solution of the ester of part C, Example 91 (1.00 g, 2.17 mmol) in toluene (4 mL) were added N-methylaniline (0.282 mL, 2.60 mmol), Cs_2CO_3 (0.990 g, 3.04 mmol), tris(dibenzylideneacetone)-dipalladium(0) (0.018 g, 0.02 mmol) and (R)-(+)-2,2'-bis(diphenylphosphino)1,1'-binaphthyl (BINAP; 0.021 g, 0.033 mmol). The resulting mixture was heated to 100 degrees Celsius for 20 hours. After cooling to ambient temperature, diethyl ether was added, the mixture was filtered through a pad of Celite®,

25

-460-

washing with diethyl ether, and the filtrate was concentrated in vacuo. Chromatography (on silica, ethyl acetate/hexane) provided the aniline as a yellow sticky gum (0.930 g, 88%).

5 Part B: To a solution of the aniline of part A (0.930 g, 1.90 mmol) in tetrahydrofuran (10 mL) was added potassium trimethylsilanolate (0.293 g, 2.28 mmol). The resulting mixture was stirred at ambient temperature for 19 hours and then additional
10 potassium trimethylsilanolate (0.024 g, 0.190 mmol) was added. After stirring at ambient temperature overnight (about 18 hours) the solvent was removed by blowing N₂ over the mixture.


To a suspension of the residue in
15 dichloromethane (10 mL) were added added *N*-methylmorpholine (0.627 mL, 5.70 mmol), *O*-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.267 g, 2.28 mmol), followed by PyBrop® (1.33 g, 2.85 mmol). The resulting mixture was stirred at ambient temperature
20 for 2 days and then concentrated in vacuo. The residue was partitioned between H₂O and ethyl acetate. The organic layer was washed with saturated NaCl and dried over Na₂SO₄. Chromatography (on silica, ethyl acetate/hexane) provided the protected hydroxamate as
25 a white solid (0.860 g, 79%).

Part C: To a solution of the protected hydroxamate of part B (0.890 g, 1.55 mmol) in dioxane (3 mL) and methanol (1 mL) was added a solution of 4*N* HCl in dioxane (5 mL). The resulting mixture was
30 stirred at ambient temperature for 1 hour, then diethyl ether (15 mL) was added. The solids were

-461-

collected by filtration to give the title compound as a white solid (0.529 g, 80%). MS MH^+ calculated for $C_{19}H_{24}O_4N_2S$: 390, found 390.

- 5 Example 93: Preparation of 4-[[4-(4-chlorophenoxy)-phenyl]sulfonyl]-N-hydroxy-4-
piperidinecarboxamide, monohydrochloride



- Part A: To a suspension of resin I (4.98 g, 5.87mmol) in 1-methyl-2-pyrrolidinone (45 mL), in a peptide flask, were added the acid of part A,
- 15 Example 83 (4.55 g, 11.74 mmol), benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonim hexafluorophosphate (6.11 g, 11.74 mmol) and *N*-methylmorpholine (2.58 mL, 23.48 mmol). The resulting mixture was agitated at ambient temperature for 14 hours. The resin was then
- 20 collected by filtration, the filtrate was removed and set aside, and the resin was washed with *N,N*-dimethylformamide, H_2O , *N,N*-dimethylformamide, methanol, dichloromethane and finally with diethyl ether. The resin was dried in vacuo at ambient
- 25 temperature to give the resin bound *p*-fluorosulfone as a yellow solid (6.72 g, 95%).

-462-

The filtrate was diluted with H₂O and extracted with ethyl acetate. The aqueous layer was acidified (pH-2.0) with 2N HCl and then extracted with ethyl acetate. The organic layer was washed
5 with saturated NaCl and dried over Na₂SO₄. The resulting residue was dissolved in 1-methyl-2-pyrrolidinone (40 mL), the above resin was added, followed by *N*-methyilmorpholine (1.50 mL, 13.64 mmol) and benzotriazole-1-yl-oxy-tris-pyrrolidino-
10 phosphonim hexafluorophosphate (3.05 g, 5.86 mmol). The resulting mixture was agitated at ambient temperature for 3.5 hours. The resin was then collected by filtration and washed with *N,N*-dimethylformamide, H₂O, *N,N*-dimethylformamide,
15 methanol, dichloromethane and finally with diethyl ether. The resin was dried in vacuo at ambient temperature to give the resin bound *p*-fluorosulfone as a pale orange solid (6.34 g, 89%). The loading (0.78 mmol/g) was determined by cleaving a small
20 portion of the resin bound *p*-fluorosulfone with 95% trifluoroacetic acid/H₂O.


Part B: To a suspension of the resin bound *p*-fluorosulfone (0.700 g, 0.546 mmol) in 1-methyl-2-pyrrolidinone (3 mL) was added *p*-chlorophenol (0.702
25 g, 5.46 mmol) and Cs₂CO₃ (1.78 g, 5.46 mmol). The resulting mixture was heated to 110 degrees Celsius for 13 hours. The resin was then collected by filtration and washed consecutively with *N,N*-dimethylformamide, H₂O, *N,N*-dimethylformamide, 2N HCl,
30 *N,N*-dimethylformamide, methanol, and dichloromethane. The resulting resin was resubjected to the above

-463-

reaction conditions for 3 hours. The resin was then collected by filtration and washed consecutively with *N,N*-dimethylformamide, H₂O, *N,N*-dimethylformamide, 2*N* HCl, *N,N*-dimethylformamide, methanol, and
5 dichloromethane. The solid was dried in vacuo at ambient temperature to provide the resin bound hydroxamate as an orange solid (0.692 g, 91%).

Part C: The resin bound hydroxamate of part B (0.692 g, 0.540 mmol) was treated with 95%
10 trifluoroacetic acid/H₂O (3 mL) for 1 hour at ambient temperature. The resin was filtered and washed with 95% trifluoroacetic acid/H₂O (3 mL) and then dichloromethane (2x 3 mL). The filtrate was then evaporated. Reverse phase chromatography (on silica,
15 acetonitrile/H₂O/ trifluoroacetic acid) provided the hydroxamate. The resulting solid was dissolved in acetonitrile (5 mL) and H₂O (0.5 mL) and treated with concentrated HCl. The resulting mixture was stirred at ambient temperature for 5 minutes and the
20 concentrated in vacuo to provide the title compound as an off-white solid (0.220 g, 91%). MS MH⁺ calculated for C₁₈H₂₀O₅N₂SCl: 411, found 411.

Example 94: Preparation of Tetrahydro-*N*-hydroxy-4-
25 [(4-phenoxyphenyl)sulfonyl]-2H-pyran-
4-carboxamide



SUBSTITUTE SHEET (RULE 26)

-464-

Part A: To a stirred solution of the methyl ester compound of Example 55, part C, (0.96 g, 3.2 mmol) in N,N-dimethylformamide (30 mL) was added
5 phenol (0.3 g, 3.2 mmol), followed by cesium carbonate (3.2 g, 10 mmol). The resulting composition was heated to 70 degrees Celsius for 5 hours. The solution remained at ambient temperature for 18 hours, was diluted with H₂O and extracted with
10 ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over sodium sulfate. The solvent was removed by rotary evaporation to yield the desired phenoxy compound (1.1 g, 92%).


Part B: Sodium hydroxide (1 g, 25 mmol)
15 was added to a solution of the phenoxy compound of part A (1.1 g, 2.9 mmol) in THF (10 mL) and ethanol (10 mL). The resulting solution was stirred at ambient temperature for 1 hour. The solution was then heated to 80 degrees Celsius for 1 hour. The
20 solvent was removed by rotary evaporation and the resulting sodium salt was acidified with 1 N HCl (50 mL) and extracted with ethyl acetate. The organic layer was dried over Na₂SO₄. The solvent was removed by rotary evaporation to yield the desired phenoxy
25 carboxylic acid (1.1 g, 99%).

Part C: To a stirred solution of the phenoxy carboxylic acid of part B (1.1 g, 3 mmol) in DMF (7 mL) was added N-hydroxybenzotriazole-H₂O (0.623 g, 4.6 mmol), followed by 1-[3-
30 (dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.634 g, 3.3 mmol). After 10 minutes,

-465-

a 50% aqueous hydroxylamine solution was added (2 mL, 30 mmol) and the solution was stirred at ambient temperature for 18 hours. The solution was diluted with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with H₂O and followed by half-saturated NaCl and then dried over Na₂SO₄. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (0.37 g, 33%). HRMS (ES⁺) MH⁺ for C₁₈H₁₉NO₆S 378.1011. Found: 378.0994.

Example 95: Preparation of Tetrahydro-N-hydroxy-4-
[[4-(phenylthio)phenyl]sulfonyl]-2H-
pyran-4-carboxamide



Part A: To a stirred solution under a nitrogen atmosphere of the methyl ester of Example 55, part C, (1.02 g, 3.4 mmol) in N,N-dimethylformamide (20 mL) was added thiophenol (0.37 g, 3.4 mmol), followed by cesium carbonate (3.3g, 10.1 mmol) and the solution was heated to 70 degrees Celsius for 17 hours. The solution remained at ambient temperature for 1 hour, was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over

-466-

Na_2SO_4 . Chromatography (on silica, ethyl acetate/hexane) provided the S-phenyl compound (0.6 g, 41%).


Part B: To a stirred solution of the S-phenyl compound of part A (0.6 g, 1.4 mmol) in THF (10 mL) and ethanol (10 mL) was added NaOH (0.8 g, 20 mmol). The solution was heated to 80 degrees Celsius for 1 hour. The solution remained at ambient temperature for 18 hours. The solvent was removed by rotary evaporation, the resulting sodium salt was acidified with 1 N HCl (25 mL), extracted with ethyl acetate, and the organic layer was dried over sodium sulfate. The solvent was removed by rotary evaporation to yield the desired S-phenyl carboxylic acid (0.6 g, quantitative yield).

Part C: To a stirred solution of the S-phenyl carboxylic acid of part B (0.6 g, 1.5 mmol) in DMF (6 mL) was added N-hydroxybenzotriazole- H_2O (0.30 g, 2.2 mmol), followed by 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (0.32 g, 1.6 mmol). After 10 minutes, a 50% aqueous hydroxylamine solution was added (1.5 mL, 22 mmol) and the solution was stirred at ambient temperature 42 hours. The solution was diluted with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with H_2O , followed by half-saturated NaCl and dried over sodium sulfate. Reverse phase chromatography (on silica, acetonitrile/ H_2O) provided the title compound as a white solid (0.15 g, 26%). HRMS (ES^+) MH^+ for $\text{C}_{18}\text{H}_{19}\text{NO}_5\text{S}_2$ 394.0783. Found: 394.0753.

-467-

Example 96: Preparation of 4-[[4-(3,4-dimethylphenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide

5



Part A: To a stirred solution of the methyl ester Example 55, part C, (1.04 g, 3.3 mmol) in N,N-dimethylformamide (30 mL) was added 3,4-dimethylphenol (0.4g, 3.3 mmol), followed by cesium carbonate (3.2 g, 10 mmol). The resulting solution was heated to 88 degrees Celsius for 5 hours. The solution was concentrated by rotary evaporation, diluted with H₂O and extracted with ethyl acetate. The organic layer dried over MgSO₄. The solvent was removed by rotary evaporation to yield the desired dimethylphenoxy compound (1.2g, 91%).


Part B: To a solution of the dimethylphenoxy compound of part A (1.2 g, 3 mmol) in THF (10 mL) and ethanol (10 mL) was added NaOH (1 g, 25 mmol). The resulting solution was heated to 80 degrees Celsius for 1 hour. The solvent was removed by rotary evaporation, the resulting sodium salt was acidified with 1 N HCl (50 mL) and extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was removed by rotary

-468-

evaporation to yield the desired dimethylphenoxy carboxylic acid (1.2 g, quantitative yield).

Part C: To a stirred solution of the dimethylphenoxy carboxylic acid of part B (1.2 g, 3 mmol) in DMF (7 mL) was added N-hydroxybenzotriazole-H₂O (0.623 g, 4.6 mmol), followed by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.634 g, 3.3 mmol). After 10 minutes, a 50% aqueous hydroxylamine solution was added (2 mL, 30 mmol) and the solution was stirred at ambient temperature 18 hours. The solution was diluted with saturated sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with H₂O and followed half-saturated NaCl and dried over Na₂SO₄. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (0.52 g, 43%). HRMS (ES⁺) MH⁺ for C₂₀H₂₃NO₅S 406.1324. Found: 406.1302.

Example 97: Preparation of Tetrahydro-N-hydroxy-4-[[4-[(6-methyl-3-pyridinyl)oxy]phenyl]-sulfonyl]-2H-pyran-4-carboxamide, monohydrochloride



25

-469-

Part A: To a stirred solution of the methyl ester of Example 55, Part C, (1.02 g, 3.4 mmol) in N,N-dimethylformamide (20 mL) was added 5-hydroxy-2-methyl-pyridine (0.54g, 5 mmol), followed by cesium carbonate (3.2g, 10 mmol). The resulting solution was heated to 70 degrees Celsius for 5 hours. The solution remained at ambient temperature for 4 days, then was diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over sodium sulfate. The solvent was removed by rotary evaporation to yield a heavy oil from which the desired white methyl pyridine compound crystallized at ambient temperature *in vacuo* (1.2 g, 94%).

Part B: To a solution of the methyl pyridine compound of part A (1.2 g, 3.2 mmol) in THF (13 mL) was added potassium trimethylsilanoate (0.5 g, 3.5 mmol). The resulting solution was stirred at ambient temperature for 18 hours, during which time a gel formed. The solvent was removed by rotary evaporation to yield the desired methyl pyridine carboxylic acid (1.4g, quantitative yield).

Part C: To a stirred solution of the methyl pyridine carboxylic acid of part B (1.4 g, 3.2 mmol) in methylene chloride (10 mL) was added bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.79 g, 3.8 mmol), followed by 4-methylmorpholine (0.97 g, 9.6 mmol), followed by O-tetrahydro-2H-pyran-yl-hydroxylamine (0.41 g, 3.5 mmol) and the solution was stirred at ambient temperature for 1.5 hours. The solution was filtered to remove a


-470-

precipitate and the solvent was removed by rotary evaporation. Chromatography (on silica, ethyl acetate/hexane) provided the O-tetrahydropyran methyl pyridine as a white solid (1.48 g, 97%).

5 Part D: Methanol (3 mL) was added to a stirred solution of the O-tetrahydropyran methyl pyridine of part C (1.48 g, 3.1 mmol) in 4 N HCl in dioxane (5 mL). The solution was stirred at ambient temperature for 3 hours and poured into ethyl ether.
10 The resulting precipitate was collected by vacuum filtration. Reverse phase chromatography (on silica, acetonitrile/H₂O/HCl) provided the title compound as a white solid (0.64 g, 53%). HRMS (ES⁺) MH⁺ for C₁₈H₂₀N₂O₆S 393.1120. Found: 393.1110.

15

Example 98: Preparation of Tetrahydro-N-hydroxy-4-
[[4-[(6-methyl-2-pyridinyl)oxy]phenyl]-
sulfonyl]-2H-pyran-4-carboxamide



20

Part A: To a stirred solution of the methyl ester of Example 55, part C, (1.0 g, 3.3 mmol) in N,N-dimethylformamide (20 mL) was added 2-hydroxy-
25 6-methyl-pyridine (0.54 g, 5 mmol), followed by cesium carbonate (3.2g, 10 mmol). The resulting solution was heated to 70 degrees Celsius for 5

-471-

hours. The solution remained at ambient temperature for 11 hours, at which time additional 2-hydroxy-6-methyl-pyridine (0.3 g, 2.7 mmol) was added to the stirred solution and the resulting solution was

5 heated to 70 degrees Celsius for 3 hours. The solution was concentrated by rotary evaporation, diluted with saturated NaCl in H₂O and extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was removed by rotary

10 evaporation and chromatography (on silica, ethyl acetate/methanol) provided the desired methyl pyridine as a white solid (0.63 g, 49%).

Part B: To a solution of the methyl pyridine compound of part A (0.63 g, 1.6 mmol) in THF

15 (13 mL) was added potassium trimethylsilanoate (0.5 g, 3.5 mmol). The resulting solution was stirred at ambient temperature for 18 hours. The precipitate that formed was removed by filtration, washed with methylene chloride and dried in vacuo to provide the

20 methyl pyridine carboxylic acid potassium salt (0.4 g, 55%).

Part C: To a stirred solution of the methyl pyridine carboxylic acid potassium salt of part B (0.4 g, 0.9 mmol) in N,N-dimethylformamide (5

25 mL) was added bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (0.5 g, 1 mmol), followed by 4-methylmorpholine (0.27 g, 2.6 mmol), followed by a 50% aqueous hydroxylamine solution (0.6 mL, 9 mmol). The resulting solution was stirred at ambient

30 temperature 32 hours. The solution was concentrated by rotary evaporation and reverse phase

-472-


chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (0.162 g, 47%).

HRMS (ES⁺) MH⁺ for C₁₈H₂₀N₂O₆S 393.1120. Found: 393.1119.

5

Example 99: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-(1H-imidazol-1-yl)phenoxy]phenyl]-
sulfonyl]-2H-pyran-4-carboxamide,
monohydrochloride

10




Part A: To a solution of the THP
pyranfluoro compound of Example 55, part C, (2.0 g,
15 5.2 mmol) in N,N-dimethylacetamide (6 mL) was added
4-(1,3-imidazole)phenol (12.9 g, 33.3 mmol), followed
by cesium carbonate (32.5 g, 99.9 mmol). The
reaction was heated at 65 degrees Celsius for twelve
hours. Removing the dimethylacetamide in vacuo
20 afforded a brown solid. Reverse phase chromatography
(on silica, acetonitrile/water) gave the THP-
protected product in solution.

Part B: A solution of 10% HCl_{aq} (100 mL)
was slowly added to the solution of the crude THP-
25 protected product from A in acetonitrile/water (100
mL). After stirring overnight (about 18 hours), the
acetonitrile was removed. The resultant precipitate

-473-

was collected, giving the title compound as a brown solid (6.0 g, 41%). MS (FAB) M⁺H calculated for C₂₁H₂₁N₃O₅S₁: 444, found 444.

5 Example 100: Preparation of 4-[[4-(4-chlorophenoxy)-phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



10


Part A: To a stirred solution of the THP
pyranfluoro compound of Example 55, Part C, (2.9 g,
7.5 mmol) in N,N-dimethylformamide (15 mL) was added
p-chloro-phenol (1.93 g, 15 mmol), followed by cesium
15 carbonate (7.3 g, 22.5 mmol). The resulting
composition was heated to 90 degrees Celsius for 1.5
hours. The solution remained at ambient temperature
for 18 hours with stirring, and dimethylformamide (20
mL) was added to the stirred solution, followed by
20 cesium carbonate (2 g, 6.2 mmol). The resulting
composition was heated to 95 degrees Celsius for 3
hours. The solution then remained at ambient
temperature 20 hours, at which time it was diluted
with H₂O and extracted with ethyl acetate. The
25 organic layer was washed with half-saturated NaCl and
dried over sodium sulfate. The solvent was removed
by rotary evaporation. Chromatography (on silica,

-474-

ethyl acetate/hexane) provided the p-chloro phenoxyphenyl THP-protected hydroxamate compound (2.9 g, 78%).

Part B: To a solution of the p-chloro phenoxyphenyl THP-protected hydroxamate compound of part A (2.9 g, 5.7 mmol) in dioxane (5 mL) was added 4N HCl in dioxane (5 mL, 20 mmol), followed by methanol (7.5 mL). The resulting solution was stirred at ambient temperature for 1 hour. The solvent was removed by rotary evaporation. Reverse phase chromatography (on silica, acetonitrile/H₂O) provided the title compound as a white solid (1.35 g, 58%). MS (FAB) MH⁺ for C₁₈H₁₈NO₆SCl 412. Found: 412.

Example 101: Preparation of 4-[[4-(3-chlorophenoxy)-phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



20

Part A: To a stirred solution of the THP pyranfluoro compound of Example 55, Part C, (5.0 g, 13 mmol) in N,N-dimethylformamide (20 mL) was added p-chloro-phenol (5 g, 39 mmol), followed by cesium carbonate (17 g, 52 mmol). The resulting solution was heated to 95 degrees Celsius for 7 hours. The solution was maintained at ambient temperature for 7


-475-

hours, diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over sodium sulfate. The solution was concentrated by rotary evaporation.

- 5 Chromatography (on silica, ethyl acetate/hexane) provided the m-chloro phenoxyphenyl THP-protected hydroxamate compound (5.2 g, 82%).

Part B: To a solution of the m-chloro phenoxyphenyl THP-protected hydroxamate compound of
10 part A (5.2 g, 10 mmol) in dioxane (5 mL) was added 4N HCl in dioxane (5 mL, 20 mmol), followed by methanol (10 mL). The resulting solution was stirred at ambient temperature for 1 hour. The solvent was removed by rotary evaporation to provide the title
15 compound as a white solid (3.4 g, 79%). HRMS (ES⁺) M + NH₄⁺ for C₁₈H₁₈NO₆SCl 429.0887. Found: 429.0880.

Example 102: Preparation of methyl 4-[4-
[(tetrahydro-4-[(hydroxyamino)carbonyl]-
20 2H-pyran-4-yl)sulfonyl]-
phenoxy]benzenepropanoate



- 25 Part A: To a stirred solution of the THP pyranfluoro compound of Example 55, part C, (5.0 g, 13 mmol) in N,N-dimethylformamide (45 mL) was added


-476-

methy 3-(4-hydroxyphenyl)-propanoate (7 g, 39 mmol), followed by cesium carbonate (17 g, 52 mmol). The resulting composition was heated to 95 degrees Celsius for 7 hours. The solution then remained at ambient temperature for 7 hours. The solution was thereafter diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over sodium sulfate. The solution was concentrated by rotary evaporation. Chromatography (on silica, ethyl acetate/hexane) provided the methyl propanoate phenoxyphenyl THP-protected hydroxamate compound (5.6 g, 79%).

Part B: To a solution of the methyl propanoate phenoxyphenyl THP-protected hydroxamate compound of part A (5.6 g, 10 mmol) in methanol (5 mL) was added 4N HCl in dioxane (5 mL, 20 mmol). The resulting solution was stirred at ambient temperature for 0.5 hours. The solvent was removed by rotary evaporation. The residue was dissolved in methylene chloride/ethyl acetate and the compound precipitated with hexane. The precipitate was washed with hexane and dried in vacuo to provide the title compound as a white solid (3.8 g, 80%). HRMS (ES⁺) M⁺ for C₂₂H₂₅NO₈S 464.138. Found: 464.135.

Example 103: Preparation of 4-[[4-[(4-fluorophenyl)-thio]phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide

-477-




Part A: To a stirred solution under a nitrogen atmosphere of the THP pyranfluoro compound of Example 55, part C, (2.9 g, 7.5 mmol) in N,N-dimethylformamide (25 mL) was added cesium carbonate (4.9 g, 15 mmol), followed by 4-fluoro-thiophenol (1.9 g, 15 mmol). The resulting composition was heated to 95 degrees Celsius for 7 hours. Cesium carbonate was added (1.2 g, 3.8 mmol) after 1 hour of heating and again at two hours. The solution remained at ambient temperature for 9 hours, was concentrated by rotary evaporation, diluted with H₂O containing 30% brine and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over sodium sulfate. The solution was concentrated by rotary evaporation. Chromatography (on silica, ethyl acetate/hexane) followed by reverse phase chromatography (acetonitrile/H₂O) provided the p-fluoro-phenyl-S-phenyl THP-protected hydroxamate compound (1.9 g, 55%).

Part B: To a solution of the p-fluoro-phenyl-S-phenyl THP-protected hydroxamate compound of part A (1.9 g, 4 mmol) in methanol (5 mL) was added 4N HCl in dioxane (5 mL, 20 mmol). The resulting solution was stirred at ambient temperature for 0.5

-478-

hours. The solvent was removed by rotary evaporation, the residue was dissolved in methylene chloride and precipitated with hexane. The precipitate was and dried in vacuo to provide the title compound as a white solid (1.5 g, 89%). HRMS (ES⁺) M+NH₄⁺ for C₁₈H₁₈NO₅S₂F 429.0954. Found: 429.0948.

Example 104: Preparation of Tetrahydro-N-hydroxy-4-
[[4-(4-pyridinylthio)phenyl]sulfonyl]-
2H-pyran-4-carboxamide,
monohydrochloride




Part A: To a stirred solution of the THP pyranfluoro compound of Example 55, Part C, (2.9 g, 7.5 mmol) in N,N-dimethylformamide (20 mL) was added potassium carbonate (2.6 g, 19 mmol), followed by 4-mercaptopyridine (1.7 g, 15 mmol). The resulting composition was heated to 75 degrees Celsius for 5 hours. Potassium carbonate was added (0.26 g, 1.9 mmol) after 1 hour of heating and again at two hours. The solution remained at ambient temperature for 14 hours. The solution was concentrated by rotary evaporation, diluted with H₂O containing 30% brine and extracted with ethyl acetate. The organic layer was washed with half-saturated NaCl and dried over Na₂SO₄. The solution was concentrated by rotary evaporation.

-479-

Chromatography (on silica, ethyl acetate/hexane) provided the mercaptopyridine THP-protected hydroxamate compound (1.2 g, 33%).

Part B: To a solution of the
5 mercaptopyridine THP-protected hydroxamate compound of part A (1.2 g, 2.5 mmol) in acetonitrile (20 mL) was added 12.5 N HCl (0.4 mL, 5 mmol), followed by methanol (3 mL). The resulting solution was stirred at ambient temperature for 1 hour. The precipitate
10 was filtered, washed with methanol followed by ethyl ether and dried in vacuo to provide the title compound as a white solid (0.92 g, 86%). HRMS (ES⁺) M+NH₄⁺ for C₁₇H₁₈N₂O₅S₂ 395.0735. Found: 395.0734.

15 Example 105: Preparation of 4-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenoxy]benzenepropanoic acid




Part A: To a stirred solution of the title compound of Example 102 (0.1 g, 0.2 mmol) in methanol (0.5 mL) was added aqueous 1 M Li(OH)₂ (0.43 mL, 0.43
25 mmol). After standing at ambient temperature 24 hours, the solution was refluxed 20 hours. The solution was lyophilized to dryness and reverse phase

-480-

chromatography provided the title compound as a white solid (9 mg, 9%). MS (FAB) $M+Li^+$ for $C_{21}H_{23}NO_8S$ 456. Found: 456.

- 5 Example 106: Preparation of Tetrahydro-N-hydroxy-4-[[4-[[1-(2-propynyl)-4-piperidinyl]-oxy]phenyl]sulfonyl]-2H-pyran-4-carboxamide, monohydrochloride



- Part A: To a heat dried three-neck flask under a nitrogen atmosphere was added NaH (1.59g of 60%, 40 mmol) slurried in N,N-dimethylformamide (50 mL). The slurry was chilled to zero degrees Celsius using an ice bath and N-Boc-4-hydroxy piperidine was added (8 g, 40 mmol) followed by a N,N-dimethylformamide rinse (10 mL). The ice bath was removed and the stirred solution permitted to reach ambient temperature over two hours. The stirred solution was again chilled to zero degrees Celsius and the methyl ester compound of Example 55, part C, (10 g, 33 mmol) dissolved in N,N-dimethylformamide (40 mL) was added. The ice bath was removed and the solution stirred at ambient temperature 48 hours. The solution was concentrated by rotary evaporation. The solution was diluted with H_2O and extracted with
- 15
- 20
- 25

-481-

ethyl acetate. The organic layer was dried over sodium sulfate. After chromatography (on silica, ethyl acetate/hexane/methanol), the crude N-Boc methyl ester was treated with 1 N HCl in methanol.

- 5 The solvent was removed by rotary evaporation. The residue was then dissolved in acetonitrile (21 mL) to which H₂O was added (21 mLs). Reverse phase chromaatography (on silica, acetonitrile/H₂O) afforded the purified piperidine methyl ester as the HCl salt
- 10 (4.9g, 35%).

- Part B: To a stirred suspension of the piperidine methyl ester HCl salt of part A (1.8 g, 4 mmol) in acetonitrile (24 mL) and was added potassium carbonate (1.8 g, 13 mmol), followed by propargyl
- 15 bromide (0.58 mL of 80% solution, 5.2 mmol). The mixture was stirred at ambient temperature for 18 hours. The solution was concentrated by rotary evaporation, diluted with H₂O and extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and
- 20 concentrated by rotary evaporation. Chromatography (on silica, methylene chloride/methanol) provided the propargyl piperidine methyl ester compound (1.1 g, 63%).

- Part C: To a solution of the propargyl
- 25 piperidine methyl ester compound of part B (1.1 g, 2.7 mmol) in THF (3 mL) was added potassium trimethylsilanoate (0.57 g, 4 mmol). After 5 minutes, THF was added (12 mL), followed by a second addition of THF (15 mL) after 10 more minutes. The
- 30 resulting solution was stirred at ambient temperature for 18 hours, during which a gel formed. The solvent

-482-

was removed by rotary evaporation, and the residue was diluted with H₂O and washed with ethyl acetate. The aqueous layer was acidified and chromatographed (on silica, acetonitrile/H₂O) to provide the desired
5 propargyl piperidine carboxylic acid after lyophilization (0.64 g, 59%).


Part D: To a stirred solution of propargyl piperidine carboxylic acid of part C (0.64 g, 1.6 mmol) in N,N-dimethylformamide (5 mL) was added 1-
10 hydroxybenzotriazole (0.3 g, 2.3 mmol), followed by 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.33 g, 1.7 mmol), followed by O-tetrahydro-2H-pyran-2-yl-hydroxylamine (0.57 g, 4.8 mmol). The solution was stirred at ambient
15 temperature 42 hours, concentrated by rotary evaporation, diluted with H₂O and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, followed by brine and dried over Na₂SO₄. The solution was concentrated by rotary
20 evaporation and chromatographed on reverse phase (on silica, acetonitrile/H₂O) to provide the title compound as a white solid upon lyophilization (0.2 g, 30%). HRMS (ES⁺) MH⁺ for C₂₀H₂₆N₂O₆S 423.159. Found: 423.159.

25

Example 107: Preparation of 4-[[4-[(1-acetyl-4-piperidinyl)oxy]phenyl]-sulfonyl]tetrahydro-N-hydroxy-
2H-pyran-4-carboxamide

30

-483-



Part A: Acetic anhydride (1.7 g, 16 mmol) was added to a stirred suspension of the piperidine methyl ester HCl salt of Example 106, part A, (1.8 g, 4 mmol) in pyridine (2 mL). The mixture was stirred at ambient temperature for 20 minutes. The solution was concentrated by rotary evaporation and chromatographed (on silica, ethyl acetate/methanol) to provide the acetyl piperidine methyl ester compound (1.5 g, 83%).

Part B: To a solution of the acetyl piperidine methyl ester compound of part A (1.5 g, 3.3 mmol) in THF (5 mL) was added potassium trimethylsilanoate (0.86 g, 6 mmol). After 5 minutes, THF was added (15 mL), followed by a second addition of THF (15 mL) after 10 more minutes. The resulting solution was stirred at ambient temperature for 18 hours. The precipitate was isolated by filtration to provide the desired acetyl piperidine carboxylic acid (1.5 g, 98%).


Part C: To a stirred solution of acetyl piperidine carboxylic acid of part B (0.9 g, 2 mmol) in dimethylacetamide (5 mL) was added bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1 g, 2.3 mmol), followed by 4-methylmorpholine (0.6 g, 6 mmol), followed by aqueous O-tetrahydro-2H-pyran-2-

-484-

yl-hydroxylamine (1.5 mL, 23 mmol) and the solution was stirred at ambient temperature 48 hours.

Reverse-phase chromatography (on silica, H₂O/acetonitrile) provided title compound as a white solid (0.1 g, 12%). MS (FAB) MH⁺ for C₁₉H₂₆N₂O₇S 427. Found: 427.

Example 108: Preparation of 4-[[4-(3-chloro-4-fluorophenoxy)phenyl]sulfonyl]-tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



Part A: To a stirred solution of the THP pyranfluoro compound of Example 55, part C, (3.2 g, 7.7 mmol) in N,N-dimethylacetamide (15 mL) was added the 3-chloro-4-fluorophenol (1.7 mL, 12 mmol), followed by cesium carbonate (5 g, 15.5 mmol). The reaction was heated at 95 degrees Celsius for 2 hours. Cesium carbonate (2.5 g, 8 mmol) was added, and the reaction was heated at 95 degrees Celsius for 6 hours. The solution remained at ambient temperature for 8 hours. The crude reaction was then filtered to remove the cesium chloride and precipitated product. The filter cake was suspended in H₂O and acidified with HCl to pH=6. After foaming


-485-

ceased, the precipitate was removed by filtration,
washed with H₂O, dissolved in H₂O/acetonitrile and
chromatographed over a reverse phase HPLC column
(H₂O/acetonitrile) to give the 3-chloro-4-fluoro
5 phenoxy THP-protected hydroxamate (1.4 g, 35%).

Part B: To a stirred solution of the 3-
chloro-4-fluoro phenoxy THP-protected hydroxamate
from part A (1.4 g, 2.7 mmol) in acetonitrile (10 mL)
was added 1N aqueous HCl (10 mL). The solution was
10 stirred at ambient temperature for 1 hour. The
acetonitrile was evaporated off at ambient
temperature under a steady stream of nitrogen until a
heavy precipitate formed. The precipitate was
filtered and the cake was washed with H₂O followed by
15 diethyl ether and dried under vacuum, giving the
title compound as a white solid (12.5g, 96%). The
compound was recrystallized from acetone/hexane,
giving white crystals (10.9 g, 86%). HRMS (ES) M+NH₄⁺
for C₁₈H₁₉NO₆SFCl 447.079. Found: 447.080.

20

Example 109: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-phenoxy)phenyl] sulfonyl 2H-
thiopyran-4-carboxamide



25

Part A: To a solution of the methylester
thiopyran compound of Part C, Example 50 (MW 318, 3

-486-


g, 1.0 equivalents) in N,N-dimethylacetamide (DMA; 40 mL) were added cesium carbonate (12g, 1.5 equivalents) and phenol (1.5g). The mixture was heated to 95 degrees Celsius for 6 hours. After the
5 reaction was cooled to ambient temperature, the reaction mixture was filtered and the N,N-dimethylacetamide was then removed via rotary evaporation. The residue was dissolved in 10% aqueous HCl (100mL) and extracted with ethyl acetate
10 (2x). The ethyl acetate extract was dried over sodium sulfate and removed under reduced pressure to give an oil. The oil was purified on silica gel to give 2 g of methyl ester. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

15 Part B: To a solution of the methyl ester compound of Part A (MW 392, 2 g) in THF (20 mL) was added potassium trimethylsilanoate (MW 128, 1.6 g, 1.2 equivalents). The mixture stirred 2-3 hours at ambient temperature until a solid precipitate
20 developed. After the hydrolysis was complete, N-methylmorpholine (2 mL) was added followed by PyBrop (2.3 g, 1.2 equivalents). The solution was stirred for 10 minutes, then aqueous hydroxylamine was added and stirring for an additional 2 hours. After
25 complete reaction (2 hours) the solvent was removed via rotary evaporation. The residue was dissolved in water/acetonitrile, made acidic with TFA (pH=2), then purified on prep RPHPLC to give 1 g the title compound as a white solid. The ¹H NMR, MS, and HPLC
30 were consistent with the desired compound. MS (CI) M+H calculated for C₁₈H₁₉NO₅S₂: 393, found 393.

-487-

Example 110: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-phenoxy)phenyl] sulfonyl 2H-
sulfonyl pyran-4-carboxamide

5



Part A: Water (50mL) was added to a solution of the compound of Example 109, part A, (2
10 g) in tetrahydrofuran (50mL). To this vigorously stirred mixture was added Oxone® (8 g, 3 equivalents). The course of the reaction was monitored by RPHPLC. After 3 hours, water was added and the product was extracted with ethyl acetate (100
15 mL, 2x). The ethyl acetate was dried over sodium sulfate. After solvent was removed via reduced pressure, 1.8 g of the phenoxy methyl ester compound was obtained as a white solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound.


20 Part B: To a solution of the phenoxy methyl ester compound of part A (MW 590, 2 g) in tetrahydrofuran (20 mL) was added potassium trimethylsilanoate (MW 128, 1.2 g, 1.2 equivalents). The mixture was stirred 2-3 hours until a solid
25 precipitate developed. After the hydrolysis was complete, N-methylmorpholine (2mL) was added followed by PyBrop (2.3 g, 1.2 equivalents). The solution was stirred for 10 minutes then aqueous hydroxylamine was

-488-

added and with stirring for an additional 2 hours. After complete reaction, (2 hours) the solvent was removed via rotary evaporation. The residue was dissolved in water/acetonitrile, made acidic with
5 trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 500 mg of the title compound as a white solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₁₈H₁₉NO₇S₂: 425, found 425.

10

Example 111: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-phenoxy)phenyl] sulfonyl 2H-
sulfoxyl pyran-4-carboxamide




15

Part A: To a solution of methyl ester of Example 109, part A, (2 g) in acetic acid/water (25/5mL) was added hydrogen peroxide (2mL, 30%
20 solution). The course of this vigorously stirred solution was monitored by RPHPLC. After 3 hours, water was added and the product was extracted with ethyl acetate (100 mL, 2x). The ethyl acetate was dried over sodium sulfate. After solvent was removed
25 via reduced pressure, 2.1 grams of the methylester sulfoxidepyran Phenyl-O-phenyl compound was obtained as a white solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

-489-

Part B: To a solution of the methylester sulfoxidepyran Phenyl-O-phenyl compound of Part A (MW 578, 1.8 g) in tetrahydrofuran (25 mL) was added potassium trimethylsilanoate (MW 128, 1.2 g, 1.2 equivalents). The mixture was stirred 2-3 hours until a solid precipitate developed. After the hydrolysis was complete, N-methyl morpholine (2 mL) was added followed by PyBrop (2.3 g, 1.2 equivalents). The solution was stirred for 10 minutes then aqueous hydroxylamine was added, with stirring for an additional 2 hours. After complete reaction (12 hours) the solvent was removed via rotary evaporation. The residue was dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 500 milligrams of the title compound as a white solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₁₈H₁₉NO₆S₂: 409, found 409.

Example 112: Preparation of tetrahydro-N-hydroxy-4-
[[4-(1-acetyl-4-(4-piperazine-
phenoxy)phenyl] sulfonyl 2H-
thiopyran-4-carboxamide



-490-


Part A: To a solution of the methylester thiopyran compound of Example 50, part C, (MW 318, 5 g, 1.0 equivalents) in N,N-dimethylacetamide (70mL) were added cesium carbonate (MW 5.5g, 1.5
5 equivalents), tetrabutylammonium fluoride (2 mL, 2 M in THF) and 1-acetyl-4-(4-hydroxyphenyl)piperazine (4.9 g). The mixture was stirred and heated at 90 degrees Celsius for 6 hours. The reaction mixture was filtered and the N,N-dimethylacetamide was then
10 removed via rotary evaporation. The residue was dissolved in water (100mL) and extracted with ethyl acetate (2x). The ethyl acetate was dried over sodium sulfate and removed under reduced pressure to give an oil. The oil was purified on silica gel to
15 give 3 g of methyl ester. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

Step B: To a solution of the methyl ester compound of Part A (MW 433, 3 g) in tetrahydrofuran (50 mL) was added potassium trimethylsilanoate (MW
20 128, 0.9 g, 1.2 equivalents). The mixture was stirred 2-3 hours until a solid precipitate developed. After the hydrolysis was complete N-methyl morpholine (2 mL) was added followed by PyBrop (3.5 g, 1.2 equivalents). The solution was stirred
25 for 10 minutes then aqueous hydroxylamine was added with stirring for an additional 2 hours. After complete reaction (2 hours) the solvent was removed via rotary evaporation. The residue was dissolved in water/acetonitrile, made acidic with trifluoroacetic
30 acid (pH=2), then purified on prep RPHPLC to give 1.2 g of the title compound as a white solid. The ¹H NMR,

-491-

MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for $C_{24}H_{29}N_3O_6S_2$: 519, found 519.

- 5 Example 113: Preparation of tetrahydro-N-hydroxy-4-
[[4-(4-thiophenoxy)phenyl] sulfonyl 2H-
thiopyran-4-carboxamide



10

Part A: To a solution of the methylester thiopyran compound of Example 50, part C, (5 g.) in acetic acid (40mL) was added water/hydrogen peroxide(8 mL, 4 mL/4 mL, 30% solution). The course
15 of this vigorously stirred solution was monitored by RPHPLC. After 3 hours at ambient temperature, water was added and the product was extracted with ethyl acetate (100 mL, 2x). The ethyl acetate was dried over sodium sulfate. After solvent was removed via
20 reduced pressure 4.5 g of the methylester sulfoxidepyran Ph-p-F was obtained as a white solid. The 1H NMR, MS, and HPLC were consistent with the desired compound.

Part B: To a solution of the methylester
25 sulfoxidepyran Ph-p-F of Part A (MW 318, 5 g, 1.0 equivalents) in DMA (70 mL) were added cesium carbonate (MW 4.5g, 1.1 equivalents) and thiophenol

-492-


(1.5 g, 1.05 equivalents). The mixture was stirred 2 hours at room temperature. The reaction mixture was filtered and the N,N-dimethylacetamide was then removed via rotary evaporation. The residue was
5 dissolved in water (100 mL) and extracted with ethyl acetate (2x). The ethyl acetate was dried over sodium sulfate and removed under reduced pressure to give an oil. The oil was purified on prep RPHPLC to give 2 g of methyl ester sulfoxidepyran Phenyl-S-Ph
10 compound. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

Part C: To a solution of the methyl ester sulfoxidepyran Phenyl-S-Ph of Part B (MW 590, 5 g) in tetrahydrofuran (100 mL) was added potassium
15 trimethylsilanoate (MW 128, 1.5 g, 2 equivalents). The mixture was stirred 2-3 hours at ambient temperature until a solid precipitate developed. After the hydrolysis was complete, N-methyl morpholine (6 mL) was added followed by PyBrop (4 g,
20 1.1 equivalents). The solution was stirred for 10 minutes then aqueous hydroxylamine was added with stirring for an additional 2 hours. After complete reaction (12 hours), the solvent was removed via rotary evaporation. The residue was dissolved in
25 water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 1.9 g of the title compound as a white solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₁₆H₁₉NO₅S₃: 425,
30 found 425.

-493-

Example 114: Preparation of tetrahydro-N-hydroxy-
4-[[4-[4-(4-hydroxyphenyl)thiophenoxy]-
phenyl] sulfonyl 2H-thiopyran-
4-carboxamide

5



Part A: To a solution of the title
compound of Example 50 (MW 402, 5 g, 1.0 equivalent)
in N,N-dimethylacetamide (70 mL) was added the 4-
hydroxythiophenol (MW 126, 1.6 g, 1.3 equivalents)
followed by potassium carbonate (MW 138, 5 g, 2.0
equivalents). The reaction was heated at 65 degrees
Celsius for 3 hours, until HPLC indicated the
reaction had finished. The reaction mixture was
filtered, the N,N-dimethylacetamide was removed in
vacuo. The residue was dissolved in water (100mL) and
extracted with ethyl acetate (2x). The ethyl acetate
was dried over sodium sulfate and removed under
reduced pressure to give the p-OH thiophenoxy
compound as a crude oil. The ¹H NMR, MS, and HPLC
were consistent with the desired compound.


Part B: The crude p-OH thiophenoxy
compound from Part A was stirred in HCl/dioxane (50
mL) for 2 hours. The solvent was removed and the
residue was dried and dissolved in
water/acetonitrile, made acidic with trifluoroacetic
acid (pH=2), then purified on prep RPHPLC to give 2.1

-494-

g of the title compound as a yellow solid. The ^1H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) $\text{M}+\text{H}$ calculated for $\text{C}_{18}\text{H}_{19}\text{NO}_5\text{S}_3$: 425, found 425.

5

Example 115: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-aminophenyl]thiophenoxy]phenyl]
sulfonyl 2H-thiopyran-4-carboxamide



10


Part A: To a solution of the title compound of Example 50 (MW 402, 5 g, 1.0 equivalents) in *N,N*-dimethylacetamide (70 mL) was added the 4-
15 aminothiophenol (MW 126, 1.6 g, 1.3 equivalents) followed by potassium carbonate (MW 138, 5 g, 2.0 equivalents). The reaction was heated at 65 °C for 3 hours, until HPLC indicated the reaction had
finished. The reaction mixture was filtered, and the
20 *N,N*-dimethylacetamide was removed in vacuo. The residue was dissolved in water (100mL) and extracted with ethyl acetate (2x). The ethyl acetate was dried over sodium sulfate and removed under reduced
pressure to give the *p*-NH₂ thiophenoxy compound as a
25 crude oil. The ^1H NMR, MS, and HPLC were consistent with the desired compound.

Part B: The crude *p*-NH₂ thiophenoxy compound of Part A was stirred in HCl/dioxane (50 mL)

-495-

for 2 hours. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 2.1 g of the title compound as a yellow solid. The ^1H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_4\text{S}_3$, $\text{C}_2\text{HF}_3\text{O}_2$: 538, found 538.

Example 116: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-tyramine)phenoxy]phenyl]
sulfonyl 2H-thiopyran-4-carboxamide




Step A: To a solution of title compound of Example 50 (MW 402, 5 g, 1.0 equivalents) in N,N-dimethylacetamide (50mL) was added the tryptamine (3 g, 2 equivalents), followed by cesium carbonate (10 g, 2.0 equivalents). The reaction was heated at 95 degrees Celsius for 5 hours, until HPLC indicated the reaction had finished. The reaction mixture was filtered, the N,N-dimethylacetamide was removed in vacuo. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (TFA; pH=2), then purified on prep RPHPLC to give 2.5 g of the crude methyl ester as a yellow solid. The ^1H NMR, MS, and HPLC were consistent with the desired compound.

-496-

Step B: The crude methyl ester from reaction Step A was stirred in aqueous HCl (50 mL) for 1 hour. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made
5 acidic with TFA (pH=2), then purified on prep RPHPLC to give 2.2 g of yellow foam solid as the trifluoroacetic acid salt of the title compound. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₂₀H₂₄N₂O₅S₂,
10 C₂HF₃O₂: 550, found 550.

Example 117: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-hydroxyphenyl glycine]]phenyl]
sulfonyl 2H-thiopyran-4-carboxamide

15



Step A: To a solution of the title compound of Example 50 (MW 402, 5 g, 1.0 equivalents)
20 in N,N-dimethylacetamide (50 mL) was added hydroxyphenylglycine (3 g, 2 equivalents), followed by cesium carbonate (10g, 2.0 equivalents). The reaction was heated at 95 degrees Celsius for 5
hours, until HPLC indicated the reaction had
25 finished. The reaction mixture was filtered, the N,N-dimethylacetamide was removed in vacuo. The solvent was removed, the residue was dried and dissolved in water/acetonitrile, made acidic with


-497-

trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 2.0 g of the crude methyl ester as a tan solid. The ^1H NMR, MS, and HPLC were consistent with the desired compound.

5 Step B: The crude methyl ester from reaction Step A was stirred in aqueous HCl (50 mL) for 1 hour. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then
10 purified on prep RPHPLC to give 2.2 g of tan foam/solid as the trifluoroacetic acid salt of the title compound. The ^1H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for $\text{C}_{20}\text{H}_{22}\text{N}_2\text{O}_5\text{S}_2$, $\text{C}_2\text{HF}_3\text{O}_2$: 580, found 580.

15

Example 118: Preparation of tetrahydro-N-hydroxy-4-
[[4-[4-hydroxyphenyl] glycine]phenyl]
sulfonyl 2H-thiopyran-4-carboxamide




20

Step A: A solution of the title compound of Example 115 (MW 518, 2.5 g, 1.0 equivalents) in THF (25 mL) and N-Boc N-hydroxysuccinyl glycine (2.1
25 g, 2 equivalents) containing N-methylmorpholine (2 mL) and 4-dimethylaminopyridine (250 mg) was stirred for 12 hours. After RPHPLC indicated complete reaction at this time, the solvent was removed under

-498-

reduced pressure to give an oil. Hydrochloric acid 10% aqueous solution was added with stirring for an additional 1-2 hours. The solution was then purified on prep RPHPLC to give 1.2 g of white foam/solid as the trifluoroacetic acid salt. The ^1H NMR, MS, and HPLC were consistent with the desired compound. The solid was dried under reduced pressure, then suspended in ethyl ether followed by addition of 4N HCl/dioxane (20 mL). The HCl salt was filtered and washed with ethyl ether to give the title compound as a tan solid (1.1 g). The ^1H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) $\text{M}+\text{H}$ calculated for $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_5\text{S}$, $\text{C}_2\text{HF}_3\text{O}_2$: 595, found 595.

Example 119: Preparation of tetrahydro-N-hydroxy-4-[[4-(4-pyridinylthio)-phenyl]sulfonyl]-2H-thiopyran-4-carboxamide, monohydrochloride



20


Step A: To a solution of the title compound of Example 50 (MW 402, 5 g, 1.0 equivalents) in N,N-dimethylacetamide (50 mL) were added 4-thiopyridine (3 g, 2 equivalents), followed by cesium carbonate (10g, 2.0 equivalents). The reaction mixture was heated at 75 degrees Celsius for 5 hours, until HPLC indicated the reaction had finished. The

-499-

reaction mixture was filtered, and the N,N-dimethylacetamide was removed *in vacuo*. The residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then
5 purified on prep RPHPLC to give 2.0 g of the crude -S-pyridyl THP-protected thiopyran compound as a brown solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

Step B: The -S-pyridyl THP-protected
10 thiopyran compound from Step A was stirred in aqueous HCl (50 mL) for 1 hour. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 1.8
15 g of tan foam/glass as the trifluoroacetic acid salt of the title compound. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₁₇H₁₈N₂O₄S₂ HCl: 447, found 447.

20 Example 120: Preparation of 4-[[4-[(4-aminophenyl)thio]phenyl]-sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide



25

Step A: To a solution of the title compound of Example 55 (MW 387, 5 g, 1.0 equivalents)

-500-

in N,N-dimethylacetamide (50 mL) were added the 4-aminothiophenol (3 g, 2 equivalents) followed by potassium carbonate (10g, 2.0 equivalents). The reaction was heated at 60 degrees Celsius for 5 hours, until HPLC indicated the reaction had finished. The reaction mixture was filtered, the DMA was removed in vacuo. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 2.0 g of the crude 4-amino-S-Ph THP-protected thiopyran as a brown solid. The ¹H NMR, MS, and HPLC were consistent with the desired compound.

Step B: The 4-amino-S-Ph THP-protected thiopyran compound of Step A was stirred in aqueous HCl (50 mL) for 1 hour. The solvent was removed and the residue was dried and dissolved in water/acetonitrile, made acidic with trifluoroacetic acid (pH=2), then purified on prep RPHPLC to give 1.4 g of tan foam/glass as the trifluoroacetic acid salt of the title compound. The ¹H NMR, MS, and HPLC were consistent with the desired compound. MS (CI) M+H calculated for C₁₈H₂₀N₂O₅S₂: 408, found 408.

Example 121: Preparation of tetrahydro-N-hydroxy-4-
[[4-[(2-methyl-5-benzothiazolyl)-
oxy]phenyl]sulfonyl]-
2H-pyran-4-carboxamide